var images_info;if (!images_info) images_info =[]; images_info["89"]={"89000":{"type":"graphic_picture","displayName":"Yaws papillomatous lesion","title":"Yaws papillomatous lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Yaws papillomatous lesion</div><div class=\"cntnt\"><img style=\"width:419px; height:751px;\" src=\"images/DERM/89000_Yawsprimarychancre.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow nodule in a patient in the primary or secondary stage; the lesion commences as a papule that enlarges and ulcerates.</div><div class=\"graphic_reference\">Courtesy of Oriol Mitj&agrave;, MD.</div><div id=\"graphicVersion\">Graphic 89000 Version 2.0</div></div></div>"},"89011":{"type":"graphic_form","displayName":"Social history pre-visit questionnaire","title":"Pre-visit questionnaire: Social history","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Pre-visit questionnaire: Social history</div><div class=\"cntnt\"><img style=\"width:620px; height:774px;\" src=\"images/PC/89011_Soci_hist_pre_visit_quest.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Division of Geriatric Medicine. UCLA Healthcare. Pre-Visit Questionnaire. Copyright &copy; 2013 The Regents of the University of California.</div><div id=\"graphicVersion\">Graphic 89011 Version 1.0</div></div></div>"},"89012":{"type":"graphic_table","displayName":"Daily activities pre-visit questionnaire","title":"Pre-visit questionnaire: Daily activities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pre-visit questionnaire: Daily activities</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Task</td> <td class=\"subtitle1\">No help needed</td> <td class=\"subtitle1\">Help needed</td> <td class=\"subtitle1\">Who helps?</td> </tr> <tr class=\"divider_bottom\"> <td>Feeding yourself</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Getting from bed to chair</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Getting to the toilet</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Getting dressed</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Bathing or showering</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Walking across the room (includes using cane or walker)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Using the telephone</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Taking your medicines</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Preparing meals</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Managing money (like keeping track of expenses or paying bills)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Moderately strenuous housework such as doing the laundry</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Shopping for personal items like toiletries or medicines</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Shopping for groceries</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Driving</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Climbing a flight of stairs</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Getting to places beyond walking distance (eg, by bus, taxi, or car)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Division of Geriatric Medicine. UCLA Healthcare. Pre-Visit Questionnaire. Copyright &copy; 2013 The Regents of the University of California.</div><div id=\"graphicVersion\">Graphic 89012 Version 1.0</div></div></div>"},"89013":{"type":"graphic_table","displayName":"Range of normal results for coagulation tests in pregnancy","title":"Range of normal results for coagulation tests in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Range of normal results for coagulation tests in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Test</td> <td class=\"subtitle1\" colspan=\"3\">Normal (reference) range</td> </tr> <tr> <td class=\"subtitle2\">First trimester</td> <td class=\"subtitle2\">Second trimester</td> <td class=\"subtitle2\">Third trimester</td> </tr> <tr> <td>Prothrombin time (seconds)</td> <td class=\"centered\">9.7 to 13.5</td> <td class=\"centered\">9.5 to 13.4</td> <td class=\"centered\">9.6 to 12.9</td> </tr> <tr> <td>Activated partial thromboplastin time&nbsp;(seconds)</td> <td class=\"centered\">23.0 to 38.9</td> <td class=\"centered\">22.9 to 38.1</td> <td class=\"centered\">22.6 to 35.0</td> </tr> <tr> <td>Platelet count (x10<sup>9</sup>/L)</td> <td class=\"centered\">174 to 391</td> <td class=\"centered\">155 to 409</td> <td class=\"centered\">146 to 429</td> </tr> <tr> <td>Fibrinogen (mg/dL)</td> <td class=\"centered\">244 to 510</td> <td class=\"centered\">291 to 538 </td> <td class=\"centered\">301 to 696</td> </tr> <tr> <td>D-dimer (micrograms/mL)</td> <td class=\"centered\">0.05 to 0.95</td> <td class=\"centered\">0.32 to 1.29</td> <td class=\"centered\">0.13 to 1.7</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Abbassi-Ghanavati M, Greer LG. Reference Table of Normal Laboratory Values in Uncomplicated Pregnancies. In: Cunningham FG, Leveno KJ, Bloom S, Hauth JC, Rouse DJ, Spong CY. Williams Obstetrics, 23rd Edition. New York: McGraw-Hill, 2010.</div><div id=\"graphicVersion\">Graphic 89013 Version 3.0</div></div></div>"},"89014":{"type":"graphic_table","displayName":"MSTS staging system for sarcomas","title":"Musculoskeletal Tumor Society (MSTS) staging system for sarcomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Musculoskeletal Tumor Society (MSTS) staging system for sarcomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Grade</td> </tr> <tr> <td>Stage IA</td> <td>Low grade, intracompartmental</td> </tr> <tr> <td>Stage IB</td> <td>Low grade, extracompartmental</td> </tr> <tr> <td>Stage IIA</td> <td>High grade, intracompartmental</td> </tr> <tr> <td>Stage IIB</td> <td>High grade, extracompartmental</td> </tr> <tr> <td>Stage III</td> <td>Systemic or regional metastases</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980; 153:106. Copyright &copy; 1980 Wolters Kluwer Health, Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 89014 Version 6.0</div></div></div>"},"89016":{"type":"graphic_table","displayName":"Normal reference range of laboratory tests in pregnant women","title":"Normal reference range of laboratory tests in pregnant women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal reference range of laboratory tests in pregnant women</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Test</td> <td class=\"subtitle1\" colspan=\"3\">Normal (reference) range</td> </tr> <tr> <td class=\"subtitle2\">First trimester</td> <td class=\"subtitle2\">Second trimester</td> <td class=\"subtitle2\">Third trimester</td> </tr> <tr> <td>Sodium (mEq/L)</td> <td class=\"centered\">135 to 139</td> <td class=\"centered\">131.8 to 136.2</td> <td class=\"centered\">134.6 to 137.4</td> </tr> <tr> <td>Potassium (mEq/L)</td> <td class=\"centered\">3.6 to 5.0</td> <td class=\"centered\">3.3 to 5.0</td> <td class=\"centered\">3.3 to 5.1</td> </tr> <tr> <td>Chloride (mEq/L)</td> <td class=\"centered\">101 to 105</td> <td class=\"centered\">97 to 109</td> <td class=\"centered\">97 to 109</td> </tr> <tr> <td>BUN (mg/dL)</td> <td class=\"centered\">7 to 12</td> <td class=\"centered\">3 to 13</td> <td class=\"centered\">3 to 11</td> </tr> <tr> <td>Creatinine (mg/dL)</td> <td class=\"centered\">0.4 to 0.7</td> <td class=\"centered\">0.4 to 0.8</td> <td class=\"centered\">0.4 to 0.9</td> </tr> <tr> <td>Calcium (mg/dL)</td> <td class=\"centered\">8.8 to 10.6</td> <td class=\"centered\">8.2 to 9.0</td> <td class=\"centered\">8.2 to 9.7</td> </tr> <tr> <td>Magnesium (mg/dL)</td> <td class=\"centered\">1.6 to 2.2</td> <td class=\"centered\">1.5 to 2.2</td> <td class=\"centered\">1.5 to 2.2</td> </tr> <tr> <td>Phosphate (mg/dL)</td> <td class=\"centered\">3.1 to 4.6</td> <td class=\"centered\">2.5 to 4.6</td> <td class=\"centered\">2.8 to 4.6</td> </tr> <tr> <td>Uric acid (mg/dL)</td> <td class=\"centered\">2.0 to 4.2</td> <td class=\"centered\">2.4 to 4.9 </td> <td class=\"centered\">3.1 to 6.3</td> </tr> <tr> <td>Albumin (g/dL)</td> <td class=\"centered\">3.1 to 5.1</td> <td class=\"centered\">2.6 to 4.5 </td> <td class=\"centered\">2.3 to 4.2</td> </tr> <tr> <td>24 hour protein excretion (mg)</td> <td class=\"centered\">19 to 141</td> <td class=\"centered\">47 to 186</td> <td class=\"centered\">46 to 185</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<DIV></DIV>&#xD;&#xA;<UL>&#xD;&#xA;<LI>Abbassi-Ghanavati M, Greer LG. Reference table of normal laboratory values in uncomplicated pregnancies. In: Williams Obstetrics, 23rd ed, Cunningham FG, Leveno KJ, Bloom S, Hauth JC, Rouse DJ, Spong CY (Eds), McGraw-Hill,&nbsp;New York 2010.</LI>&#xD;&#xA;<LI>Shakhmatova EI, Osipova NA, Natochin YV. Changes in osmolality and blood serum ion concentrations in pregnancy. Human Physiology 2000; 26:92.&nbsp;</LI></UL></div><div id=\"graphicVersion\">Graphic 89016 Version 3.0</div></div></div>"},"89023":{"type":"graphic_picture","displayName":"Infantile myofibromatosis","title":"Infantile myofibromatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Infantile myofibromatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:334px;\" src=\"images/DERM/89023_Infantile_myofibromatosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple scattered and disseminated 0.5 to 1.5 cm colorless rubbery subcutaneous nodules and red to violaceous dermal nodules in a newborn with myofibromatosis.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 89023 Version 3.0</div></div></div>"},"89025":{"type":"graphic_figure","displayName":"Paris classification of Crohns disease in children","title":"Paris classification of Crohns disease in children","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Paris classification of Crohns disease in children</div><div class=\"cntnt\"><img style=\"width:535px; height:645px;\" src=\"images/PEDS/89025_Paris_classification_Crohns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representation of the categories for location of intestinal disease used in the Paris classification of IBD in children, a modification of the Montreal classification used for adults. Upper GI disease (L4a/L4b) may coexist with lower GI disease (L1, L2 or L3). Disease location is based on macroscopic appearance of mucosal ulceration at endoscopy, or bowel wall thickening on radiography. The presence of mucosal erythema and/or granularity is not sufficient to be considered evidence of involvement. The Paris classification also incorporates categories for patient age, growth effects, and disease behavior (stricturing, penetrating, or neither).</div><div class=\"graphic_footnotes\">IBD: inflammatory bowel disease; GI: gastrointestinal.</div><div class=\"graphic_reference\">Data from: Levine A, Griffiths A, Markowitz J et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification. Inflamm Bowel Dis 2011; 17:1314.</div><div id=\"graphicVersion\">Graphic 89025 Version 2.0</div></div></div>"},"89028":{"type":"graphic_table","displayName":"Paris classification of Crohn disease in children","title":"Paris classification of Crohn disease in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Paris classification of Crohn disease in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Categories used in Montreal classification<br /> (adults)</td> <td class=\"subtitle1\">Modified categories used in Paris classification<br /> (children and adolescents)</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Age at diagnosis</strong></td> <td rowspan=\"2\">A1</td> <td>A1a</td> <td>0 to &#60;10 years</td> </tr> <tr> <td>A1b</td> <td>10 to &#60;17 years</td> </tr> <tr> <td>A2</td> <td>&nbsp;</td> <td>17 to 40 years</td> </tr> <tr class=\"divider_bottom\"> <td>A3</td> <td>&nbsp;</td> <td>&#62;40 years</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Location</strong></td> <td>L1</td> <td>&nbsp;</td> <td>Distal 1/3 of the ileum, with or without limited cecal disease</td> </tr> <tr> <td>L2</td> <td>&nbsp;</td> <td>Colonic</td> </tr> <tr> <td>L3</td> <td>&nbsp;</td> <td>Ileocolonic</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">L4</td> <td>L4a</td> <td>Upper GI disease, proximal to the Ligament of Treitz</td> </tr> <tr class=\"divider_bottom\"> <td>L4b</td> <td>Upper GI disease, between the Ligament of Treitz and the distal 1/3 of the ileum</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Behavior</strong></td> <td>B1</td> <td>&nbsp;</td> <td>Non-stricturing, non-penetrating</td> </tr> <tr> <td>B2</td> <td>&nbsp;</td> <td>Stricturing*</td> </tr> <tr> <td>B3</td> <td>&nbsp;</td> <td>Penetrating<sup>&#182;</sup></td> </tr> <tr> <td>&nbsp;</td> <td>B2B3</td> <td>Both penetrating and stricturing disease,*<sup>&#182;</sup> either at the same or different times</td> </tr> <tr class=\"divider_bottom\"> <td>P</td> <td>&nbsp;</td> <td>Perianal disease modifier</td> </tr> <tr> <td rowspan=\"2\"><strong>Growth</strong></td> <td>&nbsp;</td> <td>G<sub>0</sub></td> <td>No growth delay</td> </tr> <tr> <td>&nbsp;</td> <td>G<sub>1</sub></td> <td>Growth delay (impaired linear growth)<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The Paris classification of inflammatory bowel disease in children is a modification of the Montreal classification used for adults. This classification incorporates age categories within the pediatric range and includes categories for growth effects. In both the Montreal and Paris classification systems, upper GI disease (L4 and L4a/L4b) may coexist with lower GI disease (L1, L2, or L3). Disease extent is based on macroscopic appearance of mucosal ulceration, or bowel wall thickening on radiography. The presence of mucosal erythema and/or granularity is not sufficient to be considered evidence of involvement.</div><div class=\"graphic_footnotes\">GI: gastrointestinal.<br />* Stricturing disease refers to constant luminal narrowing demonstrated by radiologic, endoscopic or surgical examination, combined with prestenotic dilation and/or obstructive signs or symptoms.<br />&para; Penetrating disease refers to bowel perforation, intra-abdominal fistulas, inflammatory masses and/or abscesses at any time in the course of the disease, and not a secondary postoperative intra-abdominal complication. This excludes isolated perianal or rectovaginal fistulae.<br />&Delta; Impaired linear growth is manifested by either height Z-score at diagnosis that is significantly less than expected, or a significant reduction in height Z-score since diagnosis.</div><div class=\"graphic_reference\">Modified with permission from: Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification. Inflamm Bowel Dis 2011; 17:1314. DOI: <a href=\"http://journals.lww.com/ibdjournal/pages/articleviewer.aspx?year=2011&amp;issue=06000&amp;article=00009&amp;type=abstract\" target=\"_blank\">10.1002/ibd.21493</a>. Copyright &copy; 2011 Crohn's and Colitis Foundation of America, Inc. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 89028 Version 8.0</div></div></div>"},"89029":{"type":"graphic_table","displayName":"Paris classification of ulcerative colitis in children","title":"Paris classification of ulcerative colitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Paris classification of ulcerative colitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Categories used in Montreal classification<br /> (adults)</td> <td class=\"subtitle1\">Modified categories used in Paris classification<br /> (children and adolescents)</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Age at diagnosis</strong></td> <td rowspan=\"2\">A1</td> <td>A1a</td> <td>0 to &#60;10 years</td> </tr> <tr> <td>A1b</td> <td>10 to &#60;17 years</td> </tr> <tr> <td>A2</td> <td>&nbsp;</td> <td>17 to 40 years</td> </tr> <tr class=\"divider_bottom\"> <td>A3</td> <td>&nbsp;</td> <td>&#62;40 years</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Location</strong></td> <td>E1</td> <td>&nbsp;</td> <td>Ulcerative proctitis</td> </tr> <tr> <td>E2</td> <td>&nbsp;</td> <td>Left-sided ulcerative colitis (extending distal to the splenic flexure)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">E3</td> <td>E3</td> <td>Extensive (extending distally from the hepatic flexure)</td> </tr> <tr class=\"divider_bottom\"> <td>E4</td> <td>Pancolitis (including areas proximal to the hepatic flexure)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Severity</strong></td> <td>&nbsp;</td> <td>S0</td> <td>Never severe*</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>S1</td> <td>Ever severe*</td> </tr> <tr> <td rowspan=\"2\"><strong>Growth</strong></td> <td>&nbsp;</td> <td>G<sub>0</sub></td> <td>No growth delay</td> </tr> <tr> <td>&nbsp;</td> <td>G<sub>1</sub></td> <td>Growth delay (impaired linear growth)<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The Paris classification of inflammatory bowel disease in children is a modification of the Montreal classification used for adults. This classification incorporates age categories within the pediatric range and includes categories for growth effects. Disease extent is defined using macroscopic appearance rather than evidence from histology or radiology.</div><div class=\"graphic_footnotes\">* \"Severe\" is defined by a Pediatric Ulcerative Colitis Activity Index (PUCAI) &ge;65.<br />&para; Impaired linear growth is manifested by either height Z-score at diagnosis that is significantly less than expected, or a significant reduction in height Z-score since diagnosis.</div><div class=\"graphic_reference\">Modified with permission from: Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification. Inflamm Bowel Dis 2011; 17:1314. DOI: <a href=\"http://journals.lww.com/ibdjournal/pages/articleviewer.aspx?year=2011&amp;issue=06000&amp;article=00009&amp;type=abstract\" target=\"_blank\">10.1002/ibd.21493</a>. Copyright &copy; 2011 Crohn's and Colitis Foundation of America, Inc. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 89029 Version 7.0</div></div></div>"},"89030":{"type":"graphic_table","displayName":"Quick overview of initial management of pregnant women in DIC","title":"Quick overview of the components of management of the pregnant woman in DIC","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Quick overview of the components of management of the pregnant woman in DIC</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Notify staff and services that will or may be needed: anesthesia, blood bank, surgery (eg, obstetrics, pelvic surgery, maternal fetal medicine, gynecologic oncology, interventional radiology, and/or general surgery), neonatology</td> </tr> <tr> <td>Place at least two large bore (&#8805;18 gauge) catheters</td> </tr> <tr> <td>Administer crystalloid with or without colloid, blood, and blood products, as needed. O-negative red blood cells, group AB fresh frozen plasma, and lyophilized fibrinogen can be given immediately and continued until the type and cross-match is complete, at which point the patient should be switched to type-specific fresh frozen plasma and cross-match compatible red blood cells. Try to keep hemoglobin above 10 g/dL, fibrinogen level above 200 mg/dL, platelet count above 50,000/microL, and PT and PTT &#60;1.5 times control.</td> </tr> <tr> <td>Maintain oxygen saturation above 95 percent</td> </tr> <tr> <td>Keep the patient warm</td> </tr> <tr> <td>Identify and begin treatment of the triggering event</td> </tr> <tr> <td>Order laboratory panel to assess coagulation (PT, aPTT, fibrinogen); draw 5 mL blood in a red top tube and observe clot formation over 8 to 10 minutes</td> </tr> <tr> <td>&nbsp;Order baseline laboratory panel: CBC, BUN, creatinine, liver function tests</td> </tr> <tr> <td>Assess fetal status (gestational age, fetal heart rate)</td> </tr> <tr> <td>Assess maternal condition (blood loss, hemodynamic stability, uterine contractions, cervical status)</td> </tr> <tr> <td>Appropriate personnel, equipment, and supplies (eg, pelvic pack) should be available if hysterectomy is being considered</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count, PT: prothrombin time, aPTT: activated partial thromboplastin time, BUN: blood urea nitrogen</div><div id=\"graphicVersion\">Graphic 89030 Version 6.0</div></div></div>"},"89032":{"type":"graphic_picture","displayName":"Dactylitis in yaws","title":"Dactylitis in yaws","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dactylitis in yaws</div><div class=\"cntnt\"><img style=\"width:428px; height:572px;\" src=\"images/DERM/89032_Dactylitis_in_yaws.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Swelling of the second digit of a patient with yaws.</div><div class=\"graphic_reference\">Courtesy of Oriol Mitj&agrave;, MD.</div><div id=\"graphicVersion\">Graphic 89032 Version 1.0</div></div></div>"},"89033":{"type":"graphic_picture","displayName":"Yaws histopathology and immunohistochemistry","title":"Yaws","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Yaws</div><div class=\"cntnt\"><img style=\"width:572px; height:428px;\" src=\"images/DERM/89033_Yaws_histopth_immunohstochm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Micrographs of tissue specimens from patients with yaws. Immunohistochemistry with anti-<EM>Treponema pallidum</EM> antibodies (x1000) shows numerous spiral-shaped organisms in the spinous layer of the epidermis.</div><div class=\"graphic_reference\">Courtesy of Elizabeth Satter, Naval Medical Center San Diego, US, and Kevin Whitehead, Sullivan Nicolaides Pathology, Australia.</div><div id=\"graphicVersion\">Graphic 89033 Version 2.0</div></div></div>"},"89034":{"type":"graphic_picture","displayName":"Yaws osteoperiostitis","title":"Yaws osteoperiostitis","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Yaws osteoperiostitis</div><div class=\"cntnt\"><img style=\"width:488px; height:572px;\" src=\"images/DERM/89034_Yaws_osteoperiostitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of clarity of the cortex of the distal radius and ulna and organized periosteal reaction (widespread \"onion layering\") in a patient with secondary yaws.</div><div class=\"graphic_reference\">Courtesy of Oriol Mitj&agrave;, MD.</div><div id=\"graphicVersion\">Graphic 89034 Version 1.0</div></div></div>"},"89035":{"type":"graphic_algorithm","displayName":"Cutaneous porphyria blistering algorithm","title":"Algorithm for distinguishing blistering cutaneous porphyrias","html":"<div class=\"graphic\"><div style=\"width: 972px\" class=\"figure\"><div class=\"ttl\">Algorithm for distinguishing blistering cutaneous porphyrias</div><div class=\"cntnt\"><img style=\"width:952px; height:594px;\" src=\"images/HEME/89035_Cutaneous_porphyria_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm outlines an approach to the patient with suspected cutaneous porphyria and blistering photosensitivity. Fractionation of porphyrins is accompanied by determination of the plasma fluorescence peak wavelength at neutral pH. Separate algorithms are available for the patient with suspected cutanous porphyria with non-blistering photosentitivity, and the patient with suspected acute (neurovisceral) porphyria. Refer to UpToDate topics on individual porphyrias for further discussions of the clinical manifestations and diagnostic evaluation.</div><div class=\"graphic_footnotes\">ALA: delta-aminolevulinic acid; PBG: porphobilinogen; PCT: porphyria cutanea tarda; <em>UROD</em>: uroporphyrinogen decarboxylase; HCP: hereditary coproporphyria; <em>CPOX</em>: coproporphyrinogen oxidase; VP: variegate porphyria; <em>PPOX</em>: protoporphyrin oxidase; CEP: congenital erythropoietic porphyria; <em>UROS</em>: uroporphyrinogen III synthase; HEP: hepatoerythropoietic porphyria.<br />* We perform gene sequencing of the relevant gene for all cutaneous porphyrias diagnosed biochemically; this may be used for further confirmation of the diagnosis, identification of new mutations, and in some cases genetic counseling. For PCT, <em>UROD</em> gene sequencing often does not reveal a mutation; the presence of heterozygous <em>UROD</em> mutation is consistent with familial (type 2) PCT. For the other porphyrias, mutation of the associated gene is expected, and if no mutation is identified, this suggests mutation in a cryptic site, non-coding region, or regulatory gene.</div><div id=\"graphicVersion\">Graphic 89035 Version 4.0</div></div></div>"},"89036":{"type":"graphic_table","displayName":"Diagnostic testing for active porphyrias","title":"Diagnostic testing for active porphyrias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic testing for active porphyrias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Concurrent or recent clinical manifestations</td> <td class=\"subtitle1\">Initial testing</td> <td class=\"subtitle1\">Additional testing (if initial&nbsp;results are&nbsp;positive)</td> <td class=\"subtitle1\">Types of porphyria identified</td> <td class=\"subtitle1\">Enzyme and DNA tests</td> </tr> <tr> <td rowspan=\"4\">Acute neurovisceral</td> <td rowspan=\"4\">Spot urine PBG, ALA, and total porphyrins</td> <td rowspan=\"4\"> <p>Spot urine ALA, PBG,&nbsp;and total porphyrins (quantitative)</p> <p>Plasma porphyrins*</p> <p>Erythrocyte porphyrins<sup>&#182;</sup></p> Fecal porphyrins</td> <td>5-aminolevulinic acid dehydratase porphyria (ADP)</td> <td> <p>Erythrocyte ALAD</p> Sequence <em>ALAD</em> gene</td> </tr> <tr> <td>Acute intermittent porphyria (AIP)</td> <td> <p>Erythrocyte PBGD</p> Sequence <em>PBGD</em> gene</td> </tr> <tr> <td>Hereditary coproporphyria (HCP)</td> <td>Sequence <em>CPOX</em> gene</td> </tr> <tr> <td>Variegate porphyria (VP)</td> <td>Sequence <em>PPOX </em>gene</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Blistering photosensitivity</td> <td rowspan=\"5\">Total porphyrins (plasma*, serum, or spot urine), with fractionation if elevated</td> <td rowspan=\"5\"> <p>Measurement of erythrocyte total porphyrins</p> <p>Measurement of urinary ALA and PBG</p> <p>Measurement of fecal total porphyrins</p> </td> <td>Porphyria cutanea tarda (PCT)</td> <td> <p>Erythrocyte UROD</p> Sequence <em>UROD</em> gene<sup>&#916;</sup></td> </tr> <tr> <td>Hepatoerythropoietic porphyria (HEP)</td> <td> <p>Erythrocyte UROD</p> Sequence <em>UROD</em> gene</td> </tr> <tr> <td>HCP</td> <td>Sequence <em>CPOX</em> gene</td> </tr> <tr> <td>VP</td> <td>Sequence <em>PPOX </em>gene</td> </tr> <tr> <td>Congenital erythropoietic porphyria (CEP)</td> <td> <p>Erythrocyte UROS</p> Sequence <em>UROS</em> gene</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Nonblistering photosensitivity</td> <td rowspan=\"2\">Total erythrocyte porphyrins<sup>&#182;</sup></td> <td rowspan=\"2\">Erythrocyte metal-free and zinc protoporphyrin; plasma total porphyrins and fluorescence scan</td> <td>Erythropoietic protoporphyria (EPP)</td> <td>Sequence <em>FECH</em> gene</td> </tr> <tr> <td>X-linked protoporphyria (XLP)</td> <td>Sequence <em>ALAS2</em> gene</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">First-line testing for symptomatic patients&nbsp;is guided by clinical features (ie, neurovisceral, cutaneous blistering, or cutaneous nonblistering). If initial testing is positive, further comprehensive testing follows to identify the type of acute porphyria. Enzyme measurements (not available for all porphyrias) and DNA testing to identify the familial mutation are important after the type of porphyria is established. Refer to UpToDate topics on overview of porphyria and specific porphyrias for additional details and testing in asymptomatic patients.</div><div class=\"graphic_footnotes\">PBG: porphobilinogen; ALA: delta-aminolevulinic acid; ADP: delta-aminolevulinic acid dehydratase porphyria; ALAD: delta-aminolevulinic acid dehydratase; PBGD: porphobilinogen deaminase; CPOX: coproporphyrinogen oxidase; PPOX: protoporphyrin oxidase; UROD: uroporphyrinogen decarboxylase; UROS: uroporphyrinogen III synthase; FECH: ferrochelatase; ALAS2: delta-aminolevulinate synthase-2.<br />* Plasma porphyrins should include measurement of the total, fractionation if the total is elevated, and determination of the fluorescence peak wavelength at neutral pH.<br />¶&nbsp;It is important to verify&nbsp;that the method used by the laboratory measures all erythrocyte porphyrins and not just zinc protoporphyrin.<br />Δ<SUP> </SUP>UROD mutations are neither required nor specific for a&nbsp;diagnosis of PCT.&nbsp;UROD mutations are&nbsp;found in approximately 20 percent of patients with PCT and therefore are&nbsp;helpful if present. The presence of a UROD mutation is a predisposing factor but not sufficient to cause PCT.</div><div id=\"graphicVersion\">Graphic 89036 Version 10.0</div></div></div>"},"89037":{"type":"graphic_figure","displayName":"Skyla insertion device","title":"Skyla insertion device","html":"<div class=\"graphic\"><div style=\"width: 936px\" class=\"figure\"><div class=\"ttl\">Skyla insertion device</div><div class=\"cntnt\"><img style=\"width:916px; height:469px;\" src=\"images/OBGYN/89037_Skyla_insertion_device.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 Bayer HealthCare Pharmaceuticals Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89037 Version 1.0</div></div></div>"},"89038":{"type":"graphic_figure","displayName":"Pancoast ","title":"Pancoast syndrome","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Pancoast syndrome</div><div class=\"cntnt\"><img style=\"width:458px; height:495px;\" src=\"images/ONC/89038_Pancoast.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 89038 Version 1.0</div></div></div>"},"89039":{"type":"graphic_table","displayName":"OAS PI","title":"Oral allergy syndrome (OAS, also called pollen-food allergy syndrome [PFAS])","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral allergy syndrome (OAS, also called pollen-food allergy syndrome [PFAS])</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">If you are allergic to:</td> <td class=\"subtitle1\">You may get OAS symptoms when eating:</td> </tr> <tr> <td>Birch tree pollen</td> <td> <p>Apple, peach, plum, pear, cherry, apricot</p> <p>Carrot, celery</p> <p>Parsley, caraway, fennel, coriander, aniseed</p> Hazelnut, peanut, soybean</td> </tr> <tr> <td>Ragweed pollen</td> <td>Melons (cantaloupe, honeydew, watermelon), banana</td> </tr> <tr> <td>Grass pollen</td> <td> <p>Melons (cantaloupe, honeydew, watermelon), orange</p> <p>Tomato, swiss chard</p> <p>Peanut</p> Also: Hands may itch and become red if peeling/handling raw white potatoes</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89039 Version 2.0</div></div></div>"},"89041":{"type":"graphic_picture","displayName":"NICH 10 years","title":"Noninvoluting congenital hemangioma (NICH)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Noninvoluting congenital hemangioma (NICH)</div><div class=\"cntnt\"><img style=\"width:419px; height:504px;\" src=\"images/DERM/89041_NICH_10_years.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An 8 cm diameter soft compressible blue subcutaneous mass with overlying coarse telangiectasias and surrounding pallor on the arm of a 10-year-old girl. This soft-tissue mass was unchanged since birth.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 89041 Version 3.0</div></div></div>"},"89042":{"type":"graphic_picture","displayName":"CEP sun-induced skin lesions","title":"Sun-induced skin lesions in congenital erythropoietic porphyria (CEP)","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Sun-induced skin lesions in congenital erythropoietic porphyria (CEP)</div><div class=\"cntnt\"><img style=\"width:580px; height:229px;\" src=\"images/HEME/89042_CEP_sun_induced_skin_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A severely affected CEP patient who has had multiple sun-induced skin lesions. The cutaneous bullae and vesicles burst and became secondarily infected, leading to bone involvement and resultant loss of facial features and digits.</div><div class=\"graphic_reference\">Reproduced with of American Society of Hematology, from: Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Blood 2012; 120:4496; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 89042 Version 5.0</div></div></div>"},"89043":{"type":"graphic_picture","displayName":"CEP erythrodontia","title":"Erythrodontia in congenital erythropoietic porphyria (CEP)","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Erythrodontia in congenital erythropoietic porphyria (CEP)</div><div class=\"cntnt\"><img style=\"width:492px; height:371px;\" src=\"images/HEME/89043_CEP_erythrodontia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brownish discolored teeth fluoresce (erythrodontia) when exposed to ultraviolet light. The erythrodontia is the result of the accumulation of uroporphyrin I and coproporphyrin I in the patient's teeth.</div><div class=\"graphic_reference\">Reproduced with of American Society of Hematology, from: Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Blood 2012; 120:4496; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 89043 Version 5.0</div></div></div>"},"89044":{"type":"graphic_picture","displayName":"CEP porphyrinuria","title":"Porphyrinuria in congenital erythropoietic porphyria (CEP)","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Porphyrinuria in congenital erythropoietic porphyria (CEP)</div><div class=\"cntnt\"><img style=\"width:471px; height:370px;\" src=\"images/HEME/89044_CEP_porphyrinuria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine from a CEP patient that fluoresces red under ultraviolet light (left) and from a healthy person (right).</div><div class=\"graphic_reference\">Reproduced with of American Society of Hematology, from: Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Blood 2012; 120:4496; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 89044 Version 5.0</div></div></div>"},"89045":{"type":"graphic_table","displayName":"Treatment options for children with ITP","title":"First- and second-line treatment options for children with immune thrombocytopenia (ITP)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">First- and second-line treatment options for children with immune thrombocytopenia (ITP)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Initial response* (days)<sup>[1]</sup></td> <td class=\"subtitle1\">Peak response<sup>&#182;</sup> (days)<sup>[1]</sup></td> <td class=\"subtitle1\">Initial response rate</td> <td class=\"subtitle1\">Toxicities/risks</td> <td class=\"subtitle1\">Sustained response</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">First-line options for newly diagnosed or persistent ITP</td> </tr> <tr> <td class=\"indent1\">Watchful waiting</td> <td>A few days to 3 to 6 months</td> <td>&nbsp;</td> <td>Spontaneous complete remission occurs in 50 percent within one month of presentation, and 75 percent by six months</td> <td>Risk of preventable hemorrhage (low risk); need for activity restriction; familial anxiety.</td> <td>Relapse after spontaneous remission is unlikely.</td> </tr> <tr> <td class=\"indent1\"> <p>IVIG<sup>&#916;</sup></p> <p>Life-threatening bleeding: 1 gram/kg per day IV for one to three days</p> <p>&nbsp;</p> <p>Non-life-threatening bleeding: 0.8 to 1 gram/kg IV, as a single dose</p> </td> <td>1 to 3</td> <td>2 to 7</td> <td>Initially effective in &#62;80 percent of patients</td> <td> <p>Side effects include headache (can be severe, [eg, aseptic meningitis]); nausea, vomiting, fever, chills, body aches. These can be minimized&nbsp;with premedication and prolonging infusion time.<sup>&#916;</sup> </p> Transient neutropenia also may occur.</td> <td>One-third of patients fall below acceptable platelet threshold after two to six weeks.</td> </tr> <tr> <td class=\"indent1\"> <p>Anti-D<sup>&#916;</sup><sup>&#9674;</sup></p> 75 micrograms/kg IV, as a single dose</td> <td>1 to 3</td> <td>3 to 7</td> <td>Initially effective in&nbsp;70 to 80&nbsp;percent</td> <td> <p>Headache (less common than with IVIG), fever, chills, nausea and vomiting. Side effects may be reduced with premedication.<sup>&#916;</sup></p> <p>Mild hemolysis is common (eg, fall in hemoglobin by 1 to 2 g/dL). DIC and severe hemolysis or renal failure may rarely occur.</p> <p>Anti-D is contraindicated in patients who are Rh-negative or DAT-positive, or&nbsp;have had splenectomy.</p> </td> <td> <p>Similar to IVIG, although longer responses have been described with repeat dosing.</p> </td> </tr> <tr> <td class=\"indent1\"> <p>Methylprednisolone</p> <p>30 mg/kg as a single daily dose IV for 3 to 4 days</p> <p>(maximum 1000 mg per day) </p> </td> <td>2 to 14&nbsp;&nbsp;</td> <td>7 to 28</td> <td>Initially effective in&nbsp;75 to 80&nbsp;percent</td> <td>Behavioral change, sleep disturbance, hypertension, impaired glucose tolerance. </td> <td>In one-quarter to one-third of patients, platelet counts fall below acceptable thresholds after two to six weeks.</td> </tr> <tr> <td class=\"indent1\"> <p>Prednisone</p> <p>4 mg/kg per day orally for&nbsp;7 days, followed by rapid tapering<sup>&#167;</sup></p> (maximum 240 mg/day)</td> <td>4 to 14</td> <td>7 to 28</td> <td>Initially effective in up to 75 percent</td> <td> <p>Same as for&nbsp;methylprednisolone above.</p> <p>Prolonged usage may cause weight gain, osteopenia, cataracts, and growth failure.</p> </td> <td>In many patients, platelet counts fall below acceptable platelet thresholds after tapering, unless the course of prednisone is prolonged.</td> </tr> <tr> <td class=\"indent1\"> <p>Dexamethasone</p> <p>24 mg/m<sup>2</sup> for&nbsp;4 days orally or IV<sup>&#167;</sup></p> (maximum 40 mg/day)</td> <td>2 to 14</td> <td>4 to 28</td> <td>Initially effective in up to 75 percent</td> <td>Same as for&nbsp;methylprednisolone above.</td> <td>In one-third of patients, platelet counts fall below acceptable thresholds after two to six weeks.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Second-line options for chronic ITP</td> </tr> <tr> <td class=\"indent1\"> <p>Rituximab<sup>[3]</sup></p> 375 mg/m<sup>2</sup> weekly for four weeks</td> <td>7 to 56</td> <td>14 to 180</td> <td>Initial response in 40 to 50 percent</td> <td>Urticarial rash, headache, fever, and chills (mild and transient). Serum sickness in up to 10 percent of children.</td> <td>25 percent long-term response (two or more years after treatment).</td> </tr> <tr> <td class=\"indent1\">Thrombopoietin receptor agonists (eg, eltrombopag<sup>[4]</sup>, romiplostim<sup>[5]</sup>)<sup>&#165;</sup></td> <td>&nbsp;5 to 7</td> <td>&nbsp;Not established</td> <td>Approximately 80 percent of patients achieve a response</td> <td>Transaminitis, mild respiratory illness, headache, epistaxis, cataract (rare)</td> <td>The response lasts only as long as the drug is continued; these drugs do <strong>not</strong> typically induce remission.</td> </tr> <tr> <td class=\"indent1\">Splenectomy</td> <td>1 to 56</td> <td>7 to 56</td> <td>60 to 70 percent long-term response</td> <td>Complications include sepsis and portal vein thrombosis.</td> <td>70 to 80 percent of responders maintain platelet response over four years.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topic on the treatment of ITP in children for details of our approach to the initial and subsequent treatment of ITP and the overall efficacy of these treatments.</div><div class=\"graphic_footnotes\">IVIG: intravenous immune globulin; Anti-D: anti-Rho (D) immunoglobulin; IV: intravenously; DIC: disseminated intravascular coagulation; DAT: direct antiglobulin test (also known as direct Coombs test).<br />* Initial response is the first time that a response could be reasonably expected.<br />¶ Peak response is the time after which a response becomes less likely at typically used doses. These data do not address the quality of the response (ie, absolute platelet count reached or percent increase from baseline) or the likelihood of a response for any given treatment.<br />Δ When treating with either IVIG or anti-D,&nbsp;acetaminophen and/or diphenhydramine&nbsp;may be administered as premedication to minimize side effects. In our practice, we also co-administer a single dose of methylprednisolone 30 mg/kg (up to 1 gram maximum), to increase efficacy and to minimize side effects (especially headache).<br /><FONT class=lozenge>◊</FONT> Anti-D should <STRONG>not</STRONG> be used in in patients who are Rh-negative or those with a positive direct antiglobulin test (DAT, previously called Coombs test), unless this result is attributable to recent administration of anti-D. Anti-D should generally not be used in splenectomized patients because it is not effective in this group. However, in patients with severe bleeding, anti-D&nbsp;may be a useful part of combination therapy, even in splenectomized patients despite its relative lack of efficacy when used as the sole agent in these patients. Anti-D should be used with care in patients with substantial comorbidities or who have evidence of anemia or hemolysis.&nbsp; <br />§ For treatment with glucocorticoids, a variety of regimens have been used effectively. In our practice, we generally administer glucocorticoids as a short course at a very high dose, to minimize toxicity associated with long-term use and because of a potentially more rapid onset of action. Refer to UpToDate topics on management of ITP in children for additional details.<br />¥ Thrombopoietin receptor agonists are not established treatments for children with ITP. Pediatric dosing has not been established. Refer to UpToDate topics on treatment of ITP in children for additional details.</div><div class=\"graphic_reference\">Additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117:4190.</LI>&#xD;&#xA;<LI>Beck CE, Nathan PC, Parkin PC, et al. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr 2005; 147:521.</LI>&#xD;&#xA;<LI>Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012; 119:5989.</LI>&#xD;&#xA;<LI>Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 2015; 386:1649. </LI>&#xD;&#xA;<LI>Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011; 118:28.</LI></OL>Adapted from: Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168.</div><div id=\"graphicVersion\">Graphic 89045 Version 8.0</div></div></div>"},"89046":{"type":"graphic_table","displayName":"Overview of contraceptive methods","title":"Overview of contraceptive methods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of contraceptive methods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Characteristics</td> <td class=\"subtitle1\">Copper IUD</td> <td class=\"subtitle1\">Levonorgestrel-releasing IUD</td> <td class=\"subtitle1\">Contraceptive pill, patch, or ring</td> <td class=\"subtitle1\">Etonogestrel implant</td> <td class=\"subtitle1\">DMPA</td> <td class=\"subtitle1\">Male condom</td> <td class=\"subtitle1\">Diaphragm</td> </tr> <tr> <td>Pregnancy rate in the first year of use in a typical patient</td> <td>&#60;1</td> <td>&#60;1</td> <td>9</td> <td>&#60;1</td> <td>6</td> <td>18</td> <td>12</td> </tr> <tr> <td>Duration of efficacy</td> <td>10 years</td> <td>Three to&nbsp;five years (depending on type)</td> <td>Use daily (pill), weekly (patch), monthly (ring)</td> <td>Three&nbsp;years</td> <td>12 weeks</td> <td>Single use at the time of each coital act</td> <td>Reusable. Must be inserted before coitus and used with a spermicidal cream/gel.</td> </tr> <tr> <td>Hormonal exposure</td> <td>None</td> <td>Progestin</td> <td>Estrogen and progestin</td> <td>Progestin</td> <td>Progestin</td> <td>None</td> <td>None</td> </tr> <tr> <td>Effect on menses</td> <td>May be heavier</td> <td>Lighter, irregular especially in first three to six months</td> <td>Lighter, regular predictable withdrawal bleeding with cyclic use</td> <td>Lighter, irregular</td> <td>Lighter, irregular</td> <td>None</td> <td>None</td> </tr> <tr> <td>Unscheduled bleeding/spotting</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>No</td> <td>No</td> </tr> <tr> <td>Not a good choice for otherwise healthy women* with:</td> <td>Heavy or painful periods, iron deficiency anemia, severe distortion of uterine cavity, copper allergy or Wilson's disease, active pelvic infection</td> <td>Severe distortion of uterine cavity, active pelvic infection, poor tolerance of amenorrhea or unscheduled bleeding, sensitive to hormonal side effects</td> <td>Contraindications to using exogenous estrogen or who are sensitive to estrogen-related side effects (eg, nausea, breast tenderness, headache, etc), women over 35 years who smoke</td> <td>Poor tolerance of amenorrhea or unscheduled bleeding</td> <td>Poor tolerance of amenorrhea or unscheduled bleeding or known preexisting low bone mineral density, or who want to get pregnant quickly upon discontinuation</td> <td>Sensitivity or allergy to latex (non-latex condoms are available), male partner who won't use the method</td> <td>Sensitivity or allergy to latex (non-latex diaphragms are available), pelvic relaxation, difficulty with insertion or care of the diaphragm</td> </tr> <tr> <td>Access</td> <td>Must be inserted and removed by a clinician</td> <td>Must be inserted and removed by a clinician</td> <td>Prescription</td> <td>Must be inserted and removed through a tiny skin incision by a clinician with special training</td> <td>Injection by a clinician</td> <td>Over-the-counter</td> <td>Prescription</td> </tr> <tr> <td>Selected adverse events</td> <td>Uterine perforation, expulsion, increased risk of pelvic infection in the first 20 days after insertion</td> <td>Uterine perforation, expulsion, increased risk of pelvic infection in the first 20 days after insertion</td> <td>Increased risk of venous thrombosis, hepatic adenoma</td> <td>Infection or scarring at insertion/removal site, difficult removal</td> <td>May cause weight gain mood changes, and osteopenia (with long-term use)</td> <td>Condom may break</td> <td>May increase risk of urinary tract infection</td> </tr> <tr> <td>Selected advantages</td> <td>Highly effective long-acting method that can be used by women who must or choose to avoid exogenous hormones</td> <td>Reduction in menorrhagia,&nbsp;dysmenorrhea, and endometrial hyperplasia</td> <td>Benefits of estrogen include a reduction in dysmenorrhea, menorrhagia, acne vulgaris, and vasomotor symptoms (perimenopausal women)</td> <td>Highly effective long-acting method that can be used by women who must or choose to avoid estrogen</td> <td>Effective prolonged contraception that can be used by women who must or choose to avoid estrogen</td> <td>Best protection against sexually transmitted infections</td> <td>Low cost and reusable</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">IUD: intrauterine device; DMPA: depot medroxyprogesterone acetate.</div><div class=\"graphic_footnotes\">* For women with current or prior medical disorders, refer to a resource such as United States Medical Eligibility Criteria for Contraceptive Use (USMEC) (available at <A href=\"http://www.cdc.gov/\" target=_blank>www.cdc.gov</A>).</div><div id=\"graphicVersion\">Graphic 89046 Version 6.0</div></div></div>"},"89047":{"type":"graphic_table","displayName":"Bleeding severity in childhood ITP","title":"Grading of severity of bleeding symptoms in children with immune thrombocytopenia (ITP)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading of severity of bleeding symptoms in children with&nbsp;immune thrombocytopenia (ITP)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade (international consensus report)<sup>[1]</sup></td> <td class=\"subtitle1\">Bleeding severity</td> <td class=\"subtitle1\">Clinical symptoms</td> </tr> <tr> <td>Grade I</td> <td>Minor/minimal</td> <td>Few petechiae (&#8804;100 total) and/or &#8804;5 small bruises (&#8804;3 cm in diameter)</td> </tr> <tr> <td>Grade II</td> <td>Mild</td> <td>Many petechiae (&#62;100 total) and/or &#62;5 large bruises (&#62;3 cm in diameter)</td> </tr> <tr> <td>Grade III</td> <td>Moderate</td> <td>Mucosal bleeding (\"wet purpura\") that does not require immediate medical attention or supervision, such as brief epistaxis, intermittent gum bleeding, menorrhagia, and/or a lifestyle that increases bleeding risks</td> </tr> <tr> <td rowspan=\"2\">Grade IV</td> <td>Severe</td> <td>Mucosal bleeding or suspected internal hemorrhage that requires immediate medical attention (eg, severe&nbsp;GI&nbsp;bleeding, severe prolonged epistaxis, pulmonary hemorrhage,&nbsp;muscle or joint hemorrhage)</td> </tr> <tr> <td>Life-threatening</td> <td>Documented intracranial hemorrhage or life-threatening or fatal hemorrhage in any site</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This approach to grading bleeding severity in children with ITP is based on the international consensus report.<SUP>[1]</SUP></div><div class=\"graphic_footnotes\">GI: gastrointestinal.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168.</LI></OL></div><div id=\"graphicVersion\">Graphic 89047 Version 4.0</div></div></div>"},"89061":{"type":"graphic_table","displayName":"Expectation of life in the United States 2010","title":"Expectation of life by age, race, Hispanic origin, race for the non-Hispanic population, and sex: United States, 2010","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expectation of life by age, race, Hispanic origin, race for the non-Hispanic population, and sex: United States, 2010</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"19\" width=\"5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age (years)</td> <td class=\"subtitle1\" colspan=\"3\">All races and origins</td> <td class=\"subtitle1\" colspan=\"3\">White</td> <td class=\"subtitle1\" colspan=\"3\">Black</td> <td class=\"subtitle1\" colspan=\"3\">Hispanic</td> <td class=\"subtitle1\" colspan=\"3\">Non-Hispanic white</td> <td class=\"subtitle1\" colspan=\"3\">Non-Hispanic black</td> </tr> <tr> <td class=\"subtitle2\">Total</td> <td class=\"subtitle2\">Male</td> <td class=\"subtitle2\">Female</td> <td class=\"subtitle2\">Total</td> <td class=\"subtitle2\">Male</td> <td class=\"subtitle2\">Female</td> <td class=\"subtitle2\">Total</td> <td class=\"subtitle2\">Male</td> <td class=\"subtitle2\">Female</td> <td class=\"subtitle2\">Total</td> <td class=\"subtitle2\">Male</td> <td class=\"subtitle2\">Female</td> <td class=\"subtitle2\">Total</td> <td class=\"subtitle2\">Male</td> <td class=\"subtitle2\">Female</td> <td class=\"subtitle2\">Total</td> <td class=\"subtitle2\">Male</td> <td class=\"subtitle2\">Female</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">65</td> <td class=\"centered\">19.4</td> <td class=\"centered\">18.0</td> <td class=\"centered\">20.6</td> <td class=\"centered\">19.4</td> <td class=\"centered\">18.0</td> <td class=\"centered\">20.6</td> <td class=\"centered\">18.2</td> <td class=\"centered\">16.4</td> <td class=\"centered\">19.7</td> <td class=\"centered\">21.5</td> <td class=\"centered\">19.7</td> <td class=\"centered\">22.8</td> <td class=\"centered\">19.3</td> <td class=\"centered\">18.0</td> <td class=\"centered\">20.5</td> <td class=\"centered\">18.1</td> <td class=\"centered\">16.3</td> <td class=\"centered\">19.5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">70</td> <td class=\"centered\">15.7</td> <td class=\"centered\">14.5</td> <td class=\"centered\">16.7</td> <td class=\"centered\">15.7</td> <td class=\"centered\">14.5</td> <td class=\"centered\">16.6</td> <td class=\"centered\">14.9</td> <td class=\"centered\">13.3</td> <td class=\"centered\">16.1</td> <td class=\"centered\">17.6</td> <td class=\"centered\">16.0</td> <td class=\"centered\">18.7</td> <td class=\"centered\">15.6</td> <td class=\"centered\">14.4</td> <td class=\"centered\">16.6</td> <td class=\"centered\">14.8</td> <td class=\"centered\">13.2</td> <td class=\"centered\">16.0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">75</td> <td class=\"centered\">12.3</td> <td class=\"centered\">11.2</td> <td class=\"centered\">13.1</td> <td class=\"centered\">12.2</td> <td class=\"centered\">11.2</td> <td class=\"centered\">13.0</td> <td class=\"centered\">11.9</td> <td class=\"centered\">10.6</td> <td class=\"centered\">12.8</td> <td class=\"centered\">13.9</td> <td class=\"centered\">12.6</td> <td class=\"centered\">14.8</td> <td class=\"centered\">12.2</td> <td class=\"centered\">11.2</td> <td class=\"centered\">13.0</td> <td class=\"centered\">11.8</td> <td class=\"centered\">10.5</td> <td class=\"centered\">12.7</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">80</td> <td class=\"centered\">9.2</td> <td class=\"centered\">8.4</td> <td class=\"centered\">9.8</td> <td class=\"centered\">9.2</td> <td class=\"centered\">8.3</td> <td class=\"centered\">9.7</td> <td class=\"centered\">9.2</td> <td class=\"centered\">8.2</td> <td class=\"centered\">9.8</td> <td class=\"centered\">10.6</td> <td class=\"centered\">9.5</td> <td class=\"centered\">11.2</td> <td class=\"centered\">9.1</td> <td class=\"centered\">8.3</td> <td class=\"centered\">9.7</td> <td class=\"centered\">9.2</td> <td class=\"centered\">8.1</td> <td class=\"centered\">9.8</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">85</td> <td class=\"centered\">6.7</td> <td class=\"centered\">6.0</td> <td class=\"centered\">7.1</td> <td class=\"centered\">6.6</td> <td class=\"centered\">5.9</td> <td class=\"centered\">7.0</td> <td class=\"centered\">6.9</td> <td class=\"centered\">6.1</td> <td class=\"centered\">7.3</td> <td class=\"centered\">7.8</td> <td class=\"centered\">6.9</td> <td class=\"centered\">8.2</td> <td class=\"centered\">6.6</td> <td class=\"centered\">5.9</td> <td class=\"centered\">7.0</td> <td class=\"centered\">6.9</td> <td class=\"centered\">6.1</td> <td class=\"centered\">7.3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">90</td> <td class=\"centered\">4.6</td> <td class=\"centered\">4.1</td> <td class=\"centered\">4.9</td> <td class=\"centered\">4.6</td> <td class=\"centered\">4.1</td> <td class=\"centered\">4.8</td> <td class=\"centered\">5.1</td> <td class=\"centered\">4.5</td> <td class=\"centered\">5.4</td> <td class=\"centered\">5.5</td> <td class=\"centered\">4.8</td> <td class=\"centered\">5.7</td> <td class=\"centered\">4.6</td> <td class=\"centered\">4.1</td> <td class=\"centered\">4.8</td> <td class=\"centered\">5.1</td> <td class=\"centered\">4.5</td> <td class=\"centered\">5.4</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">95</td> <td class=\"centered\">3.2</td> <td class=\"centered\">2.9</td> <td class=\"centered\">3.4</td> <td class=\"centered\">3.2</td> <td class=\"centered\">2.8</td> <td class=\"centered\">3.3</td> <td class=\"centered\">3.8</td> <td class=\"centered\">3.3</td> <td class=\"centered\">3.9</td> <td class=\"centered\">3.8</td> <td class=\"centered\">3.3</td> <td class=\"centered\">3.9</td> <td class=\"centered\">3.2</td> <td class=\"centered\">2.8</td> <td class=\"centered\">3.3</td> <td class=\"centered\">3.8</td> <td class=\"centered\">3.4</td> <td class=\"centered\">3.9</td> </tr> <tr> <td class=\"centered\">100</td> <td class=\"centered\">2.3</td> <td class=\"centered\">2.1</td> <td class=\"centered\">2.3</td> <td class=\"centered\">2.3</td> <td class=\"centered\">2.0</td> <td class=\"centered\">2.3</td> <td class=\"centered\">2.8</td> <td class=\"centered\">2.5</td> <td class=\"centered\">2.9</td> <td class=\"centered\">2.7</td> <td class=\"centered\">2.4</td> <td class=\"centered\">2.7</td> <td class=\"centered\">2.2</td> <td class=\"centered\">2.0</td> <td class=\"centered\">2.3</td> <td class=\"centered\">2.9</td> <td class=\"centered\">2.6</td> <td class=\"centered\">2.9</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Arias E, Heron M, Xu JQ. United States life tables, 2014. Natl Vital Stat Rep 2017; 66:1. Available at: <A spellcheck=true href=\"https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_04.pdf\" target=_blank>https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_04.pdf</A> (Accessed on February 21, 2018).</div><div id=\"graphicVersion\">Graphic 89061 Version 3.0</div></div></div>"},"89062":{"type":"graphic_picture","displayName":"Intraarticular patellar dislocation","title":"Intraarticular patellar dislocation","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Intraarticular patellar dislocation</div><div class=\"cntnt\"><img style=\"width:584px; height:292px;\" src=\"images/EM/89062_Intrarticulr_patlar_disloct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraarticular patellar dislocations occur following a direct blow to the proximal portion of the patella of a flexed knee sufficient to avulse the deep fibers of the guadriceps tendon and permit horizontal rotation of the superior portion of the patella into the knee joint.</div><div class=\"graphic_reference\">Reproduced from: McHugh G, Ryan E, Cleary M, et al. Intra-articular dislocation of the patella. Case Rep Orthop 2013; 2013:535803. Available at: <a href=\"http://www.hindawi.com/crim/orthopedics/2013/535803/abs/\" target=\"_blank\">http://www.hindawi.com/crim/orthopedics/2013/535803/abs/</a>. (Accessed April 18, 2013). Copyright &copy; 2013 Gavin McHugh, et al.</div><div id=\"graphicVersion\">Graphic 89062 Version 1.0</div></div></div>"},"89063":{"type":"graphic_diagnosticimage","displayName":"Horizontal intraarticular patellar dislocation","title":"Intraarticular inferior patellar dislocation","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Intraarticular inferior patellar dislocation</div><div class=\"cntnt\"><img style=\"width:598px; height:418px;\" src=\"images/EM/89063_Horizintraartpateldisloc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteroposterior and lateral radiograph of the left knee showing significant osteoarthrititis and the superior pole of the patella hooked between the femoral condyles in a 93-year-old woman who, while on her hands and knees, hit the top of her knee against the edge of a refrigerator.</div><div class=\"graphic_reference\">Reproduced with permission from: Garner JP, Pike JM, George CD. Intra-articular dislocation of the patella: Two cases and literature review. J Trauma 1999; 47:780. Copyright &copy; 1999 Wolters Kluwer Health, Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 89063 Version 6.0</div></div></div>"},"89064":{"type":"graphic_diagnosticimage","displayName":"Superior patellar dislocation","title":"Superior patellar dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superior patellar dislocation</div><div class=\"cntnt\"><img style=\"width:303px; height:576px;\" src=\"images/EM/89064_Supintraarticpateldislo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral radiograph of the left knee showing superior dislocation of the patella held by interlocking osteophytes in a 61-year-old man who received a direct blow to the inferior patella during knee flexion.</div><div class=\"graphic_reference\">Reproduced with permission from: Garner JP, Pike JM, George CD. Intra-articular dislocation of the patella: Two cases and literature review. J Trauma 1999; 47:780. Copyright &copy; 1999 Wolters Kluwer Health, Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 89064 Version 7.0</div></div></div>"},"89065":{"type":"graphic_picture","displayName":"Tufted angioma","title":"Tufted angioma","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Tufted angioma</div><div class=\"cntnt\"><img style=\"width:464px; height:305px;\" src=\"images/DERM/89065_Tufted_angioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large violaceous infiltrated plaque involving the left leg of an infant with tufted angioma.</div><div id=\"graphicVersion\">Graphic 89065 Version 1.0</div></div></div>"},"89068":{"type":"graphic_figure","displayName":"Frequency of renal cysts","title":"Frequency of renal cysts among patients with tuberous sclerosis complex","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Frequency of renal cysts among patients with tuberous sclerosis complex</div><div class=\"cntnt\"><img style=\"width:540px; height:382px;\" src=\"images/NEPH/89068_Size_angiomyolipomas.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frequency of cysts at the age of the first computed tomography or ultrasonography in 164 patients with tuberous sclerosis complex.</div><div class=\"graphic_reference\">Reproduced from: Torres VE, King BF, Holley KE, et al. The kidney in the tuberous sclerosis complex. Adv Nephrol Necker Hosp 1994; 23:43. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89068 Version 1.0</div></div></div>"},"89073":{"type":"graphic_table","displayName":"Classification of internal hernias","title":"Classification of internal hernias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of internal hernias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Name</td> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td class=\"centered\">A</td> <td>Paraduodenal</td> <td>&nbsp;</td> <td>Most common</td> </tr> <tr> <td class=\"centered\">B</td> <td>Foramen of Winslow</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"centered\">C</td> <td>Intersigmoid</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"centered\">D</td> <td>Pericecal</td> <td>&nbsp;</td> <td>2nd most common</td> </tr> <tr> <td class=\"centered\">E</td> <td>Transmesenteric</td> <td>Roux-en-Y procedures</td> <td>&nbsp;</td> </tr> <tr> <td class=\"centered\">F</td> <td>Retroanastomotic</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89073 Version 2.0</div></div></div>"},"89077":{"type":"graphic_table","displayName":"Self-administered insemination procedure","title":"Procedure for self-administered insemination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Procedure for self-administered insemination</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li> <p>The time of the luteinizing hormone (LH) surge, which signifies impending ovulation, is determined using an ovulation predictor kit</p> </li> <li> <p>When the LH surge is identified, the male ejaculates into a condom without spermicide</p> </li> <li> <p>A syringe (without a needle) is then used to aspirate the semen in the condom</p> </li> <li>The syringe is inserted into the vagina and the semen is released near the cervix</li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89077 Version 1.0</div></div></div>"},"89078":{"type":"graphic_picture","displayName":"Bejel oral mucosal lesions","title":"Bejel","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Bejel</div><div class=\"cntnt\"><img style=\"width:574px; height:430px;\" src=\"images/DERM/89078_Bejel_oral_mucosal_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple mucosal erosions in the oral cavity in a patient with bejel (endemic syphilis).</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89078 Version 1.0</div></div></div>"},"89080":{"type":"graphic_diagnosticimage","displayName":"X-ray AP pelvis normal male","title":"X-ray AP pelvis normal male","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">X-ray AP pelvis normal male</div><div class=\"cntnt\"><img style=\"width:470px; height:433px;\" src=\"images/RADIOL/89080_X_ray_AP_pelv_norm_male.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An AP view of the pelvis of a young adult demonstrates a normal android pelvis.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div id=\"graphicVersion\">Graphic 89080 Version 1.0</div></div></div>"},"89081":{"type":"graphic_diagnosticimage","displayName":"AP frog leg lateral and cross table lateral of adult hip","title":"AP, frog leg lateral, and cross table lateral views of adult hip","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">AP, frog leg lateral, and cross table lateral views of adult hip</div><div class=\"cntnt\"><img style=\"width:596px; height:606px;\" src=\"images/RADIOL/89081_X_ry_AP_frog_leg_ad_hip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The x-ray of the right hip in AP (A), frog leg lateral (B), and lateral (C) projections demonstrates a normal adult hip.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div id=\"graphicVersion\">Graphic 89081 Version 1.0</div></div></div>"},"89082":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray and CT LIP","title":"Lymphoid interstitial pneumonia on chest x-ray and CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Lymphoid interstitial pneumonia on chest x-ray and CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:391px;\" src=\"images/RADIOL/89082_Chest_x_ray_CT_LIP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest x-ray (A) shows bilateral non-specific diffuse interstitial coarsening and a cyst in the right lower lobe (arrow). A coronal reconstruction of a CT scan (B) confirms the presence of cysts in the right lower lobe and left upper lobe (arrows). An axial CT scan (C) shows extensive bibasilar cystic changes (dashed arrow) and&nbsp;interstitial thickening (arrow) with changes in the left pleural space (arrowhead) following wedge biopsy. A diagnosis of LIP was confirmed by biopsy.</div><div class=\"graphic_footnotes\">CT: computed tomography. LIP: Lymphoid interstitial pneumonia</div><div id=\"graphicVersion\">Graphic 89082 Version 1.0</div></div></div>"},"89083":{"type":"graphic_diagnosticimage","displayName":"CT cystic pancreatic carcinoma presenting with ascites","title":"Cystic carcinoma of the pancreas with associated ascites on CT scan","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Cystic carcinoma of the pancreas with associated ascites on CT scan</div><div class=\"cntnt\"><img style=\"width:590px; height:450px;\" src=\"images/RADIOL/89083_CT_cystic_pancr_ascite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the upper abdomen in a patient with pancreatic carcinoma. There is a cystic mass in the tail of the pancreas (arrow) with a moderate amount of ascites (arrowhead). There is also a nodule on the surface of the liver representing metastasis (dashed arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89083 Version 1.0</div></div></div>"},"89084":{"type":"graphic_diagnosticimage","displayName":"CT of Virchows node","title":"Virchow's node on CT scan in a patient with pancreatic carcinoma ","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Virchow's node on CT scan in a patient with pancreatic carcinoma </div><div class=\"cntnt\"><img style=\"width:590px; height:317px;\" src=\"images/RADIOL/89084_CT_virchows_node.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan at the level of the thoracic inlet in a patient with pancreatic carcinoma demonstrates a left supraclavicular lymph node or \"Virchow's node\" (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89084 Version 1.0</div></div></div>"},"89085":{"type":"graphic_diagnosticimage","displayName":"CT of Sister Mary Josephs node","title":"Sister Mary Joseph’s node  on CT scan","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Sister Mary Joseph’s node  on CT scan</div><div class=\"cntnt\"><img style=\"width:590px; height:380px;\" src=\"images/RADIOL/89085_CT_sist_mary_jose_node.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the abdomen and pelvis at the level of the umbilicus shows a periumbilical nodule or \"Sister Mary Joseph's node\" (arrow). There are other peritoneal metastatic implants (double arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89085 Version 2.0</div></div></div>"},"89086":{"type":"graphic_diagnosticimage","displayName":"CT of benign pancreatic cyst","title":"Benign pancreatic cyst on CT  scan","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Benign pancreatic cyst on CT  scan</div><div class=\"cntnt\"><img style=\"width:590px; height:449px;\" src=\"images/RADIOL/89086_CT_benign_pancre_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the abdomen and pelvis at the level of the pancreas shows a benign-appearing cyst in the tail of the pancreas (arrow) likely due to pancreatitis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89086 Version 1.0</div></div></div>"},"89087":{"type":"graphic_diagnosticimage","displayName":"CT of a pancreatic cyst and polycystic kidney disease ","title":"Pancreatic cyst and polycystic kidney disease on CT scan","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pancreatic cyst and polycystic kidney disease on CT scan</div><div class=\"cntnt\"><img style=\"width:590px; height:390px;\" src=\"images/RADIOL/89087_CT_pan_cyst_polycy_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the abdomen and pelvis shows a pancreatic cyst in the uncinate process of the pancreas (arrow) in a patient with polycystic kidney disease.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89087 Version 1.0</div></div></div>"},"89088":{"type":"graphic_diagnosticimage","displayName":"CT of pancreatic IPMN ","title":"Intraductal papillary mucinous neoplasm of the pancreas on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Intraductal papillary mucinous neoplasm of the pancreas on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:185px;\" src=\"images/RADIOL/89088_CT_pancreatic_IPMN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the abdomen and pelvis in a patient with IPMN shows a mass in the head of the pancreas (arrow in panel A) and a dilated pancreatic duct in the uncinate process (arrow in panel B). Histopathology demonstrated a neoplasm with both papillary and mucinous features.</div><div class=\"graphic_footnotes\">CT: computed tomography; IPMN: intraductal papillary mucinous neoplasm.</div><div id=\"graphicVersion\">Graphic 89088 Version 1.0</div></div></div>"},"89089":{"type":"graphic_diagnosticimage","displayName":"ERCP of pancreatic intraductal papillary mucinous neoplasm ","title":"Intraductal papillary mucinous neoplasm of the pancreas on ERCP ","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Intraductal papillary mucinous neoplasm of the pancreas on ERCP </div><div class=\"cntnt\"><img style=\"width:590px; height:400px;\" src=\"images/RADIOL/89089_ERCP_pancreat_neoplasm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ERCP showing the pancreatic duct in a patient with intraductal papillary mucinous neoplasm. There is a filling defect in a dilated pancreatic duct (arrow) and there are strand-like filling defects of mucus in the pancreatic duct in the body of the pancreas (arrowheads). The endoscopist observed large amounts of mucus exuding from the pancreatic duct orifice. Histopathology of an associated pancreatic mass revealed both papillary and mucinous features.</div><div class=\"graphic_footnotes\">ERCP: endoscopic retrograde cholangiopancreatography; IPMN: intraductal papillary mucinous neoplasm.</div><div id=\"graphicVersion\">Graphic 89089 Version 1.0</div></div></div>"},"89091":{"type":"graphic_diagnosticimage","displayName":"CT of pancreatic serous cystadenoma","title":"Serous cystadenoma of the pancreas on CT","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Serous cystadenoma of the pancreas on CT</div><div class=\"cntnt\"><img style=\"width:532px; height:397px;\" src=\"images/RADIOL/89091_CT_pancr_serous_cystadenoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the abdomen and pelvis in a patient with serous cystadenoma. There is a mass in the head of the pancreas (arrow), which has a lobulated outline and a calcified central scar.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89091 Version 1.0</div></div></div>"},"89092":{"type":"graphic_diagnosticimage","displayName":"Imaging of pancreatic mucinous cystadenoma","title":"Mucinous cystadenoma of the pancreas on CT scan, ERCP, US, and MRI","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Mucinous cystadenoma of the pancreas on CT scan, ERCP, US, and MRI</div><div class=\"cntnt\"><img style=\"width:597px; height:376px;\" src=\"images/RADIOL/89092_Img_pancr_mucin_cystadenoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A CT scan shows a 6 cm cystic mass in the tail of the pancreas (arrowhead) with an enhancing wall (arrow).<BR>(B) An ERCP shows no communication of the pancreatic ductal system with the cyst seen on the CT scan, thus excluding the diagnosis of a pancreatic pseudocyst.<BR>(C) An US shows a 3 cm soft tissue nodule (arrowhead) within a 6cm cyst (+..+).<BR>(D) A T2-weighted MRI shows a low-intensity T2 dark nodule (arrow) within the cystic matrix of the mucinous cystadenoma.</div><div class=\"graphic_footnotes\">CT: computed tomography; ERCP: endoscopic retrograde cholangiopancreatography; US: ultrasound; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 89092 Version 1.0</div></div></div>"},"89093":{"type":"graphic_diagnosticimage","displayName":"CT of pancreatic cystadenocarcinoma","title":"Cystadenocarcinoma of the pancreas on CT scan","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Cystadenocarcinoma of the pancreas on CT scan</div><div class=\"cntnt\"><img style=\"width:590px; height:421px;\" src=\"images/RADIOL/89093_CT_pancr_cystadenocarcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the abdomen and pelvis in a patient with mucinous cystadenocarcinoma. There is a simple-appearing cyst with an enhancing wall in the tail of the pancreas (dashed arrow). An adjacent soft tissue mass in the body of the pancreas (arrowhead) is suspicious for malignant transformation. The neck of the pancreas (arrow) is normal.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89093 Version 1.0</div></div></div>"},"89094":{"type":"graphic_diagnosticimage","displayName":"CT cystic pancreatic carcinoma presenting with ascites 2","title":"Cystic carcinoma of the pancreas with associated ascites on CT scan","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Cystic carcinoma of the pancreas with associated ascites on CT scan</div><div class=\"cntnt\"><img style=\"width:590px; height:387px;\" src=\"images/RADIOL/89094_CT_cys_panc_carcin_ascites2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the upper abdomen in a patient with pancreatic carcinoma. There is a cystic mass in the tail of the pancreas (dashed arrow) with a moderate amount of ascites (short arrow). Metastatic disease includes a nodule on the surface of the liver&nbsp;(long arrow) and omental disease (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89094 Version 1.0</div></div></div>"},"89095":{"type":"graphic_diagnosticimage","displayName":"CT of pancreatic lymphoma","title":"Lymphoma of the pancreas on CT scan","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Lymphoma of the pancreas on CT scan</div><div class=\"cntnt\"><img style=\"width:554px; height:485px;\" src=\"images/RADIOL/89095_CT_pancreatic_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the abdomen and pelvis in a patient with lymphoma of the pancreas. There is a bulky mass of the pancreas (arrow) associated with retrocrural nodes (arrowhead) and peripancreatic nodes (dashed arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89095 Version 1.0</div></div></div>"},"89096":{"type":"graphic_diagnosticimage","displayName":"Imaging Kartageners syndrome","title":"Imaging of Kartagener's syndrome on chest and sinus radiographs and on chest computed tomography","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Imaging of Kartagener's syndrome on chest&nbsp;and sinus radiographs and on chest computed tomography</div><div class=\"cntnt\"><img style=\"width:594px; height:516px;\" src=\"images/RADIOL/89096_Imag_Kartageners_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Imaging findings of Kartagener's syndrome with situs inversus totalis, sinusitis, and bronchiectasis. PA chest&nbsp;radiograph (A) shows situs inversus totalis with dextrocardia (arrow), right-sided stomach bubble (arrowhead), and right aortic arch (dashed arrow). A radiograph&nbsp;of the sinuses (B), shows bilateral opacification of the maxillary sinuses (arrows). A CT scan through the lower chest (C), shows dextrocardia (arrow) and bronchiectasis (arrowheads). A CT scan through the abdomen (D)&nbsp;shows situs inversus with left-sided liver (arrow), right-sided stomach (arrowhead), and right-sided spleen (dashed arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; PA: posteroanterior.</div><div id=\"graphicVersion\">Graphic 89096 Version 2.0</div></div></div>"},"89097":{"type":"graphic_diagnosticimage","displayName":"Imaging and pathology PA sling tracheal stenosis","title":"Chest radiograph, angiogram, intraoperative, and pathologic images from a neonate with pulmonary artery sling and tracheal stenosis","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Chest radiograph, angiogram, intraoperative, and pathologic images from a neonate with pulmonary artery sling and tracheal stenosis</div><div class=\"cntnt\"><img style=\"width:564px; height:501px;\" src=\"images/RADIOL/89097_Img_path_PA_sling_tracheoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A chest&nbsp;radiograph shows a hyperexpanded right lung with flattening of the hemidiaphragm (arrowhead) and leftward shift of the cardiomediastinal silhouette (arrow).<br />(B) A pulmonary angiogram shows aberrant origin of the LPA (arrowhead) from the RPA (arrow).<br />(C)&nbsp;Intraoperative photograph&nbsp;demonstrates the LPA (arrow) coursing behind the trachea (*).<br />(D) Pathologic specimen shows the trachea has a focal narrowing above the bifurcation (arrow), likely due to complete tracheal rings at that location.</div><div class=\"graphic_footnotes\">LPA: left pulmonary artery; RPA: right pulmonary artery.</div><div id=\"graphicVersion\">Graphic 89097 Version 4.0</div></div></div>"},"89099":{"type":"graphic_diagnosticimage","displayName":"CT extranodal MZL of lung","title":"Chest CT - Extranodal marginal zone lymphoma  ","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Chest CT - Extranodal marginal zone lymphoma&nbsp; </div><div class=\"cntnt\"><img style=\"width:504px; height:446px;\" src=\"images/RADIOL/89099_CT_BALT_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest CT&nbsp;shows a nodule in the left lower lobe with air bronchograms (arrow). Histopathology demonstrated extranodal marginal zone lymphoma.</div><div class=\"graphic_footnotes\">CT: computed tomography</div><div id=\"graphicVersion\">Graphic 89099 Version 3.0</div></div></div>"},"89100":{"type":"graphic_picture","displayName":"Kaposiform hemangioendothelioma","title":"Kaposiform hemangioendothelioma (KHE)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kaposiform hemangioendothelioma (KHE)</div><div class=\"cntnt\"><img style=\"width:413px; height:320px;\" src=\"images/DERM/89100_Kaposifrm_hemangoendthelima .jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An infant with kaposiform hemangioendothelioma associated with the Kasabach-Merritt phenomenon.</div><div id=\"graphicVersion\">Graphic 89100 Version 1.0</div></div></div>"},"89101":{"type":"graphic_picture","displayName":"Heliotrope eruption in dermatomyositis","title":"Heliotrope eruption in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Heliotrope eruption in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:572px; height:290px;\" src=\"images/RHEUM/89101_Heliotrpe_eruptn_dermatmyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Violaceous erythema on the upper lids in a patient with dermatomyositis. Mid-facial erythema that does not spare the nasolabial folds is also present.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Callen, MD, FACP, FAAD.</div><div id=\"graphicVersion\">Graphic 89101 Version 2.0</div></div></div>"},"89102":{"type":"graphic_picture","displayName":"Eyelid edema in dermatomyositis","title":"Eyelid edema in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Eyelid edema in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:574px; height:242px;\" src=\"images/DERM/89102_Eyelid_edema_dermatomyosits.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Edematous upper and lower eyelids in a patient with dermatomyositis.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Callen, MD, FACP, FAAD.</div><div id=\"graphicVersion\">Graphic 89102 Version 1.0</div></div></div>"},"89119":{"type":"graphic_figure","displayName":"Role of the adaptive immune system in glomerulonephritis","title":"Role of the adaptive immune system in glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Role of the adaptive immune system in glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:574px; height:434px;\" src=\"images/NEPH/89119_Roleadaptimmunesysneph.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The T cell component of the adaptive immune system in glomerulonephritis (GN). Antigen is presented to naïve CD4 T cells by dendritic cells (signal 1). Depending upon the predominant cytokine environment, T cells differentiate into CD4 T cell subsets that play different roles in the pathogenesis of glomerular disease. In the presence of transforming growth factor beta (TGF-β), T regulatory cells (Tregs) develop that make TGF-β, interleukin-10 (IL-10), and cytotoxic T-lymphocyte antigen 4 (CTLA-4) that downregulate and control the immune response. IL-12 stimulates differentiation into Th1 cells that make interferon gamma (IFNγ) and TNF and produce traditional T cell/macrophage-mediated delayed-type hypersensitivity (DTH) reactions. IL-2, IL-4, and IL-13 favor the development of Th2 cells that make IL-4, IL-5, and IL-13, and lead to allergic-type hypersensitivity reactions involving immunoglobulin E (IgE) and eosinophils (Eos). The CD4 T cells most implicated in the pathogenesis of GN are Th17 cells that differentiate in the presence of TGF-β, IL-6, and especially IL-17, and those that produce IL-17a and IL-21 that facilitate recruitment of other inflammatory cells, such as neutrophils (PMNs), and also cause tissue injury directly.</div><div class=\"graphic_reference\">Reproduced with permission from: Coffman TM, Falk RJ, Molitoris BA, et al. Schrier's Diseases of the Kidney, 9th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 89119 Version 5.0</div></div></div>"},"89121":{"type":"graphic_figure","displayName":"Depiction of the natural history of glomerular crescents","title":"Depiction of the natural history of glomerular crescents","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Depiction of the natural history of glomerular crescents</div><div class=\"cntnt\"><img style=\"width:533px; height:711px;\" src=\"images/NEPH/89121_Glomerularcrescent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crescent formation. In early crescent formation, cytokines and growth factors cross the glomerular basement membrane (GBM) to initiate proliferation of the parietal epithelial cells. Small breaks in the GBM occur secondary to injury from oxidants and proteases from neutrophils and macrophages, thus allowing the macrophage to enter Bowman's space, where it can proliferate. Breaks in Bowman's capsule secondary to the periglomerular inflammation also occur, allowing the entrance of more inflammatory cells as well as fibroblasts. The proliferation of parietal and visceral epithelial cells and macrophages is associated with fibrin deposition, slowly choking the glomerular tuft until filtration becomes impossible. In the late stages, the crescent becomes fibrotic and the glomerulus, end stage. Alternatively, in less severe cases, complete restitution of the glomerular tuft can occur.</div><div id=\"graphicVersion\">Graphic 89121 Version 1.0</div></div></div>"},"89122":{"type":"graphic_picture","displayName":"Light microscopy showing the evolution of crescentic GN","title":"Light microscopy showing the evolution of crescentic glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">Light microscopy showing the evolution of crescentic glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:569px; height:381px;\" src=\"images/NEPH/89122_LtmicrspshngevlcrsntGN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light microscopy of crescentic glomerulonephritis showing different stages of crescent formation in the same patients (silver stain).<br />(A) Early stage showing necrosis of the capillary wall before development of extracapillary proliferation.<br />(B) Large necrotic area with onset of crescent formation involving proliferation of parietal epithelial cells.<br />(C) Circumferential cellular crescent.<br />(D) Late stage showing a large area of disruption of the Bowman's capsule.</div><div class=\"graphic_reference\">Courtesy of Patrice Callard, MD.</div><div id=\"graphicVersion\">Graphic 89122 Version 1.0</div></div></div>"},"89123":{"type":"graphic_algorithm","displayName":"Cutaneous porphyria non-blistering algorithm","title":"Algorithm for distinguishing non-blistering cutaneous porphyrias","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Algorithm for distinguishing non-blistering cutaneous porphyrias</div><div class=\"cntnt\"><img style=\"width:554px; height:544px;\" src=\"images/HEME/89123_Ctn_prphyr_no_blstr_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm outlines an approach to the patient with suspected cutaneous porphyria and non-blistering photosentivity. Separate algorithms are available for the patient with suspected cutanous porphyria with blistering photosentitivity, and the patient with suspected acute (neurovisceral) porphyria. Refer to UpToDate topics on individual porphyrias for further discussions of the clinical manifestations and diagnostic evaluation. Refer to content on photosensitivity disorders for other diagnostic considerations.</div><div class=\"graphic_footnotes\">EPP: erythropoietic protoporphyria; XLP: X-linked protoporphyria; <em>FECH</em>: ferrochelatase; <em>ALAS2</em>: delta-aminolevulinic acid synthase, erythroid form.<br />* We perform gene sequencing of the relevant gene for any patient with protoporphyria (<em>FECH</em> gene in EPP, <em>ALAS2</em> gene in XLP). This is used for further diagnostic confirmation and especially for genetic testing and counseling of family members.</div><div id=\"graphicVersion\">Graphic 89123 Version 6.0</div></div></div>"},"89125":{"type":"graphic_figure","displayName":"Placenta in preeclampsia","title":"Abnormal placentation in preeclampsia","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Abnormal placentation in preeclampsia</div><div class=\"cntnt\"><img style=\"width:494px; height:677px;\" src=\"images/OBGYN/89125_Placenta_in_preeclampsia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exchange of oxygen, nutrients, and waste products between the fetus and mother depends on adequate placental perfusion by maternal vessels. In normal placental development, invasive cytotrophoblasts of fetal origin invade the maternal spiral arteries, transforming them from small-caliber resistance vessels to high-caliber capacitance vessels capable of providing placental perfusion adequate to sustain the growing fetus. During the process of vascular invasion, the cytotrophoblasts differentiate from an epithelial phenotype to an endothelial phenotype, a process referred to as \"pseudovasculogenesis\" or \"vascular mimicry\" (Upper panel). In preeclampsia, cytotrophoblasts fail to adopt an invasive endothelial phenotype. Instead, invasion of the spiral arteries is shallow and they remain small caliber, resistance vessels (Lower panel).</div><div id=\"graphicVersion\">Graphic 89125 Version 1.0</div></div></div>"},"89126":{"type":"graphic_picture","displayName":"Lateral patellar dislocation","title":"Lateral patellar dislocation","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Lateral patellar dislocation</div><div class=\"cntnt\"><img style=\"width:574px; height:500px;\" src=\"images/EM/89126_Lateralpatellardislocaton.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral patellar dislocation of the left knee. Note that the knee is held in approximately 20 degrees of flexion and the patella (arrow) is laterally displaced.</div><div class=\"graphic_reference\">Reproduced with permission from: Silverberg M. Patellar dislocations. In: Greenberg's Text-Atlas of Emergency Medicine, Greenberg MI (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2003 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 89126 Version 5.0</div></div></div>"},"89127":{"type":"graphic_figure","displayName":"Medial patella anatomy","title":"Medial patella anatomy and stabilization","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Medial patella anatomy and stabilization</div><div class=\"cntnt\"><img style=\"width:514px; height:677px;\" src=\"images/EM/89127_Medial_patella_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During extension of the knee, the femoral muscles (quadriceps femoris, vastus medialis, and vastus lateralis) apply an oblique,&nbsp;laterally displacing force to the patella (black arrow, top figure). The medial patellofemoral ligament and the vastus medialis obliquus (lower figure)&nbsp;provide medial stabilization of the patella against potential patellar subluxation or dislocation.</div><div id=\"graphicVersion\">Graphic 89127 Version 1.0</div></div></div>"},"89148":{"type":"graphic_figure","displayName":"Torticollis in a child","title":"Torticollis in a child","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Torticollis in a child</div><div class=\"cntnt\"><img style=\"width:452px; height:551px;\" src=\"images/EM/89148_Torticollis_in_a_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Children with torticollis have lateral neck twisting that causes the head to tilt&nbsp;to one side&nbsp;with the chin turned out to the opposite side. Sternocleidomastoid and trapezius muscle injury&nbsp;and inflammation&nbsp;are&nbsp;common causes of acquired torticollis.&nbsp;</div><div id=\"graphicVersion\">Graphic 89148 Version 1.0</div></div></div>"},"89150":{"type":"graphic_algorithm","displayName":"Algorithm bleeding disorder evaluation child abuse","title":"Recommended pathway for evaluation of possible bleeding disorders when child abuse is suspected","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Recommended pathway for evaluation of possible bleeding disorders when child abuse is suspected</div><div class=\"cntnt\"><img style=\"width:471px; height:497px;\" src=\"images/EM/89150_Bleeddisordrevlchldabus.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">VWF: von Willebrand factor.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 131, Pages e1314-e1322, Copyright © 2013 by the AAP.</div><div id=\"graphicVersion\">Graphic 89150 Version 8.0</div></div></div>"},"89151":{"type":"graphic_algorithm","displayName":"Diagnostic evaluation of premature pubarche","title":"An approach to the diagnostic evaluation for isolated premature pubarche","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">An approach to the diagnostic evaluation for isolated premature pubarche</div><div class=\"cntnt\"><img style=\"width:471px; height:603px;\" src=\"images/PEDS/89151_Diag_evalu_prmtr_pubar_Edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A significantly advanced bone age is an indication for a screening work-up, consisting of early morning dehydroepiandrosterone sulfate (DHEAS) and testosterone levels. A bone age/height age ratio &gt;1.2 (which indicates compromised height potential) or DHEAS or testosterone level above the normal adrenarchal range (115 mcg/dL and 20 ng/dL, respectively) suggests that the premature pubarche may be caused by a hyperandrogenic disorder rather than ordinary premature adrenarche. In this case we suggest the following tests: &#xD;&#xA;<OL>&#xD;&#xA;<LI>ACTH test (measuring the responses of cortisol precursors). </LI>&#xD;&#xA;<LI>Dexamethasone androgen-suppression testing (measuring the suppression of elevated androgen levels).</LI></OL>Even if these tests are normal, clinical follow-up is indicated to rule out inordinate progression of pubarche or evidence of virilization or true puberty. This is because bone age interpretation and the precision of testosterone assays at low levels are often problematic, and because abnormal responses to these tests are not necessarily present in very rare disorders of steroid metabolism (eg, apparent/cortisone reductase deficiency and apparent DHEA sulfotransferase deficiency). Refer to UpToDate topic for details about the ACTH stimulation test and dexamethasone androgen-suppression test.</div><div class=\"graphic_footnotes\">DHEAS: dehydroepiandrosterone sulfate; ACTH: adrenocorticotropic hormone; SD: standard deviations.<br />* A baseline measurement of 17-hyroxyprogesterone (17OHP), taken at 8:00 AM, can be used as an initial screening test to determine whether to proceed to an ACTH stimulation test. If the baseline 17OHP concentration is &lt;200 ng/dL and there is no clinical evidence of progressive virilization, no further testing is needed. The child should be followed clinically for evidence of progressive puberty or virilization. If the baseline early morning 17OHP is 200-1500 ng/dL, then the child should be further evaluated with the ACTH stimulation test as shown. A baseline 17OHP level &gt;1500 ng/dL obviates the need for an ACTH&nbsp;test, as it is evidence of the 21-hydroxylase deficiency type of congenital adrenal hyperplasia.</div><div class=\"graphic_reference\">Courtesy of Robert Rosenfield, MD.</div><div id=\"graphicVersion\">Graphic 89151 Version 4.0</div></div></div>"},"89152":{"type":"graphic_table","displayName":"Probability congenital bleeding disorder intracranial hemorrhage","title":"Probability of congenital bleeding disorder causing an intracranial hemorrhage by condition*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Probability of congenital bleeding disorder causing an intracranial hemorrhage by condition*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Prevalence of condition,<br /> upper limits</td> <td class=\"subtitle1\">Prevalence of ICH,<br /> upper limits</td> <td class=\"subtitle1\">Probability*</td> </tr> <tr> <td>VWD</td> <td>1/1000</td> <td>Extremely rare</td> <td>Low</td> </tr> <tr> <td>Factor II deficiency</td> <td>1/1 million</td> <td>11 percent</td> <td>1/10 million</td> </tr> <tr> <td>Factor V deficiency</td> <td>1/1 million</td> <td>8 percent of homozygotes</td> <td>1/10 million homozygotes</td> </tr> <tr> <td>Combined factors V and VIII deficiency</td> <td>1/1 million</td> <td>2 percent</td> <td>1/50 million</td> </tr> <tr> <td>Factor VII deficiency</td> <td>1/300,000</td> <td>4-6.5 percent</td> <td>1/5 million</td> </tr> <tr> <td>Factor VIII deficiency</td> <td>1/5000 males</td> <td>5-12 percent</td> <td>1/50,000 males</td> </tr> <tr> <td>Factor IX deficiency</td> <td>1/20,000 males</td> <td>5-12 percent</td> <td>1/200,000 males</td> </tr> <tr> <td>Factor X deficiency</td> <td>1/1 million</td> <td>21 percent</td> <td>1/5 million</td> </tr> <tr> <td>Factor XI deficiency</td> <td>1/100,000</td> <td>Extremely rare</td> <td>Low</td> </tr> <tr> <td>Factor XIII deficiency</td> <td>1/2 million</td> <td>33 percent</td> <td>1/6 million</td> </tr> <tr> <td>AP deficiency</td> <td>40 cases reported</td> <td>Not reported</td> <td>Low</td> </tr> <tr> <td>PAI-1 deficiency</td> <td>Extremely rare</td> <td>Common</td> <td>Low</td> </tr> <tr> <td>Afibrinogenemia</td> <td>1/500,000</td> <td>10 percent</td> <td>1/5 million</td> </tr> <tr> <td>Dysfibrinogenemia</td> <td>1/1 million</td> <td>Single case report</td> <td>Low</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICH: intracranial hemorrhage.<BR>* \"Probability\" indicates the probability that an individual in the general population would have the following specific coagulopathy causing an ICH. The probability of having a specific bleeding disorder increases in the setting of a family history of that specific named bleeding disorder or if the patient is from an ethnicity in which a specific bleeding disorder is more common (eg, Ashkenazi Jewish people and factor XI deficiency).</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 131, Pages e1357-e1373, Copyright © 2013 by the AAP.</div><div id=\"graphicVersion\">Graphic 89152 Version 10.0</div></div></div>"},"89157":{"type":"graphic_table","displayName":"Cisplatin and FU squamous cell cancer","title":"Cisplatin and fluorouracil chemotherapy for advanced or metastatic anal squamous cell cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cisplatin and fluorouracil chemotherapy for advanced or metastatic anal squamous cell cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 28 days.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cisplatin</td> <td>75 mg/m<sup>2</sup> IV</td> <td> <p>Dilute in 250 mL normal saline (NS) and administer over 60 minutes. Do not administer with aluminum needles or sets.</p> Alternative: Dilute in 2000 mL 5% dextrose (D5W) in 1/2 or 1/3 NS containing 37.5 g of mannitol and infuse over six to eight hours.<sup>[2]</sup> Do not administer with aluminum needles or sets.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Fluorouracil</td> <td>750 mg/m<sup>2</sup> per day IV</td> <td>Dilute in 500 to 1000 mL D5W and administer as a continuous infusion over 24 hours per day for five days (120 hours). Begin after completion of cisplatin on day 1. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.</td> <td>Days 1 through 5</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. </li> <li>Alternative: Pretreatment hydration with 1 to 2 L of fluid infused for 8 to 12 hours prior to each dose of cisplatin.<sup>[2]</sup> </li> <li>Supplemental electrolytes as per institutional guidelines. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on prevention. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Routine prophylaxis is not indicated. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Cisplatin and fluorouracil are irritants but can cause significant tissue damage with a large volume, concentrated extravasation; avoid extravasation.<sup>[2,3]</sup> </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Routine primary prophylaxis with granulocyte colony stimulating factors not warranted. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown.<sup>[2]</sup> A lower starting dose of fluorouracil may be needed for patients with liver impairment.<sup>[3]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential prior to each new treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes and liver and renal function prior to each new treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess change in neurologic function prior to each treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea, stomatitis, and cutaneous toxicity (palmar-plantar erythrodysesthesias). </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold new cycle of treatment until neutrophil count &#8805;1500 cells/microL and platelet count &#62;100,000/microL. Reduce dose of cisplatin and fluorouracil by 20% for nadir grade 4 thrombocytopenia persisting longer than five days or febrile neutropenia requiring hospitalization and antibiotics. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Hold both cisplatin and fluorouracil for grade 4 diarrhea until complete resolution and then resume with a 20% dose reduction for both drugs. </li> <li><strong>NOTE:</strong> Severe diarrhea and mucositis after fluorouracil should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold cisplatin until serum creatinine is &#60;1.5 mg/dL and/or blood urea nitrogen is &#60;25 mg/dL. For grade 2 or greater nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &#60;60 mL/min.<sup>[2]</sup> </li> <li>Alternatively, consider substitution of carboplatin for cisplatin if renal impairment (creatinine clearance &#60;50 mL/min). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Palmar-plantar erythrodysesthesia</strong></td> <td colspan=\"3\"> <ul> <li>For grade 4 palmar-plantar erythrodysesthesia, withhold treatment until complete resolution then resume with a 20% dose reduction of both cisplatin and fluorouracil. </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Stomatitis</strong></td> <td colspan=\"3\"> <ul> <li>For grade 4 mucositis, hold next cycle until complete resolution and resume with 20% dose modification. For grade 3 mucositis, reduce cisplatin and fluorouracil doses by 20%. </li> <li>Refer to UpToDate topic on \"Oral toxicity associated with chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony-stimulating factor; CBC: complete blood count.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Eng C, Chang GJ, You YN, et al. Oncotarget 2014; 5:11133.</LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at http://dailymed.nlm.nih.gov, accessed June 12, 2012).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at http://dailymed.nlm.nih.gov, accessed June 12, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 89157 Version 11.0</div></div></div>"},"89158":{"type":"graphic_picture","displayName":"Shawl sign in dermatomyositis","title":"Shawl sign in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Shawl sign in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:574px; height:430px;\" src=\"images/RHEUM/89158_Shawl_sgn_n_dermatomyositis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Poikilodermatous eruption on the upper back in a patient wtih dermatomyositis.</div><div class=\"graphic_reference\">Courtesy of Ruth Ann Vleugels, MD, MPH.</div><div id=\"graphicVersion\">Graphic 89158 Version 1.0</div></div></div>"},"89161":{"type":"graphic_picture","displayName":"Holster sign in dermatomyositis","title":"Holster sign in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Holster sign in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/RHEUM/89161_Holster_dermatomyositis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Poikilodermatous changes on the lateral aspect of the thigh.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89161 Version 1.0</div></div></div>"},"89162":{"type":"graphic_picture","displayName":"Nailfold changes in dermatomyositis","title":"Nailfold changes in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Nailfold changes in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:574px; height:430px;\" src=\"images/RHEUM/89162_Nail_fld_chng_dermatomyosit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dilated capillary loops at the proximal nailfold, cuticular overgrowth, and periungual erythema.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Callen, MD, FACP, FAAD.</div><div id=\"graphicVersion\">Graphic 89162 Version 1.0</div></div></div>"},"89163":{"type":"graphic_picture","displayName":"Nailfold changes in dermatomyositis dermoscopy","title":"Nail changes in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Nail changes in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:572px; height:428px;\" src=\"images/RHEUM/89163_Nail_fld_chng_dermys_drmscp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dilated capillary loops at the proximal nailfold visualized with dermoscopy.</div><div class=\"graphic_reference\">Courtesy of Ruth Ann Vleugels, MD, MPH.</div><div id=\"graphicVersion\">Graphic 89163 Version 1.0</div></div></div>"},"89164":{"type":"graphic_picture","displayName":"Dermatomyositis involving scalp","title":"Dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Dermatomyositis</div><div class=\"cntnt\"><img style=\"width:553px; height:368px;\" src=\"images/RHEUM/89164_Dermatomyosti_involvng_sclp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Psoriasiform changes on the scalp in dermatomyositis.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Callen, MD, FACP, FAAD.</div><div id=\"graphicVersion\">Graphic 89164 Version 1.0</div></div></div>"},"89190":{"type":"graphic_figure","displayName":"Contemporary labor curves by parity","title":"Contemporary labor curves by parity","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Contemporary labor curves by parity</div><div class=\"cntnt\"><img style=\"width:511px; height:323px;\" src=\"images/OBGYN/89190_Labor_curve_by_parity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Average labor curves by parity in singleton term pregnancies with spontaneous onset of labor, vaginal delivery, and normal neonatal outcomes.</div><div class=\"graphic_reference\">Data from:&nbsp;Zhang J, Landy HJ, Branch DW, et al. Contemporary patterns of spontaneous labor with normal neonatal outcomes. Obstet Gynecol 2010; 116:1281.</div><div id=\"graphicVersion\">Graphic 89190 Version 4.0</div></div></div>"},"89191":{"type":"graphic_figure","displayName":"Contemporary estimate of labor duration by dilation at admission","title":"Contemporary estimates of labor duration by dilation at admission","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Contemporary estimates of labor duration by dilation at admission</div><div class=\"cntnt\"><img style=\"width:531px; height:349px;\" src=\"images/OBGYN/89191_Labor_duration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 95<SUP>th</SUP> percentiles of cumulative duration of labor from admission among singleton term nulliparous women with spontaneous onset of labor, vaginal delivery, and normal neonatal outcomes. Colors represent cervical dilation when women were admitted to the labor unit: green (5 cm), yellow (4 cm), blue (3 cm), red (2 cm).</div><div class=\"graphic_reference\">Data from: Zhang J, Landy HJ, Branch DW, et al. Contemporary patterns of spontaneous labor with normal neonatal outcomes. Obstet Gynecol 2010; 116:1281.</div><div id=\"graphicVersion\">Graphic 89191 Version 4.0</div></div></div>"},"89197":{"type":"graphic_picture","displayName":"Hemangiopericytoma infant","title":"Congenital hemangiopericytoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Congenital hemangiopericytoma</div><div class=\"cntnt\"><img style=\"width:504px; height:376px;\" src=\"images/DERM/89197_Hemangiopericytoma_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 2-day-old infant with a partially compressible, firm subcutaneous tumor on the palm. Histology revealed hemangiopericytoma.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 89197 Version 3.0</div></div></div>"},"89200":{"type":"graphic_diagnosticimage","displayName":"Angiogram hepatopulmonary syndrome and pulmonary AVM","title":"Hepatopulmonary syndrome with arteriovenous malformation on angiography","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Hepatopulmonary syndrome with arteriovenous malformation on angiography</div><div class=\"cntnt\"><img style=\"width:599px; height:361px;\" src=\"images/RADIOL/89200_Angiogram_pulmonary_AVM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A right pulmonary angiogram (A) shows a cluster of abnormal vessels in the right mid lung field (arrow) supplied by an artery (arrowhead) and an early draining vein (dashed arrow). Selective angiography of the artery (arrowhead in panel B) confirms the presence of an AVM (arrow) and an early draining vein (dashed arrow).</div><div class=\"graphic_footnotes\">AVM: arteriovenous malformation.</div><div id=\"graphicVersion\">Graphic 89200 Version 1.0</div></div></div>"},"89201":{"type":"graphic_diagnosticimage","displayName":"99mTc-MAA hepatopulmonary syndrome and pulmonary AVM","title":"Hepatopulmonary syndrome with arteriovenous malformation on 99mTc-MAA scan ","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Hepatopulmonary syndrome with arteriovenous malformation on 99mTc-MAA scan </div><div class=\"cntnt\"><img style=\"width:598px; height:235px;\" src=\"images/RADIOL/89201_99mTc_MAA_hep_onary_AVM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An image of the upper abdomen (A) and head (B) following injection of technetium 99mTc albumin aggregate shows abnormal accumulation of the radioisotope in the kidneys (arrows in panel A) and the brain (arrow in panel B) indicating an arteriovenous shunt.</div><div class=\"graphic_footnotes\">99mTc-MAA: technetium 99mTc albumin aggregated; AVM: arteriovenous malformation.</div><div id=\"graphicVersion\">Graphic 89201 Version 1.0</div></div></div>"},"89202":{"type":"graphic_diagnosticimage","displayName":"CT hepatopulmonary syndrome and pulmonary AVM","title":"Hepatopulmonary syndrome with arteriovenous malformation on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Hepatopulmonary syndrome with arteriovenous malformation on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:278px;\" src=\"images/RADIOL/89202_CT_hepatopulmonary_AVM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the chest (A) shows multicentric AVMs (arrowheads). A magnified view (B) highlights the largest AVM (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; AVM: arteriovenous malformation.</div><div id=\"graphicVersion\">Graphic 89202 Version 1.0</div></div></div>"},"89203":{"type":"graphic_diagnosticimage","displayName":"Hepatopulmonary syndrome and pulmonary AVM coil embolization","title":"Hepatopulmonary syndrome with arteriovenous malformation with coil embolization","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Hepatopulmonary syndrome with arteriovenous malformation with coil embolization</div><div class=\"cntnt\"><img style=\"width:598px; height:262px;\" src=\"images/RADIOL/89203_Hepatopulmon_bolization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiography of the right main pulmonary angiogram (A) following deployment of multiple coils (arrows) shows occlusion of the vessels supplying the right mid lung field. Selective angiography of the main artery supplying the AVM (B) shows occlusion of many of the branches by the deployed coils (arrows).</div><div class=\"graphic_footnotes\">AVM: arteriovenous malformation.</div><div id=\"graphicVersion\">Graphic 89203 Version 1.0</div></div></div>"},"89204":{"type":"graphic_diagnosticimage","displayName":"Angiogram pulmonary pseudoaneurysm","title":"Pseudoaneurysm of the pulmonary artery on angiography","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Pseudoaneurysm of the pulmonary artery on angiography</div><div class=\"cntnt\"><img style=\"width:599px; height:259px;\" src=\"images/RADIOL/89204_Angio_pulmona_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A selective right upper lobe pulmonary angiogram (A) shows a focal pseudoaneurysm of the artery (arrow). Imaging in the pulmonary venous phase (B) shows persistent filling of the pseudoaneurysm with contrast (arrow). Inadvertent inflation of the balloon of a Swan-Ganz catheter in wedge position resulted in the formation of a pseudoaneurysm.</div><div id=\"graphicVersion\">Graphic 89204 Version 1.0</div></div></div>"},"89206":{"type":"graphic_table","displayName":"Initial laboratory testing for children with ITP","title":"Initial laboratory testing for children with immune thrombocytopenia (ITP)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial laboratory testing for children with immune thrombocytopenia (ITP)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Laboratory tests</td> <td class=\"subtitle1\">Findings in typical ITP</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Complete blood count (CBC)</td> <td>Isolated thrombocytopenia (platelets &#60;100,000/microL), without anemia or leukopenia</td> <td>The presence of anemia or leukopenia mandates careful evaluation for disorders other than ITP</td> </tr> <tr> <td>Differential white blood cell (WBC) count</td> <td>Normal</td> <td>Suppression of total WBC count or neutrophils suggests bone marrow failure or infiltration, or active viral infection*</td> </tr> <tr> <td>Reticulocyte count</td> <td>Normal</td> <td> <ul> <li>An elevated reticulocyte count suggests a hemolytic process<sup>&#916;</sup> </li> <li>A very low reticulocyte count is consistent with bone marrow failure syndrome* </li> </ul> </td> </tr> <tr> <td>Red blood cell (RBC) indices</td> <td>Normal or minimally abnormal</td> <td> <ul> <li>Macrocytosis may be seen in acquired or inherited bone marrow failure syndromes </li> </ul> </td> </tr> <tr> <td>Examination of the peripheral blood smear</td> <td> <ul> <li>Isolated thrombocytopenia, with normal sized platelets. Sometimes platelets may be variable in size, with some large platelets. </li> <li>No evidence of hemolysis (eg, schistocytes) </li> <li>No blast cells </li> <li>Post infectious ITP may have activated lymphocytes that appear worrisomely like blasts </li> </ul> </td> <td> <ul> <li>Clumping of platelets in an asymptomatic patient suggests that the automated platelet count may not be accurate </li> <li>Predominantly very large (giant) platelets suggest a giant platelet disorder (eg, MYH9-related disease) </li> <li>Predominantly very small platelets suggest Wiskott-Aldrich syndrome </li> <li>Schistocytes suggests a hemolytic process<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td>Direct antiglobulin test (DAT, formerly known as direct Coombs test)</td> <td>Negative</td> <td>Positive DAT suggests autoimmune hemolytic anemia if the hemolysis is ongoing and if IVIG or anti-D have not been given recently (eg, within the past two weeks)</td> </tr> <tr> <td>Quantitative immunoglobulins</td> <td>Normal</td> <td>Common variable immunodeficiency (CVID) is associated with age-specific reduction in serum concentrations of IgG, in combination with low levels of IgA and/or IgM</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table outlines laboratory testing recommended as part of the <strong>initial</strong> evaluation of a child with suspected immune thrombocytopenia (ITP). The results of these initial tests, along with the history and physical examination, inform decisions about further testing to evaluate for other causes of thrombocytopenia.</div><div class=\"graphic_footnotes\">IVIG: intravenous immunoglobulin; Anti-D: anti-D immunoglobulin, also known as anti-Rho immunoglobulin.<br />* Bone marrow infiltration can be caused by a malignant process (leukemia or lymphoma), or inherited process (hemophagocytic lymphohistiocytosis). Bone marrow suppression may be idiopathic (aplastic anemia) or triggered by viral infection or drugs.<br />&Delta; A variety of disorders may cause hemolysis, including autoimmune hemolytic anemia (AIHA), hemolytic uremic syndrome (HUS), or congenital thrombotic thrombocytopenic purpura (TTP).</div><div class=\"graphic_reference\">Courtesy of James Bussel, MD.</div><div id=\"graphicVersion\">Graphic 89206 Version 2.0</div></div></div>"},"89207":{"type":"graphic_figure","displayName":"Total gastrectomy and reconstruction","title":"Total gastrectomy and reconstruction","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Total gastrectomy and reconstruction</div><div class=\"cntnt\"><img style=\"width:513px; height:675px;\" src=\"images/SURG/89207_Total.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During total gastrectomy, the stomach is removed from the esophago-gastric junction to the proximal duodenum (past the pylorus) as depicted by the shaded area in A. Gastrointestinal continuity is restored using a Roux limb of small bowel (B), which is anastomosed to the esophagus in an end-to-side fashion, with or without the creation of a pouch, or neostomach (B).</div><div id=\"graphicVersion\">Graphic 89207 Version 1.0</div></div></div>"},"89210":{"type":"graphic_figure","displayName":"Proximal gastrectomy","title":"Proximal gastrectomy","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Proximal gastrectomy</div><div class=\"cntnt\"><img style=\"width:513px; height:675px;\" src=\"images/SURG/89210_Proximal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proximal gastrectomy removes the upper portion of the stomach (shaded region in A&nbsp;between line 1 and line 2). Gastrointestinal continuity is restored by bringing up a loop of jejunum and anastomosing to the distal esophagus in an end-to-side fashion (B).</div><div id=\"graphicVersion\">Graphic 89210 Version 1.0</div></div></div>"},"89211":{"type":"graphic_figure","displayName":"Pylorus Preserving Segmental Gastrectomy","title":"Pylorus Preserving Segmental Gastrectomy","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Pylorus Preserving Segmental Gastrectomy</div><div class=\"cntnt\"><img style=\"width:489px; height:475px;\" src=\"images/SURG/89211_PPDG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pylorus-preserving segmental gastrectomy (A) is a variation of distal gastrectomy that removes the distal stomach but maintains the pyloric sphincter (shaded region between line 2 and line 3). Gastrointestinal continuity can be restored by anastomosing the remnant stomach together in an end-to-end fashion.</div><div id=\"graphicVersion\">Graphic 89211 Version 2.0</div></div></div>"},"89212":{"type":"graphic_table","displayName":"Postgastrectomy syndromes","title":"Postgastrectomy syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Postgastrectomy syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of gastric reconstruction</td> <td class=\"subtitle1\">Preservation of gastrointestinal continuity</td> <td class=\"subtitle1\">Dumping</td> <td class=\"subtitle1\">Malabsorption</td> <td class=\"subtitle1\">Alkaline reflux</td> </tr> <tr> <td>Billroth I</td> <td class=\"centered\">Duodenal, jejunal</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>Billroth II</td> <td class=\"centered\">Jejunal</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>Roux-en-Y</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td>Jejunal interposition</td> <td class=\"centered\">Duodenal</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> </tr> <tr> <td>Iliocecal interposition</td> <td class=\"centered\">Duodenal, jejunal</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89212 Version 2.0</div></div></div>"},"89213":{"type":"graphic_diagnosticimage","displayName":"Jejunogastric intussusception","title":"Jejunogastric intussusception","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Jejunogastric intussusception</div><div class=\"cntnt\"><img style=\"width:599px; height:355px;\" src=\"images/RADIOL/89213_Jejunogas_intussuscept.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A UGI (A) shows a jejunogastric intussusception with a filling defect (arrows) reflecting the intussusceptum within the lumen of the stomach. Image B is a second patient with a jejunogastric intussusception. The intussusceptum (jejunum) in the stomach (intussuscipiens) is seen as a filling defect (arrowheads). A nasogastric tube traverses the stomach and enters the efferent limb of the gastrojejunal anastomosis.</div><div class=\"graphic_footnotes\">UGI: upper gastrointestinal series.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 89213 Version 2.0</div></div></div>"},"89214":{"type":"graphic_table","displayName":"Summary of hematologic changes in pregnancy","title":"Summary of hematologic changes associated with normal pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of hematologic changes associated with normal pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td>Plasma volume</td> <td>Increased 30 to 50 percent</td> </tr> <tr> <td>Red blood cell mass</td> <td>Increased 20 to 30 percent</td> </tr> <tr> <td>Hemoglobin concentration</td> <td>Decreased</td> </tr> <tr> <td>Red cell lifespan</td> <td>Decreased slightly</td> </tr> <tr> <td>Erythropoietin</td> <td>Increased</td> </tr> <tr> <td>Mean corpuscular volume</td> <td>Increased slightly</td> </tr> <tr> <td>Platelet count</td> <td>No change to decreased slightly</td> </tr> <tr> <td>White blood cell count</td> <td>Increased (neutrophilia)</td> </tr> <tr> <td>Lymphocyte count</td> <td>No change</td> </tr> <tr> <td>Monocyte count</td> <td>No change</td> </tr> <tr> <td>Basophil count</td> <td>No change to decreased slightly</td> </tr> <tr> <td>Eosinophil count</td> <td>No change to increased slightly</td> </tr> <tr> <td>Prothrombin time</td> <td>Decreased slightly</td> </tr> <tr> <td>Bleeding time</td> <td>No change</td> </tr> <tr> <td>Total protein S antigen, free protein S antigen, protein S activity</td> <td>Decreased</td> </tr> <tr> <td>Resistance to activated protein C</td> <td>Increased</td> </tr> <tr> <td>Fibrinogen, factors II, VII, VIII, X, XII, XIII</td> <td>Increased 20 to 200 percent</td> </tr> <tr> <td>Antithrombin, protein C, factor V, factor IX</td> <td>No change to increased slightly</td> </tr> <tr> <td>von Willebrand factor</td> <td>Increased</td> </tr> <tr> <td>Thrombin activatable fibrinolytic inhibitor, PAI-1, PAI-2</td> <td>Increased</td> </tr> <tr> <td>D-dimer</td> <td>Increased</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PAI: plasminogen activator inhibitor.</div><div id=\"graphicVersion\">Graphic 89214 Version 5.0</div></div></div>"},"89218":{"type":"graphic_picture","displayName":"Tongue appearance following paraquat ingestion","title":"Tongue appearance following paraquat ingestion","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Tongue appearance following paraquat ingestion</div><div class=\"cntnt\"><img style=\"width:574px; height:381px;\" src=\"images/EM/89218_Tngu_aprn_flwn_parqu_ingstn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the tongue of a man approximately three to four days after he ingested paraquat.</div><div class=\"graphic_reference\">Photo courtesy of Professor Indika Gawarrammana. Originally published under a Creative Commons Attribution on <A style=\"FONT-STYLE: italic\" href=\"http://www.wikitox.org/\" target=_blank>www.wikitox.org</A>.</div><div id=\"graphicVersion\">Graphic 89218 Version 1.0</div></div></div>"},"89219":{"type":"graphic_diagnosticimage","displayName":"Alveolitis following paraquat ingestion","title":"Alveolitis following paraquat ingestion","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Alveolitis following paraquat ingestion</div><div class=\"cntnt\"><img style=\"width:574px; height:381px;\" src=\"images/EM/89219_Alveolit_fllwn_prqut_ingstn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain radiograph above was taken about five days following paraquat ingestion and shows diffuse alveolitis.</div><div class=\"graphic_reference\">Photo courtesy of Professor Indika Gawarrammana. Originally published under a Creative Commons Attribution on <A style=\"FONT-STYLE: italic\" href=\"http://www.wikitox.org/\" target=_blank>www.wikitox.org</A>.</div><div id=\"graphicVersion\">Graphic 89219 Version 1.0</div></div></div>"},"89220":{"type":"graphic_diagnosticimage","displayName":"Pulmonary fibrosis following paraquat ingestion","title":"Pulmonary fibrosis following paraquat ingestion","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Pulmonary fibrosis following paraquat ingestion</div><div class=\"cntnt\"><img style=\"width:574px; height:433px;\" src=\"images/EM/89220_Pulmry_fbrs_fwng_prqt_ingst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This chest CT scan, taken approximately one year following a parquat ingestion, shows pulmonary fibrosis, particularly in the left lung.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Photo courtesy of Professor Indika Gawarrammana. Originally published under a Creative Commons Attribution on <a href=\"http://www.wikitox.org/\" target=\"_blank\">www.wikitox.org</a>.</div><div id=\"graphicVersion\">Graphic 89220 Version 3.0</div></div></div>"},"89224":{"type":"graphic_picture","displayName":"Neonatal bacterial arthritis","title":"Bacterial arthritis of the knee in a neonate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bacterial arthritis of the knee in a neonate</div><div class=\"cntnt\"><img style=\"width:347px; height:563px;\" src=\"images/PEDS/89224_Neonatal_bacterial_arthrits.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><em>Escherichia coli</em> arthritis of the left knee in a neonate.</div><div id=\"graphicVersion\">Graphic 89224 Version 1.0</div></div></div>"},"89227":{"type":"graphic_picture","displayName":"Urine diquat test for paraquat","title":"Urine diquat test for paraquat","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Urine diquat test for paraquat</div><div class=\"cntnt\"><img style=\"width:588px; height:221px;\" src=\"images/EM/89227_Urine_diquat_test_paraquat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The addition of sodium bicarbonate and sodium dithionite to urine specimens containing decreasing concentrations of diquat shows characteristic color changes. This picture was taken immediately after the addition of dithionite to one of three sets of specimens. Set C is pictured here; similar results in dose-dependent color change were noted with the other sets. Each number represents decreasing concentrations of diquat or control as follows: 1—urine only, 2—730 mg/L, 3—365 mg/L, 4—219 mg/L, 5—73 mg/L, 6—51.1 mg/L, 7—36.5 mg/L, 8—21.9 mg/L, 9— 7.3 mg/L, 10—3.65 mg/L, 11—0.73 mg/L, and 12—glyphosate-only herbicide solution.</div><div class=\"graphic_reference\">Journal of Medical Toxicology, The Poison Pen: Bedside Diagnosis of Urinary Diquat, vol. 6, 2010, p. 35, Vohra R, Salazar A, Cantrell FL, et al, Copyright © 2010 The Author(s). With permission of Springer.</div><div id=\"graphicVersion\">Graphic 89227 Version 4.0</div></div></div>"},"89228":{"type":"graphic_table","displayName":"Cervical cytology incidence","title":"Relative incidence of cervical cytology results","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative incidence of cervical cytology results</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"66%\"></colgroup><colgroup width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cytology</td> <td class=\"subtitle1\">Incidence (percent)</td> </tr> <tr> <td>Negative</td> <td class=\"centered\">96</td> </tr> <tr> <td>Atypical squamous cells of undetermined significance (ASC-US)</td> <td class=\"centered\">2.8</td> </tr> <tr> <td>Low-grade squamous intraepithelial lesion (LSIL)</td> <td class=\"centered\">0.97</td> </tr> <tr> <td>High-grade squamous intraepithelial lesion (HSIL)</td> <td class=\"centered\">0.21</td> </tr> <tr> <td>Atypical glandular cells (AGC)</td> <td class=\"centered\">0.21</td> </tr> <tr> <td>Atypical squamous cells: cannot exclude high-grade squamous intraepithelial lesion (ASC-H)</td> <td class=\"centered\">0.17</td> </tr> <tr> <td>Squamous cell cervical carcinoma</td> <td class=\"centered\">4.5 per 100,000</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines. J Low Genit Tract Dis 2013; 17:S28.</div><div id=\"graphicVersion\">Graphic 89228 Version 1.0</div></div></div>"},"89229":{"type":"graphic_picture","displayName":"Gottrons papules on hand","title":"Gottron's papules in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Gottron's papules in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:574px; height:430px;\" src=\"images/DERM/89229_Gottrons_papules_on_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous to violaceous papules on the metacarpophalangeal joints and the interphalangeal joints in a patient with dermatomyositis. The eruption extends onto the skin between the joints.</div><div class=\"graphic_reference\">Courtesy of Ruth Ann Vleugels, MD, MPH.</div><div id=\"graphicVersion\">Graphic 89229 Version 1.0</div></div></div>"},"89230":{"type":"graphic_picture","displayName":"Gottrons papules in dermatomyositis","title":"Gottron's papules in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Gottron's papules in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/RHEUM/89230_Gottrons_pap_dermatomyos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous to violaceous papules over the extensor joints of the hand in a patient with dermatomyositis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89230 Version 1.0</div></div></div>"},"89236":{"type":"graphic_figure","displayName":"IgE to alpha-gal and total IgE following tick bites","title":"IgE to alpha-gal and total IgE following tick bites","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">IgE to alpha-gal and total IgE following tick bites</div><div class=\"cntnt\"><img style=\"width:374px; height:282px;\" src=\"images/ALLRG/89236_IgE_alph-gl_to_IgE_af_tk_bt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure shows how levels of total IgE and alpha-gal-specific IgE both increased in the serum of a single patient following multiple tick bites.</div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div class=\"graphic_reference\">Unpublished work from: Scott Commins, MD, Charles Lane, MD, and Thomas Platts-Mills, MD, PhD.</div><div id=\"graphicVersion\">Graphic 89236 Version 3.0</div></div></div>"},"89237":{"type":"graphic_diagnosticimage","displayName":"Thoracic fracture associated with calcaneus fracture","title":"Thoracic fracture associated with calcaneus fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracic fracture associated with calcaneus fracture</div><div class=\"cntnt\"><img style=\"width:303px; height:574px;\" src=\"images/EM/89237_Thorc_frct_asoc_calcns_frct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain radiograph shows an anterior compression fracture of the third thoracic vertebra (arrow)&nbsp;that occurred in association with a calcaneus fracture in a patient who landed feet first after falling from a height.</div><div class=\"graphic_reference\">Courtesy of Joan M Street, RT.</div><div id=\"graphicVersion\">Graphic 89237 Version 2.0</div></div></div>"},"89238":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture with subtalar joint extension","title":"Calcaneus fracture with subtalar joint extension","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Calcaneus fracture with subtalar joint extension</div><div class=\"cntnt\"><img style=\"width:574px; height:522px;\" src=\"images/EM/89238_Calcans_fract_subtr_jnt_ext.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral plain radiograph shows a calcaneal fracture (arrow)&nbsp;that extends into the posterior subtalar joint. The patient involved also sustained the thoracic spine fracture in the accompanying radiograph.</div><div class=\"graphic_reference\">Courtesy of Joan M Street, RT.</div><div id=\"graphicVersion\">Graphic 89238 Version 3.0</div></div></div>"},"89240":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture with multiple intraarticular extensions","title":"Calcaneus fracture with multiple intraarticular extensions","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Calcaneus fracture with multiple intraarticular extensions</div><div class=\"cntnt\"><img style=\"width:548px; height:529px;\" src=\"images/EM/89240_Calcns_frac_multi_intrt_ext.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This CT image of the same calcaneus fracture shows additional fracture lines, not apparent on plain x-ray, extending into the subtalar joint.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Joan M Street, RT.</div><div id=\"graphicVersion\">Graphic 89240 Version 3.0</div></div></div>"},"89241":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture CT transverse image","title":"Calcaneus fracture CT transverse image","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcaneus fracture CT transverse image</div><div class=\"cntnt\"><img style=\"width:417px; height:574px;\" src=\"images/EM/89241_Calcns_fract_CT_trnsvrs_img.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This transverse CT image of the same fracture shows an anterior fracture fragment (arrow) not apparent on the accompanying plain radiograph or the lateral CT image.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Joan M Street, RT.</div><div id=\"graphicVersion\">Graphic 89241 Version 4.0</div></div></div>"},"89242":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture CT generated 3D image","title":"Calcaneus fracture CT generated 3D image","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Calcaneus fracture CT generated 3D image</div><div class=\"cntnt\"><img style=\"width:541px; height:526px;\" src=\"images/EM/89242_Calcans_fract_CT_gen_3D_img.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This volume rendered CT image of the same injury shown in the accompanying radiographs allows better visualization of the spatial relationships of the fracture fragments.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Joan M Street, RT.</div><div id=\"graphicVersion\">Graphic 89242 Version 3.0</div></div></div>"},"89244":{"type":"graphic_picture","displayName":"Epidermal nevus histopathology","title":"Histopathologic features of epidermal nevus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of epidermal nevus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/89244_Epidermal_nevus_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathologic features of an epidermal nevus in a 21-day-old baby. Epidermal acanthosis, papillomatosis, and hyperkeratosis are characteristic of this type of lesion.</div><div class=\"graphic_reference\">Copyright © Greg Hosler, MD, PhD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 89244 Version 4.0</div></div></div>"},"89246":{"type":"graphic_table","displayName":"Response criteria for plasma cell leukemia","title":"Response criteria for plasma cell leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Response criteria for plasma cell leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Bone marrow criteria*</td> <td class=\"subtitle1\">Peripheral blood criteria*</td> <td class=\"subtitle1\">Serological criteria<sup>&#182;</sup></td> <td class=\"subtitle1\">Other criteria</td> </tr> <tr class=\"divider_bottom\"> <td>Stringent complete remission</td> <td> <p>Bone marrow plasma cells &#60;5 percent</p> <p>and</p> No malignant plasma cell by flow cytometry</td> <td>No plasma cells in peripheral blood by flow cytometry</td> <td> <p>Negative serum and urine immunofixation</p> Normal serum FLC ratio</td> <td>Absence of extramedullary disease</td> </tr> <tr class=\"divider_bottom\"> <td>Complete remission</td> <td>Bone marrow plasma cells &#60;5 percent</td> <td>No plasma cells in peripheral blood</td> <td>Negative serum and urine immunofixation<sup>&#916;</sup></td> <td>Absence of extramedullary disease</td> </tr> <tr class=\"divider_bottom\"> <td>Very good partial response</td> <td>Bone marrow plasma cells &#60;5 percent</td> <td>No plasma cells in peripheral blood</td> <td> <p>&#8805;90 percent reduction of serum M-protein</p> <p>and</p> 24-hour urinary M-protein &#60;100 mg per 24 hours<sup>&#9674;</sup></td> <td>Absence of extramedullary disease</td> </tr> <tr class=\"divider_bottom\"> <td>Partial response</td> <td>Bone marrow plasma cells 5 to 25 percent</td> <td>Peripheral blood plasma cells from 1 to 5 percent</td> <td> <p>&#8805;50 percent reduction of serum M-protein</p> <p>and</p> Reduction in 24-hour urinary M-protein by &#8805;90 percent and &#60;200 mg per 24 hours<sup>&#167;</sup></td> <td>&#8805;50 percent reduction in the size of extramedullary disease</td> </tr> <tr class=\"divider_bottom\"> <td>Stable disease</td> <td colspan=\"4\">Not meeting the criteria of either partial response or progressive disease</td> </tr> <tr class=\"divider_bottom\"> <td>Progressive disease</td> <td>&#62;25 percent increase in plasma cells in a bone marrow aspirate or absolute increase &#8805;10 percent</td> <td>&#62;5 percent absolute increase in peripheral blood plasma cells</td> <td> <p>&#62;25 percent increase in the level of the serum monoclonal paraprotein with an absolute increase &#8805;5 g/L</p> &#62;25 percent increase in the 24-hour urinary light chain excretion with an absolute increase &#8805;200 mg/24 hours</td> <td> <p>Hypercalcemia</p> <p>Definite increase in lytic bone lesions</p> Definite increase in the size or number of extramedullary disease</td> </tr> <tr> <td>Relapse from complete remission</td> <td>More than 10 percent increase in bone marrow plasma cells</td> <td>Reappearance of peripheral blood plasma cells at any level</td> <td>Reappearance of original M-protein in serum and/or urine immunofixation</td> <td>Any extramedullary disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FLC: free light chain.<br />* It is recommended that at least 200 leukocytes on blood smears and 500 nucleated cells on marrow smears be counted.<br />¶ It should be maintained for a minimum of six weeks. In case of discrepancy or undetectable serological parameter, the patient must be classified according to bone marrow criteria.<br />Δ If the serum and urine M-protein are unmeasurable, a normal serum kappa/lambda FLC ratio is also required.<br /><FONT class=lozenge>◊</FONT> If the serum and urine M-protein are unmeasurable, a ≥90 percent decrease in the difference between involved and uninvolved FLC levels is required instead of the M-protein.<br />§ If the serum and urine M-protein are unmeasurable, a ≥50 percent decrease in the difference between involved and uninvolved FLC levels is required instead of the M-protein.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Leukemia. Fern&aacute;ndez de Larrea C, Kyle RA, Durie BM, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013; 27:780. <a href=\"http://www.nature.com/leu\" target=\"_blank\">www.nature.com/leu</a>. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 89246 Version 2.0</div></div></div>"},"89247":{"type":"graphic_figure","displayName":"Tracheobronchomalacia and hyperdynamic airway collapse","title":"Changes in airway lumen during the respiratory cycle in tracheobronchomalacia and hyperdynamic airway collapse","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Changes in airway lumen during the respiratory cycle in tracheobronchomalacia and hyperdynamic airway collapse</div><div class=\"cntnt\"><img style=\"width:514px; height:505px;\" src=\"images/PULM/89247_Trchbrnchmlc_hprdn_arwy_cllps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal airway lumen during inspiration is shown with the anterior cartilaginous rings in gray and the posterior membranous tracheal wall in pale pink (A). During expiration there is inward bulging of the posterior membrane. This process is physiological and is called dynamic airway collapse (DAC) (B). The pathologic exaggeration of this process results in a reduction in cross sectional area of 70% or more and is called excessive dynamic airway collapse (EDAC) (C). In tracheobronchomalacia (TBM), a pathological collapse of the cartilaginous rings occurs. The crescent type TBM results in excessive narrowing of the sagittal (anterior-posterior) airway diameter (D). When TBM is combined with EDAC, the trachea is further flattened during expiration (E).</div><div class=\"graphic_reference\">Modified from: Murgu SD. Tracheobronchomalacia and excessive dynamic airway collapse. Respirology 2006; 11:388.</div><div id=\"graphicVersion\">Graphic 89247 Version 3.0</div></div></div>"},"89248":{"type":"graphic_diagnosticimage","displayName":"Balloon testing to evaluate safety of PPVI","title":"Balloon testing to evaluate safety of percutaneous pulmonic valve insertion","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Balloon testing to evaluate safety of percutaneous pulmonic valve insertion</div><div class=\"cntnt\"><img style=\"width:585px; height:294px;\" src=\"images/CARD/89248_Bln_tsn_szn_pro_prt_PV_inst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiographic images obtained during a balloon test performed prior to planned percutaneous pulmonic valve insertion (PPVI). The patient is a seven-year-old boy with an interrupted arch and ventricular septal defect who had previously undergone a Ross-Konno operation and two replacements of right ventricle to pulmonary artery conduits.<br />(Left panel) Aortogram showing contrast in the left main and right coronary arteries and a guidewire positioned in the right ventricular outflow tract. Note the relatively distal origin of the left coronary artery.<br />(Right panel) Aortogram during high pressure balloon inflation in the right ventricular outflow tract to the maximum final expected diameter. Note that the left coronary artery does not fill with contrast. During balloon testing, the patient experienced bradycardia with a junctional rhythm that reverted to normal sinus rhythm upon deflation of the balloon. Due to the results of this balloon test, PPVI was not performed.</div><div id=\"graphicVersion\">Graphic 89248 Version 3.0</div></div></div>"},"89249":{"type":"graphic_diagnosticimage","displayName":"Percutaneous PV insertion of Melody valve","title":"Percutaneous pulmonic valve (PV) insertion of Melody valve","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Percutaneous pulmonic valve (PV) insertion of Melody valve</div><div class=\"cntnt\"><img style=\"width:579px; height:291px;\" src=\"images/CARD/89249_Percutns_PV_insrt_Meldy_val.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral views of angiogram before (left panel) and after (right panel) pre-stenting and percutaneous pulmonic valve implantation (PPVI) in an eight-year-old girl. The girl had an interrupted aortic arch with a subaortic stenosis that was repaired using a Damus-Kaye-Stansel anastomosis and a Homograft that was bicuspidalized to a diameter of 13 mm. A covered CP stent (NuMED) was used for pre-stenting. A Melody valve (Medtronic) was used for PPVI and dilated to 18 mm. The Melody valve consists of a CP stent (NuMED)&nbsp;within which a bovine jugular venous valve is attached. Therefore, the right image depicts two&nbsp;identical stents lying inside of each other.</div><div id=\"graphicVersion\">Graphic 89249 Version 2.0</div></div></div>"},"89250":{"type":"graphic_diagnosticimage","displayName":"Percutaneous PV insertion of Sapien valve","title":"Percutaneous pulmonic valve (PV) insertion of Sapien valve","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Percutaneous pulmonic valve (PV) insertion of Sapien valve</div><div class=\"cntnt\"><img style=\"width:582px; height:289px;\" src=\"images/CARD/89250_Perctns_PV_insrt_Sapien_val.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral views of angiogram before (left panel) and after (right panel) pre-stenting and percutaneous pulmonic valve implantation (PPVI) in a 34-year-old male. The patient had a stenotic pulmonic valve that had been repaired using a transvalvular patch at the age of 23 years. Because of the large right ventricular outflow tract, pre-stenting was performed with an Andramed XXL Stent dilated to a diameter of 28 mm. An Edwards SAPIEN Pulmonic Transcatheter Heart Valve dilated to 29 mm was used for PPVI.</div><div id=\"graphicVersion\">Graphic 89250 Version 1.0</div></div></div>"},"89251":{"type":"graphic_diagnosticimage","displayName":"Stent fracture following percutaneous PV insertion","title":"Stent fracture following percutaneous pulmonic valve (PV) insertion","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Stent fracture following percutaneous pulmonic valve (PV) insertion</div><div class=\"cntnt\"><img style=\"width:584px; height:266px;\" src=\"images/CARD/89251_Stnt_frc_flng_prctn_PV_inrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest x-ray of a 24-year-old male one year after percutaneous pulmonic valve insertion (PPVI). The patient received PPVI 22 years after&nbsp;tetralogy of Fallot repair&nbsp;with a right ventricular to pulmonary artery homograft. As a newborn with tetralogy of Fallot,&nbsp;the patient had received&nbsp;a right-sided Blalock-Taussig shunt that was subsequently clipped. PPVI was performed with a Melody valve after pre-stenting with an IntraStent Max LD Stent (Covidien) dilated to 20 mm. In the right panel, enlarged detail view, the asterisk&nbsp;indicates an asymptomatic stent fracture.</div><div id=\"graphicVersion\">Graphic 89251 Version 2.0</div></div></div>"},"89260":{"type":"graphic_picture","displayName":"Kaposiform hemangioendothelioma 3","title":"Kaposiform hemangioendothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kaposiform hemangioendothelioma</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/89260_Kaposiform_hemangiotheli_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large, red-violaceous plaque on the thigh of an infant with kaposiform hemangiothelioma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89260 Version 1.0</div></div></div>"},"89261":{"type":"graphic_movie","displayName":"Trichomonad species","title":"Trichomonad species","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trichomonad species</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/89261_Trichomonadspeciesvideo.mp4\" style=\"width:432px;height:336px\"></div><img style=\"width:432px; height:315px;\" src=\"images/OBGYN/89261_Trichomonadspeciesimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Video showing Trichomonad species in motion.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Eduardo H Canessa M.Q.C.</div><div id=\"graphicVersion\">Graphic 89261 Version 2.0</div></div></div>"},"89264":{"type":"graphic_picture","displayName":"Kaposiform hemangioendothelioma leg","title":"Kaposiform hemangioendothelioma","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Kaposiform hemangioendothelioma</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/DERM/89264_Kaposiform_hemangiothe_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaposiform&nbsp;hemangioendothelioma in an infant with massive involvement of the entire leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89264 Version 1.0</div></div></div>"},"89267":{"type":"graphic_diagnosticimage","displayName":"Bohlers angle calcaneus fracture","title":"Bohler's angle calcaneus fracture","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Bohler's angle calcaneus fracture</div><div class=\"cntnt\"><img style=\"width:574px; height:522px;\" src=\"images/EM/89267_Bohlers_angle_calcans_fract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral radiograph shows a calcaneus fracture resulting in a Bohlers angle of about 18 degrees (arrow). The normal range is 20 to 40 degrees. Bohlers angle is formed by the intersection of two lines, one drawn from the most cephalic point of the calcaneal tuberosity (A) to the most cephalic point of the posterior articular facet (B), and the other drawn from point B to the most cephalic point of the anterior process (C). The arrowhead indicates the os trigonum, a normal accessory ossicle commonly mistaken for a fracture fragment.</div><div class=\"graphic_reference\">Courtesy of Joan M Street, RT.</div><div id=\"graphicVersion\">Graphic 89267 Version 3.0</div></div></div>"},"89269":{"type":"graphic_diagnosticimage","displayName":"Bohlers angle restored","title":"Bohler's angle restored","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Bohler's angle restored</div><div class=\"cntnt\"><img style=\"width:574px; height:562px;\" src=\"images/EM/89269_Bohlers_angle_restored.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This radiograph shows the same fracture of the calcaneus from the previous image after open reduction and internal fixation. Note that the Bohlers angle (arrow)&nbsp;has been restored (now about 30 degrees).</div><div class=\"graphic_reference\">Courtesy of Joan M Street, RT.</div><div id=\"graphicVersion\">Graphic 89269 Version 3.0</div></div></div>"},"89277":{"type":"graphic_diagnosticimage","displayName":"Calcaneus angle of Gissane","title":"Calcaneus: Angle of Gissane","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Calcaneus: Angle of Gissane</div><div class=\"cntnt\"><img style=\"width:574px; height:522px;\" src=\"images/EM/89277_SRC-Calcaneus_angle_of_Gissane.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral radiograph of the same fracture used to describe Bohlers angle shows the angle of Gissane. The lines used to approximate the angle of Gissane run along the superior aspect of the posterior facet and the superior aspect of the anterior process. Here the angle measures about 100 degrees, barely within the normal range (100 to 130 degrees).</div><div class=\"graphic_reference\">Courtesy of Joan M Street, RT.</div><div id=\"graphicVersion\">Graphic 89277 Version 2.0</div></div></div>"},"89278":{"type":"graphic_diagnosticimage","displayName":"Calcaneus avulsion fracture oblique view","title":"Calcaneus avulsion fracture oblique view","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Calcaneus avulsion fracture oblique view</div><div class=\"cntnt\"><img style=\"width:465px; height:574px;\" src=\"images/EM/89278_Calcans_avulsn_frac_oblq_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On this internal oblique plain radiograph of the ankle, a calcaneal avulsion fracture of the extensor digitorum brevis origin can be seen (arrow). The os tibiale externum, a normal accessory ossicle, can be seen at the opposite side of the foot in its typical location (arrowhead). Note the difference in appearance between the ragged margins of the fracture fragment and the smooth regular contours of the ossicle.</div><div class=\"graphic_reference\">Courtesy of Joan M Street, RT.</div><div id=\"graphicVersion\">Graphic 89278 Version 2.0</div></div></div>"},"89279":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture subtle findings","title":"Calcaneus fracture subtle findings","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Calcaneus fracture subtle findings</div><div class=\"cntnt\"><img style=\"width:574px; height:439px;\" src=\"images/EM/89279_Calcaneus_fract_subt_findng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The presence of a calcaneus fracture is indicated only by a subtle irregularity of the inferior cortex (arrow) on this standard lateral radiograph.</div><div class=\"graphic_reference\">Courtesy of Joan M Street, RT.</div><div id=\"graphicVersion\">Graphic 89279 Version 2.0</div></div></div>"},"89280":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture using Brodens view","title":"Calcaneus fracture using Broden's view","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Calcaneus fracture using Broden's view</div><div class=\"cntnt\"><img style=\"width:508px; height:574px;\" src=\"images/EM/89280_Calcan_fract_usng_Broden_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This radiograph using Broden's view is of the same patient as the accompanying image, but reveals fractures of the medial tuberosity (arrows).</div><div class=\"graphic_reference\">Courtesy of Joan M Street, RT.</div><div id=\"graphicVersion\">Graphic 89280 Version 2.0</div></div></div>"},"89281":{"type":"graphic_diagnosticimage","displayName":"Calcaneus anterior process fracture lateral view","title":"Calcaneus anterior process fracture lateral view","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Calcaneus anterior process fracture lateral view</div><div class=\"cntnt\"><img style=\"width:574px; height:404px;\" src=\"images/EM/89281_Calcan_ant_pros_frac_lat_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain lateral radiograph shows a fracture of the anterior process of the calcaneus (arrow). Overlying shadow makes it difficult to appreciate the full extent of the fracture.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89281 Version 1.0</div></div></div>"},"89282":{"type":"graphic_diagnosticimage","displayName":"Calcaneus anterior process fracture oblique view","title":"Calcaneus anterior process fracture oblique view","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Calcaneus anterior process fracture oblique view</div><div class=\"cntnt\"><img style=\"width:574px; height:477px;\" src=\"images/EM/89282_Calcn_antr_prc_frac_oblq_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This oblique view of the same anterior process fracture process allows better appreciation of the fracture and its extension into the calcaneocuboid joint (arrow).</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89282 Version 1.0</div></div></div>"},"89283":{"type":"graphic_diagnosticimage","displayName":"Calcaneus anterior process fracture AP view","title":"Calcaneus anterior process fracture AP view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcaneus anterior process fracture AP view</div><div class=\"cntnt\"><img style=\"width:217px; height:574px;\" src=\"images/EM/89283_Calcan_antr_proc_frac_AP_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anteroposterior (AP) view shown here is of the same patient, but the anterior process fracture cannot be seen.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89283 Version 1.0</div></div></div>"},"89285":{"type":"graphic_diagnosticimage","displayName":"Calcaneus anterior process fracture sagittal CT","title":"Calcaneus anterior process fracture on sagittal CT","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Calcaneus anterior process fracture on sagittal CT</div><div class=\"cntnt\"><img style=\"width:574px; height:466px;\" src=\"images/EM/89285_Calca_ant_proc_frac_sagt_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sagittal CT image shows a large avulsion fracture of the anterior process of the calcaneus (arrow). As demonstrated here, CT is superior to plain radiograph for determining the size, displacement, and extent of such fractures.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89285 Version 2.0</div></div></div>"},"89286":{"type":"graphic_picture","displayName":"Melasma forearms and chest","title":"Melasma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Melasma</div><div class=\"cntnt\"><img style=\"width:334px; height:504px;\" src=\"images/DERM/89286_Melasma_forearms_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Splotchy symmetric hyperpigmentation on the forearms, upper chest, and face in a 30-year-old woman. Shortly after starting oral contraceptives, she developed melasma after intense sun exposure.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 89286 Version 3.0</div></div></div>"},"89287":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture anterior process compression","title":"Compression fracture of the calcaneus anterior process","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Compression fracture of the calcaneus anterior process</div><div class=\"cntnt\"><img style=\"width:504px; height:375px;\" src=\"images/EM/89287_Calcan_fx_compres_ant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain lateral radiograph shows a compression fracture of the anterior process. The two arrows indicate the borders of the fracture fragment.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89287 Version 1.0</div></div></div>"},"89288":{"type":"graphic_picture","displayName":"Palpation calcaneus anterior process","title":"Palpation of the calcaneus anterior process","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Palpation of the calcaneus anterior process</div><div class=\"cntnt\"><img style=\"width:574px; height:430px;\" src=\"images/EM/89288_Palpation_calcan_anter_proc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To find the calcaneocuboid joint, place the tip of your thumb on the lateral malleolus and the tip of your middle finger on the proximal fifth metatarsal, as shown in the photograph. The tip of your index finger then points to the location of the joint.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD.</div><div id=\"graphicVersion\">Graphic 89288 Version 2.0</div></div></div>"},"89289":{"type":"graphic_diagnosticimage","displayName":"Calcaneus avulsion fracture extensor digitorum brevis","title":"Calcaneus avulsion fracture extensor digitorum brevis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcaneus avulsion fracture extensor digitorum brevis</div><div class=\"cntnt\"><img style=\"width:443px; height:574px;\" src=\"images/EM/89289_Calc_avu_frac_ext_digt_brev.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This AP plain radiograph of the ankle shows an avulsion fracture of the extensor digitorum brevis (arrow).</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Joan M Street, RT.</div><div id=\"graphicVersion\">Graphic 89289 Version 3.0</div></div></div>"},"89290":{"type":"graphic_picture","displayName":"Riehl melanosis","title":"Pigmented contact dermatitis (Riehl's melanosis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pigmented contact dermatitis (Riehl's melanosis)</div><div class=\"cntnt\"><img style=\"width:383px; height:574px;\" src=\"images/DERM/89290_Riehl_melanosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gray-brown, reticular facial pigmentation in a 33-year-old man with Riehl's melanosis.</div><div class=\"graphic_reference\">Reproduced with permission from: The Dermatology Online Atlas, <a href=\"http://www.dermis.net/\" target=\"_blank\">www.dermis.net</a>. Copyright &copy; 2013. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89290 Version 2.0</div></div></div>"},"89291":{"type":"graphic_table","displayName":"Cervical cytology risk of neoplasia","title":"Risk of cervical neoplasia with abnormal cervical cytology results in women ages 30 to 64","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of cervical neoplasia with abnormal cervical cytology results in women ages 30 to 64</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"55%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Cervical cytology*</td> <td class=\"subtitle1\" colspan=\"3\">Incidence (percent)</td> </tr> <tr> <td class=\"subtitle2\">CIN 2+</td> <td class=\"subtitle2\">CIN 3+<sup>&#916;</sup></td> <td class=\"subtitle2\">Cervical cancer<sup>&#9674;</sup></td> </tr> <tr> <td>Negative</td> <td class=\"centered\">0.68</td> <td class=\"centered\">0.26</td> <td class=\"centered\">0.025</td> </tr> <tr> <td>Atypical squamous cells of undetermined significance (ASC-US)</td> <td class=\"centered\">6.9</td> <td class=\"centered\">2.6</td> <td class=\"centered\">0.18</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>HPV-positive </li> </ul> </td> <td class=\"centered\">18</td> <td class=\"centered\">6.8</td> <td class=\"centered\">0.41</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>HPV-negative </li> </ul> </td> <td class=\"centered\">1.1</td> <td class=\"centered\">0.43</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Low-grade squamous intraepithelial lesion (LSIL)</td> <td class=\"centered\">16</td> <td class=\"centered\">5.2</td> <td class=\"centered\">0.16</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>HPV-positive </li> </ul> </td> <td class=\"centered\">19</td> <td class=\"centered\">6.1</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>HPV-negative </li> </ul> </td> <td class=\"centered\">5.1</td> <td class=\"centered\">2.0</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Atypical squamous cells: cannot exclude a high-grade squamous intraepithelial lesion (ASC-H)</td> <td class=\"centered\">35</td> <td class=\"centered\">18</td> <td class=\"centered\">2.6</td> </tr> <tr> <td>High-grade intraepithelial lesion</td> <td class=\"centered\">69</td> <td class=\"centered\">47</td> <td class=\"centered\">7.3</td> </tr> <tr> <td>Atypical glandular cells</td> <td class=\"centered\">13</td> <td class=\"centered\">8.5</td> <td class=\"centered\">2.7</td> </tr> <tr> <td>Squamous cell cancer</td> <td class=\"centered\">84</td> <td class=\"centered\">84</td> <td class=\"centered\">68</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HPV: human papillomavirus; CIN: cervical intraepithelial neoplasia.<br />* Results alone, unless testing for high-risk subtypes of HPV is specified.<br />&Delta; Includes adenocarcinoma in situ.<br /><span class=\"lozenge\">&loz;</span> Includes squamous cervical cancer and cervical adenocarcinoma.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis 2013; 17:S28.</li>&#xD;&#xA;    <li>Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J Low Genit Tract Dis 2013; 17:S36.</li>&#xD;&#xA;    <li>Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results. J Low Genit Tract Dis 2013; 17:S43.</li>&#xD;&#xA;    <li>Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results. J Low Genit Tract Dis 2013; 17:S50.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 89291 Version 3.0</div></div></div>"},"89292":{"type":"graphic_diagnosticimage","displayName":"Calcaneus medial process fracture axial view","title":"Calcaneus medial process fracture on axial view","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Calcaneus medial process fracture on axial view</div><div class=\"cntnt\"><img style=\"width:490px; height:574px;\" src=\"images/EM/89292_Calcaneus_med_proc_frac_axi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain axial radiograph shows a nondisplaced medial process fracture of the calcaneus (arrow).</div><div class=\"graphic_reference\">Courtesy of Joan M Street, RT.</div><div id=\"graphicVersion\">Graphic 89292 Version 2.0</div></div></div>"},"89293":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture medial process lateral view","title":"Calcaneus fracture of medial process on lateral view","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Calcaneus fracture of medial process on lateral view</div><div class=\"cntnt\"><img style=\"width:574px; height:509px;\" src=\"images/EM/89293_Calca_frac_med_proc_late_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain lateral radiograph shows the same nondisplaced fracture of the medial process as in the accompanying axial view, but the findings consist of more subtle disruptions of the cortex (arrows).</div><div class=\"graphic_reference\">Courtesy of Joan M Street, RT.</div><div id=\"graphicVersion\">Graphic 89293 Version 2.0</div></div></div>"},"89294":{"type":"graphic_diagnosticimage","displayName":"Calcaneus tuberosity avulsion fracture","title":"Calcaneus tuberosity avulsion fracture","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Calcaneus tuberosity avulsion fracture</div><div class=\"cntnt\"><img style=\"width:572px; height:574px;\" src=\"images/EM/89294_Calcaneus_tuberos_avul_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain lateral radiograph shows a tuberosity avulsion fracture of the calcaneus with significant displacement (arrow) but no visible intra-articular extension.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89294 Version 1.0</div></div></div>"},"89295":{"type":"graphic_diagnosticimage","displayName":"Calcaneus axial radiograph","title":"Calcaneus on axial radiograph","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Calcaneus on axial radiograph</div><div class=\"cntnt\"><img style=\"width:456px; height:574px;\" src=\"images/EM/89295_Calcaneus_axial_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial view of the calcaneus is seen in this plain radiograph. The projection indicated by the arrow is the sustentaculum tali, which provides the middle talar articular surface.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89295 Version 1.0</div></div></div>"},"89296":{"type":"graphic_diagnosticimage","displayName":"Comminuted calcaneus fracture lateral x-ray","title":"Comminuted calcaneus fracture lateral x-ray","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Comminuted calcaneus fracture lateral x-ray</div><div class=\"cntnt\"><img style=\"width:574px; height:502px;\" src=\"images/EM/89296_Commint_calc_frac_lat_x-ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This series of three images shows the same calcaneus fracture. The first image shows an extensively comminuted fracture on a plain lateral radiograph, but it is unclear whether the fracture involves the sustentaculum tali or extends into the subtalar joint. The sagittal CT image seen next shows clear extension into the posterior subtalar joint (arrow). The third image is an axial CT that reveals a fracture fragment that includes the sustentaculum tali (arrow).</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89296 Version 1.0</div></div></div>"},"89298":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture anterior process","title":"Calcaneus fracture of the anterior process","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Calcaneus fracture of the anterior process</div><div class=\"cntnt\"><img style=\"width:574px; height:467px;\" src=\"images/EM/89298_Calcaneus_fract_anter_procs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral plain radiograph shows a fracture of the anterior process (single arrow) that may extend into the calcaneocuboid articulation. Although there is no discrete fracture line extending into the posterior subtalar joint, it is impossible to be certain about this using only this image. A normal os trigonum (double arrows) is present.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89298 Version 1.0</div></div></div>"},"89299":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture anterior process sagittal CT","title":"Calcaneus fracture of anterior process on sagittal CT","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Calcaneus fracture of anterior process on sagittal CT</div><div class=\"cntnt\"><img style=\"width:558px; height:574px;\" src=\"images/EM/89299_Calc_frac_antr_proc_sagt_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sagittal CT image of a fracture of the anterior process of the calcaneus shows that the fracture line does not extend into the calcaneocuboid articulation or the subtalar joint.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89299 Version 2.0</div></div></div>"},"89301":{"type":"graphic_diagnosticimage","displayName":"Comminuted calcaneus fracture sagittal CT","title":"Comminuted calcaneus fracture sagittal CT","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Comminuted calcaneus fracture sagittal CT</div><div class=\"cntnt\"><img style=\"width:574px; height:483px;\" src=\"images/EM/89301_Comminu_calc_fract_sagit_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sagittal CT image seen here shows clear extension into the posterior subtalar joint (arrow).</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89301 Version 1.0</div></div></div>"},"89302":{"type":"graphic_diagnosticimage","displayName":"Comminuted calcaneus fracture axial CT","title":"Comminuted calcaneus fracture axial CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comminuted calcaneus fracture axial CT</div><div class=\"cntnt\"><img style=\"width:372px; height:574px;\" src=\"images/EM/89302_Comminut_calca_fract_axi_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image is an axial CT that reveals a fracture fragment that includes the sustentaculum tali (arrow).</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89302 Version 1.0</div></div></div>"},"89305":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture posterior body","title":"Calcaneus fracture of the posterior body","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Calcaneus fracture of the posterior body</div><div class=\"cntnt\"><img style=\"width:504px; height:396px;\" src=\"images/EM/89305_Calcaneus_fx_post_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this plain lateral radiograph, a fracture line posterior to the subtalar joint (arrow) is clearly visible, but no other fractures are apparent.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89305 Version 1.0</div></div></div>"},"89306":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture anterior posterior process","title":"Calcaneus fracture of anterior and posterior process","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Calcaneus fracture of anterior and posterior process</div><div class=\"cntnt\"><img style=\"width:504px; height:465px;\" src=\"images/EM/89306_Calcanea_ant_post_proc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sagittal CT image of the same injury demonstrates a second fracture line (arrow) anterior to the subtalar joint. Neither fracture line extends into the joint proper.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89306 Version 2.0</div></div></div>"},"89307":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture with abnormal Bohlers angle","title":"Calcaneus fracture with abnormal Bohlers angle","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Calcaneus fracture with abnormal Bohlers angle</div><div class=\"cntnt\"><img style=\"width:574px; height:453px;\" src=\"images/EM/89307_Calc_frac_wt_abnm_Bohlr_ang.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral plain radiograph is from the preceding case but lines for measuring Bohlers angle have been added. Althought the degree of fracture displacement may not be apparent on cursory view of the original radiograph, measurement of this highly abnormal Bohlers angle (negative five degrees) clearly indicates significant displacement.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89307 Version 1.0</div></div></div>"},"89308":{"type":"graphic_diagnosticimage","displayName":"Calcaneal stress fracture","title":"Calcaneal stress fracture","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Calcaneal stress fracture</div><div class=\"cntnt\"><img style=\"width:504px; height:461px;\" src=\"images/EM/89308_Calcaneal_stress_fract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain lateral radiograph shows a subtle band of sclerosis in the posterior body of the calcaneus suggesting a possible stress fracture. The patient was complaining of heel pain.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89308 Version 1.0</div></div></div>"},"89309":{"type":"graphic_diagnosticimage","displayName":"Early calcaneal stress fracture on MRI","title":"Early calcaneal stress fracture on MRI","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Early calcaneal stress fracture on MRI</div><div class=\"cntnt\"><img style=\"width:504px; height:461px;\" src=\"images/EM/89309_Earl_cal_str_fract_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This T1 weighted MRI study demonstrates a stress fracture in the posterior body of the calcaneus. The site of the lesion (arrow) corresponds with the area of subtle sclerosis seen on the accompanying plain radiograph.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89309 Version 2.0</div></div></div>"},"89310":{"type":"graphic_diagnosticimage","displayName":"Calcaneal stress fracture comparison images","title":"Calcaneal stress fracture comparison images","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Calcaneal stress fracture comparison images</div><div class=\"cntnt\"><img style=\"width:504px; height:462px;\" src=\"images/EM/89310_Calc_stress_early_heal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain radiograph taken approximately four weeks after presentation (inset) reveals a typical sclerotic band that is more prominent than the subtle sclerosis (between arrows)&nbsp;seen on the initial images, which are provided for comparison.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89310 Version 1.0</div></div></div>"},"89311":{"type":"graphic_diagnosticimage","displayName":"Calcaneus fracture MRI","title":"Calcaneus fracture MRI","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Calcaneus fracture MRI</div><div class=\"cntnt\"><img style=\"width:504px; height:432px;\" src=\"images/EM/89311_Calcaneus_fracture_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This MRI study shows a fracture through the anterior process of the calcaneus (arrow) that was not apparent on plain radiograph.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89311 Version 2.0</div></div></div>"},"89315":{"type":"graphic_form","displayName":"Ask suicide-screening questions","title":"Ask suicide-screening questions","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Ask suicide-screening questions</div><div class=\"cntnt\"><img style=\"width:582px; height:546px;\" src=\"images/PSYCH/89315_asksuicidescreenquest.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Horowitz LM, Bridge JA, Teach SJ, et al. Ask Suicide-Screening Questions (ASQ): a brief instrument for the pediatric emergency department. Arch Pediatr Adolesc Med 2012; 166:1170. Copyright &copy; 2012 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89315 Version 8.0</div></div></div>"},"89316":{"type":"graphic_picture","displayName":"Eczematid-like purpura of Doucas and Kapetanakis","title":"Eczematid-like purpura of Doucas and Kapetanakis","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Eczematid-like purpura of Doucas and Kapetanakis</div><div class=\"cntnt\"><img style=\"width:574px; height:375px;\" src=\"images/DERM/89316_Eczmtd_lik_purpr_Doc_Kaptnk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Purpuric eczematous patches with mild scale on the extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: The Dermatology Online Atlas, <a href=\"http://www.dermis.net/\" target=\"_blank\">www.dermis.net</a>. Copyright &copy; 2013. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89316 Version 1.0</div></div></div>"},"89317":{"type":"graphic_picture","displayName":"Absent testis","title":"Laparoscopic view of absent testis","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Laparoscopic view of absent testis</div><div class=\"cntnt\"><img style=\"width:513px; height:213px;\" src=\"images/PEDS/89317_Absent_testis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Left internal ring laparoscopy view with blind ending vessels (arrows) and vas deferens (arrowheads) confirming an absent testis.<br />(B) Right internal ring laparoscopy view with normal testicular vessels and vas deferens exiting the internal ring.</div><div id=\"graphicVersion\">Graphic 89317 Version 2.0</div></div></div>"},"89318":{"type":"graphic_picture","displayName":"Suprascrotal undescended testes","title":"Bilateral suprascrotal undescended testes","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Bilateral suprascrotal undescended testes</div><div class=\"cntnt\"><img style=\"width:480px; height:500px;\" src=\"images/PEDS/89318_Suprascro_undesc_teste.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral undescended testes visible on physical examination at the external ring (arrows).</div><div id=\"graphicVersion\">Graphic 89318 Version 2.0</div></div></div>"},"89319":{"type":"graphic_picture","displayName":"Intra-abdominal testis","title":"Laparoscopic view of intra-abdominal testis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Laparoscopic view of intra-abdominal testis</div><div class=\"cntnt\"><img style=\"width:504px; height:402px;\" src=\"images/PEDS/89319_Intraabdominal_testis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laparoscopic view of a right intra-abdominal testis close to the right internal ring.</div><div id=\"graphicVersion\">Graphic 89319 Version 3.0</div></div></div>"},"89320":{"type":"graphic_picture","displayName":"Ectopic testis","title":"Ectopic testis","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Ectopic testis</div><div class=\"cntnt\"><img style=\"width:482px; height:504px;\" src=\"images/PEDS/89320_Ectopic_testis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right ectopic testis palpable in the perineum.</div><div id=\"graphicVersion\">Graphic 89320 Version 2.0</div></div></div>"},"89328":{"type":"graphic_table","displayName":"Contact allergens associated with pigmented purpuric dermatoses","title":"Examples of contact allergens associated with pigmented purpuric dermatoses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of contact allergens associated with pigmented purpuric dermatoses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Disperse dyes</td> </tr> <tr> <td>Paraphenylenediamine</td> </tr> <tr> <td>Black rubber</td> </tr> <tr> <td>Cobalt</td> </tr> <tr> <td>Epoxy resin</td> </tr> <tr> <td>Methylmethacrylate</td> </tr> <tr> <td>Eutectic mixture of local anesthetics</td> </tr> <tr> <td>Benzoyl peroxide</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89328 Version 1.0</div></div></div>"},"89329":{"type":"graphic_table","displayName":"Drugs associated with pigmented purpuric dermatoses","title":"Examples of drugs that have been associated with pigmented purpuric dermatoses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of drugs that have been associated with pigmented purpuric dermatoses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Acetaminophen</td> </tr> <tr> <td>Aminoglutethimide</td> </tr> <tr> <td>Amlodipine</td> </tr> <tr> <td>Aspirin</td> </tr> <tr> <td>Bezafibrate</td> </tr> <tr> <td>Bufexamac</td> </tr> <tr> <td>Carbamazepine</td> </tr> <tr> <td>Carbromal</td> </tr> <tr> <td>Carbutamide</td> </tr> <tr> <td>Chlordiazepoxide</td> </tr> <tr> <td>Diltiazem</td> </tr> <tr> <td>Dipyridamole</td> </tr> <tr> <td>Fluorouracil (topical)</td> </tr> <tr> <td>Furosemide</td> </tr> <tr> <td>Glipizide</td> </tr> <tr> <td>Hydralazine</td> </tr> <tr> <td>Infliximab</td> </tr> <tr> <td>Interferon alpha</td> </tr> <tr> <td>Isotretinoin</td> </tr> <tr> <td>Lorazepam</td> </tr> <tr> <td>Medroxyprogesterone acetate</td> </tr> <tr> <td>Meprobamate</td> </tr> <tr> <td>Minocycline</td> </tr> <tr> <td>Nitroglycerin</td> </tr> <tr> <td>Pefloxacin</td> </tr> <tr> <td>Pseudoephedrine</td> </tr> <tr> <td>Raloxifene</td> </tr> <tr> <td>Reserpine</td> </tr> <tr> <td>Sildenafil</td> </tr> <tr> <td>Tartrazine</td> </tr> <tr> <td>Thiamine propyldisulfide</td> </tr> <tr> <td>Trichlormethiazide</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89329 Version 3.0</div></div></div>"},"89341":{"type":"graphic_figure","displayName":"Incident hemodialysis and peritoneal dialysis patients","title":"Graph showing incident home hemodialysis, in-center, and peritoneal dialysis patients","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Graph showing incident home hemodialysis, in-center, and peritoneal dialysis patients</div><div class=\"cntnt\"><img style=\"width:590px; height:458px;\" src=\"images/NEPH/89341_Incident_hd_and_pd_pts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HHD: home hemodialysis; PD: peritoneal dialysis; ICH: in-center hemodialysis.</div><div class=\"graphic_reference\">Provided by Lionel Mailloux, MD, FACP. Modified from: US Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2012. The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government. In titles, the superscript number or letter refers to the chapter, the following number or letter identifies the figure or table, and the italicized roman numeral identifies the volume. Citations should separate chapter, number, and volume by periods&mdash;ie, 3.1.ii refers to Chapter Three, Figure 1, Volume Two.</div><div id=\"graphicVersion\">Graphic 89341 Version 3.0</div></div></div>"},"89342":{"type":"graphic_figure","displayName":"Incident HHD ICH and PD pts","title":"Graph showing incident home hemodialysis, in-center, and peritoneal dialysis patients","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Graph showing incident home hemodialysis, in-center, and peritoneal dialysis patients</div><div class=\"cntnt\"><img style=\"width:556px; height:374px;\" src=\"images/NEPH/89342_Incident_hhd_ich_and_pd_pts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HHD: home hemodialysis; PD: peritoneal dialysis; ICH: in-center hemodialysis.</div><div class=\"graphic_reference\">Provided by Lionel Mailloux, MD, FACP. Modified from: US Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2012. The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government. In titles, the superscript number or letter refers to the chapter, the following number or letter identifies the figure or table, and the italicized roman numeral identifies the volume. Citations should separate chapter, number, and volume by periods&mdash;ie, 3.1.ii refers to Chapter Three, Figure 1, Volume Two.</div><div id=\"graphicVersion\">Graphic 89342 Version 3.0</div></div></div>"},"89343":{"type":"graphic_picture","displayName":"Kaposiform hemangioendothelioma 2","title":"Kaposiform hemangioendothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kaposiform hemangioendothelioma</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/89343_Kaposiform_hemangioendoth_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaposiform hemangioendothelioma presenting with a large subcutaneous mass with a purpuric, bruised appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89343 Version 1.0</div></div></div>"},"89351":{"type":"graphic_table","displayName":"Criteria for mild moderate and severe polyhydramnios","title":"Criteria for mild moderate and severe polyhydramnios","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for mild moderate and severe polyhydramnios</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mild</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe </td> </tr> <tr> <td><strong>Single deepest pocket</strong></td> <td class=\"centered\">8 to 11.9 cm</td> <td class=\"centered\">12 to 15.9 cm</td> <td class=\"centered\">&#8805;16 cm</td> </tr> <tr> <td><strong>Amniotic fluid index</strong></td> <td class=\"centered\">25 to 30 cm</td> <td class=\"centered\">30.1 to 35 cm</td> <td class=\"centered\">&#62;35 cm</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89351 Version 1.0</div></div></div>"},"89352":{"type":"graphic_algorithm","displayName":"Unsatisfactory Cytology","title":"Unsatisfactory Cytology","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Unsatisfactory Cytology</div><div class=\"cntnt\"><img style=\"width:720px; height:372px;\" src=\"images/ONC/89352_Unsatisfactory_cytology.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89352 Version 4.0</div></div></div>"},"89353":{"type":"graphic_algorithm","displayName":"NILM but EC TZ Absent","title":"Cytology NILM but EC/TZ Absent/Insufficient","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Cytology NILM but EC/TZ Absent/Insufficient</div><div class=\"cntnt\"><img style=\"width:720px; height:378px;\" src=\"images/ONC/89353_NILM_but_EC_TZ_Absent.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89353 Version 4.0</div></div></div>"},"89354":{"type":"graphic_algorithm","displayName":"Normal Cytology HPV Positive","title":"Management of Women ≥ Age 30, who are Cytology Negative, but HPV Positive","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Management of Women ≥ Age 30, who are Cytology Negative, but HPV Positive</div><div class=\"cntnt\"><img style=\"width:720px; height:390px;\" src=\"images/ONC/89354_Normal_Cytology_HPV_Positiv.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89354 Version 5.0</div></div></div>"},"89355":{"type":"graphic_algorithm","displayName":"ASC-US","title":"Management of Women with Atypical Squamous Cells of Undetermined Significance (ASC-US) on Cytology","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Management of Women with Atypical Squamous Cells of Undetermined Significance (ASC-US) on Cytology</div><div class=\"cntnt\"><img style=\"width:720px; height:336px;\" src=\"images/ONC/89355_ASC_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89355 Version 4.0</div></div></div>"},"89356":{"type":"graphic_algorithm","displayName":"ASC-US or LSIL Age 21-24","title":"Management of Women Ages 21-24 years with either Atypical Squamous Cells of Undetermined Significance (ASC-US) or Low-grade Squamous Intraepithelial Lesion (LSIL)","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Management of Women Ages 21-24 years with either Atypical Squamous Cells of Undetermined Significance (ASC-US) or Low-grade Squamous Intraepithelial Lesion (LSIL)</div><div class=\"cntnt\"><img style=\"width:720px; height:331px;\" src=\"images/ONC/89356_ASC_US_or_LSIL_Age_21_24.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89356 Version 6.0</div></div></div>"},"89357":{"type":"graphic_algorithm","displayName":"LSIL","title":"Management of Women with Low-grade Squamous Intraepithelial Lesions (LSIL)","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Management of Women with Low-grade Squamous Intraepithelial Lesions (LSIL)</div><div class=\"cntnt\"><img style=\"width:720px; height:336px;\" src=\"images/ONC/89357_LSIL.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89357 Version 7.0</div></div></div>"},"89358":{"type":"graphic_algorithm","displayName":"LSIL Pregnant Woman","title":"Management of Pregnant Women with Low-grade Squamous Intraepithelial Lesion (LSIL)","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Management of Pregnant Women with Low-grade Squamous Intraepithelial Lesion (LSIL)</div><div class=\"cntnt\"><img style=\"width:720px; height:370px;\" src=\"images/ONC/89358_LSIL_Pregnant_Woman.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89358 Version 5.0</div></div></div>"},"89359":{"type":"graphic_algorithm","displayName":"ASC-H","title":"Management of Women with Atypical Squamous Cells: Cannot Exclude High-grade SIL (ASC-H)","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Management of Women with Atypical Squamous Cells: Cannot Exclude High-grade SIL (ASC-H)</div><div class=\"cntnt\"><img style=\"width:720px; height:400px;\" src=\"images/ONC/89359_ASC_H.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89359 Version 4.0</div></div></div>"},"89360":{"type":"graphic_algorithm","displayName":"ASC-H and HSIL Age 21-24","title":"Management of Women Ages 21-24 yrs with Atypical Squamous Cells, Cannot Rule Out High Grade SIL (ASC-H) and High-grade Squamous Intraepithelial Lesion (HSIL)","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Management of Women Ages 21-24 yrs with Atypical Squamous Cells, Cannot Rule Out High Grade SIL (ASC-H) and High-grade Squamous Intraepithelial Lesion (HSIL)</div><div class=\"cntnt\"><img style=\"width:720px; height:334px;\" src=\"images/ONC/89360_ASC_H_and_HSIL_Age_21_24.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89360 Version 4.0</div></div></div>"},"89361":{"type":"graphic_algorithm","displayName":"HSIL","title":"Management of Women with High-grade Squamous Intraepithelial Lesions (HSIL)","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Management of Women with High-grade Squamous Intraepithelial Lesions (HSIL)</div><div class=\"cntnt\"><img style=\"width:720px; height:379px;\" src=\"images/ONC/89361_HSIL.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89361 Version 4.0</div></div></div>"},"89362":{"type":"graphic_algorithm","displayName":"AGC","title":"Initial Workup of Women with Atypical Glandular Cells (AGC)","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Initial Workup of Women with Atypical Glandular Cells (AGC)</div><div class=\"cntnt\"><img style=\"width:720px; height:367px;\" src=\"images/ONC/89362_AGC.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89362 Version 5.0</div></div></div>"},"89363":{"type":"graphic_algorithm","displayName":"AGC Subsequent Management","title":"Subsequent Management of Women with Atypical Glandular Cells (AGC)","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Subsequent Management of Women with Atypical Glandular Cells (AGC)</div><div class=\"cntnt\"><img style=\"width:720px; height:344px;\" src=\"images/ONC/89363_AGCSubsequentManagement.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89363 Version 5.0</div></div></div>"},"89364":{"type":"graphic_algorithm","displayName":"CIN1 Preceded by Lesser Abnormalities","title":"Management of Women with No Lesion or Biopsy-confirmed Cervical Intraepithelial Neoplasia—Grade 1 (CIN1) Preceded by \"Lesser Abnormalities\"","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Management of Women with No Lesion or Biopsy-confirmed Cervical Intraepithelial Neoplasia—Grade 1 (CIN1) Preceded by \"Lesser Abnormalities\"</div><div class=\"cntnt\"><img style=\"width:720px; height:361px;\" src=\"images/ONC/89364_CIN1_Preceded_Lesser_Abnorm.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89364 Version 4.0</div></div></div>"},"89365":{"type":"graphic_algorithm","displayName":"CIN1 Preceded by ASC-H or HSIL","title":"Management of Women with No Lesion or Biopsy-confirmed Cervical Intraepithelial Neoplasia—Grade 1 (CIN1) Preceded by ASC-H or HSIL Cytology","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Management of Women with No Lesion or Biopsy-confirmed Cervical Intraepithelial Neoplasia—Grade 1 (CIN1) Preceded by ASC-H or HSIL Cytology</div><div class=\"cntnt\"><img style=\"width:720px; height:350px;\" src=\"images/ONC/89365_CIN1_Preceded_ASC_H_or_HSIL.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89365 Version 4.0</div></div></div>"},"89366":{"type":"graphic_algorithm","displayName":"CIN1 Age 21-24","title":"Management of Women Ages 21-24 with No Lesion or Biopsy-confirmed Cervical Intraepithelial Neoplasia—Grade 1 (CIN1)","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Management of Women Ages 21-24 with No Lesion or Biopsy-confirmed Cervical Intraepithelial Neoplasia—Grade 1 (CIN1)</div><div class=\"cntnt\"><img style=\"width:720px; height:342px;\" src=\"images/ONC/89366_CIN1_Age_21_24.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89366 Version 4.0</div></div></div>"},"89367":{"type":"graphic_algorithm","displayName":"CIN2 3 Management","title":"Management of Women with Biopsy-confirmed Cervical Intraepithelial Neoplasia—Grade 2 and 3 (CIN2,3)","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Management of Women with Biopsy-confirmed Cervical Intraepithelial Neoplasia—Grade 2 and 3 (CIN2,3)</div><div class=\"cntnt\"><img style=\"width:720px; height:335px;\" src=\"images/ONC/89367_CIN2_3_Management.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89367 Version 4.0</div></div></div>"},"89368":{"type":"graphic_algorithm","displayName":"CIN2 3 in Young Women","title":"Management of Young Women with Biopsy-confirmed Cervical Intraepithelial Neoplasia—Grade 2,3 (CIN2,3) in Special Circumstances","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Management of Young Women with Biopsy-confirmed Cervical Intraepithelial Neoplasia—Grade 2,3 (CIN2,3) in Special Circumstances</div><div class=\"cntnt\"><img style=\"width:720px; height:371px;\" src=\"images/ONC/89368_CIN2_3_in_Young_Women.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from: The Journal of Lower Genital Tract Disease Volume 17, Number 5, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2013. No copies of the algorithms may be made without the prior consent of ASCCP.</div><div id=\"graphicVersion\">Graphic 89368 Version 4.0</div></div></div>"},"89375":{"type":"graphic_figure","displayName":"Paraquat poisoning nomograms","title":"Paraquat poisoning nomograms","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Paraquat poisoning nomograms</div><div class=\"cntnt\"><img style=\"width:544px; height:516px;\" src=\"images/EM/89375_Paraquat_poisnng_nmgrm_edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><br />This figure shows three lines that can be used to predict prognosis following a paraquat ingestion, each derived from a different patient data set. A fatal outcome is likely if the plasma concentration lies above any line. Samples used to measure concentrations should generally be taken at least four hours following ingestion.<br /></div><div class=\"graphic_reference\">Reproduced from: Buckley NA, Dawson AH, Whyte IM. Assessment and Treatment of Poisoning. Hypertox 2012. <A href=\"http://www.hypertox.com/\" target=_blank>www.hypertox.com</A>. Available at: <A href=\"http://curriculum.toxicology.wikispaces.net/2.2.7.3.1+Paraquat\" target=_blank>http://curriculum.toxicology.wikispaces.net/2.2.7.3.1+Paraquat</A> (Accessed on January 13, 2017).</div><div id=\"graphicVersion\">Graphic 89375 Version 6.0</div></div></div>"},"89377":{"type":"graphic_table","displayName":"Abnormal screening results for normal people","title":"Relation between number of different screening tests ordered and percentage of normal people with at least one abnormal test result","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relation between number of different screening tests ordered and percentage of normal people with at least one abnormal test result</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Number of tests</td> <td class=\"subtitle1\">People with at least one abnormality<br /> (percent)</td> </tr> <tr> <td class=\"centered\">1</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">23</td> </tr> <tr> <td class=\"centered\">20</td> <td class=\"centered\">64</td> </tr> <tr> <td class=\"centered\">100</td> <td class=\"centered\">99.4</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Sackett DL. Clinical diagnosis and the clinical laboratory. Clin Invest Med 1978; 1:37. Reproduced with permission from: Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 89377 Version 6.0</div></div></div>"},"89378":{"type":"graphic_figure","displayName":"Benefits and harms of preventive activity","title":"Weighing the benefits and harms when deciding about a preventive activity: Comparing estimated benefits and harms of screening mammography","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Weighing the benefits and harms when deciding about a preventive activity: Comparing estimated benefits and harms of screening mammography</div><div class=\"cntnt\"><img style=\"width:516px; height:648px;\" src=\"images/PC/89378_Benefitharmpreventact.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chances among 1000 women who undergo annual screening mammography for 10 years: (A) of experiencing a false-positive mammogram, undergoing a breast biopsy, and developing breast cancer; and (B) being cured of breast cancer regardless of screening, being diagnosed with non-invasive ductal carcinoma in situ, and averting death from breast cancer because of screening mammography.</div><div class=\"graphic_reference\">Estimates calculated from:<br /><OL>&#xD;&#xA;<LI>Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2008, National Cancer Institute 2011. Bethesda, MD. Available at <A href=\"http://seer.cancer.gov/csr/1975_2008/\" target=_blank>http://seer.cancer.gov/csr/1975_2008/</A>. (Accessed January 13, 2012.)</LI>&#xD;&#xA;<LI>Hubbard RA, Kerlikowske K, Flowers CI, et al. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography. Ann Intern Med 2011; 155:481.</LI>&#xD;&#xA;<LI>Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009; 151:738.</LI></OL>Reproduced with permission from: Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2013. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 89378 Version 6.0</div></div></div>"},"89383":{"type":"graphic_diagnosticimage","displayName":"Calcaneus lateral and axial views","title":"Calcaneus: Normal lateral and axial views","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Calcaneus: Normal lateral and axial views</div><div class=\"cntnt\"><img style=\"width:582px; height:302px;\" src=\"images/EM/89383_Calcaneus_lateral_axial_vws.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain radiographs above show a standard lateral and axial view of a normal calcaneus.</div><div class=\"graphic_reference\">Courtesy of Cooper Dean, MD.</div><div id=\"graphicVersion\">Graphic 89383 Version 1.0</div></div></div>"},"89385":{"type":"graphic_table","displayName":"GEMOX hepatic","title":"Gemcitabine and oxaliplatin (GEMOX) for locally advanced or metastatic hepatocellular cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gemcitabine and oxaliplatin (GEMOX) for locally advanced or metastatic hepatocellular cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 28 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Gemcitabine</td> <td>1000 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline* (concentration no more than 40 mg/mL) and administer over 30 minutes.</td> <td>Days 1 and 15</td> </tr> <tr class=\"divider_bottom\"> <td>Oxaliplatin</td> <td>100 mg/m<sup>2</sup> IV<sup>&#182;</sup></td> <td>Dilute in 500 mL 5% dextrose in water (D5W)* and administer over two hours.</td> <td>Days 1 and 15</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE.</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin is an irritant but can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Routine prophylaxis is not indicated for gemcitabine or oxaliplatin.</li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated (incidence of neutropenic fever was 6%<sup>[2]</sup>).</li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatitis B issues</strong></td> <td colspan=\"3\"> <ul> <li>Patients should be screened for hepatitis B and C prior to starting chemotherapy, and if positive, considered for antiviral prophylaxis starting before chemotherapy to prevent HBV reactivation.<sup>[2]</sup></li> <li>Refer to UpToDate on \"Hepatitis B virus reactivation associated with immunosuppressive therapy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of gemcitabine may be needed for patients with liver impairment.<sup>[3]</sup> A lower starting dose of oxaliplatin may be needed for severe renal impairments.<sup>[4]</sup></li> <li>Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity.</li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>QT prolongation and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes (especially potassium and magnesium) and liver and renal function prior to each treatment.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential prior to each treatment.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for neurotoxicity prior to each new treatment cycle.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess pulmonary function prior to each new treatment cycle.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Chemotherapy may be administered if on each day of treatment, the absolute neutrophil count is &#8805;800/microL and the platelet count is &#8805;60,000/microL.<sup>[1]</sup> If blood cell counts are inadequate, delay treatment until recovery. For intracycle grade 3 or 4 hematologic toxicity, postpone subsequent cycle until recovery; then reduce gemcitabine to 800 mg/m<sup>2</sup> and oxaliplatin to 85 mg/m<sup>2</sup>.<sup>[2]</sup> Discontinue treatment for repeated grade 3 or 4 toxicity.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong><sup>&#916;</sup></td> <td colspan=\"3\"> <ul> <li>For grade 2 sensory peripheral neuropathy, reduce oxaliplatin dose to 85 mg/m<sup>2</sup>.<sup>[1]</sup> For grade 3 cumulative sensory peripheral neuropathy, discontinue oxaliplatin and continue gemcitabine alone as initially scheduled.<sup>[2]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients.</li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.<sup>[3]</sup> Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>A variety of manifestations of pulmonary toxicity have been reported with gemcitabine. Discontinue gemcitabine immediately and permanently. Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded.</li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity</strong></td> <td colspan=\"3\"> <ul> <li>If grade 3 to 4 non-neurosensory, non-hematologic toxicity occurs during the cycle, postpone subsequent cycle until recovery; then reduce gemcitabine dose to 800 mg/m<sup>2</sup> and the oxaliplatin dose to 85 mg/m<sup>2</sup>.<sup>[2]</sup> Discontinue treatment for repeated grade 3 or 4 toxicity.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factors; HBV: hepatitis B virus; ECG: electrocardiogram; CBC: complete blood count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies). Oxaliplatin is incompatible with normal saline, and a D5W flush is recommended prior to starting the drug infusion.<br />¶ Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.<br />Δ The original protocols<SUP>[1,2]</SUP> utilized a unique oxaliplatin-specific neurotoxicity scale.<SUP>[5]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Mir O, et al. Med Oncol 2012; 29:2793.</LI>&#xD;&#xA;<LI>Louafi S, et al. Cancer 2007; 109:1384.</LI>&#xD;&#xA;<LI>Gemcitabine hydrochloride injection. United States Prescribing Information. US National Library of Medicine. Available online at dailymed.nlm.nih.gov, accessed June 5, 2012.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. Available online at dailymed.nlm.nih.gov, accessed on June 5, 2012.</LI>&#xD;&#xA;<LI>Caussanel JP, et al. J Natl Cancer Inst 1990; 82:1046.</LI></OL></div><div id=\"graphicVersion\">Graphic 89385 Version 12.0</div></div></div>"},"89386":{"type":"graphic_table","displayName":"TAC","title":"Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy for node-positive breast cancer<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy for node-positive breast cancer<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 21 days.<br /> Duration of therapy: 6 cycles.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Doxorubicin</strong></td> <td>50 mg/m<sup>2</sup></td> <td>Dilute with normal saline (NS) to a final concentration of 2 mg/mL and administer as an IV bolus over three to five minutes into a free flowing IV infusion of NS or 5 percent dextrose in water (D5W). If needed, doxorubicin can be further diluted after reconstitution in NS or D5W and given as a slow IV infusion administered over 15 to 60 minutes<sup>[1,2]</sup>.</td> <td>Day 1</td> </tr> <tr> <td><strong>Cyclophosphamide</strong></td> <td>500 mg/m<sup>2</sup></td> <td>Dilute with 250 to 500 mL NS or D5W and administer over 30 to 60 minutes. Alternatively, cyclophosphamide can be diluted after reconstitution with NS or D5W and given as slow IV infusion over 5 minutes (for doses up to 2 grams)<sup>[1,3]</sup>.</td> <td>Day 1</td> </tr> <tr> <td><strong>Docetaxel</strong></td> <td>75 mg/m<sup>2</sup></td> <td>Given 1 hour after cyclophosphamide. Dilute in 250 mL (NS) to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes<sup>[1,4]</sup>.</td> <td>Day 1</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations (any of the following can be eliminated if not applicable):</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hydration:</strong> Patients receiving cyclophosphamide should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days thereafter) and void frequently to reduce the risk of hemorrhagic cystitis<sup>[3]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> HIGH (&#62;90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Dexamethasone premedication (8 mg orally every 12 hours for six doses beginning the day before treatment started) should be given to prevent docetaxel-related hypersensitivity and fluid retention<sup>[1,4]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Doxorubicin is a vesicant and can cause significant tissue damage if extravasation occurs. For peripheral infusions, the IV line should be recently placed into a large, intact vein, with good blood return established immediately prior to starting the infusion. The IV or catheter site should be continuously monitored throughout drug administration infusion. If extravasation occurs, apply ice to the site and consider use of dexrazoxane. Docetaxel is an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with antimicrobials was implemented in this study. Patients received ciprofloxacin 500 mg twice daily on days 5 through 14 of each cycle. Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) was not permitted. However, secondary prophylaxis with G-CSF (administered on days 4 through 11) was mandatory after an episode of febrile neutropenia or infection in subsequent cycles<sup>[1]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> Dose adjustment is not necessary for doxorubicin and docetaxel in renal impairment. A lower starting dose of cyclophosphamide may be needed in patient with baseline renal dysfunction. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\". A lower starting dose for cyclophosphamide and doxorubicin may be needed in patients with hepatic impairment. Docetaxel should not be administered to patients with a serum bilirubin above the upper limit of normal (ULN) or to patients with transaminase elevations &#62;1.5 x ULN. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiac issues:</strong> Doxrubicin is associated with cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline left ventricular ejection fraction (LVEF) prior to administration. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or any other anthracyclines<sup>[2]</sup>. Refer to UpToDate topics on \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\" and \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for known drug interactions:</strong> Caution is needed when administering docetaxel with strong CYP3A4 inhibitors. Although specific dose recommendations are not available, the United States Prescribing Information suggests close monitoring for toxicity and consideration of docetaxel dose reduction if coadministration with a strong CYP3A4 inhibitor cannot be avoided<sup>[4]</sup>.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count every three weeks prior to each treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Serum electrolytes and liver and renal function tests every three weeks prior to each treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Cumulative doxorubicin dose should be monitored. Reassess LVEF periodically during docetaxel, doxorubicin, and cyclophosphamide (TAC) therapy as clinically indicated.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for hepatic and renal dysfunction:</strong> Dose modifications were planned according to standard toxicity criteria<sup>[1]</sup>. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiotoxicity:</strong> Guidelines for managing doxorubicin in patients with symptomatic cardiac dysfunction or asymptomatic changes in LVEF during therapy are addressed in detail separately. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cutaneous, mucosal, and neurologic toxicity:</strong> For severe or cumulative cutaneous reactions (erythema and desquamation), grade 3 or 4 stomatitis, or moderate neurosensory signs and/or symptoms, reduce docetaxel dose<sup>[4]</sup>. Discontinue if toxicity persists.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Discontinuation of treatment:</strong> Required in this study for any grade 4 nonhematologic toxicity (according to National Cancer Institute Common Toxicity Criteria), any grade 3 toxicity after dose reduction, or clinically significant cardiac event<sup>[1]</sup>.</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Martin M, et al. N Engl J Med 2005; 352:2302.</li>&#xD;&#xA;    <li>Doxorubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on May 10, 2012).</li>&#xD;&#xA;    <li>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on May 10, 2012).</li>&#xD;&#xA;    <li>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on May 10, 2012).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 89386 Version 10.0</div></div></div>"},"89388":{"type":"graphic_form","displayName":"Skin testing form for evaluation of insulin allergy","title":"Skin testing form for evaluation of insulin allergy","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Skin testing form for evaluation of insulin allergy</div><div class=\"cntnt\"><img style=\"width:580px; height:771px;\" src=\"images/ALLRG/89388_Form_im_insulin_reactions.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* If safe and validated skin tests are available.<br />&Delta; Other insulin preparations used by patient in the past.</div><div id=\"graphicVersion\">Graphic 89388 Version 4.0</div></div></div>"},"89389":{"type":"graphic_picture","displayName":"NICH leg","title":"Noninvoluting congenital hemangioma (NICH)","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Noninvoluting congenital hemangioma (NICH)</div><div class=\"cntnt\"><img style=\"width:574px; height:359px;\" src=\"images/DERM/89389_NICH_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Noninvoluting congenital hemangiomas presenting as a flat bluish lesion with overlying telangiectasias resembling a vascular stain. &nbsp;</div><div id=\"graphicVersion\">Graphic 89389 Version 2.0</div></div></div>"},"89391":{"type":"graphic_picture","displayName":"Infantile hemangioma precursor","title":"Nascent infantile hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nascent infantile hemangioma</div><div class=\"cntnt\"><img style=\"width:382px; height:574px;\" src=\"images/DERM/89391_Infantile_hemangiom_precrsr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In some newborns,&nbsp;a patch of telangiectasias with surrounding pallor is&nbsp;a&nbsp;premonitory cutaneous mark of infantile hemangiomas.</div><div id=\"graphicVersion\">Graphic 89391 Version 1.0</div></div></div>"},"89392":{"type":"graphic_picture","displayName":"Eczematid-like purpura of Doucas and Kapetanakis close view","title":"Eczematid-like purpura of Doucas and Kapetanakis","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Eczematid-like purpura of Doucas and Kapetanakis</div><div class=\"cntnt\"><img style=\"width:574px; height:430px;\" src=\"images/DERM/89392_Eczmd-lk_prp_Duc_Kptn_cl_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Purpuric, erythematous patches with scale.</div><div id=\"graphicVersion\">Graphic 89392 Version 1.0</div></div></div>"},"89394":{"type":"graphic_picture","displayName":"Volar skin histopathology","title":"Histopathology of the volar skin","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Histopathology of the volar skin</div><div class=\"cntnt\"><img style=\"width:590px; height:354px;\" src=\"images/DERM/89394_Volarskinhistopathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This tissue section was cut perpendicularly to the parallel skin markings. The ridges (orange bars) and furrows (arrows) are recognized on the surface. Under the epidermis, two kinds of epidermal rete ridges are recognized: the crista profunda intermedia (dashed arrows) underlying the surface ridges and the crista profunda limitans (arrowheads) underlying the surface furrows. The crista profunda intermedia is passed through by an intraepidermal eccrine duct.</div><div id=\"graphicVersion\">Graphic 89394 Version 2.0</div></div></div>"},"89395":{"type":"graphic_picture","displayName":"Volar skin electron microscopy","title":"Surface electron microscopy of plantar skin","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Surface electron microscopy of plantar skin</div><div class=\"cntnt\"><img style=\"width:594px; height:463px;\" src=\"images/DERM/89395_Volar_skin_electron_microsc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On the undersurface of the epidermis, two kinds of main longitudinal ridges, the crista profunda limitans and the crista profunda intermedia, are observed as parallel rows. Eccrine ducts are recognized as tube-like projections from the crista profunda intermedia. The short transverse ridges are also detected, bridging the main longitudinal ridges.</div><div class=\"graphic_reference\">Courtesy of Tetsuya Tsuchida, MD, PhD.</div><div id=\"graphicVersion\">Graphic 89395 Version 1.0</div></div></div>"},"89396":{"type":"graphic_figure","displayName":"Dermoscopic pattern volar skin","title":"Schematic representation of the dermoscopic patterns of melanocytic lesions located on the palms and soles","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Schematic representation of the dermoscopic patterns of melanocytic lesions located on the palms and soles</div><div class=\"cntnt\"><img style=\"width:577px; height:474px;\" src=\"images/DERM/89396_Dermascopic_patt_volar_skin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parallel furrow, lattice-like, and fibrillar patterns are major dermoscopic patterns seen in acquired melanocytic nevus of the palms and soles, whereas the parallel ridge pattern is the most sensitive and specific dermoscopic pattern detected in acral melanoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Saida T. Textbook of Dermoscopy, Nankodo Co. Ltd, Tokyo, 2011. Copyright &copy; 2011 Toshiaki Saida, MD, PhD.</div><div id=\"graphicVersion\">Graphic 89396 Version 2.0</div></div></div>"},"89397":{"type":"graphic_picture","displayName":"Melanoma parallel ridge pattern","title":"Parallel ridge pattern seen on dermoscopic examination of melanoma of palms and soles","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Parallel ridge pattern seen on dermoscopic examination of melanoma of palms and soles</div><div class=\"cntnt\"><img style=\"width:597px; height:382px;\" src=\"images/DERM/89397_Melan_parallel_ridg_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parallel ridge pattern represents band-like pigmentation on the ridges of the skin markings. In this melanoma in situ (A), the pattern covers almost all the lesion. In an early invasive melanoma of the sole (B), the parallel ridge pattern is detected only in the lower portion of the lesion (circle) and irregular diffuse pigmentation is observed in the upper portion.</div><div id=\"graphicVersion\">Graphic 89397 Version 1.0</div></div></div>"},"89398":{"type":"graphic_picture","displayName":"Plantar melanoma macular dermoscopy","title":"Dermoscopic features of macular areas of melanoma on the sole","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of macular areas of melanoma on the sole</div><div class=\"cntnt\"><img style=\"width:532px; height:447px;\" src=\"images/DERM/89398_Sole_melanoma_macular_derm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the macular areas of this advanced melanoma, the parallel ridge pattern is detected focally (red rectangle). An irregular fibrillar pattern (blue circle) and the parallel furrow pattern (green rounded rectangle) are also focally detected.</div><div id=\"graphicVersion\">Graphic 89398 Version 1.0</div></div></div>"},"89400":{"type":"graphic_picture","displayName":"Plantar melanoma diffuse pigmentation","title":"Dermoscopic image of irregular diffuse pigmentation in a melanoma on the sole","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of irregular diffuse pigmentation in a melanoma on the sole</div><div class=\"cntnt\"><img style=\"width:590px; height:518px;\" src=\"images/DERM/89400_Sole_melanoma_diffuse_pigm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this advanced melanoma, irregular diffuse, structureless pigmentation of variable shades from tan to brownish black, predominates. Hints of the parallel ridge pattern also can be recognized.</div><div id=\"graphicVersion\">Graphic 89400 Version 1.0</div></div></div>"},"89401":{"type":"graphic_table","displayName":"CPE ranking","title":"Central nervous system penetration effectiveness ranking of antiretroviral agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Central nervous system penetration effectiveness ranking of antiretroviral agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug class</td> <td class=\"subtitle1\" colspan=\"4\">CPE score</td> </tr> <tr> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">2</td> <td class=\"subtitle2\">3</td> <td class=\"subtitle2\">4</td> </tr> <tr class=\"divider_bottom\"> <td>NRTI</td> <td> <p>Tenofovir*</p> Didanosine<sup>&#182;</sup></td> <td> <p>Lamivudine*</p> Stavudine<sup>&#182;</sup></td> <td> <p>Emtricitabine*</p> Abacavir*</td> <td>Zidovudine<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>INSTI</td> <td>&nbsp;</td> <td>Elvitegravir/cobicistat*</td> <td>Raltegravir*</td> <td>Dolutegravir*</td> </tr> <tr class=\"divider_bottom\"> <td>PI</td> <td> <p>Saquinavir-ritonavir<sup>&#182;</sup></p> <p>Nelfinavir-ritonavir<sup>&#182;</sup></p> Tipranavir-ritonavir<sup>&#182;</sup></td> <td>Boosted atazanavir<sup>&#916;</sup></td> <td> <p>Boosted darunavir*</p> <p><em>Boosted lopinavir</em><sup>&#9674;</sup></p> <p>Indinavir-ritonavir<sup>&#182;</sup></p> Fosamprenavir-ritonavir<sup>&#182;</sup></td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>NNRTI</td> <td>&nbsp;</td> <td>Etravirine<sup>&#182;</sup></td> <td> <p>Efavirenz<sup>&#916;</sup></p> <p>Rilpivirine<sup>&#916;</sup></p> Delavirdine<sup>&#182;</sup></td> <td>Nevirapine<sup>&#182;</sup></td> </tr> <tr> <td>Entry/fusion inhibitor</td> <td>Enfuvirtide<sup>&#182;</sup></td> <td>&nbsp;</td> <td>Maraviroc<sup>&#182;</sup></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A CPE score of 4 indicates the best penetration into the central nervous system, with inhibitory concentrations achieved in CSF. A score of 1 indicates poor penetration. The table also incorporates recommendations on selecting antiretroviral agents for initial therapy from the United States Department of Health and Human Services. Boosting of atazanavir, darunavir, or lopinavir is with ritonavir or cobicistat.</div><div class=\"graphic_footnotes\">CPE: central nervous system penetration effectiveness; NRTI: nucleos(t)ide reverse transcriptase inhibitor; INSTI: integrase inhibitor; PI: protease inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor.<br />* Agents included in recommended regimens for initial therapy.<br />&para; Agents that are not used in regimens for initial therapy.<br />&Delta; Agents included in alternative regimens for initial therapy.<br /><span class=\"lozenge\">&loz;</span> <em>Agents included in other regimens for initial therapy.</em></div><div class=\"graphic_reference\">Adapted from: Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 2011; 19:137.</div><div id=\"graphicVersion\">Graphic 89401 Version 4.0</div></div></div>"},"89402":{"type":"graphic_picture","displayName":"Advanced sole melanoma dermoscopy","title":"Dermoscopic features of advanced melanoma of the sole ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of advanced melanoma of the sole </div><div class=\"cntnt\"><img style=\"width:450px; height:363px;\" src=\"images/DERM/89402_Adv_sole_melanom_derm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is an ulcerated nodule on the right, surrounded by a blue white veil (star). The parallel ridge pattern (square) as well as the irregular fibrillar pattern (circle) are also detected.</div><div class=\"graphic_reference\">Reproduced with permission from: John Wiley &amp; Sons, Inc. Saida T, Koga H, Uhara H. Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol 2011; 38:25. Copyright © 2011 Japanese Dermatological Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89402 Version 5.0</div></div></div>"},"89403":{"type":"graphic_picture","displayName":"Parallel furrow pattern variants","title":"Dermoscopic images of variants of the parallel furrow pattern in acquired melanocytic nevi of palms and soles","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Dermoscopic images of variants of the parallel furrow pattern in acquired melanocytic nevi of palms and soles</div><div class=\"cntnt\"><img style=\"width:597px; height:391px;\" src=\"images/DERM/89403_Parall_furrow_patt_variants.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the parallel furrow pattern, parallel pigmented lines are detected along the furrows of the skin markings. Variants of this pattern include: (A) single solid line variant, (B) double solid line variant, (C) single dotted line variant, and (D) double dotted line variant.</div><div id=\"graphicVersion\">Graphic 89403 Version 1.0</div></div></div>"},"89404":{"type":"graphic_picture","displayName":"Combination dermoscopic patterns in acral nevi","title":"Combination of the three major dermoscopic patterns in melanocytic nevi of the palms and soles","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Combination of the three major dermoscopic patterns in melanocytic nevi of the palms and soles</div><div class=\"cntnt\"><img style=\"width:561px; height:456px;\" src=\"images/DERM/89404_Comdermpatternacralnevi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this nevus, the three major benign dermoscopic patterns, the parallel furrow (blue circle), fibrillar (dashed red circle), and lattice-like pattern (dotted green circle), are detected. Note that they are arranged in an orderly fashion.<br />Inset: clinical photograph.</div><div class=\"graphic_reference\">Reproduced with permission from: Saida T, Koga H. Dermoscopic patterns of acral melanocytic nevi: Their variations, changes, and significance. Arch Dermatol 2007; 143:1423. Copyright &copy; 2007 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89404 Version 7.0</div></div></div>"},"89405":{"type":"graphic_picture","displayName":"Dermoscopic patterns acral nevi","title":"Combination of the parallel furrow pattern and other benign dermoscopic patterns in acquired melanocytic nevi of the palms and soles","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Combination of the parallel furrow pattern and other benign dermoscopic patterns in acquired melanocytic nevi of the palms and soles</div><div class=\"cntnt\"><img style=\"width:511px; height:240px;\" src=\"images/DERM/89405_Dermo_patt_acral_nevi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) In this lesion, the parallel furrow pattern is associated with the lattice-like pattern in the center of the lesion.<br />(B) The parallel furrow pattern shows transition to the fibrillar pattern on the right side of this lesion.</div><div class=\"graphic_reference\">Reproduced with permission from: John Wiley &amp; Sons, Inc. Saida T, Koga H, Uhara H. Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol 2011; 38:25. Copyright © 2011 Japanese Dermatological Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89405 Version 5.0</div></div></div>"},"89406":{"type":"graphic_picture","displayName":"Pityriasis lichenoides chronica on legs","title":"Pityriasis lichenoides chronica","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pityriasis lichenoides chronica</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/89406_Pityr_lichen_chronica_legs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple red-brown papules with adherent scale and hypopigmented macules on the legs.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89406 Version 1.0</div></div></div>"},"89407":{"type":"graphic_picture","displayName":"Pityriasis lichenoides chronica lesions","title":"Pityriasis lichenoides chronica","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Pityriasis lichenoides chronica</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89407_Pityriasis_licheno_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red-brown macules with adherent scale in a patient with pityriasis lichenoides chronica.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89407 Version 1.0</div></div></div>"},"89408":{"type":"graphic_picture","displayName":"Pityriasis lichenoides chronica extensive hypopigmentation","title":"Pityriasis lichenoides chronica","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Pityriasis lichenoides chronica</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/DERM/89408_Pityri_lich_chron_ext_hypo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scattered red-brown scaly papules and numerous hypopigmented macules in a patient with pityriasis lichenoides chronica.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89408 Version 1.0</div></div></div>"},"89410":{"type":"graphic_table","displayName":"Summary of pregnancy outcomes with short and long IPI","title":"Summary of pregnancy outcomes associated with short and long interpregnancy intervals","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of pregnancy outcomes associated with short and long interpregnancy intervals</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Short interpregnancy interval<br /> (variously defined)</td> <td class=\"subtitle1\">Long interpregnancy interval<br /> (at least 24 months)</td> </tr> <tr> <td><strong>Low birth weight</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Small for gestational age</strong></td> <td class=\"centered\">&#8593; or &#8596;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Preterm premature rupture of membranes</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Preterm birth</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Congenital anomalies</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> </tr> <tr> <td><strong>Autism</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Schizophrenia</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Labor dystocia</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#8593;</td> </tr> <tr> <td><strong>Fetal, neonatal, or infant death</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Maternal anemia</strong></td> <td class=\"centered\">&#8593; or &#8596;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Preeclampsia</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> </tr> <tr> <td><strong>Maternal death</strong></td> <td class=\"centered\">&#8593; or &#8596;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Miscarriage</strong></td> <td class=\"centered\">&#8595; or &#8596;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Stillbirth</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Uterine rupture at TOLAC</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TOLAC: trial of labor after cesarean delivery.</div><div id=\"graphicVersion\">Graphic 89410 Version 2.0</div></div></div>"},"89411":{"type":"graphic_diagnosticimage","displayName":"Imaging pectus excavatum","title":"Pectus excavatum on chest x-ray and CT scan","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Pectus excavatum on chest x-ray and CT scan</div><div class=\"cntnt\"><img style=\"width:499px; height:494px;\" src=\"images/RADIOL/89411_Imag_pectus_excavatum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) A P-A view of the chest shows horizontally oriented posterior ribs (arrow) and an ill defined right heart border (arrowhead) which has been shifted to the left behind the sternum and in front of the vertebral column. The anterior ribs are oriented vertically (dashed arrow).<BR>(Panel B) A lateral view of the chest shows a posteriorly positioned sternum (arrow).<BR>(Panel C) An axial CT scan of the chest at the level of the heart shows a depressed sternum, a compressed right atrium (arrowhead), and leftward displacement of the heart.<BR>(Panel D) A sagittal reformat of the CT scan of the chest through the sternum shows posterior displacement of the sternum (arrowhead) and compression of the right atrium (arrow).</div><div class=\"graphic_footnotes\">P-A: posteroanterior; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89411 Version 1.0</div></div></div>"},"89412":{"type":"graphic_diagnosticimage","displayName":"CT scan pleural lipoma","title":"Pleural lipoma on CT scan","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Pleural lipoma on CT scan</div><div class=\"cntnt\"><img style=\"width:599px; height:257px;\" src=\"images/RADIOL/89412_CT_scan_pleural_lipoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the upper chest shows a low-atenuation pleural mass (arrow in image A), corresponding to fat attenuation coefficient (B).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89412 Version 2.0</div></div></div>"},"89413":{"type":"graphic_diagnosticimage","displayName":"CT scan pericardial lipoma","title":"Pericardial lipoma on CT scan","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Pericardial lipoma on CT scan</div><div class=\"cntnt\"><img style=\"width:599px; height:241px;\" src=\"images/RADIOL/89413_CT_pericardial_lipoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the mid-chest shows a large low-density pericardial lipoma (arrow in panel A). A CT reformatted in the sagittal plane shows a lipoma posterior to the heart (arrow) and pressing against the esophagus (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89413 Version 1.0</div></div></div>"},"89414":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray pericardial lipoma","title":"Pericardial lipoma on chest x-ray","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Pericardial lipoma on chest x-ray</div><div class=\"cntnt\"><img style=\"width:599px; height:310px;\" src=\"images/RADIOL/89414_Chest_x_pericardia_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A P-A chest x-ray (A) shows the border of the left ventricle (arrowhead) surrounded by a lower density border of a pericardial lipoma (arrow). A lateral view (B) shows the posteriorly positioned low-density lipoma of the pericardium (arrow).</div><div class=\"graphic_footnotes\">P-A: posteroanterior.</div><div id=\"graphicVersion\">Graphic 89414 Version 1.0</div></div></div>"},"89415":{"type":"graphic_diagnosticimage","displayName":"Catheter-based angiogram of a pulmonary embolus","title":"Catheter-based angiogram of a pulmonary embolus","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Catheter-based angiogram of a pulmonary embolus</div><div class=\"cntnt\"><img style=\"width:531px; height:600px;\" src=\"images/RADIOL/89415_Cathtr-angigrm_pulm_embolus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary embolus. Frontal image from a selective right pulmonary artery angiogram shows a filling defect (arrow).</div><div id=\"graphicVersion\">Graphic 89415 Version 2.0</div></div></div>"},"89418":{"type":"graphic_algorithm","displayName":"Empiric antimicrobial gram-negative bacillary bacteremia","title":"Algorithm for empiric antimicrobial selection for gram-negative bacillary bacteremia","html":"<div class=\"graphic\"><div style=\"width: 828px\" class=\"figure\"><div class=\"ttl\">Algorithm for empiric antimicrobial selection for gram-negative bacillary bacteremia</div><div class=\"cntnt\"><img style=\"width:808px; height:590px;\" src=\"images/ID/89418_Antmcrbl_gram-neg_bacterem.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm reflects a general approach to the empiric selection of antibiotic therapy for gram-negative bacillary bacteremia. Patients with a history of infection with extremely drug-resistant organisms (such as carbapenem-resistant Enterobacteriaceae) warrant additional consideration and consultation with an expert in infectious diseases.</div><div class=\"graphic_footnotes\">* Immunocompromising conditions include: Poorly controlled diabetes mellitus, chronic high-dose corticosteroid use, use of other immunosuppressive agents, neutropenia, advanced HIV infection, B or T leukocyte deficiency.<br />¶ Healthcare exposures include: Hospitalization, hemodialysis, residence in a long-term care facility, and intravenous antibiotic use or chemotherapy.<br />Δ Empiric therapy should be further tailored based on additional history, prior history of multidrug-resistant gram-negative pathogens, and likely source of infection. As an example, a carbapenem (imipenem, meropenem, or doripenem) is preferable for a patient with a history of infection with ESBL-producing organisms within the prior six months. Alternatively, for a patient with gram-negative bacteremia in the setting of cholangitis, a beta-lactam/beta-lactamase inhibitor or a carbapenem may be preferable to provide anaerobic coverage. For patients with sepsis or septic shock, broad-spectrum gram-positive coverage is often also used until cultures have been finalized. Drug dose lists are for adult patients with normal renal function. Refer to other UpToDate content for options for patients with severe beta-lactam allergies.<br /><FONT class=lozenge>◊</FONT> Aminoglycoside dosing depends on the patient's weight and creatinine clearance. Dosing adjustments should be based upon the results of serum drug concentration monitoring. Refer to other UpToDate content on aminoglycoside dosing.</div><div id=\"graphicVersion\">Graphic 89418 Version 5.0</div></div></div>"},"89431":{"type":"graphic_table","displayName":"CAPOX hepatobiliary","title":"Capecitabine and oxaliplatin for locally advanced or metastatic hepatocellular or biliary cancer<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Capecitabine and oxaliplatin for locally advanced or metastatic hepatocellular or biliary cancer<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.<br /> <strong>Duration of therapy:</strong> Treatment is continued until disease progression, unacceptable toxicity, or patient withdrawal. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Oxaliplatin</td> <td>130 mg/m<sup>2</sup> IV*</td> <td>Dilute in 500 mL 5% dextrose in water (D5W)<sup>&#182;</sup> and administer over two hours.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Capecitabine<sup>&#916;</sup></td> <td>1000 mg/m<sup>2</sup> per dose, by mouth</td> <td>Twice daily (total dose 2000 mg/m<sup>2</sup> per day). Swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets.<sup>&#9674;</sup></td> <td>Days 1 through 14</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin: MODERATE.</li> <li>Oral capecitabine: LOW.</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen for oxaliplatin.</li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin is an irritant but can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topic \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors is not indicated (estimated risk of febrile neutropenia is &#60;5%<sup>[1,2]</sup>).</li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Lower starting doses of oxaliplatin and capecitabine may be needed for renal impairment.<sup>[3,4]</sup></li> <li>Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity.</li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Prolongation of the corrected QT (QTc) interval and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QTc interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin.</li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes (especially potassium and magnesium) and liver and renal function every three weeks prior to each new cycle of treatment.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea and palmar-plantar erythrodysesthesias during treatment.</li> <li>Refer to UpToDate topics on \"Enterotoxicity of chemotherapeutic agents\" and \"Cutaneous complications of conventional chemotherapy agents\".</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease.</li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>A new cycle of treatment should not start until neutrophils recover to &#62;1500/microL and platelets recover to &#62;100,000/microL. Interrupt capecitabine for any grade 2 or worse hematologic toxicity and delay treatment until complete recovery or improvement to &#8804;grade 1.<sup>[1]</sup> Reduce the capecitabine dose by 25% in subsequent cycles at the first occurrence of a grade 2 or grade 3 toxicity, and by 50% at the second occurrence of a given grade 2 or grade 3 toxicity or at the first occurrence of a grade 4 event. Discontinue capecitabine permanently if, despite dose reduction, hematologic toxicity occurs for the third time at grade 2 or grade 3, or a second time at grade 4. After recovery, reduce oxaliplatin by 25% for any intracycle grade 3 or 4 neutropenia or thrombocytopenia.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine and delay oxaliplatin for any grade 2 or worse gastrointestinal toxicity; restart treatment only after complete recovery or improvement to &#8804;grade 1.<sup>[1]</sup> After recovery, reduce the dose of oxaliplatin by 25% after the first episode of grade 3 or worse diarrhea or mucositis. Reduce the capecitabine dose by 25% in subsequent cycles at the first occurrence of grade 2 or 3 toxicity, and by 50% at the second occurrence of a given grade 2 or grade 3 toxicity or at the first occurrence of a grade 4 event. Discontinue capecitabine permanently if, despite dose reduction, a given toxicity occurs for the third time at grade 2 or grade 3, or a second time at grade 4.<sup>[1]</sup></li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong><sup>&#167;</sup></td> <td colspan=\"3\"> <ul> <li>Reduce the dose of oxaliplatin by 25% for painful paresthesias lasting 8 to 14 days (without functional impairment; grade 2). Reduce oxaliplatin by 50% if persistent (&#62;14 days) paresthesias (without functional impairment; grade 3) and discontinue oxaliplatin for beginning functional impairment (grade 4).<sup>[1]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded.</li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity (including heptotoxicity)</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine and delay oxaliplatin for any grade 2 or worse non-neurologic toxicity (except alopecia); restart treatment only after complete recovery or improvement to &#8804;grade 1.<sup>[1]</sup> Reduce the dose of oxaliplatin by 25% for drug-related grade 3 toxicity.</li> <li>Reduce the capecitabine dose by 25% in subsequent cycles at the first occurrence of a grade 2 or grade 3 toxicity, and by 50% at the second occurrence of a given grade 2 or grade 3 toxicity or at the first occurrence of a grade 4 event. Discontinue capecitabine permanently if, despite dose reduction, a given toxicity occurs for the third time at grade 2 or grade 3, or a second time at grade 4.<sup>[1]</sup></li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><strong>Doses of capecitabine omitted for toxicity are not replaced or restored; instead the patient should resume with the next planned treatment cycle.</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factor; ECG: electrocardiogram; CBC: complete blood count; INR: international normalized ratio.<br />* Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.<br />¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies). Oxaliplatin is incompatible with normal saline and a D5W flush is recommended prior to starting the drug infusion.<br />Δ No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br /><FONT class=lozenge>◊</FONT> Extemporaneous compounding of liquid dosage forms has been recommended, but IV therapies may be more appropriate for patients with significant swallowing difficulty.<br />§ Neurotoxicity was graded in the original study based on the Levis scale: grade 1, paresthesias of moderate intensity lasting less than seven days; grade 2, painful paresthesias lasting 8 to 14 days (without functional impairment); grade 3, persistent (&gt;14 days) paresthesias (without functional impairment); grade 4, beginning functional impairment.<SUP>[1]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Nehls O, et al. Br J Cancer 2008; 98:309.</LI>&#xD;&#xA;<LI>Boige V, et al. Br J Cancer 2007; 97:862.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016).</LI>&#xD;&#xA;<LI>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 89431 Version 18.0</div></div></div>"},"89432":{"type":"graphic_diagnosticimage","displayName":"Chest CT and x-ray H7N9 influenza","title":"Chest CT and x-ray images of a patient with avian influenza A H7N9 virus infection","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Chest CT and x-ray images of a patient with avian influenza A H7N9 virus infection</div><div class=\"cntnt\"><img style=\"width:595px; height:534px;\" src=\"images/ID/89432_Chest_CT_x_H7N9_influ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT: computed tomography.<br />Images were taken 1, 5, 7, and 11 days after illness onset.<br />(Panels A and B) CT scan images on day 1, showing bilateral pleural effusion but no obvious lesions.<br />(Panel C) CT scan image on day 5, showing extensive ground-glass opacity and consolidation.<br />(Panels D and E) X-ray images on days 7 and 11, respectively, showing reduced light transmittance on both sides of the lung.</div><div class=\"graphic_reference\">Reproduced from: Lu S, Zheng Y, Li T, et al. Clinical findings for early human cases of influenza A(H7N9) virus infection, Shanghai, China. Emerg Infect Dis 2013. DOI: 10.3201/eid1907.130612.</div><div id=\"graphicVersion\">Graphic 89432 Version 2.0</div></div></div>"},"89433":{"type":"graphic_diagnosticimage","displayName":"Chest CT H7N9 influenza","title":"Chest CT images of a patient with avian influenza A H7N9 virus infection","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Chest CT images of a patient with avian influenza A H7N9 virus infection</div><div class=\"cntnt\"><img style=\"width:598px; height:240px;\" src=\"images/ID/89433_Chest_CT_H7N9_influen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Image taken 6 days after illness onset shows ground-glass opacity in the left lower and right upper lobes.<br />(Panel B) Image taken 16 days after illness onset shows absorption of ground-glass opacity.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced from: Lu S, Zheng Y, Li T, et al. Clinical findings for early human cases of influenza A(H7N9) virus infection, Shanghai, China. Emerg Infect Dis 2013. DOI: 10.3201/eid1907.130612.</div><div id=\"graphicVersion\">Graphic 89433 Version 3.0</div></div></div>"},"89435":{"type":"graphic_table","displayName":"Cervical screening recs PI","title":"Cervical cancer screening recommendations in the United States: At what age and how often?","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cervical cancer screening recommendations in the United States: At what age and how often?</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age to start routine screening</td> <td class=\"subtitle1\" rowspan=\"2\">Age to stop routine screening</td> <td class=\"subtitle1\" colspan=\"2\">Screen how often?</td> <td class=\"subtitle1\" rowspan=\"2\">Should women who have had a hysterectomy get screened?</td> <td class=\"subtitle1\" rowspan=\"2\">Should women who got the HPV vaccine be screened?</td> </tr> <tr> <td class=\"subtitle2\">Age 21 to 29</td> <td class=\"subtitle2\">Age 30 and older</td> </tr> <tr> <td>Screening should start at age 21. Women younger than 21 should not be screened, even if they have started having sex.</td> <td>Women age 65 and older should stop getting screened if they meet all 3 of these requirements: <ul> <li>They have never smoked&nbsp;</li> <li>&nbsp;They do not have a new sex partner since their last Pap&nbsp;test</li> <li>They had Pap tests done regularly until they turned 65 </li> <li>They had 3 normal Pap tests in a row </li> <li>They had no abnormal Pap tests in the past 10 years </li> </ul> </td> <td>Pap test every 3 years</td> <td> <p>Pap test plus HPV test every 5 years</p> <p>Or</p> Pap test every 3 years</td> <td>Screening is not needed if the hysterectomy was done for reasons other than cancer and the cervix was removed as part of surgery.</td> <td>Women who have had the HPV vaccine do need to be screened. The vaccine reduces the risk of cervical cancer, but does not eliminate it.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>These recommendations apply only to women at AVERAGE RISK.</STRONG> They do <STRONG>not </STRONG>apply to women who have certain risk factors. Risk factors include past cervical cancer or abnormal test results, exposure to a drug called \"DES\" while in the womb, or a weakened immune system (for example, in women with HIV infection).</div><div class=\"graphic_footnotes\">HPV: human papillomavirus; HIV: human immunodeficiency virus; DES: diethylstilbestrol.</div><div id=\"graphicVersion\">Graphic 89435 Version 4.0</div></div></div>"},"89436":{"type":"graphic_figure","displayName":"H7N9 genetic evolution","title":"Genetic evolution of H7N9 virus in China, 2013","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Genetic evolution of H7N9 virus in China, 2013</div><div class=\"cntnt\"><img style=\"width:575px; height:345px;\" src=\"images/ID/89436_H7N9_genetic_evolution.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The eight genes of the H7N9 virus are closely related to avian influenza viruses found in domestic ducks, wild birds, and domestic poultry in Asia. The virus likely emerged from \"reassortment,\" a process in which two or more influenza viruses co-infect a single host and exchange genes. This can result in the creation of a new influenza virus. Experts think multiple reassortment events led to the creation of the H7N9 virus. These events may have occurred in habitats shared by wild and domestic birds and/or in live bird/poultry markets where different species of birds are bought and sold for food. As the above diagram shows, the H7N9 virus likely obtained its HA (hemagglutinin) gene from domestic ducks, its NA (neuraminidase) gene from wild birds, and its six remaining genes from multiple related H9N2 influenza viruses in domestic poultry.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Images of Avian Influenza A H7N9. Available at: <A href=\"http://www.cdc.gov/flu/avianflu/h7n9-images.htm\" target=_blank>http://www.cdc.gov/flu/avianflu/h7n9-images.htm</A> (Accessed May 17, 2013).</div><div id=\"graphicVersion\">Graphic 89436 Version 1.0</div></div></div>"},"89437":{"type":"graphic_table","displayName":"Signs of volume depletion dehydration","title":"Signs of volume depletion/dehydration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs of volume depletion/dehydration</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Dry mucous membranes (dry mouth)</td> </tr> <tr> <td>Decreased skin turgor</td> </tr> <tr> <td>Increased thirst</td> </tr> <tr> <td>Altered mental status (confusion, lethargy)</td> </tr> <tr> <td>Dizziness, lightheadedness</td> </tr> <tr> <td>Headache</td> </tr> <tr> <td>Tachycardia, palpitations</td> </tr> <tr> <td>Hypotension, orthostasis</td> </tr> <tr> <td>Presyncope or syncope</td> </tr> <tr> <td>Weakness, fatigue</td> </tr> <tr> <td>Decreased urine output, concentrated urine (deep yellow or amber color)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89437 Version 1.0</div></div></div>"},"89438":{"type":"graphic_table","displayName":"Gastroenteritis alarm symptoms and signs","title":"Gastroenteritis alarm symptoms and signs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gastroenteritis alarm symptoms and signs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Volume depletion/dehydration: <ul> <li>Dry mucous membranes (dry mouth) </li> <li>Decreased skin turgor </li> <li>Increased thirst </li> <li>Altered mental status (confusion, lethargy) </li> <li>Dizziness, lightheadedness</li> <li>Headache</li> <li>Tachycardia, palpitations </li> <li>Hypotension, orthostasis </li> <li>Presyncope or syncope </li> <li>Weakness, fatigue </li> <li>Decreased urine output, concentrated urine (deep yellow or amber color) </li> </ul> </td> </tr> <tr> <td>Bloody stool/rectal bleeding</td> </tr> <tr> <td>Weight loss</td> </tr> <tr> <td>Severe abdominal pain</td> </tr> <tr> <td>Prolonged symptoms (more than a week)</td> </tr> <tr> <td>Recent hospitalization or antibiotics</td> </tr> <tr> <td>Age &#8805;65 years</td> </tr> <tr> <td>Comorbidities such as HIV and diabetes (immunocompromised status)</td> </tr> <tr> <td>Pregnancy</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89438 Version 1.0</div></div></div>"},"89445":{"type":"graphic_picture","displayName":"Positive insulin skin tests","title":"Positive insulin skin tests","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Positive insulin skin tests</div><div class=\"cntnt\"><img style=\"width:431px; height:648px;\" src=\"images/ALLRG/89445_Positive_insulin_skin_tests.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the skin test results of a patient with immediate insulin hypersensitivity. All of the insulins tested were positive. White arrows point to the central wheals within&nbsp;each erythematous area.</div><div class=\"graphic_reference\">Courtesy of Lucie Heinzerling, MD, PhD, MPH.</div><div id=\"graphicVersion\">Graphic 89445 Version 2.0</div></div></div>"},"89448":{"type":"graphic_algorithm","displayName":"SCID NBS algorithm","title":"Newborn screening algorithm for severe combined immunodeficiency (SCID) in California","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Newborn screening algorithm for severe combined immunodeficiency (SCID) in California</div><div class=\"cntnt\"><img style=\"width:593px; height:503px;\" src=\"images/ALLRG/89448_SCID_NBS_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">California's SCID newborn screening (NBS) algorithm. Infants are categorized according to TREC copy numbers, beta-actin amplification, and nursery as proxy for clinical status. Positive cases are immediately recalled for flow cytometry. Incomplete cases (infants with DNA amplification failure results and positive infants in NICU) are recalled for a repeat TREC determination. Infants with two low TREC results are also recalled for flow cytometry. Results are interpreted by designated consultant immunologists, and abnormal results trigger referral for further investigation.</div><div class=\"graphic_footnotes\">qPCR: quantitative polymerase chain reaction; TREC: T cell receptor excision circles; DNA: deoxyribonucleic acid; NICU: neonatal intensive care unit.</div><div id=\"graphicVersion\">Graphic 89448 Version 2.0</div></div></div>"},"89450":{"type":"graphic_picture","displayName":"Lattice pattern","title":"Dermoscopic image of an acquired melanocytic nevus on the palm: The lattice-like pattern","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of an acquired melanocytic nevus on the palm: The lattice-like pattern</div><div class=\"cntnt\"><img style=\"width:485px; height:462px;\" src=\"images/DERM/89450_Lattice_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On dermoscopic examination, this acquired melanocytic nevus on the palm shows a pigment distribution that forms linear lines along and across the surface furrows in a lattice-like fashion.</div><div id=\"graphicVersion\">Graphic 89450 Version 1.0</div></div></div>"},"89451":{"type":"graphic_picture","displayName":"Fibrillar pattern","title":"Dermoscopic image of an acquired melanocytic nevus on the sole: The fibrillar pattern","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of an acquired melanocytic nevus on the sole: The fibrillar pattern</div><div class=\"cntnt\"><img style=\"width:590px; height:430px;\" src=\"images/DERM/89451_Fibrillar_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this regular fibrillar pattern, the starting points of the fibrils align on the lines corresponding to the surface furrows (arrows).</div><div id=\"graphicVersion\">Graphic 89451 Version 1.0</div></div></div>"},"89452":{"type":"graphic_picture","displayName":"Parallel furrow fibrillar transition pattern","title":"Dermoscopic parallel furrow pattern and fibrillar pattern","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Dermoscopic parallel furrow pattern and fibrillar pattern</div><div class=\"cntnt\"><img style=\"width:596px; height:305px;\" src=\"images/DERM/89452_Paral_furrow_fibril_transit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Because of the oblique arrangement of the cornified layer, the parallel furrow pattern sometimes shows features of fibrillar pattern. If the fibrils do not reach the neighboring furrow (A), the pattern is classified as parallel furrow pattern. If the fibrils reach or cross the neighboring furrow (B) or cover at least the whole width of one surface ridge, the pattern is classified as fibrillar.</div><div id=\"graphicVersion\">Graphic 89452 Version 1.0</div></div></div>"},"89455":{"type":"graphic_picture","displayName":"Regular and irregular fibrillar pattern","title":"Dermoscopic features of regular and irregular fibrillar pattern","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of regular and irregular fibrillar pattern</div><div class=\"cntnt\"><img style=\"width:597px; height:354px;\" src=\"images/DERM/89455_Reg_irreg_fibrillar_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the regular fibrillar pattern of benign nevi (A), the overall arrangement of the fibrils is mostly symmetric and the starting points of the fibrils align on straight lines corresponding to the surface furrows. In contrast, in the irregular fibrillar pattern seen in melanoma (B), the fibrils are variable in color and thickness and are arranged in a disorderly, haphazard fashion. Their starting points do not align on a straight line.</div><div id=\"graphicVersion\">Graphic 89455 Version 1.0</div></div></div>"},"89457":{"type":"graphic_picture","displayName":"Minor dermoscopic patterns acral nevi","title":"Minor dermoscopic patterns seen in acquired melanocytic nevi of palms and soles","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Minor dermoscopic patterns seen in acquired melanocytic nevi of palms and soles</div><div class=\"cntnt\"><img style=\"width:597px; height:294px;\" src=\"images/DERM/89457_Minor_derm_pattern_acr_nevi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Globular pattern.<br />(B) Acral reticular pattern.</div><div id=\"graphicVersion\">Graphic 89457 Version 1.0</div></div></div>"},"89464":{"type":"graphic_picture","displayName":"Dermoscopy of acral congenital nevi 1","title":"Dermoscopic features of congenital melanocytic nevus on the palms and soles: The parallel furrow pattern","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of congenital melanocytic nevus on the palms and soles: The parallel furrow pattern</div><div class=\"cntnt\"><img style=\"width:590px; height:406px;\" src=\"images/DERM/89464_Derm_acral_congenital_nevi1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this plantar congenital nevus, the typical parallel furrow pattern is associated with a grayish-brown background pigmentation. The gray tone reflects the melanin granules in the dermis derived from the prominent intradermal component of congenital nevi.</div><div id=\"graphicVersion\">Graphic 89464 Version 1.0</div></div></div>"},"89466":{"type":"graphic_picture","displayName":"Dermoscopy of acral congenital nevi 2","title":"Dermoscopic features of congenital nevi of the palms and soles: The crista dotted pattern","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of congenital nevi of the palms and soles: The crista dotted pattern</div><div class=\"cntnt\"><img style=\"width:502px; height:385px;\" src=\"images/DERM/89466_Derm_acral_congenital_nevi2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the crista dotted pattern, brown globules are regularly distributed on the surface ridges. The globules correspond to nevus cell nests surrounding the distal portion of the eccrine ducts, which open in the center of the ridges.</div><div id=\"graphicVersion\">Graphic 89466 Version 1.0</div></div></div>"},"89467":{"type":"graphic_picture","displayName":"Dermoscopy of acral congenital nevi 3","title":"Dermoscopic features of congenital nevi of palms and soles: The peas-in-a-pod pattern","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of congenital nevi of palms and soles: The peas-in-a-pod pattern</div><div class=\"cntnt\"><img style=\"width:590px; height:280px;\" src=\"images/DERM/89467_Derm_acral_congenital_nevi3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peas-in-a-pod, commonly detected in congenital nevus on the palms and soles, is regarded as a combination of the parallel furrow pattern and crista dotted pattern.</div><div id=\"graphicVersion\">Graphic 89467 Version 1.0</div></div></div>"},"89468":{"type":"graphic_picture","displayName":"Dermoscopy of acral congenital nevi 4","title":"Dermoscopic features of a congenital plantar nevus","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of a congenital plantar nevus</div><div class=\"cntnt\"><img style=\"width:598px; height:469px;\" src=\"images/DERM/89468_Derm_acral_congenital_nevi4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this plantar congenital nevus, the dermoscopic pattern is similar to the parallel ridge pattern. However, the color is grayish and the pigmented bands are segmented, resembling the crista dotted pattern. These findings help in differentiating this pattern from the classic parallel ridge pattern seen in melanoma. Subtle features of the parallel furrow pattern, which is typical of acquired acral melanocytic nevi,&nbsp;are detected on the left side of this lesion.</div><div id=\"graphicVersion\">Graphic 89468 Version 2.0</div></div></div>"},"89469":{"type":"graphic_picture","displayName":"Dermoscopy acral nevus transition zone","title":"Dermoscopic features of an acral melanocytic nevus located in the transition zone between glabrous and nonglabrous skin","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of an acral melanocytic nevus located in the transition zone between glabrous and nonglabrous skin</div><div class=\"cntnt\"><img style=\"width:590px; height:405px;\" src=\"images/DERM/89469_Derm_acral_nevus_trans_zone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this nevus located on the side of a toe, a densely arranged reticular or branched pigmentation is observed. Inset: clinical photo. Note that the histopathological features of melanocytic nevi located on the transition zone between glabrous and nonglabrous skin often mimic those of melanoma, showing prominent proliferation of solitary melanocytes within the epidermis.</div><div class=\"graphic_reference\">Courtesy of Akemi Ishida-Yamamoto, MD, PhD</div><div id=\"graphicVersion\">Graphic 89469 Version 2.0</div></div></div>"},"89470":{"type":"graphic_table","displayName":"Content of the patient centered interview in palliative care","title":"Content of the patient centered interview in palliative care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Content of the patient centered interview in palliative care</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Understanding about the nature of the illness:</td> </tr> <tr> <td class=\"indent1\">Tell me about your illness. What is your understanding about your condition?</td> </tr> <tr> <td class=\"indent1\">What do you think about why it happened?</td> </tr> <tr> <td class=\"indent1\">What have you been told about its seriousness?</td> </tr> <tr> <td class=\"indent1\">What have you been told about your treatment options?</td> </tr> <tr> <td class=\"indent1\">What are likely to be the next stages?</td> </tr> <tr> <td class=\"indent1\">What kinds of questions do you have?</td> </tr> <tr> <td class=\"subtitle1_single\">Preferences for information giving and decision-making:</td> </tr> <tr> <td class=\"indent1\">Do you like to get all the facts about your condition or just the broad picture? Or even being excluded from any bad news?<sup>[1]</sup></td> </tr> <tr> <td class=\"indent1\">When we need to make serious decisions about your health care, do you manage it alone or share it with family or leave it to the family or the doctors?</td> </tr> <tr> <td class=\"subtitle1_single\">Hopes:</td> </tr> <tr> <td class=\"indent1\">What are you most hoping for in the coming days? Wishes?</td> </tr> <tr> <td class=\"indent1\">What things are most important to you now? What matters most to you for the future?</td> </tr> <tr> <td class=\"indent1\">Do you have any particular goals for your time? Do you have things that you are hoping to accomplish?</td> </tr> <tr> <td class=\"subtitle1_single\">Concerns:</td> </tr> <tr> <td class=\"indent1\">What are your foremost concerns about your illness these days? Your worries? Your fears?</td> </tr> <tr> <td class=\"indent1\">What has been your previous experience with this sort of illness? What have you heard about it?</td> </tr> <tr> <td class=\"indent1\">What are your concerns for the future if your condition worsens?</td> </tr> <tr> <td class=\"indent1\">Do you think about dying?</td> </tr> <tr> <td class=\"subtitle1_single\">Coping:</td> </tr> <tr> <td class=\"indent1\">How has the illness affected you?</td> </tr> <tr> <td class=\"indent1\">What has been most difficult about this illness for you?</td> </tr> <tr> <td class=\"indent1\">How are you managing? How are your spirits?</td> </tr> <tr> <td class=\"indent1\">How is your family coping?</td> </tr> <tr> <td class=\"indent1\">When you have had to face difficult situations in the past, how did you cope?</td> </tr> <tr> <td class=\"indent1\">What has been helpful to you now?</td> </tr> <tr> <td class=\"indent1\">How have you been helped though all this?</td> </tr> <tr> <td class=\"subtitle1_single\">Existential/spiritual issues:</td> </tr> <tr> <td class=\"indent1\">How are you making sense of this illness and why it happened?</td> </tr> <tr> <td class=\"indent1\">Do you have ideas about why bad things happen to good people?</td> </tr> <tr> <td class=\"indent1\">Were you brought up in any religious tradition?</td> </tr> <tr> <td class=\"indent1\">Do you currently have any religious or spiritual practice? How does that give your life meaning?</td> </tr> <tr> <td class=\"indent1\">How have these beliefs influenced you at this time? Helped?</td> </tr> <tr> <td class=\"indent1\">What are your beliefs about death and what comes afterward?</td> </tr> <tr> <td class=\"subtitle1_single\">Closure and reconciliation:</td> </tr> <tr> <td class=\"indent1\">Are there ways that you can help your family prepare for your death? Ways they can be helpful?</td> </tr> <tr> <td class=\"indent1\">Are there relationships where you feel something important has been left unsaid? Do you have relationships that need healing?</td> </tr> <tr> <td class=\"indent1\">How would you like to say good-bye to the people who have been important to you?</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Back AL, Arnold RM. Discussing prognosis: \"How much do you want to know?\" talking to patients who are prepared for explicit information. J Clin Oncol 2006; 24:4209.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 89470 Version 1.0</div></div></div>"},"89471":{"type":"graphic_table","displayName":"Responding to emotions patient-centered palliat care interview","title":"Responding to emotions in the patient-centered palliative care interview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Responding to emotions in the patient-centered palliative care interview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Elicitation:</td> </tr> <tr> <td class=\"indent1\">How are you dealing with all this?</td> </tr> <tr> <td class=\"indent1\">How are you getting along emotionally with this condition?</td> </tr> <tr> <td class=\"indent1\">How is it affecting your family?</td> </tr> <tr> <td class=\"subtitle1_single\">Acknowledgement:</td> </tr> <tr> <td class=\"indent1\">So you were upset...</td> </tr> <tr> <td class=\"indent1\">I can see how that must have been discouraging...</td> </tr> <tr> <td class=\"indent1\">I appreciate that you are worried about how your husband is coping...</td> </tr> <tr> <td class=\"subtitle1_single\">Exploration:</td> </tr> <tr> <td class=\"indent1\">Tell me more about what was most upsetting.</td> </tr> <tr> <td class=\"indent1\">Tell me more about how your family is coping.</td> </tr> <tr> <td class=\"indent1\">When you said, \"It's all over,\" I wonder if you were talking about dying?</td> </tr> <tr> <td class=\"subtitle1_single\">Legitimization:</td> </tr> <tr> <td class=\"indent1\">It is completely understandable to be (frightened) in these circumstances.</td> </tr> <tr> <td class=\"indent1\">Most people have strong emotional reactions to such news.</td> </tr> <tr> <td class=\"subtitle1_single\">Empathy:</td> </tr> <tr> <td class=\"indent1\">I imagine that must have been devastating news.</td> </tr> <tr> <td class=\"indent1\">I can really see why that was so upsetting.</td> </tr> <tr> <td class=\"subtitle1_single\">Non abandonment:</td> </tr> <tr> <td class=\"indent1\">We will work with you to sort this all out.</td> </tr> <tr> <td class=\"indent1\">Our team will follow-up with you both here in the hospital and after discharge.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89471 Version 1.0</div></div></div>"},"89472":{"type":"graphic_table","displayName":"Template for palliative care service consultation","title":"Template for palliative care service consultation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Template for palliative care service consultation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Date of initial consultation:</td> </tr> <tr class=\"divider_bottom\"> <td>Referring provider:</td> </tr> <tr> <td class=\"subtitle1_single\">Reason for consultation:</td> </tr> <tr> <td class=\"indent1\">Pain control</td> </tr> <tr> <td class=\"indent1\">Non pain symptom management</td> </tr> <tr> <td class=\"indent1\">Psychosocial/spiritual support</td> </tr> <tr> <td class=\"indent1\">Establishing goals of care</td> </tr> <tr> <td class=\"indent1\">Interfamily conflict</td> </tr> <tr> <td class=\"indent1\">Family-clinician negotiation</td> </tr> <tr> <td class=\"indent1\">Withdrawal of life-sustaining treatment</td> </tr> <tr> <td class=\"indent1\">Terminal care</td> </tr> <tr> <td class=\"indent1\">Inpatient hospice referral</td> </tr> <tr> <td class=\"indent1\">Disposition</td> </tr> <tr> <td class=\"indent1\">Other:</td> </tr> <tr> <td class=\"subtitle1_single\">History of the present illness:</td> </tr> <tr> <td class=\"subtitle1_single\">Palliative review of symptoms<br /> <span class=\"small\">(may include standardized numerical [eg, Likert] or categorical recording method)</span></td> </tr> <tr> <td class=\"sublist2_start\">Performance status</td> </tr> <tr> <td class=\"sublist2\"><strong>ECOG</strong></td> </tr> <tr> <td class=\"sublist2\">0 - fully active</td> </tr> <tr> <td class=\"sublist2\">1 - restricted strenuous activity</td> </tr> <tr> <td class=\"sublist2\">2 - ambulatory, unable to work</td> </tr> <tr> <td class=\"sublist2\">3 - limited self-care, bed- chair &#62;50 waking hours/week</td> </tr> <tr> <td class=\"sublist2\">4 - bed-chair confined, no self-care</td> </tr> <tr> <td class=\"sublist2_start\">Pain</td> </tr> <tr> <td class=\"sublist2\">Pain description:</td> </tr> <tr> <td class=\"sublist2\">Pain intensity [0 to 10]:</td> </tr> <tr> <td class=\"indent1\">Dyspnea:</td> </tr> <tr> <td class=\"indent1\">Cough:</td> </tr> <tr> <td class=\"indent1\">Nutritional status (weight change, appetite, taste disturbance):</td> </tr> <tr> <td class=\"indent1\">Oral symptoms (xerostomia, dysphagia, odynophagia):</td> </tr> <tr> <td class=\"indent1\">Nausea/vomiting:</td> </tr> <tr> <td class=\"indent1\">Constipation/diarrhea:</td> </tr> <tr> <td class=\"indent1\">Urination problems:</td> </tr> <tr> <td class=\"indent1\">Sleep:</td> </tr> <tr> <td class=\"indent1\">Fatigue:</td> </tr> <tr> <td class=\"indent1\">Sedation:</td> </tr> <tr> <td class=\"indent1\">Cognitive/memory problems:</td> </tr> <tr> <td class=\"indent1\">Anxiety:</td> </tr> <tr> <td class=\"indent1\">Depression:</td> </tr> <tr> <td class=\"indent1\">Concerns/worries:</td> </tr> <tr> <td class=\"indent1\">Other:</td> </tr> <tr> <td class=\"subtitle1_single\">Goals of care</td> </tr> <tr> <td class=\"subtitle2_left\">Information sharing preferences</td> </tr> <tr> <td class=\"sublist2_start\">Patient's understanding of medical condition and prognosis:</td> </tr> <tr> <td class=\"sublist2\">Knows diagnosis: Yes/No</td> </tr> <tr> <td class=\"sublist2\">Knows prognosis</td> </tr> <tr> <td class=\"sublist3\">Terminal</td> </tr> <tr> <td class=\"sublist3\">Life-threatening</td> </tr> <tr> <td class=\"sublist3\">Serious</td> </tr> <tr> <td class=\"sublist3\">Not life-threatening</td> </tr> <tr> <td class=\"sublist3\">Not serious</td> </tr> <tr> <td class=\"sublist3\">Not discussed</td> </tr> <tr> <td class=\"sublist2_start\">Patient's preference about sharing medical information:</td> </tr> <tr> <td class=\"sublist2\">Patient alone should receive all information</td> </tr> <tr> <td class=\"sublist2\">Patient and family may receive information</td> </tr> <tr> <td class=\"sublist2\">Only family or specific family member(s) should receive information</td> </tr> <tr> <td class=\"sublist2\">Patient declines information sharing</td> </tr> <tr> <td class=\"sublist2\">Unsure</td> </tr> <tr> <td class=\"indent1\">Family's or surrogate's awareness of illness:</td> </tr> <tr> <td class=\"subtitle2_left\">Decision making preferences</td> </tr> <tr> <td class=\"sublist2_start\">Patient's decision-making preferences:</td> </tr> <tr> <td class=\"sublist2\">Fully involved</td> </tr> <tr> <td class=\"sublist2\">Speak to family</td> </tr> <tr> <td class=\"sublist2\">Leave to MD</td> </tr> <tr> <td class=\"sublist2\">Unsure</td> </tr> <tr> <td class=\"subtitle2_left\">Patient understanding of illness and prognosis</td> </tr> <tr> <td class=\"subtitle2_left\">Hopes and concerns</td> </tr> <tr> <td class=\"subtitle2_left\">Previous experiences with end of life decisions</td> </tr> <tr> <td class=\"subtitle2_left\">Attitudes about diminished functional states and use of \"aggressive\" life-sustaining care</td> </tr> <tr> <td class=\"indent1\">Unacceptable states (eg, unable to think or communicate or live independently)</td> </tr> <tr> <td class=\"subtitle2_left\">Advance directives</td> </tr> <tr> <td class=\"sublist2_start\">Health care proxy:</td> </tr> <tr> <td class=\"sublist2\">Name:</td> </tr> <tr> <td class=\"sublist2\">Address:</td> </tr> <tr> <td class=\"sublist2\">Telephone:</td> </tr> <tr> <td class=\"sublist2\">Location of proxy document:</td> </tr> <tr> <td class=\"subtitle2_left\">Limitations on life sustaining treatments (should conform to orders)</td> </tr> <tr> <td class=\"indent1\">Full Code, discussed with patient or surrogate</td> </tr> <tr> <td class=\"indent1\">Full Code, default, discussion not possible/appropriate presently</td> </tr> <tr> <td class=\"sublist2_start\">Limitation of life-sustaining treatment:</td> </tr> <tr> <td class=\"sublist2\">No cardiopulmonary resuscitation</td> </tr> <tr> <td class=\"sublist2\">No endotracheal intubation or mechanical ventilation</td> </tr> <tr> <td class=\"sublist2\">No noninvasive ventilatory support (BiPAP, CPAP)</td> </tr> <tr> <td class=\"sublist2\">Other instructions:</td> </tr> <tr> <td class=\"sublist2\">Comfort care form or physician orders for life sustaining treatment: Yes/No</td> </tr> <tr> <td class=\"subtitle2_left\">End of life plans</td> </tr> <tr> <td class=\"indent1\">Patient preference for place of death: Home ____ Hospital ____ Other ____</td> </tr> <tr> <td class=\"indent1\">Funeral arrangements/wishes:</td> </tr> <tr> <td class=\"subtitle1_single\">PMHx:</td> </tr> <tr> <td class=\"subtitle2_left\">Hospitalizations:</td> </tr> <tr> <td class=\"subtitle2_left\">Operations:</td> </tr> <tr> <td class=\"subtitle2_left\">Other serious illnesses:</td> </tr> <tr> <td class=\"subtitle2_left\">Allergies, adverse reactions:</td> </tr> <tr> <td class=\"subtitle2_left\">Current medications and complementary therapies:</td> </tr> <tr> <td class=\"subtitle2_left\">Social history</td> </tr> <tr> <td class=\"indent1\">Place of birth:</td> </tr> <tr> <td class=\"indent1\">Education:</td> </tr> <tr> <td class=\"indent1\">Martial status: Single ____ Married ____ Divorced ____</td> </tr> <tr> <td class=\"indent1\">Children:</td> </tr> <tr> <td class=\"indent1\">Work:</td> </tr> <tr> <td class=\"indent1\">Hobbies/joys:</td> </tr> <tr> <td class=\"indent1\">Habits:</td> </tr> <tr> <td class=\"indent1\">Patient coping:</td> </tr> <tr> <td class=\"indent1\">Support system:</td> </tr> <tr> <td class=\"indent1\">Family support:</td> </tr> <tr> <td class=\"indent1\">Family coping:</td> </tr> <tr> <td class=\"indent1\">Financial issues:</td> </tr> <tr> <td class=\"indent1\">Cultural issues:</td> </tr> <tr> <td class=\"subtitle2_left\">Spiritual history</td> </tr> <tr> <td class=\"indent1\">Religious/spiritual orientation:</td> </tr> <tr> <td class=\"indent1\">Involvement in a spiritual community:</td> </tr> <tr> <td class=\"indent1\">Desire for further chaplaincy support: Yes/No</td> </tr> <tr> <td class=\"subtitle2_left\">Family history:</td> </tr> <tr> <td class=\"subtitle1_single\">Physical examination:</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory studies:</td> </tr> <tr> <td class=\"subtitle1_single\">Impression/problems:</td> </tr> <tr> <td class=\"indent1\">1.</td> </tr> <tr> <td class=\"indent1\">2.</td> </tr> <tr> <td class=\"indent1\">3.</td> </tr> <tr> <td class=\"subtitle1_single\">Suggestions/plans:</td> </tr> <tr> <td class=\"indent1\">1.</td> </tr> <tr> <td class=\"indent1\">2.</td> </tr> <tr> <td class=\"indent1\">3.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89472 Version 2.0</div></div></div>"},"89473":{"type":"graphic_picture","displayName":"Black heel dermoscopy","title":"Dermoscopic features of the \"black heel\"","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of the \"black heel\"</div><div class=\"cntnt\"><img style=\"width:446px; height:461px;\" src=\"images/DERM/89473_Black_heel_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The \"black heel\" results from the formation of tiny petechiae in the superficial skin tissue of the heel caused in most cases by friction with tight, ill-fitted sport shoes. Reddish to black globular pigmentation on the ridges (the pebbles on the ridges) is characteristic. Inset: clinical photograph.</div><div id=\"graphicVersion\">Graphic 89473 Version 1.0</div></div></div>"},"89474":{"type":"graphic_picture","displayName":"Hematoma dermoscopy","title":"Dermoscopic features of superficial hematoma in the plantar skin","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of superficial hematoma in the plantar skin</div><div class=\"cntnt\"><img style=\"width:582px; height:459px;\" src=\"images/DERM/89474_Hematoma_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On dermoscopy, a superficial hematoma in the plantar skin shows a pigment distribution reminiscent of the parallel ridge pattern. However, the reddish tone and demarcation of the lesion and the presence of reddish black globules are helpful in differentiating hematomas from melanocytic lesions.</div><div id=\"graphicVersion\">Graphic 89474 Version 1.0</div></div></div>"},"89475":{"type":"graphic_picture","displayName":"Drug induced pigmentation dermoscopy","title":"Dermoscopic features of pigmentation induced by 5-fluorouracil","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of pigmentation induced by 5-fluorouracil</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/89475_Drug_induced_pigment_dermos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The drug-induced light brown pigmentation is accentuated on the surface ridges, resembling the parallel ridge pattern. This pigmentation can be differentiated from melanoma based upon the presence of multiple brown macules bilaterally on the palms and soles and history of drug intake.</div><div id=\"graphicVersion\">Graphic 89475 Version 1.0</div></div></div>"},"89476":{"type":"graphic_figure","displayName":"Minimally invasive PI","title":"Minimally invasive surgery","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Minimally invasive surgery</div><div class=\"cntnt\"><img style=\"width:522px; height:526px;\" src=\"images/PI/89476_Minimally_invasive_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 89476 Version 1.0</div></div></div>"},"89477":{"type":"graphic_algorithm","displayName":"Dermoscopic 3-step algorithm","title":"The 3-step dermoscopic algorithm for the diagnosis and management of acquired melanocytic lesions of the palms and soles","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">The 3-step dermoscopic algorithm for the diagnosis and management of acquired melanocytic lesions of the palms and soles</div><div class=\"cntnt\"><img style=\"width:520px; height:256px;\" src=\"images/DERM/89477_Derm_3_step_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: John Wiley &amp; Sons, Inc. Saida T, Koga H, Uhara H. Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol 2011; 38:25. Copyright &copy; 2011 Japanese Dermatological Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89477 Version 5.0</div></div></div>"},"89478":{"type":"graphic_table","displayName":"Emergent reversal of anticoagulation from warfarin in adults","title":"Emergent reversal of anticoagulation from warfarin for life-threatening hemorrhage in adults: Suggested approaches based upon available resources","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Emergent reversal of anticoagulation from warfarin for life-threatening hemorrhage in adults: Suggested approaches based upon available resources</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">A. If 4-factor prothrombin complex concentrate (4F PCC) is available (preferred approach):</td> </tr> <tr> <td class=\"indent1\">1. Give 4F PCC* 1500 to 2000 units<sup>&#182;</sup> IV over 10 minutes. Check INR 15 minutes after completion of the infusion. If INR is not &#8804;1.5, give additional 4F PCC (refer to topic or drug reference for details).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">2. Give vitamin K 10 mg IV over 10 to 20 minutes.</td> </tr> <tr> <td class=\"subtitle2_left\">B. If 3-factor prothrombin complex concentrate (3F PCC) is available but 4F PCC is not available:</td> </tr> <tr> <td class=\"indent1\">1. Give 3F PCC* 1500 to 2000 units<sup>&#182;</sup> IV over 10 minutes. Check INR 15 minutes after completion of the infusion. If INR is not &#8804;1.5, give additional 3F PCC (refer to topic or drug reference for details).</td> </tr> <tr> <td class=\"indent1\">2. Give Factor VIIa 20 mcg/kg IV <strong>OR</strong> give FFP 2 units IV by rapid infusion. Factor VIIa may be preferred if volume overload is a concern.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">3. Give vitamin K 10 mg IV over 10 to 20 minutes.</td> </tr> <tr> <td class=\"subtitle2_left\">C. Neither 3F PCC nor 4F PCC is available:</td> </tr> <tr> <td class=\"indent1\">1. Give FFP 2 units IV by rapid infusion. Check INR 15 minutes after completion of infusion. If INR &#8805;1.5, administer 2 additional units of FFP IV rapid infusion. Repeat process until INR &#8804;1.5. May wish to administer loop diuretic between FFP infusions if volume overload is a concern.</td> </tr> <tr> <td class=\"indent1\">2. Give vitamin K 10 mg IV over 10 to 20 minutes.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These products and doses are for use in life-threatening bleeding only. Evidence of life-threatening bleeding and over-anticoagulation with a vitamin K antagonist (eg, warfarin) are required. Anaphylaxis and transfusion reactions can occur.<br />It may be reasonable to thaw four units of FFP while awaiting the PT/INR. The transfusion service may substitute other plasma products for FFP (eg, Plasma Frozen Within 24 Hours After Phlebotomy [PF24]); these products are considered clinically interchangeable. PCC will reverse anticoagulation within minutes of administration; FFP administration can take hours due to the volume required; vitamin K effect takes 12 to 24 hours, but administration of vitamin K is needed to counteract the long half-life of warfarin. Subsequent monitoring of the PT/INR is needed to guide further therapy. Refer to topics on warfarin reversal in individual situations for further management.</div><div class=\"graphic_footnotes\">PCC: unactivated prothrombin complex concentrate; 4F PCC: PCC containing coagulation factors II, VII, IX, X, protein S and protein C; 3F PCC: PCC containing factors II, IX, and X and only trace factor VII; FFP: fresh frozen plasma; PT: prothrombin time; INR: international normalized ratio; FEIBA: factor eight inhibitor bypassing agent.<br />* Before use, check product label to confirm factor types (3 versus 4 factor) and concentration. Activated complexes and single-factor IX products (ie, FEIBA, AlphaNine, Mononine, Immunine, BeneFix) are NOT used for warfarin reversal.<br />¶ PCC doses shown are those suggested for initial treatment of emergency conditions. Subsequent treatment is based on INR and patient weight if available. Refer to topic and Lexicomp drug reference included with UpToDate for INR-based dosing.</div><div id=\"graphicVersion\">Graphic 89478 Version 8.0</div></div></div>"},"89481":{"type":"graphic_table","displayName":"Comorbidity factors","title":"Comorbidity factors in the Prostate Cancer Outcomes Study","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comorbidity factors in the Prostate Cancer Outcomes Study</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major factors at time of diagnosis:</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Bleeding gastrointestinal ulcer</td> </tr> <tr> <td class=\"indent1\">Chronic lung disease</td> </tr> <tr> <td class=\"indent1\">Heart failure</td> </tr> <tr> <td class=\"indent1\">Stroke</td> </tr> <tr> <td class=\"indent1\">Myocardial infarction</td> </tr> <tr> <td class=\"indent1\">Angina/chest pain</td> </tr> <tr> <td class=\"indent1\">Cirrhosis or liver disease</td> </tr> <tr> <td class=\"indent1\">Arthritis</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> </tr> <tr> <td class=\"indent1\">Depression</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Daskivich TJ, Fan K, Koyama T, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med 2013; 158:709.</div><div id=\"graphicVersion\">Graphic 89481 Version 3.0</div></div></div>"},"89482":{"type":"graphic_figure","displayName":"Other cause and prostate cancer mortality incidence ","title":"Cumulative incidence curves for other-cause and prostate cancer–specific mortality, by number of comorbid conditions","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Cumulative incidence curves for other-cause and prostate cancer–specific mortality, by number of comorbid conditions</div><div class=\"cntnt\"><img style=\"width:548px; height:576px;\" src=\"images/ONC/89482_Cumulative_inciden_curves.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Daskivich TJ, Fan K, Koyama T, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med 2013; 158:709. Copyright © 2013 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 89482 Version 4.0</div></div></div>"},"89483":{"type":"graphic_picture","displayName":"HIV gingivitis","title":"HIV gingivitis (also called generalized linear gingival erythema) in a child","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">HIV gingivitis (also called generalized linear gingival erythema) in a child</div><div class=\"cntnt\"><img style=\"width:575px; height:175px;\" src=\"images/PEDS/89483_Gnrzd_lnr_gngvl_erythm_chld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized linear gingival erythema in a nine-year-old girl with HIV infection. Note the 2 to 3 mm band of pronounced redness at the gingival margins.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 89483 Version 2.0</div></div></div>"},"89484":{"type":"graphic_picture","displayName":"Peripheral ossifying fibroma","title":"Peripheral ossifying fibroma","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Peripheral ossifying fibroma</div><div class=\"cntnt\"><img style=\"width:527px; height:185px;\" src=\"images/PEDS/89484_Peripherl_ossifying_fibroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral ossifying fibroma of the lower anterior gingiva in a seven-year-old girl.</div><div id=\"graphicVersion\">Graphic 89484 Version 1.0</div></div></div>"},"89485":{"type":"graphic_picture","displayName":"Early gingival overgrowth","title":"Early gingival overgrowth","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Early gingival overgrowth</div><div class=\"cntnt\"><img style=\"width:490px; height:323px;\" src=\"images/PEDS/89485_Early_gingival_overgrowth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early gingival overgrowth in a 16-year-old taking cyclosporin following solid organ transplant. The gingival overgrowth starts in the interdental papilla area (arrow). It can be stabilized with aggressive oral hygiene.</div><div id=\"graphicVersion\">Graphic 89485 Version 2.0</div></div></div>"},"89486":{"type":"graphic_figure","displayName":"Corneal topography OCR difference map","title":"Corneal topography: Difference map for overnight corneal reshaping (OCR)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corneal topography: Difference map for overnight corneal reshaping (OCR)</div><div class=\"cntnt\"><img style=\"width:341px; height:670px;\" src=\"images/PC/89486_Corn_topo_CR_rence_map.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Prefitting topography map.<br />(B) Post-fitting topography map (after two months of OCR).<br />(C) Difference map: Computer analysis of location and quantity of corneal curvature changes.</div><div class=\"graphic_footnotes\">OCR: overnight corneal reshaping.</div><div class=\"graphic_reference\">Courtesy of Michael J Lipson, OD, FAAO.</div><div id=\"graphicVersion\">Graphic 89486 Version 1.0</div></div></div>"},"89487":{"type":"graphic_picture","displayName":"Black heel 1 ","title":"Black heel (calcaneal petechiae)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Black heel (calcaneal petechiae)</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89487_Black_heel_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The black specks on the heel result from intradermal hemorrhage due to trauma (eg, friction against shoes during vigorous sports).</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89487 Version 2.0</div></div></div>"},"89488":{"type":"graphic_picture","displayName":"Black heel 2","title":"Black heel (calcaneal petechiae)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Black heel (calcaneal petechiae)</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89488_Black_heel_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aggregated black specks on the heel resulting from intraepidermal hemorrhage caused by shear-force injuries (eg, during vigorous sports).</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89488 Version 2.0</div></div></div>"},"89489":{"type":"graphic_picture","displayName":"Acquired torticollis with atlantoaxial rotary subluxation","title":"Acquired torticollis with atlantoaxial rotary subluxation","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Acquired torticollis with atlantoaxial rotary subluxation</div><div class=\"cntnt\"><img style=\"width:539px; height:598px;\" src=\"images/EM/89489_Acq_torticollis_atlantoaxia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The head of this child is in the typical position of rotatory atlanto-axial subluxation: tilted to the left, with the chin rotated to the right. Unlike in patients who have congenital muscular torticollis, the right sternocleidomastoid muscle is tight, suggesting an attempt to straighten the neck.<br />(B, C) Dynamic computed-tomography scans of the upper cervical spine in a patient who had rotatory atlanto-axial subluxation. (B) The head is rotated approximately 45 degrees to one side, with the contralateral lateral mass of the first cervical vertebra moving forward on the cephalad articulating facet of the second cervical vertebra. (C) The head cannot be rotated past the midline, and the relationship of the first and second cervical vertebrae is unchanged.</div><div class=\"graphic_reference\">Reproduced with permission: Phillips WA, Hensinger RN. The management of rotatory atlanto-axial subluxation in children. J Bone Joint Surg 1989; 71-A: 664. Copyright &copy; 1989 Journal of Bone and Joint Surgery, Inc. All rights reserved. <a href=\"http://jbjs.org/\" target=\"_blank\">http://jbjs.org/</a>.</div><div id=\"graphicVersion\">Graphic 89489 Version 3.0</div></div></div>"},"89492":{"type":"graphic_picture","displayName":"Peutz-Jeghers thumb","title":"Cutaneous hyperpigmentation in Peutz-Jeghers syndrome","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Cutaneous hyperpigmentation in Peutz-Jeghers syndrome</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/DERM/89492_Peutz_Jeghers_thumb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hyperpigmented macules on the volar aspect of the thumb in a patient with Peutz-Jeghers syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89492 Version 2.0</div></div></div>"},"89493":{"type":"graphic_picture","displayName":"Peutz-Jeghers hand","title":"Peutz-Jeghers syndrome","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Peutz-Jeghers syndrome</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/DERM/89493_Peutz_Jeghers_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hyperpigmented macules on the dorsum of the hand of a patient with Peutz-Jeghers syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89493 Version 1.0</div></div></div>"},"89495":{"type":"graphic_figure","displayName":"Mini gastric bypass","title":"Mini gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mini gastric bypass</div><div class=\"cntnt\"><img style=\"width:422px; height:594px;\" src=\"images/SURG/89495_Mini_gastric_bypass.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 89495 Version 1.0</div></div></div>"},"89496":{"type":"graphic_picture","displayName":"Body MRI with multiple schwannomas","title":"Body MRI with multiple schwannomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Body MRI with multiple schwannomas</div><div class=\"cntnt\"><img style=\"width:420px; height:265px;\" src=\"images/ONC/89496_Char_MR_imag_schwannom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging (MRI)&nbsp;with short T1 inversion recovery (STIR)&nbsp;sequences in a patient with schwannomatosis. Multiple schwannomas (yellow arrows) are visualized on coronal thoracic spine (A), coronal cervical spine (B), and axial lower extremity (C) STIR images.</div><div id=\"graphicVersion\">Graphic 89496 Version 1.0</div></div></div>"},"89498":{"type":"graphic_figure","displayName":"Abdominal incisions for major liver surgery","title":"Abdominal incisions for major liver surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abdominal incisions for major liver surgery</div><div class=\"cntnt\"><img style=\"width:391px; height:427px;\" src=\"images/SURG/89498_Abdominal_incisions_liver.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 89498 Version 1.0</div></div></div>"},"89499":{"type":"graphic_figure","displayName":"Dissection of the porta hepatis","title":"Dissection of the porta hepatis","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Dissection of the porta hepatis</div><div class=\"cntnt\"><img style=\"width:494px; height:455px;\" src=\"images/SURG/89499_Dissect_porta_hepatis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 89499 Version 1.0</div></div></div>"},"89500":{"type":"graphic_diagnosticimage","displayName":"CT abdominal gossypiboma","title":"Retained surgical foreign body on CT","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Retained surgical foreign body on CT</div><div class=\"cntnt\"><img style=\"width:596px; height:263px;\" src=\"images/RADIOL/89500_CT_abdominal_gossypiboma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 75-year-old male presents with a palpable mass in the left hemiabdomen. He had abdominal surgery six years prior following a motor vehicle accident. A CT scan through the abdomen (A) shows a large cystic mass associated with a hyperattenuating foreign body (arrow) consistent with a gossypiboma. Image B shows the inferior extent of the mass. The mass was resected and pathology showed sponge-like foreign material with associated xanthogranulomatous inflammation.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89500 Version 1.0</div></div></div>"},"89501":{"type":"graphic_figure","displayName":"Left hepatectomy","title":"Left hepatectomy","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Left hepatectomy</div><div class=\"cntnt\"><img style=\"width:518px; height:452px;\" src=\"images/SURG/89501_L_hepat.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 89501 Version 1.0</div></div></div>"},"89502":{"type":"graphic_figure","displayName":"Right hepatectomy","title":"Right hepatectomy","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Right hepatectomy</div><div class=\"cntnt\"><img style=\"width:487px; height:387px;\" src=\"images/SURG/89502_R_hepat.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 89502 Version 1.0</div></div></div>"},"89503":{"type":"graphic_figure","displayName":"Anterior approach to right hepatectomy","title":"Anterior approach to right hepatectomy","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Anterior approach to right hepatectomy</div><div class=\"cntnt\"><img style=\"width:498px; height:447px;\" src=\"images/SURG/89503_Ant_approach_R_hepat.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 89503 Version 1.0</div></div></div>"},"89504":{"type":"graphic_figure","displayName":"Division of inferior vena cava ligament","title":"Division of inferior vena cava ligament","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Division of inferior vena cava ligament</div><div class=\"cntnt\"><img style=\"width:373px; height:448px;\" src=\"images/SURG/89504_Div_IVC_ligament.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 89504 Version 1.0</div></div></div>"},"89505":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray - Acquired neonatal pleural effusion","title":"Chest radiograph of acquired left-sided pleural effusion in a newborn infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of acquired left-sided pleural effusion in a newborn infant</div><div class=\"cntnt\"><img style=\"width:427px; height:326px;\" src=\"images/PEDS/89505_Chst_x_acqu_neonat_eff.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">L: left; RT: right.</div><div id=\"graphicVersion\">Graphic 89505 Version 2.0</div></div></div>"},"89507":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph congenital chylous pleural effusion","title":"Chest radiographs of congenital chylous pleural effusions in a newborn infant","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Chest radiographs of congenital chylous pleural effusions in a newborn infant</div><div class=\"cntnt\"><img style=\"width:462px; height:221px;\" src=\"images/PEDS/89507_Chest_x_bilat_effusions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anteroposterior view of a chest radiograph in a newborn infant showing the white out appearance of bilateral chylous effusions.<br />(B) There is clearing of the left lung field with placement of a left chest tube.</div><div class=\"graphic_footnotes\">L: left.</div><div id=\"graphicVersion\">Graphic 89507 Version 1.0</div></div></div>"},"89508":{"type":"graphic_diagnosticimage","displayName":"Chest x-rays - Hemothorax in a premature neonate","title":"Chest radiographs of a very premature infant with hemothorax","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiographs of a very premature infant with hemothorax</div><div class=\"cntnt\"><img style=\"width:396px; height:173px;\" src=\"images/PEDS/89508_Chest_x_hemothor_prem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Figure A is the initial chest radiograph demonstrating respiratory distress syndrome in a premature infant born at 23 weeks of gestation.<br />(B) Figure B is a radiograph performed less than one hour later demonstrating bilateral effusions due to hemothorax precipitated by disseminated intravascular coagulation.</div><div id=\"graphicVersion\">Graphic 89508 Version 3.0</div></div></div>"},"89509":{"type":"graphic_diagnosticimage","displayName":"Pleural effusion and trisomy 21","title":"Congenital pleural effusion in an infant with trisomy 21","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital pleural effusion in an infant with trisomy 21</div><div class=\"cntnt\"><img style=\"width:191px; height:214px;\" src=\"images/PEDS/89509_Pleural_effus_trison_12_SRC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right-sided congenital pleural effusion in a newborn infant with trisomy 21 (Down syndrome).</div><div id=\"graphicVersion\">Graphic 89509 Version 1.0</div></div></div>"},"89510":{"type":"graphic_diagnosticimage","displayName":"Postmortem chest x-ray of a neonate with hydrops fetalis","title":"Postmortem chest radiograph of a neonate with hydrops fetalis and pleural effusions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postmortem chest radiograph of a neonate with hydrops fetalis and pleural effusions</div><div class=\"cntnt\"><img style=\"width:268px; height:384px;\" src=\"images/PEDS/89510_Postmort_chest_x_neo_hydro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postmortem chest radiograph of a neonate with hydrops fetalis and pleural effusions. The infant could not be resuscitated despite the aspiration of more than 80 mL of fluid and copious amounts of air. Note the very small lung bud seen in the presence of a right-sided pneumothorax.</div><div id=\"graphicVersion\">Graphic 89510 Version 2.0</div></div></div>"},"89512":{"type":"graphic_table","displayName":"Influence of HER2 overexpression and prognosis in gastric cancer","title":"Influence of HER2 overexpression and prognosis in esophagogastric cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Influence of HER2 overexpression and prognosis in esophagogastric cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Disease stage</td> <td class=\"subtitle1\">Tumor site</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">HER2-positive rate (percent)</td> <td class=\"subtitle1\">Association with survival: Median OS in HER2-positive versus HER2-negative patients</td> </tr> <tr> <td>AVAGAST<sup>[1]</sup></td> <td class=\"centered\">Metastatic*</td> <td class=\"centered\">G, GEJ</td> <td class=\"centered\">712</td> <td class=\"centered\">FP with and without bevacizumab</td> <td class=\"centered\">NR</td> <td class=\"centered\">Null: 9.8 versus 10.5 months (NSS)<sup>&#182;</sup></td> </tr> <tr> <td>Europe/USA collaboration<sup>&#916;</sup><sup>[2]</sup></td> <td class=\"centered\">Metastatic</td> <td class=\"centered\">G, GEJ</td> <td class=\"centered\">381</td> <td class=\"centered\">Chemotherapy</td> <td class=\"centered\">20</td> <td class=\"centered\">Favorable: 13.9 versus 11.4 months (p = 0.047)<sup>&#182;</sup></td> </tr> <tr> <td>EXPAND<sup>[3,4]</sup></td> <td class=\"centered\">Metastatic*</td> <td class=\"centered\">G, GEJ</td> <td class=\"centered\">679</td> <td class=\"centered\">FP with and without cetuximab</td> <td class=\"centered\">21</td> <td class=\"centered\"> <p>Favorable in control arm: 14.0 versus 9.7 months (NSS)</p> Favorable in treatment arm: 13.3 versus 9.2 months (NSS)</td> </tr> <tr> <td>REAL3<sup>[5]</sup></td> <td class=\"centered\">Metastatic*</td> <td class=\"centered\">G, GEJ, E</td> <td class=\"centered\">174</td> <td class=\"centered\">EOC with and without panitumumab</td> <td class=\"centered\">16</td> <td class=\"centered\">Null: Details not reported</td> </tr> <tr> <td>ACTS-GC<sup>[6]</sup></td> <td class=\"centered\">Operable</td> <td class=\"centered\">G</td> <td class=\"centered\">829</td> <td class=\"centered\">Surgery with and without S1</td> <td class=\"centered\">13.6</td> <td class=\"centered\">Null: Five-year OS 64 versus 68 percent (NSS)<sup>&#182;</sup></td> </tr> <tr> <td>MAGIC<sup>[7]</sup></td> <td class=\"centered\">Operable</td> <td class=\"centered\">G, GEJ, E</td> <td class=\"centered\">415</td> <td class=\"centered\">Surgery with and without ECF</td> <td class=\"centered\">10.9</td> <td class=\"centered\">Null: Details not reported</td> </tr> <tr> <td>INT0116<sup>[8]</sup></td> <td class=\"centered\">Operable</td> <td class=\"centered\">G, GEJ</td> <td class=\"centered\">258</td> <td class=\"centered\">Surgery with and without chemoradiotherapy</td> <td class=\"centered\">10.9</td> <td class=\"centered\"> <p>Null in control arm: 22 versus 24 months (p = 0.76)</p> Adverse in chemoradiotherapy arm: 16 versus 44 months (p = 0.025)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HER2: human epidermal growth factor receptor 2; G: gastric; GEJ: gastroesophageal junction; E: esophagus; OS: overall survival; NR: not reported; ECF: epirubicin, cisplatin, fluorouracil; FP: fluoropyrimidine plus cisplatin; EOC: epirubicin, oxaliplatin, and capecitabine; S1: ftorafur (tegafur), gimeracil, oteracil; NSS: not statistically significant.<br />* Includes locally advanced unresectable.<br />¶ Analysis combined all patients.<br />Δ Pooled analysis of six first-line trials utilizing various combinations of fluorouracil, oxaliplatin, cisplatin, and/or docetaxel.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012; 30:2119.</LI>&#xD;&#xA;<LI>Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012; 23:2656.</LI>&#xD;&#xA;<LI>Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancel Oncol 2013; 14:490.</LI>&#xD;&#xA;<LI>Lordick F, Kang YK, Salman P, et al. Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. J Clin Oncol 2013; 31:abstr 4021.</LI>&#xD;&#xA;<LI>Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14:481.</LI>&#xD;&#xA;<LI>Terashima M, Kitada K, Ochiai A, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012; 18:5992.</LI>&#xD;&#xA;<LI>Okines AF, Thompson LC, Cunningham D, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol 2013; 24:1253.</LI>&#xD;&#xA;<LI>Gordon MA, Gundacker HM, Benedetti J, et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 2013 [ahead of print].</LI></OL></div><div id=\"graphicVersion\">Graphic 89512 Version 3.0</div></div></div>"},"89513":{"type":"graphic_diagnosticimage","displayName":"X-ray of retained surgical needle","title":"Retained surgical needle on x-ray","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Retained surgical needle on x-ray</div><div class=\"cntnt\"><img style=\"width:490px; height:488px;\" src=\"images/RADIOL/89513_Xray_retain_surg_needl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A portable intraoperative A-P x-ray of the pelvis shows a retained needle in the pelvis (arrow).</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 89513 Version 1.0</div></div></div>"},"89515":{"type":"graphic_picture","displayName":"Ulcerated atypical fibroxanthoma","title":"Ulcerated atypical fibroxanthoma","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Ulcerated atypical fibroxanthoma</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89515_Ulcer_atypic_fibroxanthoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89515 Version 1.0</div></div></div>"},"89516":{"type":"graphic_picture","displayName":"Atypical fibroxanthoma histopathology","title":"Atypical fibroxanthoma","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Atypical fibroxanthoma</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89516_Atypic_fibroxanthoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tissue specimen of atypical fibroxanthoma demonstrating highly pleomorphic spindle cells, multinucleated giant cells, and atypical mitoses.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89516 Version 2.0</div></div></div>"},"89519":{"type":"graphic_diagnosticimage","displayName":"CT of multifocal pulmonary emboli","title":"CT of multifocal pulmonary emboli","html":"<div class=\"graphic\"><div style=\"width: 769px\" class=\"figure\"><div class=\"ttl\">CT of multifocal pulmonary emboli</div><div class=\"cntnt\"><img style=\"width:749px; height:282px;\" src=\"images/RADIOL/89519_CT_multifocal_pulm_emboli.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multifocal pulmonary emboli. Chest CT angiogram images show filling defects in the pulmonary arteries of to the lingula (A, arrow) and right lower lobe (B, arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89519 Version 2.0</div></div></div>"},"89520":{"type":"graphic_diagnosticimage","displayName":"V/Q scan and CT of small pulmonary emboli","title":"V/Q scan and CT of small pulmonary emboli","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">V/Q scan and CT of small pulmonary emboli</div><div class=\"cntnt\"><img style=\"width:599px; height:240px;\" src=\"images/RADIOL/89520_Imaging_small_PE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small pulmonary emboli. VQ scan left anterior oblique view perfusion image (A)&nbsp;shows a subsegmental defect (arrowhead) reported as intermediate probability of pulmonary embolism.&nbsp;Chest CT pulmonary angiogram&nbsp;(B) shows&nbsp;a thrombus in one of&nbsp;the left lower lobe pulmonary artery branches&nbsp;(arrow).</div><div class=\"graphic_footnotes\">V/Q: ventilation/perfusion; CT: computed tomography. </div><div id=\"graphicVersion\">Graphic 89520 Version 3.0</div></div></div>"},"89521":{"type":"graphic_diagnosticimage","displayName":"V/Q scan low probability of pulmonary embolism","title":"V/Q scan low probability of pulmonary embolism","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">V/Q scan low probability of pulmonary embolism</div><div class=\"cntnt\"><img style=\"width:597px; height:245px;\" src=\"images/RADIOL/89521_VQ_CT_PA_in_pneumonia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low probability V/Q scan. Anterior&nbsp;view perfusion image&nbsp;from a V/Q scan (A) shows a right lower lobe defect (arrow).&nbsp;Chest CT pulmonary angiogram&nbsp;(B)&nbsp;shows&nbsp;bilateral lower lobe opacities (arrowheads) suggestive of pneumonia and no thrombus in the pulmonary arteries (not shown).</div><div class=\"graphic_footnotes\">V/Q scan: ventilation/perfusion scan; CT: computed tomography </div><div id=\"graphicVersion\">Graphic 89521 Version 3.0</div></div></div>"},"89522":{"type":"graphic_picture","displayName":"Slapped cheek rash 2","title":"Slapped cheek rash of parvovirus B19","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Slapped cheek rash of parvovirus B19</div><div class=\"cntnt\"><img style=\"width:599px; height:327px;\" src=\"images/PEDS/89522_Slapped_cheek_rash_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A child with the characteristic malar (\"slapped cheek\") rash associated with parvovirus B19 (erythema infectiosum, fifth disease).</div><div id=\"graphicVersion\">Graphic 89522 Version 2.0</div></div></div>"},"89535":{"type":"graphic_picture","displayName":"Atypical fibroxanthoma histopathology 2","title":"Atypical fibroxanthoma","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Atypical fibroxanthoma</div><div class=\"cntnt\"><img style=\"width:583px; height:198px;\" src=\"images/DERM/89535_Atypclfibrxnthmhistpthg2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The tumor is composed of a cellular mass of malignant cells that are unconnected to the epidermis.<BR>(B) Highly pleomorphic spindle cells are present with some multinucleated giant cells and scattered mitoses, including atypical forms.</div><div class=\"graphic_reference\">Reproduced with permission from: Beer TW, Lam MH, Heenan PJ. Tumors of fibrous tissue involving the skin. In: Lever's Histopathology of the Skin, 10th ed, Elder DE, Elenitsas R, Johnson B Jr, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 89535 Version 5.0</div></div></div>"},"89539":{"type":"graphic_table","displayName":"Prevalence of anxiety disorders in children and adolescents","title":"Prevalence of anxiety disorders in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of anxiety disorders in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\"> <p>Great Smoky Mountains Study of Youth*<sup>[1] </sup>(percentage)</p> </td> <td class=\"subtitle1\">National Comorbidity Survey Replication--Adolescent Supplement<sup>&#182;[2] </sup>(percentage)</td> <td class=\"subtitle1\">Healthy Birth Cohort Study<sup>&#916;</sup><sup>[3]</sup>(percentage)</td> <td class=\"subtitle1\">Psychiatric Disorders Among Adolescents Study<sup>&#9674;</sup><sup>[4]</sup>(percentage)</td> </tr> <tr> <td><strong>Generalized anxiety disorder</strong></td> <td class=\"centered\">1.67 &#177; 0.61</td> <td class=\"centered\">1.1 &#177; 0.2</td> <td class=\"centered\">0.3 &#177; 0.2</td> <td class=\"centered\">0.41</td> </tr> <tr> <td><strong>Social anxiety disorder</strong></td> <td class=\"centered\">0.58 &#177; 0.32</td> <td class=\"centered\">8.2 &#177; 0.4</td> <td class=\"centered\">0.3 &#177; 0.2</td> <td class=\"centered\">1.64</td> </tr> <tr> <td><strong>Panic disorder</strong></td> <td class=\"centered\">0.03 &#177; 0.03</td> <td class=\"centered\">1.9 &#177; 0.2</td> <td class=\"centered\">N/A</td> <td class=\"centered\">0.65</td> </tr> <tr> <td><strong>Agoraphobia</strong></td> <td class=\"centered\">0.07 &#177; 0.05</td> <td class=\"centered\">1.8 &#177; 0.2</td> <td class=\"centered\">0.3 &#177; 0.2</td> <td class=\"centered\">4.5</td> </tr> <tr> <td><strong>Specific phobia</strong></td> <td class=\"centered\">0.27 &#177; 0.1</td> <td class=\"centered\">15.8 &#177; 0.8</td> <td class=\"centered\">20 &#177; 2.4</td> <td class=\"centered\">N/A</td> </tr> <tr> <td><strong>Obsessive-compulsive disorder</strong></td> <td class=\"centered\">0.17 &#177; 0.08</td> <td class=\"centered\">N/A</td> <td class=\"centered\">0.2 &#177; 0.2</td> <td class=\"centered\">N/A</td> </tr> <tr> <td><strong>Acute stress disorder</strong></td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> </tr> <tr> <td><strong>Posttraumatic stress disorder</strong></td> <td class=\"centered\">0.02 &#177; 0.96</td> <td class=\"centered\">3.9 &#177; 0.4</td> <td class=\"centered\">0.3 &#177; 0.2</td> <td class=\"centered\">0.59</td> </tr> <tr> <td><strong>Separation anxiety disorder</strong></td> <td class=\"centered\">3.49 &#177; 0.75</td> <td class=\"centered\">1.6 &#177; 0.2</td> <td class=\"centered\">3.8 &#177; 1.2</td> <td class=\"centered\">N/A</td> </tr> <tr> <td><strong>Selective mutism</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">N/A: not applicable.<br />* The Great Smoky Mountains Study of Youth assessed the 3-month prevalence of DSM-III-R disorders among 1015 children aged 9, 11, and 13.<br />¶ The National Comorbidity Survey Replication--Adolescent Supplement measured the estimates of 12-month prevalence of DSM-IV anxiety disorders among 10,148 adolescents aged 13 to 17 years.<br />Δ The Healthy Birth Cohort Study presents 12-month prevalence data for DSM-IV disorders in the early elementary school years (mean age of 6.6, n = 441).<br /><FONT class=lozenge>◊</FONT> The Psychiatric Disorders Among Adolescents Study assessed the 12-month prevalence of DSM-IV disorders among 4175 youths aged 11 to 17.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Costello EJ, Angold A, Burns BJ, et al. The Great Smoky Mountains Study of Youth: Goals, design, methods, and the prevalence of DSM-III-R disorders. Arch Gen Psychiatry 1996; 53:1129.</li>&#xD;&#xA;    <li>Merikangas KR, He JP, Burstein M, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication--Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 2010; 49:980.</li>&#xD;&#xA;    <li>Carter AS, Wagmiller RJ, Gray SA, et al. Prevalence of DSM-IV disorder in a representative, healthy birth cohort at school entry: sociodemographic risks and social adaptation. J Am Acad Child Adolesc Psychiatry 2010; 49:686.</li>&#xD;&#xA;    <li>Roberts RE, Roberts CR, Xing Y. Rates of DSM-IV psychiatric disorders among adolescents in a large metropolitan area. J Psychiatr Res 2007; 41:959.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 89539 Version 2.0</div></div></div>"},"89540":{"type":"graphic_table","displayName":"Antimicrobial prophylaxis for breast surgery","title":"Antimicrobial prophylaxis for breast surgery in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial prophylaxis for breast surgery in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nature of operation</td> <td class=\"subtitle1\">Common pathogens</td> <td class=\"subtitle1\">Recommended antimicrobials</td> <td class=\"subtitle1\">Usual adult dose</td> <td class=\"subtitle1\">Redose interval</td> </tr> <tr> <td> <p>Reduction mammoplasty</p> <p>Mammoplasty</p> <p>Lumpectomy</p> <p>Mastectomy</p> Axillary node dissection</td> <td class=\"centered\">&ndash;</td> <td>None</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Breast cancer procedures</td> <td rowspan=\"3\"><em>Staphylococcus aureus</em>, <em>S. epidermidis</em>, streptococci*</td> <td>Cefazolin</td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>4 hours</td> </tr> <tr> <td><strong>OR</strong> vancomycin</td> <td>15 mg/kg (max 2 g)</td> <td>N/A</td> </tr> <tr> <td><strong>OR</strong> clindamycin</td> <td>900 mg IV</td> <td>6 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">IV: intravenous.</div><div class=\"graphic_footnotes\">* A higher rate of infection due to gram-negative organisms occurs in the setting of procedures involving macerated, moist environments (such as under the axilla of an obese individual) and among patients with diabetes. In the setting of risk for surgical site infections due to gram-negative pathogens, an additional agent may be warranted (such as an gentamicin 5 mg/kg IV, aztreonam 2 g IV, ciprofloxacin 400 mg IV, or levofloxacin 500 mg IV).</div><div class=\"graphic_reference\">Source: Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 2013; 14:73.</div><div id=\"graphicVersion\">Graphic 89540 Version 6.0</div></div></div>"},"89545":{"type":"graphic_table","displayName":"Treatment of erosive or nonerosive GERD","title":"Treatment of erosive or nonerosive gastroesophageal reflux disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of erosive or nonerosive gastroesophageal reflux disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Low dose (adult, oral)</td> <td class=\"subtitle1\">Standard dose (adult, oral)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Histamine 2 receptor antagonists*</td> </tr> <tr> <td class=\"indent1\">Famotidine</td> <td>10 mg twice daily<sup>&#182;</sup></td> <td>20 mg twice daily<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Ranitidine</td> <td>75 mg twice daily<sup>&#182;</sup></td> <td>150 mg twice daily<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Nizatidine</td> <td>75 mg twice daily<sup>&#182;</sup></td> <td>150 mg twice daily</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cimetidine</td> <td>200 mg twice daily<sup>&#182;</sup></td> <td>400 mg twice daily<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Proton pump inhibitors</td> </tr> <tr> <td class=\"indent1\">Omeprazole</td> <td>20 mg daily<sup>&#182;</sup></td> <td>40 mg daily</td> </tr> <tr> <td class=\"indent1\">Lansoprazole</td> <td>15 mg daily<sup>&#182;</sup></td> <td>30 mg daily</td> </tr> <tr> <td class=\"indent1\">Esomeprazole</td> <td>20 mg daily</td> <td>40 mg daily</td> </tr> <tr> <td class=\"indent1\">Pantoprazole</td> <td>20 mg daily<sup>&#182;</sup></td> <td>40 mg daily</td> </tr> <tr> <td class=\"indent1\">Dexlansoprazole</td> <td>Not available</td> <td>30 mg daily, 60 mg daily</td> </tr> <tr> <td class=\"indent1\">Rabeprazole</td> <td>10 mg daily<sup>&#9674;</sup></td> <td>20 mg daily</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease; US: United States.<br />* Histamine 2 receptor antagonists require dose adjustment in the setting of renal insufficiency.<br />¶ Available without a prescription (over the counter) in the US.<br />Δ The daily dose for initial healing of esophagitis with erosions and symptoms of GERD in the US prescribing information is up to twice the standard dose shown in this table.<br /><FONT class=lozenge>◊</FONT> Strength not available in US. Available elsewhere.</div><div class=\"graphic_reference\">Prepared with data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kahrilas PJ, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135:1383.</li>&#xD;&#xA;    <li>Anon. American Gastroenterological Association Institute Technical Review on the Management of Gastroesophageal Reflux Disease. Gastroenterology 2008; 135:1392.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 89545 Version 3.0</div></div></div>"},"89547":{"type":"graphic_figure","displayName":"WLS options PI","title":"Weight loss procedures","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Weight loss procedures</div><div class=\"cntnt\"><img style=\"width:539px; height:687px;\" src=\"images/PI/89547_WLSoptionsPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These drawings show how the most common weight loss procedures work.</div><div id=\"graphicVersion\">Graphic 89547 Version 2.0</div></div></div>"},"89548":{"type":"graphic_figure","displayName":"Immunofluorescence stain intensity schistosomal glomerulopathy","title":"Immunofluorescence staining intensity in schistosomal glomerulopathy","html":"<div class=\"graphic\"><div style=\"width: 652px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence staining intensity in schistosomal glomerulopathy</div><div class=\"cntnt\"><img style=\"width:632px; height:416px;\" src=\"images/NEPH/89548_Imnflrs_stn_intn_schst_glmr.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Barsoum R, Nabil M, Saady G, et al. Immunoglobulin-A and the pathogenesis of schistosomal glomerulopathy. Kidney Int 1996; 50:920.</div><div id=\"graphicVersion\">Graphic 89548 Version 1.0</div></div></div>"},"89558":{"type":"graphic_picture","displayName":"Tinea nigra","title":"Tinea nigra","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Tinea nigra</div><div class=\"cntnt\"><img style=\"width:490px; height:361px;\" src=\"images/DERM/89558_Tinea_nigra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A well-dermarcated brown patch on the palm of a three-year-old boy with tinea nigra. The patch had been slowly expanding for six months. A potassium hydroxide preparation revealed grayish brown branching hyphae typical of tinea nigra which is caused by a dermatiaceous fungus Phaeoannellomyces werneckii.</div><div class=\"graphic_reference\">Copyright © Samuel Freire da Silva, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 89558 Version 3.0</div></div></div>"},"89568":{"type":"graphic_figure","displayName":"Cases rubella and CRS US","title":"Reported cases of rubella and congenital rubella syndrome (CRS) — National Notifiable Diseases Surveillance System, United States, 2004-2012","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Reported cases of rubella and congenital rubella syndrome (CRS) — National Notifiable Diseases Surveillance System, United States, 2004-2012</div><div class=\"cntnt\"><img style=\"width:516px; height:298px;\" src=\"images/PEDS/89568_Cases_rubella_and_CRS_US.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* By year of birth.</div><div class=\"graphic_reference\">Reproduced from: Three cases of congenital rubella syndrome in the postelimination era--Maryland, Alabama, and Illinois, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:226.</div><div id=\"graphicVersion\">Graphic 89568 Version 1.0</div></div></div>"},"89570":{"type":"graphic_figure","displayName":"Electrical activation of the right atrium in atrial flutter","title":"Electrical activation of the right atrium in atrial flutter","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Electrical activation of the right atrium in atrial flutter</div><div class=\"cntnt\"><img style=\"width:470px; height:504px;\" src=\"images/CARD/89570_Elect_activ_trial_flutt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electroanatomical (3D) mapping using the CARTO system. The right atrium (RA) is depicted in the LAO projection. The circular \"cutout\" area in the forefront of the picture represents the tricuspid valve annulus. The red area is the inferolateral RA, the yellow-green area at the bottom of the picture is near the inferior vena cava, the yellow dots are at the region of the His bundle (AV node), and the blue area is the superior RA. The top of the picture is the superior vena cava region. The color (red-orange-yellow-green-blue-purple) represents the direction of electrical activation in the RA during typical (counterclockwise) atrial flutter. Each flutter wave seen on ECG represents a single electrical activation of this entire circuit.</div><div id=\"graphicVersion\">Graphic 89570 Version 1.0</div></div></div>"},"89571":{"type":"graphic_diagnosticimage","displayName":"ECG of counterclockwise typical atrial flutter","title":"ECG of counterclockwise typical atrial flutter","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">ECG of counterclockwise typical atrial flutter</div><div class=\"cntnt\"><img style=\"width:504px; height:310px;\" src=\"images/CARD/89571_ECG_counter_typ_atri.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sawtooth-like oscillations of baseline between flutter waves, best seen in the inferior leads.</div><div class=\"graphic_footnotes\">* Negative flutter waves in II, III, aVF, V6. Positive flutter waves in V1.<br />ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 89571 Version 2.0</div></div></div>"},"89576":{"type":"graphic_diagnosticimage","displayName":"ECG of clockwise typical atrial flutter","title":"ECG of clockwise typical atrial flutter","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">ECG of clockwise typical atrial flutter</div><div class=\"cntnt\"><img style=\"width:504px; height:249px;\" src=\"images/CARD/89576_ECG_clockwise_flutter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sawtooth-like oscillations of baseline between flutter waves, best seen in inferior leads.</div><div class=\"graphic_footnotes\">* Positive flutter waves in II, III, aVF, V6. Negative flutter waves in V1.<br />ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 89576 Version 2.0</div></div></div>"},"89577":{"type":"graphic_diagnosticimage","displayName":"ECG of atypical atrial flutter","title":"ECG of atypical atrial flutter","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">ECG of atypical atrial flutter</div><div class=\"cntnt\"><img style=\"width:504px; height:260px;\" src=\"images/CARD/89577_ECG_atyp_atrial_flutter.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 89577 Version 2.0</div></div></div>"},"89578":{"type":"graphic_table","displayName":"Muscle compartment contents","title":"Muscle compartment contents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Muscle compartment contents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Compartment</td> <td class=\"subtitle1\">Contents</td> </tr> <tr> <td>Thigh - anterior</td> <td> <p>Muscles: sartorius, quadriceps (rectus femoris, vastus lateralis, vastus intermedius, vastus medialis)</p> <p>Femoral nerve</p> Saphenous nerve</td> </tr> <tr> <td>Thigh - posterior</td> <td> <p>Muscles: biceps femoris, semitendinosus, semimembranosus</p> Sciatic nerve</td> </tr> <tr> <td>Thigh - medial</td> <td> <p>Muscles: gracilis, adductor longus, adductor brevis, adductor magnus</p> Obturator nerve</td> </tr> <tr> <td>Leg - anterior</td> <td> <p>Muscles: tibialis anterior, extensor hallucis longus, extensor digitorum longus, peroneus tertius</p> Deep peroneal nerve</td> </tr> <tr> <td>Leg - lateral</td> <td> <p>Muscles: fibularis longus, fibularis brevis</p> Superficial peroneal nerve</td> </tr> <tr> <td>Leg - deep posterior</td> <td> <p>Muscles: popliteus, flexor hallucis longus, flexor digitorum longus, tibialis posterior</p> Tibial nerve</td> </tr> <tr> <td>Leg - superficial posterior</td> <td>Muscles: gastrocnemius, soleus, plantaris</td> </tr> <tr> <td>Arm - anterior</td> <td> <p>Muscles: biceps brachii, brachialis, coracobrachialis</p> <p>Ulnar nerve</p> Median nerve</td> </tr> <tr> <td>Arm - posterior</td> <td> <p>Muscles: triceps brachii, anconeus</p> Radial nerve</td> </tr> <tr> <td>Forearm - deep and superficial volar</td> <td> <p>Muscles: superficial (flexor carpi radialis, palmaris longus, flexor carpi ulnaris, pronator teres, flexor digitorum superficialis); deep (flexor digitorum profundus, flexor pollicis longus, pronator quadratus)</p> <p>Ulnar nerve</p> Median nerve</td> </tr> <tr> <td>Forearm - dorsal</td> <td> <p>Muscles: brachioradialis, extensor carpi radialis longus, extensor carpi radialis brevis, extensor carpi ulnaris, extensor digitorum, extensor digiti minimi, abductor pollicis longus, extensor pollicis brevis, extensor pollicis longus, extensor indicis, supinator, anconeus</p> Radial nerve</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Important compartment syndrome findings:</td> </tr> <tr> <td colspan=\"2\"><strong>Pain is the most important finding.</strong> Any pain with passive stretch is worrisome.</td> </tr> <tr> <td colspan=\"2\">Palpate for tender and tense compartments</td> </tr> <tr> <td colspan=\"2\">Late findings can include motor deficits involving the muscles of the involved compartment and sensory deficits involving the nerves in the involved compartment</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89578 Version 1.0</div></div></div>"},"89579":{"type":"graphic_picture","displayName":"Cord or advanced Dupuytren's","title":"\"Cord\" or advanced Dupuytren's","html":"<div class=\"graphic\"><div style=\"width: 809px\" class=\"figure\"><div class=\"ttl\">\"Cord\" or advanced Dupuytren's</div><div class=\"cntnt\"><img style=\"width:789px; height:424px;\" src=\"images/RHEUM/89579_Crd_advnc_dpytrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrow indicates the thickening (cord) of the palmar fascia.</div><div class=\"graphic_reference\">Courtesy of Philip E Blazar, MD.</div><div id=\"graphicVersion\">Graphic 89579 Version 3.0</div></div></div>"},"89580":{"type":"graphic_figure","displayName":"Biomarker release patterns in myocardial infarction","title":"Biomarker release patterns in myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 665px\" class=\"figure\"><div class=\"ttl\">Biomarker release patterns in myocardial infarction</div><div class=\"cntnt\"><img style=\"width:645px; height:348px;\" src=\"images/CARD/89580_Biomarker_release_patterns.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">By permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89580 Version 1.0</div></div></div>"},"89583":{"type":"graphic_figure","displayName":"Factors that blunt counter-regulatory response to exercise","title":"Factors that blunt the normal counter-regulatory response to exercise or hypoglycemia","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Factors that blunt the normal counter-regulatory response to exercise or hypoglycemia</div><div class=\"cntnt\"><img style=\"width:458px; height:278px;\" src=\"images/PEDS/89583_Fact_blunt_counter_reg_resp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several factors blunt the counterregulatory hormone response to exercise and to subsequent hypoglycemia, which contribute to a vicious cycle that predisposes the individual to a further deterioration in glucose control.</div><div class=\"graphic_footnotes\">* These effects on counter-regulatory responses during exercise are more prominent in males as compared with females.<sup>[1,2]</sup></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Galassetti P, Tate D, Neill RA, Morrey S, Wasserman DH, Davis SN. Effect of sex on counter-regulatory responses to exercise after antecedent hypoglycemia in Type 1 diabetes. Am J Physiol Endocrinol Metab. 2004 Jul; 287(1):E16-24.</li>&#xD;&#xA;    <li>Galassetti P, Neill AR, Tate D, Ertl AC, Wasserman DH, Davis SN. Sexual dimorphism in counter-regulatory responses to hypoglycemia after antecedent exercise. J Clin Endocrinol Metab. 2001; 86:3516-24.</li>&#xD;&#xA;</ol>&#xD;&#xA;<br />Adapted from: Tsintzas K, MacDonald IA. Endocrine and metabolic responses to exercise. In: Type 1 diabetes: Clinical management of the athlete, Gallen I (Ed), Springer-Verlag, London, 2012.</div><div id=\"graphicVersion\">Graphic 89583 Version 2.0</div></div></div>"},"89596":{"type":"graphic_diagnosticimage","displayName":"CT trapped lung ","title":"Trapped lung on CT scan following drainage of effusion","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Trapped lung on CT scan following drainage of effusion</div><div class=\"cntnt\"><img style=\"width:590px; height:359px;\" src=\"images/RADIOL/89596_CT_trapped_lung_thorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the lower chest shows chronic atelectasis with thickened visceral pleura (arrow). Following drainage of the effusion, the lung failed to expand creating a vacuum and an air-fluid level (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89596 Version 1.0</div></div></div>"},"89597":{"type":"graphic_diagnosticimage","displayName":"X-ray Bartons fracture dislocation wrist","title":"Plain x-ray of Barton’s fracture dislocation of wrist","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Plain x-ray of Barton’s fracture dislocation of wrist</div><div class=\"cntnt\"><img style=\"width:599px; height:299px;\" src=\"images/RADIOL/89597_X_barton_fract_disloc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is a 40-year-old man who presented with wrist pain following a fall on an outstretched hand, and found to have a Barton's fracture/dislocation. Image A is an AP radiograph of the right wrist demonstrating an intraarticular fracture of the distal radius (arrow). Image B is a lateral radiograph demonstrating an intraarticular radial fracture with dorsally-displaced radial bone fragments (arrow) and dorsal dislocation of the carpal bones with respect to the radius (arrowhead), consistent with a Barton's fracture/dislocation.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of Aaron Harman, MD.</div><div id=\"graphicVersion\">Graphic 89597 Version 1.0</div></div></div>"},"89598":{"type":"graphic_diagnosticimage","displayName":"CT splenosis","title":"Splenosis on CT scan","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Splenosis on CT scan</div><div class=\"cntnt\"><img style=\"width:590px; height:435px;\" src=\"images/RADIOL/89598_CT_splenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 55 year-old woman had a total splenectomy for traumatic splenic rupture. A&nbsp;CT scan taken a number of years later for unrelated purposes showed two foci of splenosis (arrows) and a surgical clip (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89598 Version 2.0</div></div></div>"},"89599":{"type":"graphic_diagnosticimage","displayName":"Frykman Type VI fracture distal radioulnar joint ulnar styloid","title":"X-ray of Frykman Type VI fracture of distal radioulnar joint and ulnar styloid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">X-ray of Frykman Type VI fracture of distal radioulnar joint and ulnar styloid</div><div class=\"cntnt\"><img style=\"width:298px; height:418px;\" src=\"images/RADIOL/89599_X_ray_frykman_type_VI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;anteroposterior plain radiograph&nbsp;of the left wrist shows a distal radial fracture involving the distal radioulnar joint (arrowhead) and&nbsp;a transverse ulnar styloid fracture (arrow).</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 89599 Version 1.0</div></div></div>"},"89600":{"type":"graphic_diagnosticimage","displayName":"X-ray Frykman Type VII radiocarpal and radioulnar fracture","title":"Xray of Frykman Type VII radioulnar and radiocarpal fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Xray of Frykman Type VII radioulnar and radiocarpal fracture</div><div class=\"cntnt\"><img style=\"width:300px; height:495px;\" src=\"images/RADIOL/89600_X_ray_Frykman_tul_joint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;anteroposterior plain radiograph&nbsp;of the wrist shows a radioulnar fracture (arrow), and a fracture into the radiocarpal joint (arrowhead).</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 89600 Version 1.0</div></div></div>"},"89604":{"type":"graphic_table","displayName":"Causes of hip pain clinical features","title":"Clinical, laboratory, and radiographic features of selected causes of hip pain in children unrelated to acute trauma or fracture","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical, laboratory, and radiographic features of selected causes of hip pain in children unrelated to acute trauma or fracture</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Typical age/risk factors</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Laboratory features</td> <td class=\"subtitle1\">Radiographic features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Infectious</td> </tr> <tr> <td class=\"indent1\">Septic arthritis of the hip</td> <td> <p>0 to 6 years</p> M&#62;F</td> <td> <p>Fever and ill-appearance</p> <p>Pain with any active or passive motion and refusal to bear weight</p> Preferred position: Flexion, abduction, and external rotation of the hip</td> <td> <p>Elevated WBC count (&#62;12,000 cells/microL), ESR (&#62;40 mm/hour), and CRP (&#62;2 mg/dL [20 mg/L])</p> Positive synovial fluid or blood culture</td> <td>Unilateral joint effusion</td> </tr> <tr> <td class=\"indent1\">Septic arthritis of the sacroiliac joint</td> <td>Late childhood</td> <td> <p>Pain over sacrum</p> <p>Fever</p> Pain with maneuvers that twist the pelvis (eg, positive FABERE test)</td> <td> <p>Elevated WBC count, ESR, CRP</p> Positive synovial fluid or blood culture</td> <td> <p>Widening of the joint space</p> Blurring of the subchondral plate</td> </tr> <tr> <td class=\"indent1\">Lyme disease</td> <td> <p>Any age</p> Residence in or travel to Lyme endemic region</td> <td> <p>Fever uncommon</p> Willing to bear weight</td> <td>IgG antibodies to <em>Borrelia burgdorferi</em></td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Osteomyelitis of femoral head or pelvis</td> <td>&nbsp;</td> <td> <p>Fever and ill appearance</p> <p>Localized pain</p> Decreased mobility (but may permit passive motion of the hip)</td> <td>Elevated WBC count, ESR, and CRP</td> <td> <p>Early (3 to 7 days): deep soft-tissue swelling; obliteration of fat pads</p> Late (10 to 21 days): lytic sclerosis; periosteal new bone formation</td> </tr> <tr> <td class=\"indent1\">Psoas abscess (referred pain)</td> <td>&nbsp;</td> <td>Pain is increased with hip extension but diminished with hip flexion</td> <td>Elevated WBC count, ESR, and CRP</td> <td> <p>Loss of psoas muscle definition</p> <p>Abnormal soft tissue shadows</p> (CT is preferred study)</td> </tr> <tr> <td class=\"indent1\">Appendicitis or abdominal/pelvic abscess (referred pain)</td> <td>Any age</td> <td>Associated gastrointestinal complaints (pain, vomiting, anorexia)</td> <td>Elevated WBC count, ESR, CRP</td> <td> <p>Calcified appendicolith</p> (US is usually the preferred initial imaging study)</td> </tr> <tr> <td class=\"indent1\">Discitis (referred pain)</td> <td>0 to 5 years</td> <td> <p>Loss of lumbar lordosis</p> <p>Refusal to bend forward</p> Minimal systemic toxicity</td> <td> <p>WBC count usually normal</p> Elevated ESR</td> <td> <p>Narrowing of intervertebral joint space after two to three weeks of symptoms, followed by destruction of vertebral end-plated and disc herniation</p> Diagnosis is best made by MRI</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Inflammatory</td> </tr> <tr> <td class=\"indent1\">Transient synovitis</td> <td> <p>3 to 8 years </p> <p>M&#62;F</p> Fall/winter season</td> <td> <p>Afebrile</p> Well-appearing</td> <td> <p>WBC count &#60;12,000 cells/microL</p> <p>ESR &#60;20 mm/hour</p> CRP &#60;2 mg/dL (20 mg/L)</td> <td>Unilateral or bilateral joint effusion</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"5\">Systemic arthritis</td> </tr> <tr> <td class=\"sublist2\">Juvenile idiopathic arthritis (formerly juvenile rheumatoid arthritis)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">Rarely causes isolated hip pain</td> <td class=\"sublist_other\"> <p>Elevated ESR and/or CRP</p> <p>Positive ANA, RF, or CCP in some cases</p> </td> <td class=\"sublist_other\"> <p>Joint space narrowing</p> Erosive changes of the femoral head and acetabula</td> </tr> <tr> <td class=\"sublist2\">Infectious arthritis (eg, Lyme arthritis, acute rheumatic fever, disseminated gonorrhea)</td> <td class=\"sublist_other\">Variable ages</td> <td class=\"sublist_other\">Associated clinical features of underlying infection</td> <td class=\"sublist_other\">Depend upon underlying infection</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Postinfectious or reactive</td> <td class=\"sublist_other\">Variable ages</td> <td class=\"sublist_other\">History of antecedent respiratory, gastrointestinal, or genitourinary infection</td> <td class=\"sublist_other\"> <p>Elevated ESR or CRP</p> Evidence of antecedent or concomitant infection</td> <td class=\"sublist_other\">Evidence of enthesitis or arthritis</td> </tr> <tr> <td class=\"indent1\">Idiopathic chondrolysis of the hip</td> <td>10 to 20 years</td> <td> <p>Insidious onset</p> <p>Decreased range of motion in all planes</p> Absence of systemic symptoms</td> <td>None</td> <td>Narrowing of the joint space, osteopenia, protrusion acetabuli, and premature physial fusion</td> </tr> <tr> <td class=\"indent1\">Chronic recurrent multifocal osteomyelitis</td> <td> <p>Any age</p> F&#62;M</td> <td> <p>Fever (rarely)</p> <p>Bone pain</p> May be associated with pustular eruption on palms and soles</td> <td>Elevated ESR or CRP (sometimes)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Mechanical/orthopedic</td> </tr> <tr> <td class=\"indent1\">Slipped capital femoral epiphysis</td> <td> <p>Early adolescence</p> <p>Mean age:<br /> Girls: 12 years<br /> Boys: 13.5 years</p> <p>M&#62;F (slightly)</p> <p>Obesity</p> Endocrine disorders</td> <td> <p>Bilateral in 20 to 40 percent of cases</p> Pain may be localized to the knee or thigh</td> <td>Normal WBC count, ESR, CRP</td> <td> <p>Nondisplaced: Normal or widening and irregularity of the capital femoral physis, osteopenia, and increased density of the metaphysis</p> Displaced: Posterior displacement of femoral epiphysis</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"5\">Avascular necrosis</td> </tr> <tr> <td class=\"sublist2\">Legg-Calv&#233;-Perthes disease</td> <td class=\"sublist_other\"> <p>3 to 12 years</p> M&#62;&#62;F</td> <td class=\"sublist_other\"> <p>Insidious onset</p> Pain increases with activity</td> <td class=\"sublist_other\">Normal WBC count, ESR, CRP</td> <td class=\"sublist_other\"> <p>Early: Joint space widening and subchondral fracture</p> Late: Sclerosis, fragmentation, subchondral collapse of the ossification center</td> </tr> <tr> <td class=\"sublist2\">Secondary avascular necrosis</td> <td class=\"sublist_other\">Variable ages</td> <td class=\"sublist_other\">Signs and symptoms of underlying condition (eg, renal failure, glucocorticoid use, systemic lupus erythematosus)</td> <td class=\"sublist_other\">Depend upon underlying condition</td> <td class=\"sublist_other\"> <p>Early: Joint space widening and subchondral fracture</p> Late: Sclerosis, fragmentation, subchondral collapse of the ossification center</td> </tr> <tr> <td class=\"indent1\">Femoral stress fracture</td> <td> <p>Adolescents and young adults</p> Endurance sports</td> <td> <p>Pain may localize to the anterior thigh</p> Pain reproduced with hopping on affected leg</td> <td>Normal WBC count, ESR, CRP</td> <td>Periosteal elevation, cortical thickening, sclerosis, fracture line</td> </tr> <tr> <td class=\"indent1\">Muscular strain</td> <td>Any age</td> <td> <p>Pain with movement</p> Weakness</td> <td>Normal WBC count, ESR, CRP</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Iliac apophysitis</td> <td> <p>Adolescents</p> Sports that involve twisting (eg, golf), sprinting, and kicking</td> <td> <p>Pain and swelling at iliac crest</p> Slowly progressive pain with activity</td> <td>Normal WBC count, ESR, CRP</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Snapping iliopsoas tendon</td> <td>Young athletes (ballet, karate)</td> <td> <p>Snapping sensation in anterior groin</p> Sensation may be reproduced by bringing the hip from a flexed abducted position to an extended adducted position</td> <td>Normal WBC count, ESR, CRP</td> <td>Catching of the posterior iliotibial band or anterior portion of the gluteus maximus muscle over the greater trochanter can be seen on dynamic ultrasonography</td> </tr> <tr> <td class=\"indent1\">Trochanteric bursitis</td> <td>&nbsp;</td> <td> <p>Lateral hip pain over the outer thigh</p> Pain aggravated by direct pressure</td> <td>Normal WBC count, ESR, CRP</td> <td>Calcification occasionally present in the region of the bursa or adjacent soft tissues</td> </tr> <tr> <td class=\"indent1\">Acetabular labral tear</td> <td> <p>Adolescent athletes, particularly sports that involve pivoting or twisting</p> History of Legg-Calv&#233;-Perthes disease or SCFE</td> <td> <p>Snapping, catching</p> Pain with internal rotation and extension</td> <td>Normal WBC count, ESR, CRP</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Femoroacetabular impingement</td> <td>Dancers</td> <td> <p>Groin pain with turning, twisting, and squatting</p> Pain is reproduced with flexion and internal rotation of the hip</td> <td>Normal WBC count, ESR, CRP</td> <td>Nonspherical femoral head; lack of femoral head-neck offset; acetabular overcoverage</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Neoplastic</td> </tr> <tr> <td class=\"indent1\">Osteoid osteoma</td> <td>10 to 20 years</td> <td> <p>Nocturnal pain</p> Prompt relief with NSAIDs</td> <td>&nbsp;</td> <td>Osteoid nidus with or without calcification (osteoid nidus may be obscured by dense sclerosis)</td> </tr> <tr> <td class=\"indent1\">Malignant neoplasms, primary or metastatic (eg, leukemia, lymphoma, Ewing sarcoma, etc)</td> <td>Variable ages</td> <td> <p>Nighttime pain</p> <p>Constant pain (unchanged by activity)</p> <p>Pain &#60;3 months duration</p> Systemic symptoms (eg, fever, weight loss)</td> <td> <p>Abnormal CBC (anemia, leukopenia, thrombocytopenia)</p> Elevated LDH, uric acid</td> <td> <p>Bony destruction</p> Subtle signs of space-occupying lesion (separation or thinning of the pedicles)</td> </tr> <tr> <td class=\"indent1\">Pigmented villonodular synovitis</td> <td>Adults</td> <td> <p>Recurrent joint effusions</p> Minimal pain</td> <td>&nbsp;</td> <td>Well circumscribed areas of bone erosion</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">M: male; F: female; WBC: white blood cell; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; FABERE: <strong>F</strong>lexion of the hip and knee, <strong>AB</strong>duction and <strong>E</strong>xternal <strong>R</strong>otation of the hip, <strong>E</strong>xtension of the opposite hip (also called the figure-of-four test); IgG: immunoglobin G; CT: computed tomography; US: ultrasonography; MRI: magnetic resonance imaging; ANA: antinuclear antibodies; RF: rheumatoid factor; CCP: cyclic citrullinated peptides; SCFE: slipped capital femoral epiphysis; NSAIDs: nonsteroidal anti-inflammatory drugs; CBC: complete blood count; LDH: lactate dehydrogenase.</div><div id=\"graphicVersion\">Graphic 89604 Version 4.0</div></div></div>"},"89606":{"type":"graphic_figure","displayName":"Rotavirus","title":"Rotavirus structure and composition","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rotavirus structure and composition</div><div class=\"cntnt\"><img style=\"width:405px; height:338px;\" src=\"images/PEDS/89606_Rotavirus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rotavirus is a spherical virus. The rotavirus genome consists of 11 double-stranded RNA segments that generate six structural proteins (VP1, VP2, VP3, VP4, VP6, and VP7) and six nonstructural proteins (NSP1-6). NSP5 and NSP6 are encoded by genome segment 11. Each virus particle is constructed as a triple layer coat composed of the structural proteins. The outer protein coat is made of VP4 (P) proteins and VP7 (G) proteins. The VP4 protein forms spikes on the outer coat and attaches the virion to the host cell, playing a key role in cell penetration and virulence.</div><div class=\"graphic_reference\">Reproduced from: Rotavirus. National Institute of Allergy and Infectious Diseases. Available at:www.niaid.nih.gov/topics/rotavirus/Pages/rotavirusIllustration.aspx (Accessed on May 22, 2013).</div><div id=\"graphicVersion\">Graphic 89606 Version 2.0</div></div></div>"},"89607":{"type":"graphic_figure","displayName":"Rotavirus vaccines","title":"Rotavirus vaccines","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Rotavirus vaccines</div><div class=\"cntnt\"><img style=\"width:530px; height:657px;\" src=\"images/PEDS/89607_Rotavirus_vaccines.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Attenuated human rotavirus vaccine (RV1, HRV) is a monovalent vaccine derived from the most common human rotavirus serotype combination (G1P[8]) that has been attenuated by serial passage in cell culture. <br />(B) Pentavalent human-bovine rotavirus reassortant vaccine (RV5, PRV) is a reassortant vaccine that combines the bovine strain, WC3, and a single gene encoding an outer capsid protein (VP7 or VP4) from the most common human serotypes: G1, G2, G3, G4, and P[8].</div><div class=\"graphic_reference\">Panel B modified from: Offit PA, Clark HF. RotaTeq:&nbsp;A pentavalent bovine—human reassortant rotavirus vaccine. Pediatr Ann 2006; 35:29.</div><div id=\"graphicVersion\">Graphic 89607 Version 2.0</div></div></div>"},"89608":{"type":"graphic_picture","displayName":"Splinter hemorrhages Darier","title":"Splinter hemorrhages in Darier disease","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Splinter hemorrhages in Darier disease</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89608_Splinter_hemorrhag_Darier.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distal splinter hemorrhages of the nail in a patient with Darier disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89608 Version 1.0</div></div></div>"},"89610":{"type":"graphic_picture","displayName":"Sigmoid volvulus intraoperative finding","title":"Sigmoid volvulus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sigmoid volvulus</div><div class=\"cntnt\"><img style=\"width:425px; height:504px;\" src=\"images/GAST/89610_Sigmoid_volvulus_intra_find.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative finding: volvulus of the sigmoid colon.</div><div class=\"graphic_reference\">Reproduced from: Salas S, Angel CA, Salas N, et al. Sigmoid volvulus in children and adolescents. J Am Coll Surg 2000; 190:717. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89610 Version 1.0</div></div></div>"},"89616":{"type":"graphic_diagnosticimage","displayName":"RML atelectasis I","title":"Right middle lobe atelectasis after right upper lobe lobectomy","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Right middle lobe atelectasis after right upper lobe lobectomy</div><div class=\"cntnt\"><img style=\"width:574px; height:524px;\" src=\"images/PULM/89616_RUL_atelectasis_IV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Status post right upper lobe lobectomy. Right middle lobe atelectasis framed by a hyperexpanded right lower lobe caudally and cranially.</div><div id=\"graphicVersion\">Graphic 89616 Version 2.0</div></div></div>"},"89622":{"type":"graphic_picture","displayName":"Acral nevus histo","title":"Histopathologic features of acral nevi","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of acral nevi</div><div class=\"cntnt\"><img style=\"width:515px; height:154px;\" src=\"images/DERM/89622_Acralnevushisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathologic features of acral nevus of the junctional type. The cornified layer slants slightly.<br />(A) Nevus cells arranged in nests are predominantly located in the crista profunda limitans (arrows), and only a few melanocytes are detected in the crista profunda intermedia (asterisks) (hematoxylin-eosin stain).<br />(B) Melanin granules in the cornified layer are detected as parallel columns regularly situated under the surface furrows (arrows), whereas they are mostly absent in the cornified layer under the surface ridges (asterisks) (Fontana-Masson stain).</div><div class=\"graphic_reference\">Reproduced with permissiomn from: Saida T, Koga H, Goto Y, Uhara H. Characteristic distribution of melanin columns in the cornified layer of acquired acral nevus: An important clue for histopathologic differentiation from early acral melanoma. Am J Dermatopathol 2011; 33:468. DOI: <A href=\"http://journals.lww.com/amjdermatopathology/pages/articleviewer.aspx?year=2011&amp;issue=07000&amp;article=00003&amp;type=abstract\" target=_blank>10.1097/DAD.0b013e318201ac8f</A>. Copyright © 2011 International Society of Dermatopathology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 89622 Version 6.0</div></div></div>"},"89623":{"type":"graphic_picture","displayName":"Early acral melanoma histo","title":"Histopathologic features of early acral melanoma","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of early acral melanoma</div><div class=\"cntnt\"><img style=\"width:513px; height:142px;\" src=\"images/DERM/89623_Earacralmelanohisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathologic features of the macular portion of an acral melanoma showing the parallel ridge pattern on dermoscopy.<br />(A) Melanocytes arranged as solitary units are mainly observed in the crista profunda intermedia (asterisks), although a few melanocytes are also detected in the crista profunda limitans (arrows) (hematoxylin-eosin stain).<br />(B) Melanin granules in the cornified layer are mostly derived from melanocytes in the crista profunda intermedia (Fontana-Masson stain). They are detected as broad columns under the surface ridges (blue bars). Melanin granules are mostly absent in the cornified layer under the surface furrow, corresponding to the underlying crista profunda limitans (arrows). This distribution corresponds well to the dermoscopic parallel ridge pattern.</div><div class=\"graphic_reference\">Reproduced with permissiomn from: Saida T, Koga H, Goto Y, Uhara H. Characteristic distribution of melanin columns in the cornified layer of acquired acral nevus: An important clue for histopathologic differentiation from early acral melanoma. Am J Dermatopathol 2011; 33:468. DOI: <A href=\"http://journals.lww.com/amjdermatopathology/pages/articleviewer.aspx?year=2011&amp;issue=07000&amp;article=00003&amp;type=abstract\" target=_blank>10.1097/DAD.0b013e318201ac8f</A>. Copyright © 2011 International Society of Dermatopathology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 89623 Version 6.0</div></div></div>"},"89626":{"type":"graphic_picture","displayName":"Lichen planus following Blaschko lines","title":"Lichen planus following the lines of Blaschko","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Lichen planus following the lines of Blaschko</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89626_Lichen_planus_Blaschko_line.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Violaceous plaque with fine scale following the lines of Blaschko.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89626 Version 1.0</div></div></div>"},"89633":{"type":"graphic_table","displayName":"GemCis biliary tract","title":"Gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.<br /> <strong>Duration of therapy:</strong> Maximum of 8 cycles.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cisplatin</td> <td>25 mg/m<sup>2</sup> IV daily</td> <td>Dilute in 1000 mL normal saline (NS)* with 20 mEq (20 mmol) of potassium chloride and 2 grams (8 mmol) of magnesium sulfate and administer over 60 minutes. Do not administer with aluminum needles or intravenous sets. Follow infusion with 500 mL NS over 30 minutes.</td> <td>Days 1 and 8</td> </tr> <tr class=\"divider_bottom\"> <td>Gemcitabine</td> <td>1000 mg/m<sup>2</sup> IV daily</td> <td>Dilute in 250 mL NS (concentration no more than 40 mg/mL) and administer over 30 minutes after cisplatin and IV fluid.</td> <td>Days 1 and 8</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Pretreatment hydration with 1 to 2 L of fluid infused during and following each dose of cisplatin.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE (30 to 90%). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Routine prophylaxis is not indicated for cisplatin or gemcitabine. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>The exact incidence of febrile neutropenia was not reported; however, 25% had grade 3 or 4 neutropenia.<sup>[1]</sup> Decisions about primary prophylaxis with G-CSF should be individualized according to current guidelines. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Patients with a calculated glomerular filtration rate &#60;45 mL/min were excluded from the trial.<sup>[1]</sup> A lower starting dose of gemcitabine may be needed for patients with liver impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Obtain CBC with differential and platelet count and assess serum electrolytes and renal function prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess pulmonary function at baseline and as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>A new cycle of treatment should not start until neutrophils recover to &#62;1500 cells/microL and platelets recover to &#62;100,000/microL. Intracycle dose reduction: Omit day 8 chemotherapy for neutrophil count &#60;500 cells/microL or platelet count &#60;50,000/microL. Reduce day 8 dose of gemcitabine by 25% for neutrophil count &#62;500 but &#60;1000 cells/microL, or platelet count &#62;50,000 but &#60;100,000/microL. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.<sup>[3]</sup> Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP. </li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>A variety of manifestations of pulmonary toxicity have been reported with gemcitabine. Discontinue gemcitabine immediately and permanently. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL.<sup>[2]</sup> For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &#60;60 mL/min.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factors; CBC: complete blood count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Valle J, et al. NEJM 2010; 362:1273.</LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed June 1, 2012).</LI>&#xD;&#xA;<LI>Gemcitabine hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed June 1, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 89633 Version 8.0</div></div></div>"},"89638":{"type":"graphic_movie","displayName":"Medial collateral ligament examination","title":"Medial collateral ligament examination","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Medial collateral ligament examination</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/89638_Medcollaterligexamvideo.mp4\" style=\"width:496px;height:288px\"></div><img style=\"width:590px; height:333px;\" src=\"images/EM/89638_Medcollaterligexamimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video demonstrates the valgus stress examination of the medial collateral ligament with the knee in slight flexion and in full extension.</div><div class=\"graphic_reference\">Courtesy of William W Dexter, MD, FACSM.</div><div id=\"graphicVersion\">Graphic 89638 Version 1.0</div></div></div>"},"89640":{"type":"graphic_figure","displayName":"Vocal cord movement","title":"Vocal cord movement","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Vocal cord movement</div><div class=\"cntnt\"><img style=\"width:482px; height:473px;\" src=\"images/PULM/89640_Vocal_cord_movement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal vocal cord abduction&nbsp;at midinspiration. The anterior&nbsp;tracheal rings are visible beyond the vocal cords.&nbsp;(B) Paradoxic adduction of the vocal cords&nbsp;at midinspiration, as seen in most cases of VCD. (C) Partial adduction of the vocal cords with a posterior opening or \"chinking\", as seen during inspiration&nbsp;in a small percentage of VCD cases.</div><div class=\"graphic_reference\">Hoyte FC. Vocal cord dysfunction. In: Conditions mimicking asthma, Choo EM (Ed), Elsevier, Philadelphia 2013.</div><div id=\"graphicVersion\">Graphic 89640 Version 2.0</div></div></div>"},"89645":{"type":"graphic_movie","displayName":"Endometriosis peritoneal lesions","title":"Types of peritoneal implants in endometriosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Types of peritoneal implants in endometriosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/89645_Endometperitlesionsvideo.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:576px; height:345px;\" src=\"images/OBGYN/89645_Endometperitlesionsvideo.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Michael D Mueller, MD.</div><div id=\"graphicVersion\">Graphic 89645 Version 2.0</div></div></div>"},"89648":{"type":"graphic_form","displayName":"Classification of endometriosis 2","title":"American Society for Reproductive Medicine revised classification of endometriosis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">American Society for Reproductive Medicine revised classification of endometriosis</div><div class=\"cntnt\"><img style=\"width:540px; height:682px;\" src=\"images/OBGYN/89648_Class_endometriosis_2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* If the fimbriated end of the fallopian tube is completely enclosed, change the point assignment to 16. Denote appearance of superficial implant types as red ([R], red-pink, flamelike, vesicular blobs, clear vesicles), white ([W], opacifications, peritoneal defects, yellow-brown), or black ([B], black, hemosiderin deposits, blue). Denote percent of total described as R__ percent, W__ percent, and B __ percent. Total should equal 100 percent.</div><div class=\"graphic_reference\">Original figure modified for this publication. American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67:817. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89648 Version 2.0</div></div></div>"},"89658":{"type":"graphic_movie","displayName":"Laser ablation endometriosis","title":"Laser ablation of endometriosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laser ablation of endometriosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/89658_Laserablatendometrvideo.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:576px; height:404px;\" src=\"images/OBGYN/89658_Laserablatendometrimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Michael D Mueller, MD.</div><div id=\"graphicVersion\">Graphic 89658 Version 1.0</div></div></div>"},"89660":{"type":"graphic_movie","displayName":"Excision endometriosis","title":"Laparoscopic excision of endometriotic lesions","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic excision of endometriotic lesions</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/89660_Excisionendometriosvideo.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:576px; height:374px;\" src=\"images/OBGYN/89660_Excisionendometriosimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Michael D Mueller, MD.</div><div id=\"graphicVersion\">Graphic 89660 Version 1.0</div></div></div>"},"89663":{"type":"graphic_table","displayName":"PHQ-2 questionnaire","title":"Short Patient Health Questionnaire (PHQ-2)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Short Patient Health Questionnaire (PHQ-2)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\" style=\"font-size: 14px;\" colspan=\"3\"><strong>Name:</strong></td> <td class=\"highlight_gray_text\" style=\"font-size: 14px;\" colspan=\"3\"><strong>Date:</strong></td> </tr> <tr class=\"divider_top divider_bottom\"> <td colspan=\"2\"><strong>Over the past two weeks, how often have you been bothered by any of the following problems?</strong></td> <td><strong>Not at all</strong></td> <td><strong>Several days</strong></td> <td><strong>More than half the days</strong></td> <td><strong>Nearly every day</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Little interest or pleasure in doing things?</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Feeling down, depressed, or hopeless?</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Total point score:</strong></td> <td><strong>____</strong></td> <td>____</td> <td>+ ____</td> <td>+ ____</td> <td>+ ____</td> </tr> <tr class=\"divider_top divider_bottom\"> <td class=\"highlight_gray_text\" style=\"font-size: 14px;\" colspan=\"6\"><strong>Score interpretation<sup>[1]</sup>:</strong></td> </tr> <tr class=\"divider_top divider_bottom\"> <td colspan=\"2\"><strong>PHQ-2 score</strong></td> <td colspan=\"2\"><strong>Probability of major depressive disorder (%)</strong></td> <td colspan=\"2\"><strong>Probability of any depressive disorder (%)</strong></td> </tr> <tr> <td class=\"centered\" colspan=\"2\">1</td> <td class=\"centered\" colspan=\"2\">15.4</td> <td class=\"centered\" colspan=\"2\">36.9</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">2</td> <td class=\"centered\" colspan=\"2\">21.1</td> <td class=\"centered\" colspan=\"2\">48.3</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">3</td> <td class=\"centered\" colspan=\"2\">38.4</td> <td class=\"centered\" colspan=\"2\">75.0</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">4</td> <td class=\"centered\" colspan=\"2\">45.5</td> <td class=\"centered\" colspan=\"2\">81.2</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">5</td> <td class=\"centered\" colspan=\"2\">56.4</td> <td class=\"centered\" colspan=\"2\">84.6</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">6</td> <td class=\"centered\" colspan=\"2\">78.6</td> <td class=\"centered\" colspan=\"2\">92.9</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 2003; 41:1284.</li>&#xD;&#xA;</ol>&#xD;&#xA;PHQ-2 reproduced with the permission of Pfizer Inc.</div><div id=\"graphicVersion\">Graphic 89663 Version 2.0</div></div></div>"},"89664":{"type":"graphic_movie","displayName":"Examination posterior cul-de-sac endometriosis","title":"Bimanual pelvic examination during laparoscopy for posterior cul-de-sac endometriosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bimanual pelvic examination during laparoscopy for posterior cul-de-sac endometriosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/89664_Exampostculdesacvideo.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:576px; height:460px;\" src=\"images/OBGYN/89664_Exampostculdesacimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dan I Lebovic, MD.</div><div id=\"graphicVersion\">Graphic 89664 Version 1.0</div></div></div>"},"89665":{"type":"graphic_form","displayName":"WHO-5 questionnaire","title":"WHO (Five) Well-Being Index (1998 version)","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">WHO (Five) Well-Being Index (1998 version)</div><div class=\"cntnt\"><img style=\"width:617px; height:579px;\" src=\"images/PC/89665_WHO5_questionnaire.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>Scoring:</STRONG><br /><UL>&#xD;&#xA;<LI>The raw score is calculated by totalling the figures of the five answers. The raw score ranges from 0 to 25, 0 representing worst possible and 25 representing best possible quality of life.</LI>&#xD;&#xA;<LI>To obtain a percentage score ranging from 0 to 100, the raw score is multiplied by 4. A percentage score of 0 represents worst possible, whereas a score of 100 represents best possible quality of life.</LI></UL><STRONG>Interpretation:</STRONG><br /><UL>&#xD;&#xA;<LI>It is recommended to administer the Major Depression (ICD-10) Inventory if the raw score is below 13 or if the patient has answered 0 to 1 to any of the five items. A score below 13 indicates poor wellbeing and is an indication for testing for depression under ICD-10.</LI></UL><STRONG>Monitoring change:</STRONG><br /><UL>&#xD;&#xA;<LI>In order to monitor possible changes in wellbeing, the percentage score is used. A 10% difference indicates a significant change.</LI></UL></div><div class=\"graphic_footnotes\">ICD-10: International Classification of Diseases, Tenth Revision.</div><div class=\"graphic_reference\">Originally published in: World Health Organization Psychiatric Research Unit. Who (Five) Well-Being Index (1998 version). WHO Collaborating Center for Mental Health 1998. Reprinted with permission from: the World Health Organization. Republished in: Bech P. Clinical Psychometrics. Wiley-Blackwell, Oxford, 2012.</div><div id=\"graphicVersion\">Graphic 89665 Version 2.0</div></div></div>"},"89667":{"type":"graphic_diagnosticimage","displayName":"X-ray Hutchinsons radiocarpal fracture","title":"X-ray of Hutchinson's radiocarpal fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">X-ray of Hutchinson's radiocarpal fracture</div><div class=\"cntnt\"><img style=\"width:190px; height:392px;\" src=\"images/RADIOL/89667_X_Hutch_radiocar_fract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior plain x-ray of the right hand shows an intra-articular fracture through the radial styloid process (arrow) with minimal displacement.</div><div id=\"graphicVersion\">Graphic 89667 Version 2.0</div></div></div>"},"89668":{"type":"graphic_table","displayName":"Gem plus nabpaclitaxel","title":"Gemcitabine plus nanoparticle albumin-bound paclitaxel (nabpaclitaxel) for advanced pancreatic cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gemcitabine plus nanoparticle albumin-bound paclitaxel (nabpaclitaxel) for advanced pancreatic cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 4 weeks. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Nabpaclitaxel*</td> <td>125 mg/m<sup>2</sup> IV</td> <td>Administer undiluted over 30 minutes.</td> <td>Days 1, 8, and 15</td> </tr> <tr class=\"divider_bottom\"> <td>Gemcitabine</td> <td>1000 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (concentration no greater than 40 mg/mL) and administer over 30 to 60 minutes, after nabpaclitaxel.</td> <td>Days 1, 8, and 15</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE.</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Nabpaclitaxel can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\"</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedication to prevent hypersensitivity reactions is generally not needed. Premedication may be needed in patients who have had a prior hypersensitivity reaction to nabpaclitaxel.</li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>The incidence of febrile neutropenia with this regimen is 3%.<sup>[1]</sup> Primary prophylaxis with granulocyte colony stimulating factors is not indicated.</li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose for gemcitabine and nabpaclitaxel may be needed for patients with liver impairment. <strong>Do not administer nabpaclitaxel to patients with pancreatic cancer and moderate to severe liver impairment (AST &#60;10 times the upper limit of normal [ULN] and total bilirubin &#62;1.5 times the ULN OR AST &#62;10 times the ULN OR bilirubin &#62;5 times the ULN).</strong></li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelets weekly during treatment.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess comprehensive metabolic panel prior to each cycle or when clinically indicated during treatment.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for infusion reactions.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for extravasation.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Sensory neuropathy occurs frequently with nabpaclitaxel; assess for changes in neurologic function prior to each treatment cycle.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for signs and symptoms of pneumonitis.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li><strong>Do not administer</strong> nabpaclitaxel and gemcitabine on day 1 of each new cycle unless ANC is &#62;1500 cells/microL and platelet count is &#62;100,000/microL.<sup>[2]</sup> <strong>For severe neutropenia or thrombocytopenia during therapy or febrile neutropenia,</strong> dose reduction guidelines are provided in the United States Prescribing Information.<sup>[2]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Sepsis</strong></td> <td colspan=\"3\"> <ul> <li>Sepsis has occurred in patients with or without neutropenia (risk factors are biliary obstruction or presence of a biliary stent). Initiate broad spectrum antibiotics in the presence of fever, even if not neutropenic. Interrupt nabpaclitaxel and gemcitabine until sepsis resolves and, if neutropenic, until neutrophils are at least 1500 cells/microL, then resume at lower doses.<sup>[2]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>Thrombotic microangiopathy (TMA; also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine in individuals who have received a large or small cumulative dose.<sup>[3]</sup> Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Peripheral neuropathy</strong></td> <td colspan=\"3\"> <ul> <li>Withhold nabpaclitaxel for grade 3 or worse neuropathy during therapy.<sup>[2]</sup> Resume nabpaclitaxel at reduced dose (25%) only after recovery to &#8804;grade 1. For grade 2 to 3 cutaneous toxicity, reduce nabpaclitaxel dose by 25% and gemcitabine dose by 20%. For grade 3 mucositis or diarrhea, withhold therapy until improves to &#8804;grade 1, then resume with reduction of nabpaclitaxel dose by 25% and gemcitabine dose by 20%.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear gemcitabine dose recommendations in these patients. <strong>Nabpaclitaxel is not recommended for individuals with preexisting moderate to severe hepatic impairment; the need for further dose adjustments because of hepatotoxicity in subsequent courses should be based on individual tolerance and clinician judgment</strong>.<sup>[2]</sup></li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>A variety of manifestations of pulmonary toxicity have been reported with gemcitabine. Pneumonitis has occurred with the use of nabpaclitaxel in combination with gemcitabine. Permanently discontinue treatment with both agents.<sup>[2]</sup></li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; AST: aspartate aminotransferase; CBC: complete blood count; ANC: absolute neutrophil count.<br />* Do not substitute paclitaxel for nabpaclitaxel.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine N Engl J Med 2013; 369:1691.</LI>&#xD;&#xA;<LI>Paclitaxel protein bound particles for injectable suspension (albumin-bound). United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed April 24, 2013).</LI>&#xD;&#xA;<LI>Gemcitabine hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed April 24, 2013).</LI></OL></div><div id=\"graphicVersion\">Graphic 89668 Version 19.0</div></div></div>"},"89669":{"type":"graphic_figure","displayName":"Partial gastrectomy and reconstruction","title":"Partial gastrectomy and reconstruction","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Partial gastrectomy and reconstruction</div><div class=\"cntnt\"><img style=\"width:529px; height:699px;\" src=\"images/SURG/89669_Distal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distal (partial) gastrectomy is performed by removing the distal portion of the stomach (shaded region between line 2 and line 4). Gastrointestinal continuity can be restored using one of three techniques. The first (B), known as a Billroth I reconstruction, anastomoses the stomach to the duodenal remnant. The Billroth II reconstruction (C) brings up a loop of proximal jejunum to create an end-to-side gastrojejunoctomy. Another option is a Roux-en-Y gastrojejunostomy (C), in which the more distal jejunum is anastomosed to the stomach in an end-to-side fashion.</div><div id=\"graphicVersion\">Graphic 89669 Version 3.0</div></div></div>"},"89670":{"type":"graphic_table","displayName":"Group D Streptococcus nomenclature","title":"Former (phenotypic) and current (genotypic) denominations of the species within the <EM>Streptococcus bovis/Streptococcus equinus</EM> complex","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Former (phenotypic) and current (genotypic) denominations of the species within the <EM>Streptococcus bovis/Streptococcus equinus</EM> complex</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Former denomination</td> <td class=\"subtitle1\">Current denomination</td> <td class=\"subtitle1\">Synonym</td> </tr> <tr> <td><em>S. bovis</em> biotype I</td> <td><em>S. gallolyticus</em></td> <td><em>S. gallolyticus</em> subsp <em>gallolyticus</em></td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><em>S. bovis</em> biotype II.1</td> <td><em>S. lutetiensis</em></td> <td><em>S. infantarius</em> subsp <em>coli</em></td> </tr> <tr> <td><em>S. infantarius</em></td> <td><em>S. infantarius</em> subsp <em>infantarius</em></td> </tr> <tr class=\"divider_top\"> <td><em>S. bovis</em> biotype II.2</td> <td><em>S. pasteurianus</em></td> <td><em>S. gallolyticus</em> subsp <em>pasteurianus</em></td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Chirouze C, Patry I, Duval X, et al. Streptococcus bovis/Streptococcus equinus complex fecal carriage, colorectal carcinoma, and infective endocarditis: a new appraisal of a complex connection. Eur J Clin Microbiol Infect Dis 2013.</li>&#xD;&#xA;    <li>Poyart C, Quesne G, Trieu-Cuot P. Taxonomic dissection of the Streptococcus bovis group by analysis of manganese-dependent superoxide dismutase gene (sodA) sequences: reclassification of 'Streptococcus infantarius subsp. coli' as Streptococcus lutetiensis sp. nov. and of Streptococcus bovis biotype 11.2 as Streptococcus pasteurianus sp. nov. Int J Syst Evol Microbiol 2002; 52:1247.</li>&#xD;&#xA;    <li>Schlegel L, Grimont F, Ageron E, et al. Reappraisal of the taxonomy of the Streptococcus bovis/Streptococcus equinus complex and related species: description of Streptococcus gallolyticus subsp. gallolyticus subsp. nov., S. gallolyticus subsp. macedonicus subsp. nov. and S. gallolyticus subsp. pasteurianus subsp. nov. Int J Syst Evol Microbiol 2003; 53:631.</li>&#xD;&#xA;</ol>&#xD;&#xA;<br />Modified from: Boleij A, van Gelder MM, Swinkels DW, Tjalsma H. Clinical importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis 2011; 53:870. By permission of the Infectious Diseases Society of America. Copyright &copy; 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 89670 Version 12.0</div></div></div>"},"89672":{"type":"graphic_table","displayName":"Radiation-induced skin changes","title":"Radiation-induced acute and chronic skin changes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiation-induced acute and chronic skin changes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Acute skin effects (hours to weeks)</td> <td class=\"subtitle1\" colspan=\"2\">Chronic skin effects (months to years)</td> </tr> <tr> <td class=\"subtitle2\">Description</td> <td class=\"subtitle2\">Dose (Gy)</td> <td class=\"subtitle2\">Description</td> <td class=\"subtitle2\">Dose (Gy)</td> </tr> <tr> <td>Erythema/hyperpigmentation</td> <td class=\"centered\">2 to 20</td> <td>Delayed ulceration</td> <td class=\"centered\">&#62;45</td> </tr> <tr> <td>Epilation</td> <td class=\"centered\">6 to 10</td> <td>Dermal necrosis</td> <td class=\"centered\">&#62;45</td> </tr> <tr> <td>Dry desquamation</td> <td class=\"centered\">20 to 25</td> <td>Fibrosis</td> <td class=\"centered\">&#62;45</td> </tr> <tr> <td>Moist desquamation</td> <td class=\"centered\">30 to 40</td> <td>Telangiectasia</td> <td class=\"centered\">&#62;45</td> </tr> <tr> <td>Ulceration</td> <td class=\"centered\">&#62;40</td> <td>&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Mendelsohn FA, Divino CM, Reis ED, Kerstein MD. Wound care after radiation therapy. Adv Skin Wound Care 2002; 15:216.</li>&#xD;&#xA;    <li>Jensen JM, Gau T, Schultze J, et al. Treatment of Acute Radiodermatitis with an Oil-in-Water Emulsion Following Radiation Therapy for Breast Cancer: A Controlled, Randomized Trial. Strahlenther Onkol 2011; 187:378.</li>&#xD;&#xA;    <li>Schmuth M, Sztankay A, Weinlich G, et al. Permeability barrier function of skin exposed to ionizing radiation. Arch Dermatol 2001; 137:1019.</li>&#xD;&#xA;    <li>Bridges BA, Adam A, Holt D, et al. High dose radiation effects and tissue injury: Report of the independent advisory group on ionizing radiation. In: Radiation, chemical, and environmental hazards, Elsevier, Chilton 2009.</li>&#xD;&#xA;    <li>Brown KR, Rzucidlo E. Acute and chronic radiation injury. J Vasc Surg 2011; 53:15S.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 89672 Version 2.0</div></div></div>"},"89673":{"type":"graphic_picture","displayName":"Progression of radiation dermatitis","title":"Progression of radiation dermatitis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Progression of radiation dermatitis</div><div class=\"cntnt\"><img style=\"width:598px; height:247px;\" src=\"images/DERM/89673_Progression_radiation_derm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The images show radiation dermatitis at four different stages of severity in fair skin (A-D) and darkly-pigmented skin (E-H). Radiation dermatitis ranges from faint erythema and hyperpigmentation (A, E) to definite erythema and hyperpigmentation with dry fine desquamation (B, F) to early moist desquamation, and patchy crusting (C, G) to moist desquamation, superficial ulceration, and peeling in sheets (D, H).</div><div class=\"graphic_reference\">Reproduced with permission from: Ryan JL, Heckler CE, Ling M, et al. Curcumin for radiation dermatitis: A randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients. Radiat Res 2013; 180:34. Copyright &copy; 2013 Radiation Research Society. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89673 Version 1.0</div></div></div>"},"89674":{"type":"graphic_diagnosticimage","displayName":"Longitudinal US of flexor pollicis longus","title":"Longitudinal ultrasound imaging of normal flexor pollicis longus tendon","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Longitudinal ultrasound imaging of normal flexor pollicis longus tendon</div><div class=\"cntnt\"><img style=\"width:561px; height:271px;\" src=\"images/RHEUM/89674_Lngtdnl_US_flxr_polcs_longs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal scan of the flexor pollicis longus tendon, demonstrating its fibrillar nature and hyperechogenicity.</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 89674 Version 1.0</div></div></div>"},"89675":{"type":"graphic_diagnosticimage","displayName":"Longitudinal Achilles tendinitis US","title":"Longitudinal ultrasound image of Achilles tendinitis, enthesitis, and retrocalcaneal bursitis","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Longitudinal ultrasound image of Achilles tendinitis, enthesitis, and retrocalcaneal bursitis</div><div class=\"cntnt\"><img style=\"width:574px; height:299px;\" src=\"images/RHEUM/89675_Longtdnl_Achles_tendints_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal scan of active Achilles enthesitis (arrow), tendinitis (arrowhead), and retrocalcaneal bursitis (*).</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 89675 Version 1.0</div></div></div>"},"89676":{"type":"graphic_diagnosticimage","displayName":"RA wrist power Doppler","title":"Power Doppler longitudinal ultrasound imaging of the wrist in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Power Doppler longitudinal ultrasound imaging of the wrist in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:586px; height:310px;\" src=\"images/RHEUM/89676_RA_wrist_power_Doppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Semi-quantitative power Doppler scoring system, grade 0 to 3. Longitudinal scans of synovitis of the wrist at dorsal aspect in rheumatoid arthritis.</div><div class=\"graphic_footnotes\">R: radius; L: lunate; C: capitate.</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 89676 Version 1.0</div></div></div>"},"89677":{"type":"graphic_diagnosticimage","displayName":"RA wrist synovitis power Doppler","title":"Power Doppler ultrasound imaging of wrist synovitis in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Power Doppler ultrasound imaging of wrist synovitis in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:586px; height:202px;\" src=\"images/RHEUM/89677_RA_wrst_synovits_pwr_Dopplr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Monitoring synovial response to treatment of synovitis of the wrist at the dorsal aspect in a patient with rheumatoid arthritis.</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 89677 Version 1.0</div></div></div>"},"89678":{"type":"graphic_diagnosticimage","displayName":"Gout on US","title":"Ultrasound imaging of gouty arthritis","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Ultrasound imaging of gouty arthritis</div><div class=\"cntnt\"><img style=\"width:573px; height:298px;\" src=\"images/RHEUM/89678_Gout_on_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical ultrasound gout features in a first metatarsal-phalangeal joint at the dorsal aspect, including heterogenic synovitis (*) and double contour sign (arrows).</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 89678 Version 1.0</div></div></div>"},"89689":{"type":"graphic_picture","displayName":"Endomyocardial biopsy amyloid cardiomyopathy low power","title":"Endomyocardial biopsy amyloid cardiomyopathy low power","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endomyocardial biopsy amyloid cardiomyopathy low power</div><div class=\"cntnt\"><img style=\"width:346px; height:574px;\" src=\"images/CARD/89689_Endmc_bps_amyld_crdm_lw_pwr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power image of an endomyocardial biopsy in a patient with TTR amyloidosis stained with sulfated Alcian blue. The amyloid stains turquoise, and the cardiac myocytes stain yellow-brown.</div><div id=\"graphicVersion\">Graphic 89689 Version 1.0</div></div></div>"},"89690":{"type":"graphic_picture","displayName":"Endomyocardial biopsy amyloid cardiomyopathy high power","title":"Endomyocardial biopsy amyloid cardiomyopathy high power","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Endomyocardial biopsy amyloid cardiomyopathy high power</div><div class=\"cntnt\"><img style=\"width:574px; height:432px;\" src=\"images/CARD/89690_Endmy_bips_amy_crdm_hgh_pwr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-powered view of section of an endomyocardial biopsy in a patient with TTR amyloidosis stained with sulfated Alcian blue. Green staining is amyloid. Note the extensive replacement of myocardium by the extracellular amyloid deposits.</div><div id=\"graphicVersion\">Graphic 89690 Version 1.0</div></div></div>"},"89691":{"type":"graphic_diagnosticimage","displayName":"Acoustic shadowing on ultrasound","title":"Acoustic shadowing on musculoskeletal ultrasound imaging","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Acoustic shadowing on musculoskeletal ultrasound imaging</div><div class=\"cntnt\"><img style=\"width:471px; height:405px;\" src=\"images/RHEUM/89691_Acoustic_shadowng_ultrasoud.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adjacent to the long head of shoulder biceps tendon (BT), linear calcification (arrow) shows acoustic shadowing deep to the calcification (*). Anterior transverse scan of shoulder.</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 89691 Version 1.0</div></div></div>"},"89692":{"type":"graphic_diagnosticimage","displayName":"Post-septic shoulder bursitis ultrasound","title":"Enhancement artifact on musculoskeletal ultrasound imaging of shoulder","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Enhancement artifact on musculoskeletal ultrasound imaging of shoulder</div><div class=\"cntnt\"><img style=\"width:574px; height:525px;\" src=\"images/RHEUM/89692_Pst_spt_shuldr_burst_ultrsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Post-septic shoulder bursitis, showing proliferative synovitis (*), fluid (+), and enhancement artifact (arrows). Anterior transverse scan.</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 89692 Version 1.0</div></div></div>"},"89693":{"type":"graphic_diagnosticimage","displayName":"Peroneus tendon US enhancement artifact","title":"Enhancement artifact on musculoskeletal ultrasound imaging of peroneus tendon","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Enhancement artifact on musculoskeletal ultrasound imaging of peroneus tendon</div><div class=\"cntnt\"><img style=\"width:574px; height:422px;\" src=\"images/RHEUM/89693_Peroneus_tendon_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clearly visualized peroneus tendon, surrounded by fluid (*). Longitudinal scan. The image of the tendon is particularly well-visualized, in part due to enhanced through-transmission.</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 89693 Version 1.0</div></div></div>"},"89694":{"type":"graphic_diagnosticimage","displayName":"Edge shadowing on ultrasound","title":"Edge shadowing on musculoskeletal ultrasound imaging","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Edge shadowing on musculoskeletal ultrasound imaging</div><div class=\"cntnt\"><img style=\"width:574px; height:377px;\" src=\"images/RHEUM/89694_Edge_shadowng_on_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rheumatoid nodule localized in a finger flexor tendon, showing the ultrasonographic artifact of edge shadowing (indicated by arrows). Transverse scan.</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 89694 Version 1.0</div></div></div>"},"89695":{"type":"graphic_waveform","displayName":"ECG amyloid cardiomyopathy","title":"ECG amyloid cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">ECG amyloid cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:586px; height:309px;\" src=\"images/CARD/89695_ECG_amyloid_cardiomyopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical electrocardiogram in a patient with AL amyloidosis, showing low limb lead voltage, left axis deviation, and Q waves (pseudo-MI pattern) leads V1-V3.</div><div id=\"graphicVersion\">Graphic 89695 Version 1.0</div></div></div>"},"89696":{"type":"graphic_diagnosticimage","displayName":"Technetium pyrophosphate imaging amyloid cardiomyopathy","title":"Technetium pyrophosphate imaging amyloid cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 685px\" class=\"figure\"><div class=\"ttl\">Technetium pyrophosphate imaging amyloid cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:665px; height:525px;\" src=\"images/CARD/89696_Techn_pyrophosphate_amyloid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Technetium pyrophosphate scan in an 80-year-old man with mild heart failure and concentric left ventricular thickening on echocardiography. There was no history of hypertension. Images (all resting) show intense diffuse uptake of the isotope throughout the myocardium, highly suggestive of transthyretin (TTR) amyloidosis.</div><div id=\"graphicVersion\">Graphic 89696 Version 2.0</div></div></div>"},"89697":{"type":"graphic_movie","displayName":"Echo parasternal long axis amyloid cardiomyopathy","title":"Echo parasternal long axis amyloid cardiomyopathy","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Echo parasternal long axis amyloid cardiomyopathy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/89697_Echoparalongamyloidvideo.mp4\" style=\"width:496px;height:352px\"></div><img style=\"width:570px; height:431px;\" src=\"images/CARD/89697_Echoparlongamyloidimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal long axis view of a patient with severe AL amyloidosis, showing reduced left ventricular ejection fraction, marked left ventricular wall thickening, and a moderate size pericardial effusion. There is increased echogenicity of the myocardium.</div><div id=\"graphicVersion\">Graphic 89697 Version 1.0</div></div></div>"},"89698":{"type":"graphic_movie","displayName":"Echo subcostal long axis amyloid cardiomyopathy","title":"Echo subcostal long axis amyloid cardiomyopathy","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Echo subcostal long axis amyloid cardiomyopathy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/89698_Echsubcostlongamylvideo.mp4\" style=\"width:496px;height:352px\"></div><img style=\"width:543px; height:430px;\" src=\"images/CARD/89698_Echsubcostlongamylimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcostal echocardiographic view showing reduced left ventricular ejection fraction, marked left ventricular wall thickening, and a moderate size pericardial effusion. There is increased echogenicity of the myocardium as well as right ventricular thickening and markedly enlarged atria.</div><div id=\"graphicVersion\">Graphic 89698 Version 1.0</div></div></div>"},"89699":{"type":"graphic_movie","displayName":"Echo apical four chamber amyloid cardiomyopathy","title":"Echo apical four chamber amyloid cardiomyopathy","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Echo apical four chamber amyloid cardiomyopathy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/89699_Echapicalfouramylovideo.mp4\" style=\"width:496px;height:352px\"></div><img style=\"width:551px; height:429px;\" src=\"images/CARD/89699_Echapicalfouramyloimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical-chamber echocardiogram in a patient with mild heart failure due to senile systemic amyloidosis. There is marked left ventricular thickening, with normal left ventricular ejection fraction. Left ventricular thickening in TTR amyloidosis is often severe despite minimal symptoms, whereas AL amyloid patients usually have severe heart failure with only moderate left ventricular thickening.</div><div id=\"graphicVersion\">Graphic 89699 Version 1.0</div></div></div>"},"89701":{"type":"graphic_table","displayName":"Risk factors for radiation dermatitis","title":"Risk factors for radiation dermatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for radiation dermatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Body site</td> </tr> <tr> <td class=\"indent1\">Anterior of neck</td> </tr> <tr> <td class=\"indent1\">Extremities</td> </tr> <tr> <td class=\"indent1\">Chest/breast</td> </tr> <tr> <td class=\"indent1\">Abdomen</td> </tr> <tr> <td class=\"indent1\">Face</td> </tr> <tr> <td class=\"indent1\">Scalp (hair follicles)</td> </tr> <tr> <td class=\"subtitle1_single\">Patient-related factors</td> </tr> <tr> <td class=\"indent1\">Obesity</td> </tr> <tr> <td class=\"indent1\">Age (older)</td> </tr> <tr> <td class=\"indent1\">Sex (female)</td> </tr> <tr> <td class=\"indent1\">Chronic sun exposure</td> </tr> <tr> <td class=\"indent1\">Smoking</td> </tr> <tr> <td class=\"indent1\">Breast reconstruction/implants</td> </tr> <tr> <td class=\"subtitle1_single\">Pre-existing disorders</td> </tr> <tr> <td class=\"indent1\">Connective tissue disorders (scleroderma)</td> </tr> <tr> <td class=\"indent1\">Radiosensitivity disorders (ataxia telangiectasia)</td> </tr> <tr> <td class=\"subtitle1_single\">Drug-induced radiation recall</td> </tr> <tr> <td class=\"indent1\">Anthracyclines (doxorubicin)</td> </tr> <tr> <td class=\"indent1\">Taxanes (docetaxel, paclitaxel)</td> </tr> <tr> <td class=\"indent1\">Antimetabolites (gemcitabine, capecitabine)</td> </tr> <tr> <td class=\"indent1\">Antibiotics</td> </tr> <tr> <td class=\"indent1\">Antituberculosis medications</td> </tr> <tr> <td class=\"indent1\">Simvastatin</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89701 Version 4.0</div></div></div>"},"89702":{"type":"graphic_table","displayName":"Radiation dermatitis scoring systems","title":"Scoring systems for acute radiation dermatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Scoring systems for acute radiation dermatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Classification scale</td> <td class=\"subtitle1\">Scores</td> <td class=\"subtitle1\">Clinical description</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">RTOG</td> <td class=\"centered\">0</td> <td>No change</td> </tr> <tr> <td class=\"centered\">1</td> <td>Erythema; dry desquamation, epilation</td> </tr> <tr> <td class=\"centered\">2</td> <td>Bright erythema, moist desquamation, edema</td> </tr> <tr> <td class=\"centered\">3</td> <td>Confluent moist desquamation, pitting edema</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">4</td> <td>Ulceration, hemorrhage, necrosis</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">NCI CTCAE</td> <td class=\"centered\">0</td> <td>No change</td> </tr> <tr> <td class=\"centered\">1</td> <td>Faint erythema or dry desquamation</td> </tr> <tr> <td class=\"centered\">2</td> <td>Moderate to brisk erythema; patchy, moist desquamation, mostly confined to skin folds and creases; moderate edema</td> </tr> <tr> <td class=\"centered\">3</td> <td>Moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or abrasion</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">4</td> <td>Life-threatening consequences; skin necrosis or ulceration of full thickness dermis; spontaneous bleeding from involved site; skin graft indicated</td> </tr> <tr> <td rowspan=\"9\">Radiation dermatitis severity</td> <td class=\"centered\">0.0</td> <td>None</td> </tr> <tr> <td class=\"centered\">0.5</td> <td>Patchy or faint erythema; faint hyperpigmentation</td> </tr> <tr> <td class=\"centered\">1.0</td> <td>Faint, diffuse erythema; diffuse hyperpigmentation; mild epilation</td> </tr> <tr> <td class=\"centered\">1.5</td> <td>Definite erythema; extreme darkening/hyperpigmentation</td> </tr> <tr> <td class=\"centered\">2.0</td> <td>Definite erythema/hyperpigmentation with fine dry desquamation and mild edema</td> </tr> <tr> <td class=\"centered\">2.5</td> <td>Definite erythema/hyperpigmentation with branny/scaly desquamation</td> </tr> <tr> <td class=\"centered\">3.0</td> <td>Deep red erythema with diffuse dry desquamation; peeling in sheets</td> </tr> <tr> <td class=\"centered\">3.5</td> <td>Violaceous erythema with early moist desquamation; peeling in sheets; patchy crusting</td> </tr> <tr> <td class=\"centered\">4.0</td> <td>Violaceous erythema with diffuse moist desquamation; patchy crusting; ulceration; necrosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RTOG: Radiation Therapy Oncology Group; NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Ryan JL. Ionizing radiation: the good, the bad, and the ugly. J Invest Dermatol 2012; 132:985.</LI>&#xD;&#xA;<LI>Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <A spellcheck=true href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=_blank>https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</A> (Accessed March 27, 2018).</LI>&#xD;&#xA;<LI>Pommier P, Gomez F, Sunyach MP, et al. Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol 2004; 22:1447.</LI>&#xD;&#xA;<LI>Okunieff P, Xu J, Hu D, et al. Curcumin protects against radiation-induced acute and chronic cutaneous toxicity in mice and decreases mRNA expression of inflammatory and fibrogenic cytokines. Int J Radiat Oncol Biol Phys 2006; 65:890.</LI>&#xD;&#xA;<LI>Ryan JL, Ling M, Williams JP, et al. Curcumin intervention and plasma biomarkers for radiation dermatitis in breast cancer patients. J Invest Dermatol 2011; 131:S90.</LI></OL></div><div id=\"graphicVersion\">Graphic 89702 Version 3.0</div></div></div>"},"89703":{"type":"graphic_figure","displayName":"MERS-CoV cases by country","title":"Confirmed cases of Middle East respiratory syndrome coronavirus 2012 to 2017, as of 10 February 2017","html":"<div class=\"graphic\"><div style=\"width: 1036px\" class=\"figure\"><div class=\"ttl\">Confirmed cases of Middle East respiratory syndrome coronavirus 2012 to 2017, as of 10 February 2017</div><div class=\"cntnt\"><img style=\"width:1016px; height:680px;\" src=\"images/ID/89703_MERS-CoV_cases_country_2017.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: World Health Organization. Emergencies preparedness, response: Middle East respiratory syndrome coronavirus (MERS-CoV) maps and epicurves, 10 February 2017. <A href=\"http://www.who.int/emergencies/mers-cov/map-10-february-2017.png?ua=1\" target=_blank>http://www.who.int/emergencies/mers-cov/map-10-february-2017.png?ua=1</A> (Accessed on February 14, 2017).</div><div id=\"graphicVersion\">Graphic 89703 Version 10.0</div></div></div>"},"89709":{"type":"graphic_diagnosticimage","displayName":"Malignant mesothelioma","title":"Malignant mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Malignant mesothelioma</div><div class=\"cntnt\"><img style=\"width:565px; height:215px;\" src=\"images/PULM/89709_Malignant_mesothelioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT scan (A) and coronal&nbsp;reconstruction (B) show circumferential nodular pleural thickening in the left hemithorax.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89709 Version 2.0</div></div></div>"},"89710":{"type":"graphic_diagnosticimage","displayName":"Pleural carcinomatosis","title":"Pleural carcinomatosis","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Pleural carcinomatosis</div><div class=\"cntnt\"><img style=\"width:584px; height:247px;\" src=\"images/PULM/89710_Pleural_carcinomatosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest frontal radiograph (A) and axial CT scan (B) show right-sided anterolateral and anteromedial nodular pleural thickening.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89710 Version 2.0</div></div></div>"},"89711":{"type":"graphic_diagnosticimage","displayName":"Calcified parietal pleural plaques","title":"Calcified parietal pleural plaques","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Calcified parietal pleural plaques</div><div class=\"cntnt\"><img style=\"width:576px; height:549px;\" src=\"images/PULM/89711_Calcfd_paritl_pleurl_plaqus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows extensive focal parietal pleural plaques with calcifications leading to so called dripping candle and rolled border features.</div><div id=\"graphicVersion\">Graphic 89711 Version 1.0</div></div></div>"},"89712":{"type":"graphic_diagnosticimage","displayName":"Parietal pleural plaque","title":"Parietal pleural plaque","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Parietal pleural plaque</div><div class=\"cntnt\"><img style=\"width:574px; height:447px;\" src=\"images/PULM/89712_Parietal_pleural_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows flat pleural plaques forming so called mesa or table mountain configuration.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89712 Version 2.0</div></div></div>"},"89713":{"type":"graphic_diagnosticimage","displayName":"Extensive calcifications in pleural plaques","title":"Extensive calcifications in pleural plaques","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Extensive calcifications in pleural plaques</div><div class=\"cntnt\"><img style=\"width:576px; height:510px;\" src=\"images/PULM/89713_Extensv_calcfctn_plurl_plaq.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 89713 Version 1.0</div></div></div>"},"89714":{"type":"graphic_diagnosticimage","displayName":"Fibrous tumor of the pleura in the right major fissure","title":"Fibrous tumor of the pleura originating in the right major fissure","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Fibrous tumor of the pleura originating in the right major fissure</div><div class=\"cntnt\"><img style=\"width:585px; height:221px;\" src=\"images/PULM/89714_Fibrs_tumr_pler_rgh_mjr_fis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT scan (A) and coronal MPR (B) demonstrate a triangular or wedge-shaped mass in the superior aspect of the right major interlobar fissure.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89714 Version 2.0</div></div></div>"},"89718":{"type":"graphic_picture","displayName":"Petechiae PI","title":"Petechiae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Petechiae</div><div class=\"cntnt\"><img style=\"width:347px; height:432px;\" src=\"images/PI/89718_Petechiae_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Leslie Raffini, MD.</div><div id=\"graphicVersion\">Graphic 89718 Version 1.0</div></div></div>"},"89719":{"type":"graphic_picture","displayName":"Purpura PI","title":"Purpura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Purpura</div><div class=\"cntnt\"><img style=\"width:249px; height:360px;\" src=\"images/PI/89719_Purpura_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Charles V Sanders. From: The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div id=\"graphicVersion\">Graphic 89719 Version 2.0</div></div></div>"},"89720":{"type":"graphic_table","displayName":"Diagnosis and treatment of eosinophilic esophagitis ACG 2013","title":"American College of Gastroenterology clinical guidelines on eosinophilic esophagitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American College of Gastroenterology clinical guidelines on eosinophilic esophagitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnosis</td> </tr> <tr> <td class=\"subtitle2_single\">Definition and causes of esophageal eosinophilia</td> </tr> <tr> <td class=\"indent1\">1. Esophageal eosinophilia, the finding of eosinophils in the squamous epithelium of the esophagus, is abnormal and the underlying cause should be identified. (Recommendation strong, evidence moderate)</td> </tr> <tr> <td class=\"subtitle2_single\">Definition of EoE and diagnostic criteria</td> </tr> <tr> <td class=\"indent1\">2. EoE is clinicopathologic disorder diagnosed by clinicians taking into consideration both clinical and pathologic information without either of these parameters interpreted in isolation, and defined by the following criteria: <ul> <li>Symptoms related to esophageal dysfunction </li> <li>Eosinophil-predominant inflammation on esophageal biopsy, characteristically consisting of a peak value of &#8805;15 eos/hpf </li> <li>Mucosal eosinophilia is isolated to the esophagus and persists after a PPI trial </li> <li>Secondary causes of esophageal eosinophilia excluded </li> <li>A response to treatment (dietary elimination; topical corticosteroids) supports, but is not required for, diagnosis. (Strong recommendation, low evidence) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">3. Esophageal biopsies are required to diagnose EoE. Two to four biopsies should be obtained from both the proximal and distal esophagus to maximize the likelihood of detecting esophageal eosinophilia in all patients in whom EoE is being considered. (Recommendation strong, evidence low)</td> </tr> <tr> <td class=\"indent1\">4. At the time of initial diagnosis, biopsies should be obtained from the antrum and/or duodenum to rule out other causes of esophageal eosinophilia in all children and in adults with gastric or small intestinal symptoms or endoscopic abnormalities. (Recommendation strong, evidence low)</td> </tr> <tr> <td class=\"subtitle2_single\">Diagnostic challenges: PPI-responsive esophageal eosinophilia and GERD</td> </tr> <tr> <td class=\"indent1\">5. PPI-REE should be diagnosed when patients have esophageal symptoms and histologic findings of esophageal eosinophilia, but demonstrate symptomatic and histologic response to proton-pump inhibition. At this time, the entity is considered distinct from EoE, but not necessarily a manifestation of GERD. (Recommendation conditional, evidence low)</td> </tr> <tr> <td class=\"indent1\">6. To exclude PPI-REE, patients with suspected EoE should be given a two-month course of a PPI followed by endoscopy with biopsies. (Recommendation strong, evidence low)</td> </tr> <tr> <td class=\"indent1\">7. A clinical, endoscopic and/or histologic response to a PPI does not establish gastroesophageal reflux as the cause of esophageal eosinophilia. To determine whether reflux is contributing to esophageal eosinophilia, additional evaluation for GERD, as per standard clinical practice, is recommended. This may include ambulatory pH testing in selected cases. (Recommendation conditional, evidence low)</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"subtitle2_single\">Endpoints of treatment in EoE</td> </tr> <tr> <td class=\"indent1\">8. The endpoints of therapy of EoE include improvements in clinical symptoms and esophageal eosinophilic inflammation. While complete resolution of symptoms and pathology is an ideal endpoint, acceptance of a range of reductions in symptoms and histology is a more realistic and practical goal in clinical practice. (Recommendation conditional, evidence low)</td> </tr> <tr> <td class=\"indent1\">9. Symptoms are an important parameter of response in EoE, but cannot be used alone as a reliable determinant of disease activity and response to therapy, given that compensatory dietary and lifestyle factors can mask symptoms. (Recommendation conditional, evidence moderate)</td> </tr> <tr> <td class=\"subtitle2_single\">Pharmacologic treatments</td> </tr> <tr> <td class=\"indent1\">10. Topical steroids (ie, fluticasone or budesonide, swallowed rather than inhaled, for an initial duration of eight weeks) are a first-line pharmacologic therapy for treatment of EoE. (Recommendation strong, evidence high)</td> </tr> <tr> <td class=\"indent1\">11. Prednisone may be useful to treat EoE if topical steroids are not effective or in patients who require rapid improvement in symptoms. (Recommendation conditional, evidence low)</td> </tr> <tr> <td class=\"indent1\">12. Patients without symptomatic and histologic improvement after topical steroids might benefit from a longer course of topical steroids, higher doses of topical steroids, systemic steroids, elimination diet, or esophageal dilation (Recommendation conditional, evidence low). There are few data to support the use of mast cell stabilizers or leukotriene inhibitors, and biologic therapies remain experimental at this time.</td> </tr> <tr> <td class=\"subtitle2_single\">Dietary treatments</td> </tr> <tr> <td class=\"indent1\">13. Dietary elimination can be considered as an initial therapy in the treatment of EoE in both children and adults. (Strong recommendation, evidence moderate)</td> </tr> <tr> <td class=\"indent1\">14. The decision to use a specific dietary approach (elemental, empiric, or targeted elimination diet) should be tailored to individual patient needs and available resources. (Recommendation conditional, evidence moderate)</td> </tr> <tr> <td class=\"indent1\">15. Clinical improvement and endoscopy with esophageal biopsy should be used to assess response to dietary treatment when food antigens are either being withdrawn from or reintroduced to the patient. (Recommendation conditional, evidence low)</td> </tr> <tr> <td class=\"indent1\">16. Gastroenterologists should consider consultation with an allergist to identify and treat extraesophageal atopic conditions, assist with treatment of EoE, and to help guide elemental and elimination diets. (Recommendation conditional, evidence low)</td> </tr> <tr> <td class=\"subtitle2_single\">Endoscopic treatment</td> </tr> <tr> <td class=\"indent1\">17. Esophageal dilation, approached conservatively, may be used as an effective therapy in symptomatic patients with strictures that persist in spite of medical or dietary therapy. (Recommendation conditional, evidence moderate)</td> </tr> <tr> <td class=\"indent1\">18. Patients should be well informed of the risks of esophageal dilation in EoE including post-dilation chest pain, which occurs in up to 75 percent of patients, bleeding, and esophageal perforation. (Recommendation conditional, evidence moderate)</td> </tr> <tr> <td class=\"subtitle1_single\">Outcomes</td> </tr> <tr> <td class=\"subtitle2_single\">Natural history of EoE</td> </tr> <tr> <td class=\"indent1\">19. While knowledge of the natural history of EoE is limited, patients should be counseled about the high likelihood of symptom recurrence after discontinuing treatment due to the chronic nature of this disease. (Recommendation strong, moderate evidence)</td> </tr> <tr> <td class=\"subtitle2_single\">Maintenance therapy</td> </tr> <tr> <td class=\"indent1\">20. The overall goal of maintenance therapy is to minimize symptoms and prevent complications of EoE, preserve quality of life, with minimal long-term adverse effects of treatments. (Recommendation conditional, evidence low)</td> </tr> <tr> <td class=\"indent1\">21. Maintenance therapy with topical steroids and/or dietary restriction should be considered for all patients, but particularly in those with severe dysphagia or food impaction, high-grade esophageal stricture and rapid symptomatic/histologic relapse following initial therapy. (Recommendation conditional, evidence low)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EoE: eosinophilic esophagitis; eos: eosinophils; GERD: gastroesophageal reflux disease; hpf: high-power field; PPI: proton pump inhibitor; PPI-REE: proton pump inhibitor responsive esophageal eosinophilia.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: American Journal of Gastroenterology. Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol 2013; 108:679. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 89720 Version 1.0</div></div></div>"},"89722":{"type":"graphic_picture","displayName":"Cross pelvic posture","title":"Cross pelvic posture","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Cross pelvic posture</div><div class=\"cntnt\"><img style=\"width:472px; height:668px;\" src=\"images/EM/89722_Cross_pelvic_posture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cross pelvic posture is defined by an increased lumbar lordosis and anterior tilt of the pelvis and is associated with tight hip flexor (iliopsoas and rectus femoris) and lumbar extensor (lumbar erector spinae) muscles, weak hip extensor (gluteus maximus) and lumbar flexor (rectus abdominus) muscles, and sacroiliac joint dysfunction. These musculoskeletal abnormalities place added stress on the hamstring muscles during activity.</div><div id=\"graphicVersion\">Graphic 89722 Version 1.0</div></div></div>"},"89724":{"type":"graphic_table","displayName":"Differentiated thyroid cancer ongoing monitoring","title":"Differentiated thyroid cancer: Ongoing monitoring","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differentiated thyroid cancer: Ongoing monitoring</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"4\">Response to therapy</td> </tr> <tr> <td class=\"subtitle2\">Excellent</td> <td class=\"subtitle2\">Biochemical incomplete</td> <td class=\"subtitle2\">Structural incomplete</td> <td class=\"subtitle2\">Indeterminate</td> </tr> <tr> <td><strong>Non-stimulated Tg</strong></td> <td>Every one to two years</td> <td>Every six months</td> <td>Every six months</td> <td>6 to 12 months</td> </tr> <tr> <td><strong>Stimulated Tg</strong></td> <td>Not needed</td> <td>May be repeated at two to three-year intervals if needed to establish an excellent response to therapy</td> <td>Not needed</td> <td>May be repeated at two to three-year intervals if needed to establish an excellent response to therapy</td> </tr> <tr> <td><strong>Neck ultrasound</strong></td> <td>Consider at three to five-year intervals</td> <td>Yearly for five years</td> <td>Yearly for five years</td> <td>6 to 12-month intervals for five years</td> </tr> <tr> <td><strong>Diagnostic WBS</strong></td> <td>Not indicated</td> <td>Not usually done*</td> <td>To evaluate RAI avidity of structural disease</td> <td>Not usually done*</td> </tr> <tr> <td><strong>MRI, CT</strong></td> <td>Not indicated</td> <td>Not indicated*</td> <td>6 to 12-month intervals depending on rate of progression</td> <td>Not indicated*</td> </tr> <tr> <td><strong>FDG-PET</strong></td> <td>Not indicated</td> <td>Not indicated*</td> <td>To identify additional sites of disease and for prognostic purposes</td> <td>Not indicated*</td> </tr> <tr> <td><strong>Serum TSH<sup>&#182;</sup></strong></td> <td>0.5 to 2.0 mU/L</td> <td>0.1 to 0.5 mU/L</td> <td>&#60;0.1 mU/L</td> <td>0.1 to 0.5 mU/L</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; FDG-PET: fludeoxyglucose-positron emission tomography; &nbsp;MRI: magnetic resonance imaging; RAI: radioiodine; Tg: thyroglobulin; TSH: thyroid-stimulating hormone; WBS: whole-body scan.<br />* Consider if non-stimulated Tg is greater than 10 ng/mL or Tg is rising.<br />¶ TSH goals are modified based on concurrent medical conditions that increase the risk of TSH suppression.</div><div class=\"graphic_reference\">Data from: Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1.</div><div id=\"graphicVersion\">Graphic 89724 Version 4.0</div></div></div>"},"89730":{"type":"graphic_figure","displayName":"Knee meniscus and related anatomy","title":"Knee menisci and related anatomy","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Knee menisci and related anatomy</div><div class=\"cntnt\"><img style=\"width:553px; height:522px;\" src=\"images/EM/89730_Kneemeniscianatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Superior view.<br />(B) Posterior view.</div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 89730 Version 6.0</div></div></div>"},"89733":{"type":"graphic_picture","displayName":"Knee ligaments anterior view","title":"Knee ligaments: Anterior view","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Knee ligaments: Anterior view</div><div class=\"cntnt\"><img style=\"width:563px; height:366px;\" src=\"images/EM/89733_Kneeligamanteriview.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 89733 Version 6.0</div></div></div>"},"89737":{"type":"graphic_picture","displayName":"Anterior knee external anatomy","title":"Anterior knee external anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior knee external anatomy</div><div class=\"cntnt\"><img style=\"width:342px; height:378px;\" src=\"images/EM/89737_Antkneeexternalanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 89737 Version 6.0</div></div></div>"},"89739":{"type":"graphic_picture","displayName":"Anterior knee joint line palpation and anatomy","title":"Anterior knee joint line palpation and anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior knee joint line palpation and anatomy</div><div class=\"cntnt\"><img style=\"width:401px; height:599px;\" src=\"images/EM/89739_Ant_knee_jnt_palp_anat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior joint line is readily palpated by placing your thumbs in the recesses just inferolateral and inferomedial to the patella, as demonstrated in the photograph.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD.</div><div id=\"graphicVersion\">Graphic 89739 Version 2.0</div></div></div>"},"89740":{"type":"graphic_picture","displayName":"Lateral knee structures to palpate","title":"Lateral knee structures to palpate","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Lateral knee structures to palpate</div><div class=\"cntnt\"><img style=\"width:602px; height:692px;\" src=\"images/EM/89740_Lat_knee_struct_palpat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph depicts the general location of the structures that should be palpated during examination of the lateral knee.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD.</div><div id=\"graphicVersion\">Graphic 89740 Version 3.0</div></div></div>"},"89741":{"type":"graphic_picture","displayName":"Location of pes anserine","title":"Location of pes anserine","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Location of pes anserine</div><div class=\"cntnt\"><img style=\"width:504px; height:368px;\" src=\"images/EM/89741_Location_pes_anserine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pes anserine is the insertion of the medial hamstring muscle tendons and is located approximately 6 cm distal to the knee joint line along the anteromedial tibial shaft.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD.</div><div id=\"graphicVersion\">Graphic 89741 Version 2.0</div></div></div>"},"89742":{"type":"graphic_picture","displayName":"Thomas test of hip flexor and knee extensor tightness","title":"Thomas test of hip flexor and knee extensor tightness","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Thomas test of hip flexor and knee extensor tightness</div><div class=\"cntnt\"><img style=\"width:526px; height:344px;\" src=\"images/EM/89742_Thom_hp_flex_knee_ext.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Thomas Test is used to assess tightness in the hip flexors and knee extensors.&nbsp;If the&nbsp;hip flexors are&nbsp;tight, the thigh of the dangling extremity inclines toward the ceiling;&nbsp;if the&nbsp;knee extensors are&nbsp;tight, the dangling leg inclines away from the examining table. The patient in the photograph demonstrates tight knee extensors&nbsp;and hip flexors.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD.</div><div id=\"graphicVersion\">Graphic 89742 Version 2.0</div></div></div>"},"89743":{"type":"graphic_picture","displayName":"Popliteal angle for hamstring tightness","title":"Popliteal angle for hamstring tightness","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Popliteal angle for hamstring tightness</div><div class=\"cntnt\"><img style=\"width:386px; height:526px;\" src=\"images/EM/89743_Popliteal_hmstg_tight.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hamstring flexibility can be assessed using the popliteal angle. A normal angle is 0 to 10 degrees for adult women and 20 to 30 degrees for adult men.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD.</div><div id=\"graphicVersion\">Graphic 89743 Version 2.0</div></div></div>"},"89745":{"type":"graphic_picture","displayName":"Valgus and varus stress tests of the knee","title":"Valgus and varus stress tests of the knee","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Valgus and varus stress tests of the knee</div><div class=\"cntnt\"><img style=\"width:515px; height:173px;\" src=\"images/EM/89745_Valg_var_stss_tst_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The valgus stress test (photo A) is used to assess the integrity of the medial collateral ligament, while the varus stress test (photo B)&nbsp;is used to assess the lateral collateral ligament.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD.</div><div id=\"graphicVersion\">Graphic 89745 Version 3.0</div></div></div>"},"89746":{"type":"graphic_table","displayName":"Comparison of DSM-5 criteria for bipolar I and bipolar II","title":"Comparison of DSM-5 criteria for bipolar I disorder and bipolar II disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of DSM-5 criteria for bipolar I disorder and bipolar II disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Bipolar I disorder</td> <td class=\"subtitle1\">Bipolar II disorder</td> </tr> <tr> <td><strong>Manic episode(s)</strong></td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td><strong>Hypomanic episode(s)</strong></td> <td class=\"centered\">Commonly occur, but not required</td> <td class=\"centered\">Yes</td> </tr> <tr> <td><strong>Major depressive episode(s)</strong></td> <td class=\"centered\">Usually occur, but not required</td> <td class=\"centered\">Yes</td> </tr> <tr> <td><strong>Mixed features</strong></td> <td class=\"centered\">May occur</td> <td class=\"centered\">May occur</td> </tr> <tr> <td><strong>Anxious distress</strong></td> <td class=\"centered\">May occur</td> <td class=\"centered\">May occur</td> </tr> <tr> <td><strong>Rapid cycling</strong></td> <td class=\"centered\">May occur</td> <td class=\"centered\">May occur</td> </tr> <tr> <td><strong>Psychotic features</strong></td> <td class=\"centered\">May occur</td> <td class=\"centered\">May occur</td> </tr> <tr> <td><strong>Catatonia</strong></td> <td class=\"centered\">May occur</td> <td class=\"centered\">May occur</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifrth Edition, American Psychiatric Association, Arlington, VA, 2013.</div><div id=\"graphicVersion\">Graphic 89746 Version 4.0</div></div></div>"},"89752":{"type":"graphic_picture","displayName":"Urticaria on abdomen","title":"Urticaria on abdomen","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Urticaria on abdomen</div><div class=\"cntnt\"><img style=\"width:574px; height:382px;\" src=\"images/ALLRG/89752_Urticariaonabdomen.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 89752 Version 2.0</div></div></div>"},"89763":{"type":"graphic_picture","displayName":"ILVEN","title":"Inflammatory linear verrucous epidermal nevus (ILVEN)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Inflammatory linear verrucous epidermal nevus (ILVEN)</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/DERM/89763_ILVEN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, hyperkeratotic papules in a linear distribution on the foot of an infant with inflammatory linear verrucous epidermal nevus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89763 Version 1.0</div></div></div>"},"89766":{"type":"graphic_table","displayName":"Guidelines for pre-exercise insulin reduction","title":"Guidelines for the reduction of pre-meal dose of rapid-acting insulin (eg, lispro, aspart or glulisine) for patients with type 1 diabetes mellitus in anticipation of post-prandial exercise","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for the reduction of pre-meal dose of rapid-acting insulin (eg, lispro, aspart or glulisine) for patients with type 1 diabetes mellitus in anticipation of post-prandial exercise</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Exercise intensity</td> <td class=\"subtitle1\" colspan=\"2\">Percent reduction in pre-meal bolus insulin dose</td> </tr> <tr> <td class=\"subtitle2\">30 minutes of exercise</td> <td class=\"subtitle2\">60 minutes of exercise</td> </tr> <tr> <td>Low (25 percent VO<sub>2</sub>max)</td> <td class=\"centered\">25*</td> <td class=\"centered\">50</td> </tr> <tr> <td>Moderate (50 percent VO<sub>2</sub>max)</td> <td class=\"centered\">50</td> <td class=\"centered\">75</td> </tr> <tr> <td>High (75 percent VO<sub>2</sub>max)</td> <td class=\"centered\">75</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These estimates are designed for individuals with type 1 diabetes mellitus managed intensively with a basal-bolus insulin regimen (eg, insulin glargine-lispro).</div><div class=\"graphic_footnotes\">* Extrapolated.</div><div class=\"graphic_reference\">Used with permission of American Diabetes Association, from: Rabasa-Lhoret R, Bourque J, Ducros F, Chiasson J-L, Guidelines for premeal insulin dose reduction for post-prandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (Ultralente-Lispro), Diabetes Care 2001; 24:625, Copyright &copy; 2001; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 89766 Version 3.0</div></div></div>"},"89777":{"type":"graphic_picture","displayName":"Linear, verrucous epidermal nevus 1","title":"Linear, verrucous epidermal nevus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear, verrucous epidermal nevus</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/89777_Linear_verruc_epid_nevus_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brown, hyperkeratotic papules forming a linear plaque on the preauricular region of a child with a verrucous, linear epidermal nevus.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89777 Version 2.0</div></div></div>"},"89779":{"type":"graphic_picture","displayName":"Epidermal nevus bilateral","title":"Linear verrucous epidermal nevus","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Linear verrucous epidermal nevus</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89779_Epidermal_nevus_bilateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple linear plaques formed by coalescing verrucous papules in a patient with bilateral linear verrucous epidermal nevus.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89779 Version 1.0</div></div></div>"},"89782":{"type":"graphic_picture","displayName":"Systematized epidermal nevus 1","title":"Systematized epidermal nevus (nevus unius lateris)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Systematized epidermal nevus (nevus unius lateris)</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/89782_Systemat_epidermal_nevus_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear, verrucous epidermal nevus with extensive distribution on one side of the body. Note the transverse configuration on the trunk and the linear configuration on the arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89782 Version 3.0</div></div></div>"},"89783":{"type":"graphic_picture","displayName":"Systematized epidermal nevus 2","title":"Systematized epidermal nevus","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Systematized epidermal nevus</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89783_Systematized_epiderm_nev_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear, verrucous, epidermal nevus with widespread bilateral distribution is also called ichthyosis hystrix.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89783 Version 2.0</div></div></div>"},"89784":{"type":"graphic_picture","displayName":"Epidermal nevus Proteus syndrome","title":"Epidermal nevus associated with Proteus syndrome","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Epidermal nevus associated with Proteus syndrome</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89784_Epidermal_nevus_Proteus_syn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive verrucous epidermal nevus with sharp midline demarcation (nevus unius lateris) in an infant with Proteus syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89784 Version 1.0</div></div></div>"},"89794":{"type":"graphic_table","displayName":"Common infections in CVID","title":"Infections most commonly seen in patients with common variable immunodeficiency (CVID)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infections most commonly seen in patients with common variable immunodeficiency (CVID)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>Lungs</strong> <ul> <li>Pneumonia (bacterial, especially encapsulated bacteria/mycoplasma) </li> <li>Bronchiectasis resulting from recurrent infections </li> <li>Acute or chronic bronchitis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Head and neck</strong> <ul> <li>Rhinosinusitis (bacterial, especially encapsulated bacteria, and viral) </li> <li>Otitis media </li> <li>Conjunctivitis (especially nonencapsulated H. influenzae) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Gastrointestinal tract</strong> <ul> <li>Acute infectious diarrhea (Norovirus, Campylobacter jejuni, Salmonella)</li> <li>Acute or chronic infections with Giardia lamblia (causing diarrhea, malabsorption, weight loss) </li> <li>Helicobacter pylori </li> <li>Cytomegalovirus </li> <li>Bacterial overgrowth </li> <li>Cryptosporidium </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Urinary tract</strong> <ul> <li>Mycoplasma/ureaplasma species </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Joints</strong> <ul> <li>Septic arthritis (acute monoarthritis or chronic degenerative polyarthritis) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Skin</strong> <ul> <li>Herpes zoster </li> <li>Molluscum </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Central nervous system</strong> <ul> <li>Meningitis </li> </ul> </td> </tr> <tr> <td><strong>Systemic</strong> <ul> <li>Bacterial sepsis, especially encapsulated bacteria </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89794 Version 3.0</div></div></div>"},"89795":{"type":"graphic_diagnosticimage","displayName":"Juvenile idiopathic arthritis radiograph","title":"Juvenile idiopathic arthritis radiograph: Joint destruction","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Juvenile idiopathic arthritis radiograph: Joint destruction</div><div class=\"cntnt\"><img style=\"width:574px; height:456px;\" src=\"images/PEDS/89795_Juveil_idpthc_arthr_radgrph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph of a 15-year-old boy with a four-year course of incompletely controlled systemic symptoms and hip arthritis. It demonstrates a pattern of bilaterally symmetric hip joint-space narrowing and erosive changes of the femoral heads and acetabulae.</div><div class=\"graphic_reference\">Copyright © 2017 American College of Rheumatology. Used with permission.</div><div id=\"graphicVersion\">Graphic 89795 Version 11.0</div></div></div>"},"89796":{"type":"graphic_algorithm","displayName":"Celiac disease diagnostic testing algorithm","title":"Celiac disease diagnostic testing algorithm","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Celiac disease diagnostic testing algorithm</div><div class=\"cntnt\"><img style=\"width:586px; height:371px;\" src=\"images/GAST/89796_Celiac_diagn_testing_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DGP: deamidated gliadin peptide; HLA: human leukocyte antigen; Ig: immunoglobulin; TTGA: tissue transglutaminase antibody.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: American Journal of Gastroenterology. Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: Diagnosis and management of celiac disease. Am J Gastroenterol 2013; 108:656. Copyright &copy; 2013. <a href=\"http://www.nature.com/ajg\" target=\"_blank\">www.nature.com/ajg</a>.</div><div id=\"graphicVersion\">Graphic 89796 Version 1.0</div></div></div>"},"89797":{"type":"graphic_table","displayName":"Histologic classifications for celiac disease","title":"Summary of histologic classifications for celiac disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of histologic classifications for celiac disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Marsh modified (Oberhuber)</td> <td class=\"subtitle1\" colspan=\"3\">Histologic criterion</td> <td class=\"subtitle1\" rowspan=\"2\">Corazza</td> </tr> <tr> <td class=\"subtitle2\">Increased intraepithelial lymphocytes*</td> <td class=\"subtitle2\">Crypt hyperplasia</td> <td class=\"subtitle2\">Villous atrophy</td> </tr> <tr> <td>Type 0</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td>None</td> </tr> <tr> <td>Type 1</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> <td>Grade A</td> </tr> <tr> <td>Type 2</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td>&nbsp;</td> </tr> <tr> <td>Type 3a</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes (partial)</td> <td>Grade B1</td> </tr> <tr> <td>Type 3b</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes (subtotal)</td> <td>&nbsp;</td> </tr> <tr> <td>Type 3c</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes (total)</td> <td>Grade B2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* &gt;40 intraepithelial lymphocytes per 100 enterocytes for Marsh modified (Oberhuber); &gt;25 intraepithelial lymphocytes per 100 enterocytes for Corazza.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: American Journal of Gastroenterology. Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: Diagnosis and management of celiac disease. Am J Gastroenterol 2013; 108:656. Copyright &copy; 2013. <a href=\"http://www.nature.com/ajg\" target=\"_blank\">www.nature.com/ajg</a>.</div><div id=\"graphicVersion\">Graphic 89797 Version 1.0</div></div></div>"},"89799":{"type":"graphic_algorithm","displayName":"Approach to monitoring celiac disease","title":"Approach to monitoring celiac disease","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Approach to monitoring celiac disease</div><div class=\"cntnt\"><img style=\"width:605px; height:684px;\" src=\"images/GAST/89799_Appr_monitor_celiac_disease.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DXA: dual-energy x-ray absorptiometry.<BR>* Tissue transglutaminase and deamidated gliadin peptide can be used for monitoring celiac disease.<BR><FONT class=bullet>•</FONT> Other tests may include complete blood count, alanine aminotransferase, vitamins (A, D, E, B12), copper, zinc, carotene, folic acid, ferritin, and iron.<BR>Δ Blood tests at follow-up should be individualized to verify correction of laboratory tests that were abnormal at baseline.<BR><FONT class=lozenge>◊</FONT> The role of biopsy for monitoring celiac disease is discussed in detail in the text.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: American Journal of Gastroenterology. Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: Diagnosis and management of celiac disease. Am J Gastroenterol 2013; 108:656. Copyright © 2013. <A href=\"http://www.nature.com/ajg\" target=_blank>www.nature.com/ajg</A>.</div><div id=\"graphicVersion\">Graphic 89799 Version 1.0</div></div></div>"},"89800":{"type":"graphic_algorithm","displayName":"Approach to nonresponsive celiac disease","title":"An approach to the investigation of nonresponsive celiac disease and refractory celiac disease","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">An approach to the investigation of nonresponsive celiac disease and refractory celiac disease</div><div class=\"cntnt\"><img style=\"width:568px; height:747px;\" src=\"images/GAST/89800_Appr_investigation_NRCD_RCD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NRCD: nonresponsive celiac disease; RCD: refractory celiac disease. DGP: deamidated gliadin peptide; EMA: endomysium antibodies; HLA: human leukocyte antigen; GFD: gluten-free diet; IELs: intraepithelial lymphocytes; TTGA: tissue transglutaminase antibody.<BR>* NRCD may be defined as persistent symptoms, signs, or laboratory abnormalities typical of celiac disease despite 6 to 12 months of dietary gluten avoidance.<BR><FONT class=bullet>•</FONT> Causes of nonceliac, small intestinal villous atrophy that may be misdiagnosed as celiac disease include autoimmune enteropathy, tropical sprue, small intestinal bacterial overgrowth, hypogammaglobulinemia and combined variable immunodeficiency, collagenous sprue, eosinophilic enteritis, Crohn disease, and peptic duodenitis.<BR>Δ Conditions that present clinically in a similar fashion to celiac disease but where villous atrophy is not evident include irritable bowel syndrome, food intolerances, small intestinal bacterial overgrowth, eosinophilic enteritis, Crohn disease, and microscopic colitis.<BR><FONT class=lozenge>◊</FONT> Positive celiac serologies despite 12 months of treatment with a gluten-free diet suggest that there may be ongoing gluten ingestion.<BR>§ RCD may be defined as persistent or recurrent malabsorptive symptoms and signs with small intestinal villous atrophy despite a strict GFD for more than 12 months and in the absence of other disorders, including overt lymphoma.<BR>¥ Abnormal intestinal lymphocytes may be identified by immunohistochemistry of IELs or by flow cytometry showing an increased number of CD3-positive cells lacking CD8, or by the identification of clonal T-cell receptor gene rearrangement by molecular analysis.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: American Journal of Gastroenterology. Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: Diagnosis and management of celiac disease. Am J Gastroenterol 2013; 108:656. Copyright &copy; 2013. <a href=\"http://www.nature.com/ajg\" target=\"_blank\">www.nature.com/ajg</a>.</div><div id=\"graphicVersion\">Graphic 89800 Version 1.0</div></div></div>"},"89802":{"type":"graphic_table","displayName":"Diseases associated with a positive ANA","title":"Diseases associated with a positive ANA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diseases associated with a positive ANA</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"65%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Percent with positive ANA</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Systemic autoimmune diseases</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">SLE</td> </tr> <tr> <td class=\"sublist2\">Active</td> <td class=\"sublist_other_centered\">98 to 100 percent</td> </tr> <tr> <td class=\"sublist2\">Remission</td> <td class=\"sublist_other_centered\">90 percent</td> </tr> <tr> <td class=\"indent1\">Scleroderma</td> <td class=\"centered\">95 percent</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis</td> <td class=\"centered\">45 percent</td> </tr> <tr> <td class=\"indent1\">Sj&#246;gren's syndrome</td> <td class=\"centered\">60 percent</td> </tr> <tr> <td class=\"indent1\">Mixed connective tissue disease</td> <td class=\"centered\">100 percent</td> </tr> <tr> <td class=\"indent1\">Drug-induced LE</td> <td class=\"centered\">80 to 95 percent</td> </tr> <tr> <td class=\"indent1\">Raynaud's phenomenon</td> <td class=\"centered\">40 percent</td> </tr> <tr> <td class=\"indent1\">Polymyositis/dermatomyositis</td> <td class=\"centered\">35 percent</td> </tr> <tr> <td class=\"indent1\">Juvenile idiopathic arthritis</td> <td class=\"centered\">15 to 40 percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Organ-specific autoimmune diseases</td> </tr> <tr> <td class=\"indent1\">Hashimotos thyroiditis</td> <td class=\"centered\">50 percent</td> </tr> <tr> <td class=\"indent1\">Graves' disease</td> <td class=\"centered\">50 percent</td> </tr> <tr> <td class=\"indent1\">Autoimmune hepatitis</td> <td class=\"centered\">70 percent</td> </tr> <tr> <td class=\"indent1\">Primary biliary cirrhosis</td> <td class=\"centered\">50 to 70 percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Infectious diseases*</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Viral:</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">EBV</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">HIV</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">HCV</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Parvovirus 19</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Bacterial:</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">SBE</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Syphilis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Malignancies*</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Lymphoproliferative diseases</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Paraneoplastic syndromes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Miscellaneous diseases*</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Interstitial pulmonary fibrosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ANA: antinuclear antibodies; SLE: systemic lupus erythematosus; EBV: Epstein-Barr virus; HCV: hepatitis C virus; SBE: subacute bacterial endocarditis.<br />* Although positive tests of ANA are reported in these diseases more often than in healthy controls, precise estimates vary.</div><div class=\"graphic_reference\">Courtesy of Donald B Bloch, MD.</div><div id=\"graphicVersion\">Graphic 89802 Version 2.0</div></div></div>"},"89803":{"type":"graphic_picture","displayName":"Four common ANA staining patterns","title":"Four common ANA staining patterns","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Four common ANA staining patterns</div><div class=\"cntnt\"><img style=\"width:511px; height:511px;\" src=\"images/RHEUM/89803_Four_com_ANA_stain_pat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the homogeneous pattern (A), the entire nucleus is diffusely stained. The chromosomes at the metaphase plate are also stained. In the speckled pattern (B), very small, uniform, fluorescent dots are seen throughout the nucleus. The centromere pattern (C) is characterized by the presence of 30 to 60 dots distributed throughout the nucleus in resting cells. The dots localize to chromosomes at the metaphase plate in dividing cells. The nucleolar staining pattern is shown in (D).</div><div class=\"graphic_reference\">Courtesy of Donald B Bloch, MD.</div><div id=\"graphicVersion\">Graphic 89803 Version 2.0</div></div></div>"},"89804":{"type":"graphic_picture","displayName":"Lichen striatus 1","title":"Lichen striatus","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Lichen striatus</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89804_Lichen_striatus_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear, erythematous, and scaly papular eruption on the leg of a child with lichen striatus.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89804 Version 1.0</div></div></div>"},"89805":{"type":"graphic_picture","displayName":"Lichen striatus 2","title":"Lichen striatus","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Lichen striatus</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89805_Lichen_striatus_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear eruption of skin-colored papules in a child with lichen striatus.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89805 Version 1.0</div></div></div>"},"89806":{"type":"graphic_picture","displayName":"Incontinentia pigmenti verrucous","title":"Incontinentia pigmenti","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Incontinentia pigmenti</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89806_Incontin_pigmenti_verrucous.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous stage of incontinentia pigmenti in an infant, presenting with warty, linear plaques located mainly on the extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89806 Version 1.0</div></div></div>"},"89807":{"type":"graphic_picture","displayName":"Incontinentia pigmenti hyperpigmentation","title":"Incontinentia pigmenti","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incontinentia pigmenti</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/89807_Incontin_pigmenti_hyperpigm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigmentary stage of incontinentia pigmenti with linear and whorled hyperpigmented areas.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89807 Version 1.0</div></div></div>"},"89808":{"type":"graphic_table","displayName":"Pediatric stages of CKD","title":"Stages of chronic kidney disease for children based on the KDIGO 2012 clinical practice guideline","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of chronic kidney disease for children based on the KDIGO 2012 clinical practice guideline</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">GFR category</td> <td class=\"subtitle1\">GFR<br /> (mL/min/1.73 m<sup>2</sup>)</td> <td class=\"subtitle1\">Terms</td> </tr> <tr> <td>G1</td> <td>&#8805;90</td> <td>Normal or high</td> </tr> <tr> <td>G2</td> <td>60 to 89</td> <td>Mildly decreased*</td> </tr> <tr> <td>G3a</td> <td>45 to 59</td> <td>Mildly to moderately decreased</td> </tr> <tr> <td>G3b</td> <td>30 to 44</td> <td>Moderately to severely decreased</td> </tr> <tr> <td>G4</td> <td>15 to 29</td> <td>Severely decreased</td> </tr> <tr> <td>G5</td> <td>&#60;15</td> <td>Kidney failure</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In the absence of evidence of kidney damage, neither GFR category G1 nor G2 fulfill the criteria for CKD.</div><div class=\"graphic_footnotes\">KDIGO: Kidney Disease: Improving Global Outcomes; GFR: glomerular filtration rate; CKD: chronic kidney disease.<br />* Relative to young adult level.</div><div class=\"graphic_reference\">Reprinted with permission from: Macmillan Publishers Ltd: Kidney International Supplements. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Chapter 1: Definition and classification of CKD. Kidney Int Suppl 2013; 3:19. Copyright © 2013. <A href=\"http://www.nature.com/kisup\" target=_blank>www.nature.com/kisup</A>.</div><div id=\"graphicVersion\">Graphic 89808 Version 2.0</div></div></div>"},"89810":{"type":"graphic_table","displayName":"Differential diagnosis endemic treponematoses","title":"Differential diagnosis for the mucocutaneous manifestations of endemic treponematoses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis for the mucocutaneous manifestations of endemic treponematoses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Yaws</td> </tr> <tr> <td class=\"subtitle2_single\">Primary and secondary lesions (mother and daughter yaws)</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Leishmaniasis</td> </tr> <tr> <td class=\"indent1\">Paracoccidioidomycosis</td> </tr> <tr> <td class=\"indent1\">Pyoderma</td> </tr> <tr> <td class=\"indent1\">Ecthyma</td> </tr> <tr> <td class=\"indent1\">Tropical ulcer</td> </tr> <tr> <td class=\"indent1\">Chancroid</td> </tr> <tr> <td class=\"indent1\">Cutaneous diphtheria</td> </tr> <tr> <td class=\"subtitle2_single\">Papulosquamous secondary lesions</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Psoriasis</td> </tr> <tr> <td class=\"indent1\">Eczema</td> </tr> <tr> <td class=\"indent1\">Arthropod bites</td> </tr> <tr> <td class=\"indent1\">Scabies</td> </tr> <tr> <td class=\"indent1\">Dermatophytosis</td> </tr> <tr> <td class=\"indent1\">Tuberculoid leprosy</td> </tr> <tr> <td class=\"subtitle2_single\">Tertiary gummatous lesions</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Lupus vulgaris</td> </tr> <tr> <td class=\"indent1\">Deep fungal infections (including South American blastomycosis)</td> </tr> <tr> <td class=\"indent1\">Mycobacterial infection</td> </tr> <tr> <td class=\"indent1\">Rhinosporidiosis</td> </tr> <tr> <td class=\"indent1\">Rhinoscleroma</td> </tr> <tr> <td class=\"subtitle1_single\">Pinta</td> </tr> <tr> <td class=\"subtitle2_single\">Primary and secondary lesions</td> </tr> <tr> <td class=\"indent1\">Eczema</td> </tr> <tr> <td class=\"indent1\">Classic or atrophic lichen planus</td> </tr> <tr> <td class=\"indent1\">Tinea corporis</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Tuberculoid leprosy</td> </tr> <tr> <td class=\"indent1\">Psoriasis</td> </tr> <tr> <td class=\"indent1\">Pellagra and other vitamin deficiencies</td> </tr> <tr> <td class=\"indent1\">Lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Yaws</td> </tr> <tr> <td class=\"subtitle2_single\">Dyschromic lesions</td> </tr> <tr> <td class=\"indent1\">Pityriasis alba</td> </tr> <tr> <td class=\"indent1\">Vitiligo</td> </tr> <tr> <td class=\"indent1\">Tinea versicolor</td> </tr> <tr> <td class=\"indent1\">Melasma</td> </tr> <tr> <td class=\"indent1\">Leprosy</td> </tr> <tr> <td class=\"indent1\">Erythema dyschronicum perstans</td> </tr> <tr> <td class=\"subtitle1_single\">Bejel</td> </tr> <tr> <td class=\"subtitle2_single\">Mucosal and perioral lesions</td> </tr> <tr> <td class=\"indent1\">Oral herpes simplex</td> </tr> <tr> <td class=\"indent1\">Aphthous ulcers</td> </tr> <tr> <td class=\"indent1\">Angular cheilitis</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"subtitle2_single\">Cutaneous primary and secondary lesions</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Condyloma acuminata</td> </tr> <tr> <td class=\"indent1\">Molluscum contagiosum</td> </tr> <tr> <td class=\"indent1\">Seborrheic dermatitis</td> </tr> <tr> <td class=\"indent1\">Psoriasis</td> </tr> <tr> <td class=\"indent1\">Dermatophytosis</td> </tr> <tr> <td class=\"subtitle2_single\">Tertiary gummatous lesions</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Deep fungal infections</td> </tr> <tr> <td class=\"indent1\">Leishmaniasis</td> </tr> <tr> <td class=\"indent1\">Mycobacterial infection</td> </tr> <tr> <td class=\"indent1\">Rhinosporidiosis</td> </tr> <tr> <td class=\"indent1\">Rhinoscleroma</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Marrouche N, Ghosn SH. Endemic (nonvenereal) treponematoses. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al (Eds), McGraw Hill 2012. p.2493.</LI>&#xD;&#xA;<LI>Farnsworth N, Rosen T. Endemic treponematosis: Review and update. Clin Dermatol 2006; 24:181.</LI></OL></div><div id=\"graphicVersion\">Graphic 89810 Version 2.0</div></div></div>"},"89811":{"type":"graphic_diagnosticimage","displayName":"Lateral patellar dislocation and osteochondral fracture","title":"Lateral patellar dislocation and osteochondral fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral patellar dislocation and osteochondral fracture</div><div class=\"cntnt\"><img style=\"width:391px; height:590px;\" src=\"images/RADIOL/89811_X_lat_pat_disloc_fract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An anteroposterior radiograph of the knee shows lateral dislocation of the patella (arrow) and an osteochondral fracture (arrowhead). The patient is a 37-year-old woman.</div><div id=\"graphicVersion\">Graphic 89811 Version 3.0</div></div></div>"},"89822":{"type":"graphic_algorithm","displayName":"Transition to oral antibiotics for CAP","title":"Transitioning inpatients with community-acquired pneumonia from IV to oral antibiotics","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Transitioning inpatients with community-acquired pneumonia from IV to oral antibiotics</div><div class=\"cntnt\"><img style=\"width:606px; height:572px;\" src=\"images/ID/89822_Trans_oral_antibiotics_CAP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Patients should show some clinical response before switching to oral medications. Fever may persist with lobar pneumonia. Cough from pneumococcal pneumonia may not clear for a week; abnormal chest radiograph findings usually clear within 4 weeks but may persist for 12 weeks in older individuals and those with underlying pulmonary disease.<br />(B) Risk factors for drug-resistant <em>Streptococcus pneumoniae</em> are:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>Age &gt;65 years</li>&#xD;&#xA;    <li>Beta-lactam, macrolide, or fluoroquinolone therapy within the past three to six months</li>&#xD;&#xA;    <li>Alcoholism</li>&#xD;&#xA;    <li>Medical comorbidities</li>&#xD;&#xA;    <li>Immunosuppressive illness or therapy</li>&#xD;&#xA;    <li>Exposure to a child in a daycare center</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">* Generally avoid in patients with known QT interval prolongation or risk factors for QT interval prolongation.<br />&para; Dose adjustment is necessary in patients with renal insufficiency.<br />&Delta; If the patient has already received 1.5 g of azithromycin, atypical coverage can be discontinued.</div><div id=\"graphicVersion\">Graphic 89822 Version 3.0</div></div></div>"},"89823":{"type":"graphic_algorithm","displayName":"Duration of antibiotics for CAP","title":"Duration of antibiotics for community-acquired pneumonia in inpatients","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Duration of antibiotics for community-acquired pneumonia in inpatients</div><div class=\"cntnt\"><img style=\"width:578px; height:425px;\" src=\"images/ID/89823_Duration_antibiotics_CAP.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 89823 Version 1.0</div></div></div>"},"89824":{"type":"graphic_algorithm","displayName":"Management of delayed insertion or reinsertion of the ring","title":"Management of delayed insertion or reinsertion of the contraceptive vaginal ring","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Management of delayed insertion or reinsertion of the contraceptive vaginal ring</div><div class=\"cntnt\"><img style=\"width:518px; height:379px;\" src=\"images/OBGYN/89824_Mngmnt_dlyd_insrt_rnsrt_rng.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* If removal takes place but the woman is unsure of how long the ring has been removed, consider the ring to have been removed for ≥48 hours since a ring should have been inserted or reinserted.</div><div class=\"graphic_reference\">Reproduced from: US Selected Practice Recommendations for Contraceptive Use, 2013: Adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use, 2nd Ed. MMWR Morb Mortal Wkly Rep 2013; 62:1.</div><div id=\"graphicVersion\">Graphic 89824 Version 1.0</div></div></div>"},"89825":{"type":"graphic_table","displayName":"How to start contraception","title":"How to start contraception","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">How to start contraception</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Contraceptive method</td> <td class=\"subtitle1\">When to start (if the provider is reasonably certain that the woman is not pregnant)</td> <td class=\"subtitle1\">Additional contraception (ie, back-up) needed</td> <td class=\"subtitle1\">Examinations or tests needed before initiation*</td> </tr> <tr> <td>Copper-containing IUD</td> <td class=\"centered\">Anytime</td> <td>Not needed</td> <td>Bimanual examination and cervical inspection<sup>&#182;</sup></td> </tr> <tr> <td>Levonorgestrel-releasing IUD</td> <td class=\"centered\">Anytime</td> <td>If &#62;7 days after menses started, use back-up method or abstain for 7 days</td> <td>Bimanual examination and cervical inspection<sup>&#182;</sup></td> </tr> <tr> <td>Implant</td> <td class=\"centered\">Anytime</td> <td>If &#62;5 days after menses started, use back-up method or abstain for 7 days</td> <td>None</td> </tr> <tr> <td>Injectable</td> <td class=\"centered\">Anytime</td> <td>If &#62;7 days after menses started, use back-up method or abstain for 7 days</td> <td>None</td> </tr> <tr> <td>Combined hormonal contraceptive</td> <td class=\"centered\">Anytime</td> <td>If &#62;5 days after menses started, use back-up method or abstain for 7 days</td> <td>Blood pressure measurement</td> </tr> <tr> <td>Progestin-only pill</td> <td class=\"centered\">Anytime</td> <td>If &#62;5 days after menses started, use back-up method or abstain for 2 days</td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index; CDC: Centers for Disease Control and Prevention; IUD: intrauterine device; STD: sexually transmitted disease.<br />* Weight (BMI) measurement is not needed to determine medical eligibility for any methods of contraception because all methods can be used (United States Medical Eligibility Criteria for Contraceptive Use 2010, US MEC 1) or generally can be used (US MEC 2) among obese women. However, measuring weight and calculating BMI (weight [kg]/height [m<SUP>2</SUP>]) at baseline might be helpful for monitoring any changes and counseling women who might be concerned about weight change perceived to be associated with their contraceptive method.<br />¶ Most women do not require additional STD screening at the time of IUD insertion if they have already been screened according to Centers for Disease Control and Prevention's (CDC) STD Treatment Guidelines (available at <A href=\"http://www.cdc.gov/std/treatment\" target=_blank>http://www.cdc.gov/std/treatment</A>). If a woman has not been screened according to guidelines, screening can be performed at the time of IUD insertion, and insertion should not be delayed. Women with purulent cervicitis or current chlamydial infection or gonorrhea should not undergo IUD insertion (US MEC 4). Women who have a very high individual likelihood of STD exposure (eg, those with a currently infected partner) generally should not undergo IUD insertion (US MEC 3). For these women, IUD insertion should be delayed until appropriate testing and treatment occurs.</div><div class=\"graphic_reference\">Reproduced from: US Selected Practice Recommendations for Contraceptive Use, 2013: Adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use, 2<SUP>nd</SUP> ed. MMWR Morb Mortal Wkly Rep 2013; 62:1.</div><div id=\"graphicVersion\">Graphic 89825 Version 5.0</div></div></div>"},"89826":{"type":"graphic_algorithm","displayName":"Management of bleeding associated with contraception","title":"Management of women with bleeding irregularities while using contraception","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Management of women with bleeding irregularities while using contraception</div><div class=\"cntnt\"><img style=\"width:581px; height:470px;\" src=\"images/OBGYN/89826_Mngmnt_bldng_assc_contrcptn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CHC: combined hormonal contraceptive; COC: combined oral contraceptive; Cu-IUD: copper-containing intrauterine device; DMPA: depot medroxyprogesterone acetate; LNG-IUD: levonorgestrel-releasing intrauterine device; NSAIDs: nonsteroidal antiinflammatory drugs.<br />* If clinically warranted, evaluate for underlying condition. Treat the condition or refer for care.<br />&Delta; Heavy or prolonged bleeding, either unscheduled or menstrual, is uncommon.</div><div class=\"graphic_reference\">Reproduced from: US Selected Practice Recommendations for Contraceptive Use, 2013: Adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use, 2nd Ed. MMWR Morb Mortal Wkly Rep 2013; 62:1.</div><div id=\"graphicVersion\">Graphic 89826 Version 1.0</div></div></div>"},"89833":{"type":"graphic_picture","displayName":"Tufted angioma histo","title":"Histopathologic features of tufted angioma","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of tufted angioma</div><div class=\"cntnt\"><img style=\"width:514px; height:237px;\" src=\"images/DERM/89833_Tufted_angioma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tufted angioma.<BR>(A) Low magnification of a skin punch biopsy demonstrating clusters of tightly packed spindle cells within the papillary and reticular dermis.<BR>(B) High magnification demonstrates \"cannonball\" configuration of the short spindled endothelial cells lining small vessels. Extravasated red blood cells and platelet microthrombi may be present.</div><div id=\"graphicVersion\">Graphic 89833 Version 3.0</div></div></div>"},"89834":{"type":"graphic_picture","displayName":"KHE histo","title":"Histopathologic features of kaposiform hemangioendothelioma","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of kaposiform hemangioendothelioma</div><div class=\"cntnt\"><img style=\"width:515px; height:388px;\" src=\"images/DERM/89834_KHE_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Spindle cell lesion involving multiple planes of tissue.<br />(B) Coalescing lobules.<br />(C) Extravasated red blood cells, hemosiderin, & platelet microthrombus (insert).<br />(D) Immunoreactive to PROX-1 (lymphatic endothelial marker).</div><div id=\"graphicVersion\">Graphic 89834 Version 2.0</div></div></div>"},"89835":{"type":"graphic_picture","displayName":"Rubber band ligation of internal hemorrhoid","title":"Rubber band ligation of internal hemorrhoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rubber band ligation of internal hemorrhoid</div><div class=\"cntnt\"><img style=\"width:349px; height:267px;\" src=\"images/SURG/89835_Rubberband_ligat_int_hemorr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the forceps inserted through the anoscope in preparation to release the rubber band and ligate the internal hemorrhoid.</div><div class=\"graphic_reference\">Richard Billingham, M.D.</div><div id=\"graphicVersion\">Graphic 89835 Version 2.0</div></div></div>"},"89836":{"type":"graphic_picture","displayName":"RICH NICH histo","title":"Histopathologic features of congenital hemangiomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of congenital hemangiomas</div><div class=\"cntnt\"><img style=\"width:426px; height:516px;\" src=\"images/DERM/89836_RICH_NICH_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Large lobules with vary in size.<br />(B) Lobules composed of thin-walled capillaries.<br />(C) \"Hobnailed\" endothelial cells.<br />(D) Eosinophilic globules.<br />(E) Dilated malformed vessels.<br />(F) Endothelial cells immunonegative for GLUT-1.</div><div id=\"graphicVersion\">Graphic 89836 Version 2.0</div></div></div>"},"89837":{"type":"graphic_table","displayName":"Medicare hospice benefit guidelines for dementia prognosis","title":"Medicare hospice benefit guidelines for determining prognosis in dementia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medicare hospice benefit guidelines for determining prognosis in dementia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td colspan=\"2\"><strong>To be eligible for hospice, patients must meet both of the following criteria:</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">I. Functional Assessment Staging (FAST): Patient must be at or beyond stage 7; unable to walk, dress, and bathe without assistance; urinary and fecal incontinence (intermittent or constant); no consistently meaningful verbal communication (stereotypical phrases only or the ability to speak is limited to six or fewer intelligible words)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">II. Medical conditions: Patients must have had at least one of the listed medical conditions over the prior year</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">I. Functional Assessment Staging (FAST)</td> </tr> <tr> <td class=\"subtitle2\">Stage</td> <td class=\"subtitle2\">Features</td> </tr> <tr> <td class=\"centered\">1</td> <td>No objective or subjective difficulties</td> </tr> <tr> <td class=\"centered\">2</td> <td>Subjective complaints of forgetting</td> </tr> <tr> <td class=\"centered\">3</td> <td>Decreased job functioning evident to coworkers; difficulty traveling to new locations</td> </tr> <tr> <td class=\"centered\">4</td> <td>Decreased ability performing complex tasks, eg, planning dinner for guests, handling finances</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">5</td> <td>Requires assistance to choose proper clothes for day, season, or occasion</td> </tr> <tr> <td class=\"centered\">6a</td> <td>Cannot dress without assistance; occasionally or more frequently</td> </tr> <tr> <td class=\"centered\">6b</td> <td>Cannot bathe without assistance; occasionally or more frequently</td> </tr> <tr> <td class=\"centered\">6c</td> <td>Cannot toilet without assistance; occasionally or more frequently</td> </tr> <tr> <td class=\"centered\">6d</td> <td>Incontinent of urine; occasionally or frequently</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">6e</td> <td>Incontinent of bowel; occasionally or frequently</td> </tr> <tr> <td class=\"centered\">7a</td> <td>Speech limited to fewer than&nbsp;six intelligible words during an average day</td> </tr> <tr> <td class=\"centered\">7b</td> <td>Speech limited to single intelligible word during an average day</td> </tr> <tr> <td class=\"centered\">7c</td> <td>Unable to ambulate independently</td> </tr> <tr> <td class=\"centered\">7d</td> <td>Cannot sit up independently</td> </tr> <tr> <td class=\"centered\">7e</td> <td>Cannot smile</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">7f</td> <td>Cannot hold head up independently</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">II. Medical conditions</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol> <li>Aspiration pneumonia </li> </ol> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"2\"> <li>Pyelonephritis </li> </ol> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"3\"> <li>Septicemia </li> </ol> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"4\"> <li>Decubitus ulcer, multiple, stage 3 to&nbsp;4 </li> </ol> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"5\"> <li>Recurrent fever after treatment with antibiotics </li> </ol> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"6\"> <li>Inability to maintain sufficient fluid and calorie intake with 10% weight loss during the previous&nbsp;six months or serum albumin &#60;2.5 g/dL </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Centers for Medicare &amp; Medicaid Services. Local Coverage Determination (LCD) for Hospice Determining Terminal Status (L32015) <a href=\"http://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=32015&amp;ContrId=236&amp;ver=14&amp;ContrVer=2&amp;CntrctrSelected=236*2&amp;Cntrctr=236&amp;name=CGS+Administrators%2c+LLC+(15004%2c+HHH+MAC)&amp;s=11&amp;DocType=Active&amp;bc=AggAAAIAAAAAAA%3d%3d&amp;amp;\" target=\"_blank\">http://www.cms.gov</a> (Accessed on July 17, 2013).</div><div id=\"graphicVersion\">Graphic 89837 Version 6.0</div></div></div>"},"89843":{"type":"graphic_table","displayName":"Minimal criteria for initiation of antimicrobials","title":"Minimal criteria for initiation of antimicrobial use for suspected infections in nursing home residents with advanced dementia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Minimal criteria for initiation of antimicrobial use for suspected infections in nursing home residents with advanced dementia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Suspected urinary tract infection</td> <td class=\"subtitle1\">Suspected lower respiratory tract infection</td> <td class=\"subtitle1\">Suspected skin infection</td> <td class=\"subtitle1\">Febrile episode</td> </tr> <tr> <td><strong>A. No indwelling foley catheter</strong><br /> Acute dysuria alone <strong>OR</strong><br /> temperature &#62;37.9&#176;C<br /> <strong>AND</strong> &#8805;1 of following*: <ol> <li>New or worse frequency </li> <li>Urgency </li> <li>Costovertebral tenderness </li> <li>Gross hematuria </li> <li>Suprapubic pain </li> <li>Mental status change<sup>&#182;</sup> </li> <li>Rigors </li> </ol> <br /> <strong>B. Indwelling foley catheter</strong><br /> &#8805;1 of following: <ol> <li>Temperature &#62;37.9&#176;C </li> <li>Rigors </li> <li>Change in mental status<sup>&#182;</sup> </li> </ol> </td> <td><strong>A. Temperature &#62;38.9&#176;C</strong><br /> &#8805;1 of following: <ol> <li>Respiratory rate &#62;25 breaths/minute </li> <li>New productive cough </li> </ol> <br /> <strong>B. Temperature &#60;38.9&#176;C</strong><br /> New productive cough <strong>AND</strong> &#8805;1 of the following: <ol> <li>Pulse &#62;100 beats/minute </li> <li>Respiratory rate &#62;25 breaths/minute </li> <li>Rigors </li> <li>Change in mental status<sup>&#182;</sup> </li> </ol> <br /> <strong>C. Afebrile with COPD</strong><br /> New/increased cough with purulent sputum </td> <td>New or increased purulent drainage<br /> <strong>OR</strong> &#8805;1 of the following*: <ol> <li>Temperature &#62;37.9&#176;C </li> <li>Redness </li> <li>New or increased swelling </li> <li>Warmth </li> <li>Tenderness </li> </ol> </td> <td>Temperature &#62;37.9&#176;C<br /> <strong>AND</strong> &#8805;1 of the following: <ol> <li>Change in mental status<sup>&#182;</sup> </li> <li>Rigors </li> <li>Unstable vital signs<sup>&#916;</sup> </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Urgency, frequency, skin tenderness, costovertebral tenderness and suprapubic pain may be difficult to evaluate in advanced dementia but accepted criteria if present.<br />¶ Diagnostic criteria for delirium can be diffiicult to evaluate in advanced dementia, therefore any change from baseline mental status considered.<br />Δ Unstable vital signs = sysolic blood pressure &lt;90 mmHg or heart rate &gt;100 beats/min or respiratory rate &gt;25 breaths/minute.</div><div id=\"graphicVersion\">Graphic 89843 Version 4.0</div></div></div>"},"89862":{"type":"graphic_diagnosticimage","displayName":"Patellar tendon rupture with superior patellar dislocation","title":"Patellar tendon rupture with superior patellar dislocation on knee radiograph and magnetic resonance imaging","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">Patellar tendon rupture with superior patellar dislocation on knee radiograph and magnetic resonance imaging</div><div class=\"cntnt\"><img style=\"width:589px; height:370px;\" src=\"images/RADIOL/89862_X_MRI_super_patel_disl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral radiograph of the knee (A) shows superior dislocation of the patella (arrowhead) and soft tissue swelling below the patella (arrow). A T2 weighted magnetic resonance image in sagittal projection (B) shows rupture of the patella tendon (between arrows). There is fluid accumulation at the site of the tear (arrowhead). The patient is a 42-year-old male.</div><div id=\"graphicVersion\">Graphic 89862 Version 3.0</div></div></div>"},"89871":{"type":"graphic_diagnosticimage","displayName":"CT left suppurative thyroiditis left pyriform sinus fistula","title":"CT demonstrating left suppurative thyroiditis due to left pyriform sinus fistula","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">CT demonstrating left suppurative thyroiditis due to left pyriform sinus fistula</div><div class=\"cntnt\"><img style=\"width:453px; height:261px;\" src=\"images/RADIOL/89871_CT_l_suppurat_thyr_fist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT of the neck in a two year old patient presenting with swelling and tenderness of the left neck.<br />(A) A CT scan of the neck at the level of the thyroid gland shows an irregular, peripherally enhancing low attenuation left perithyroidal collection (arrow) in a patient with suppurative thyroiditis due to a left pyriform sinus fistula.<br />(B) A coronal reconstruction of the CT scan shows the superomedial collection displacing the poorly defined superior pole of the left lobe of the thyroid gland (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Caroline Robson, MD.</div><div id=\"graphicVersion\">Graphic 89871 Version 1.0</div></div></div>"},"89876":{"type":"graphic_picture","displayName":"Nevus sebaceous","title":"Nevus sebaceous","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Nevus sebaceous</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89876_Nevus_sebaceous.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nevus sebaceous on the scalp of a child presenting as a solitary, yellow-orange, hairless plaque.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89876 Version 2.0</div></div></div>"},"89877":{"type":"graphic_picture","displayName":"Nevus sebaceous dark skin","title":"Nevus sebaceous","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Nevus sebaceous</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89877_Nevus_sebaceous_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nevus sebaceous presenting as a brown, smooth, hairless plaque on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89877 Version 2.0</div></div></div>"},"89878":{"type":"graphic_picture","displayName":"Nevus sebaceous infant","title":"Nevus sebaceous","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Nevus sebaceous</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89878_Nevus_sebaceous_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nevus sebaceous presenting as a yellow, linear plaque on the cheek of an infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89878 Version 3.0</div></div></div>"},"89886":{"type":"graphic_picture","displayName":"BPDCN skin biopsy","title":"Blastic plasmacytoid dendritic cell neoplasm skin biopsy","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Blastic plasmacytoid dendritic cell neoplasm skin biopsy</div><div class=\"cntnt\"><img style=\"width:584px; height:223px;\" src=\"images/HEME/89886_BPDCNskinbiopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Skin biopsy shows extensive lymphoid infiltration of the entire dermis. Note a Grenz zone is present between the epidermis and the infiltrate. No epidermal involvement is demonstrated. The skin biopsy showed that the tumor cells were positive for CD4, CD56, and CD68, but were negative for CD3, CD5, CD8, CD20, myeloperoxidase, and lysozyme. H&amp;E, x4.<br />(B) High magnification of the skin biopsy shows immature nuclear chromatin pattern with occasional nucleoli. H&amp;E, x100.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application: Blastic plasmacytoid dendritic cell neoplasm. In: Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\">www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 89886 Version 5.0</div></div></div>"},"89887":{"type":"graphic_picture","displayName":"BPDCN bone marrow aspirate","title":"Blastic plasmacytoid dendritic cell neoplasm bone marrow aspirate","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Blastic plasmacytoid dendritic cell neoplasm bone marrow aspirate</div><div class=\"cntnt\"><img style=\"width:574px; height:430px;\" src=\"images/HEME/89887_BPDCNbonemarrowaspirate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate shows blast-like cells with irregular nuclei and immature chromatin pattern. Wright-Giemsa, x100.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinical application: Blastic plasmacytoid dendritic cell neoplasm. In: Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 89887 Version 5.0</div></div></div>"},"89900":{"type":"graphic_diagnosticimage","displayName":"CT liver infarction subcapsular hematoma HELLP syndrome","title":"Liver infarction subcapsular hematoma HELLP syndrome on CT scan","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Liver infarction subcapsular hematoma HELLP syndrome on CT scan</div><div class=\"cntnt\"><img style=\"width:599px; height:275px;\" src=\"images/RADIOL/89900_CT_liv_infar_HELLP_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the upper abdomen (A) shows a large subcapsular hematoma compressing the liver (arrow). Image B shows a large and irregular perfusion defect involving the right lobe and part of the left lobe of the liver (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography; HELLP: H: hemolysis, EL: elevated liver enzymes, LP: low platelets counts.</div><div class=\"graphic_reference\">Courtesy of Jonathan B Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 89900 Version 1.0</div></div></div>"},"89901":{"type":"graphic_diagnosticimage","displayName":"CT liver infarction HELLP syndrome","title":"Liver infarction HELLP syndrome on CT scan","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Liver infarction HELLP syndrome on CT scan</div><div class=\"cntnt\"><img style=\"width:547px; height:468px;\" src=\"images/RADIOL/89901_CT_liv_infarctio_HELLP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the upper abdomen shows multiple perfusion defects (arrowheads) in the posterior aspect of the right lobe of the liver. A subcapsular hematoma is present (arrow). The spleen is enlarged (dashed arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; HELLP: H: hemolysis, EL: elevated liver enzymes, LP: low platelets counts.</div><div class=\"graphic_reference\">Courtesy of Jonathan B Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 89901 Version 1.0</div></div></div>"},"89903":{"type":"graphic_picture","displayName":"Secondary lesion of yaws","title":"Yaws","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Yaws</div><div class=\"cntnt\"><img style=\"width:403px; height:462px;\" src=\"images/DERM/89903_Secondary_lesion_yaws.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Secondary yaws. Papules and plaques with scale and erosions on the extremity.</div><div id=\"graphicVersion\">Graphic 89903 Version 2.0</div></div></div>"},"89905":{"type":"graphic_picture","displayName":"Chondrodermatitis nodularis helicis","title":"Chondrodermatitis nodularis helicis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chondrodermatitis nodularis helicis</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/89905_Chondrodermatit_nod_helicis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, crusted nodule located at the superior helical rim of the ear.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89905 Version 1.0</div></div></div>"},"89909":{"type":"graphic_table","displayName":"Autoantibodies and associated neuropathies","title":"Autoantibodies and associated neuropathies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Autoantibodies and associated neuropathies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibody</td> <td class=\"subtitle1\">Clinical features of associated neuropathy</td> <td class=\"subtitle1\">Associated systemic disease</td> </tr> <tr class=\"divider_bottom\"> <td>GM1</td> <td>Multifocal motor neuropathy; may also be elevated in motor neuron disease, Guillain-Barr&#233; syndrome and its variants</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>MAG; SGPG</td> <td>Demyelinating neuropathy, most often with distal predominantly sensory symptoms (DADS phenotype)</td> <td>IgM monoclonal gammopathy of undetermined significance (MGUS)</td> </tr> <tr class=\"divider_bottom\"> <td>GQ1b</td> <td>Miller Fisher syndrome; Bickerstaff encephalitis, pharyngeal-cervical-brachial weakness; \"anti-GQ1b antibody syndrome\"</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>GD1a</td> <td>Axonal Guillain-Barr&#233; syndrome</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>GD1b</td> <td>Sensory-predominant neuropathy; motor neuron disease; Guillain-Barr&#233; syndrome</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Sulfatide</td> <td>Sensory-predominant neuropathy</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Galopin (IgM kappa)</td> <td>Gait ataxia with late onset polyneuropathy (GALOP) syndrome</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Hu (ANNA-1)</td> <td>Sensory neuronopathy; autonomic and sensorimotor polyneuropathy</td> <td>Cancer, typically small cell lung cancer (SCLC). May also be associated with limbic encephalitis.</td> </tr> <tr class=\"divider_bottom\"> <td>CV2/CRMP-5; amphiphysin; Ri (ANNA-2), ANNA-3; N-type calcium channel antibodies</td> <td>Sensorimotor polyneuropathy</td> <td>Cancer, typically SCLC, thymoma, breast cancer. Antibodies are associated with other neurologic syndromes including limbic encephalitis.</td> </tr> <tr class=\"divider_bottom\"> <td>C-ANCA; P-ANCA</td> <td>Painful mononeuritis multiplex; distal symmetric polyneuropathy less common</td> <td>Systemic vasculitis: Churg-Strauss; polyarteritis nodosa; granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr class=\"divider_bottom\"> <td>ANA; RF</td> <td>Painful neuropathy; mononeuritis multiplex</td> <td>Rheumatoid arthritis; systemic vasculitis</td> </tr> <tr class=\"divider_bottom\"> <td>Ro/SSA; La/SSB</td> <td>Painful sensory, predominantly small-fiber, neuropathy; sensory neuronopathy</td> <td>Sj&#246;gren syndrome</td> </tr> <tr> <td>Gliadin; endomysial; tTG (tissue trans-glutaminase)</td> <td>Mild distal sensory polyneuropathy</td> <td>Celiac disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ANA: antinuclear antibodies; ANCA: antineutrophil cytoplasmic antibodies; ANNA: antineuronal nuclear antibodies; CRMP: collapsin response mediator protein; MAG: myelin-associated glycoprotein; RF: rheumatoid factor; SGPG: sulfoglucuronyl glycosphingolipid; tTG: tissue transglutaminase.</div><div id=\"graphicVersion\">Graphic 89909 Version 2.0</div></div></div>"},"89910":{"type":"graphic_figure","displayName":"Blood supply to the small intestine","title":"Blood supply to the small intestine","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Blood supply to the small intestine</div><div class=\"cntnt\"><img style=\"width:540px; height:598px;\" src=\"images/SURG/89910_Blood_suppl_small_intestine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The blood supply to the small and large bowel is derived from the celiac artery and SMA. The celiac axis primarily provides blood flow to the stomach, liver, spleen, and pancreas but is also a source of collateral flow when blood flow in the SMA is reduced. The SMA gives rise to the inferior pancreaticoduodenal artery, the middle colic artery, right colic artery, and&nbsp;many jejunal and ileal branches. The jejunal and ileal&nbsp;branches supply the jejunum and ileum, respectively. The ileocolic artery supplies the distal ileum, cecum, and proximal ascending colon.</div><div class=\"graphic_footnotes\">SMA: superior mesenteric artery</div><div id=\"graphicVersion\">Graphic 89910 Version 4.0</div></div></div>"},"89911":{"type":"graphic_figure","displayName":"Collateral circulation to the intestines","title":"Collateral circulation to the intestines","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Collateral circulation to the intestines</div><div class=\"cntnt\"><img style=\"width:540px; height:686px;\" src=\"images/SURG/89911_Collateral_circulat_intest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An abundant collateral blood supply exists between the SMA and IMA and the IMA and internal iliac arteries. The arcades of the SMA and IMA interconnect at the base and border of the mesentery. The connection at the base of the mesentery is called the arc of Riolan, whereas the connection along the mesenteric border is known as the marginal artery of Drummond. Ischemic damage to the rectum is rare since the rectum has a dual blood supply from the IMA and iliac arteries. Collateral flow between the IMA and iliac arteries occurs via the superior and middle/inferior rectal vessels. Despite the presence of collaterals, the colon circulation has two watershed areas that are vulnerable to ischemia during systemic hypotension: the&nbsp;narrow terminal branches of the SMA supply the splenic flexure, and the&nbsp;narrow terminal branches of the IMA supply the rectosigmoid junction.</div><div class=\"graphic_footnotes\">SMA: superior mesenteric artery; IMA: inferior mesenteric artery.</div><div id=\"graphicVersion\">Graphic 89911 Version 5.0</div></div></div>"},"89913":{"type":"graphic_figure","displayName":"Molecular correlates patient survival metabolic pathways B","title":"Molecular correlates of patient survival involve metabolic pathways: Part B","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Molecular correlates of patient survival involve metabolic pathways: Part B</div><div class=\"cntnt\"><img style=\"width:577px; height:679px;\" src=\"images/ONC/89913_Mole_corr_pat_surv_path_A.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sample profiles were separated into discovery and validation subsets, with the top survival correlates within the discovery subset being defined for each of the four platforms examined (mRNA, microRNA, protein, DNA methylation). Kaplan-Meier plots show results of applying the four prognostic signatures to the validation subset, comparing survival for patients with predicted higher risk (red, top third of signature scores), lower risk (blue, bottom third) or intermediate risk (grey, middle third); successful predictions were observed in each case.</div><div class=\"graphic_footnotes\">* Discovery: batches 32-50-64-65-69. Validation: batches 63-68-70-82-90-105.<br /><span class=\"bullet\">&#8226;</span> After pre-filtering.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Nature. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 49:47. Copyright © 2013. <A href=\"http://www.nature.com/nature/\" target=_blank>www.nature.com/nature/</A>.</div><div id=\"graphicVersion\">Graphic 89913 Version 1.0</div></div></div>"},"89918":{"type":"graphic_picture","displayName":"Tophus of the ear","title":"Tophus of the ear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tophus of the ear</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/89918_Tophus_of_the_ear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A yellowish nodule is present on the helix of this patient with chronic tophaceous gout.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89918 Version 1.0</div></div></div>"},"89919":{"type":"graphic_picture","displayName":"Basal cell carcinoma ear","title":"Basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:550px; height:576px;\" src=\"images/DERM/89919_Basal_cell_carcinoma_ear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcerated basal cell carcinoma on the helix of an 82-year-old patient.</div><div class=\"graphic_reference\">Reproduced with permission from DermIS: Dermatology Information System. <a href=\"http://www.dermis.net/\" target=_blank>www.dermis.net</a>. Copyright © 2014. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89919 Version 1.0</div></div></div>"},"89920":{"type":"graphic_picture","displayName":"Squamous cell carcinoma ear","title":"Squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/DERM/89920_Squamous_cell_carcinoma_ear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Squamous cell carcinoma presenting as a crusted nodule on the helix of the ear.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89920 Version 1.0</div></div></div>"},"89921":{"type":"graphic_table","displayName":"Decompression and feeding intubations in gastroparesis patients","title":"Intubations for decompression and feeding in patients with gastroparesis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intubations for decompression and feeding in patients with gastroparesis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of access</td> <td class=\"subtitle1\">Usefulness</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr class=\"divider_bottom\"> <td>Nasogastric tube</td> <td>Gastric decompression in acute management</td> <td> <p>Not meant for long-term use</p> <p>Large tube size often causes discomfort</p> Is a poor choice for feeding due to delayed gastric emptying as significant gastroesophageal reflux can occur</td> </tr> <tr class=\"divider_bottom\"> <td>Nasoduodenal/nasojejunal tube</td> <td>Used to give trial feedings to determine if jejunal feedings are tolerated. May be acceptable if there are no other options.</td> <td> <p>Not for long-term use</p> Vomiting may expel the tube into the stomach</td> </tr> <tr class=\"divider_bottom\"> <td>Gastrostomy tubes</td> <td>May be used for venting of secretions to decrease vomiting and fullness</td> <td> <p>Poor choice for feeding due to delayed gastric emptying</p> May prevent proper electrode placement for gastric electrical stimulation</td> </tr> <tr class=\"divider_bottom\"> <td>PEG-J or Jet-PEG</td> <td> <p>Allows the patient to vent gastric secretions to decrease/prevent persistent emesis</p> <p>Provides jejunal feedings</p> New PEG-Js have distal feeding ports to reduce duodenogastric reflux</td> <td> <p>Migration of the J-tube extension into stomach</p> <p>Pyloric obstruction from J-tube</p> May prevent proper electrode placement for gastric electrical stimulation</td> </tr> <tr class=\"divider_bottom\"> <td>Jejunostomy (surgical, endoscopic, radiographic)</td> <td> <p>Stable access for reliable jejunal nutrient delivery</p> Avoids gastric penetration that would interfere with proper electrode placement for gastric electrical stimulation</td> <td>Cannot vent stomach</td> </tr> <tr> <td>Dual gastrostomy and jejunostomy</td> <td>Two sites &#8212; one for venting and one for enteral nutrition</td> <td> <p>Increased risk of leakage, infection</p> Cosmetic issues</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PEG: percutaneous endoscopic gastrostomy; PEG-J: percutaneous endoscopic gastrostomy with jejunal extension tube.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: American Journal of Gastroenterology. Camilleri M, Parkman HP, Shafi MA, et al. ACG clinical guideline: Management of Gastroparesis. Am J Gastroenterol 2013; 108:18. Copyright &copy; 2013. <a href=\"http://www.nature.com/ajg\" target=\"_blank\">www.nature.com/ajg</a>.</div><div id=\"graphicVersion\">Graphic 89921 Version 2.0</div></div></div>"},"89929":{"type":"graphic_table","displayName":"Characteristics of depression case-finding instruments validated","title":"Characteristics of depression case-finding instruments validated","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of depression case-finding instruments validated</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Instrument</td> <td class=\"subtitle1\">Sensitivity* (percent)</td> <td class=\"subtitle1\">Specificity<sup>&#182;</sup> (percent)</td> <td class=\"subtitle1\"> <p>Number of items<sup>&#916;</sup>&nbsp;</p> </td> <td class=\"subtitle1\">Response format</td> <td class=\"subtitle1\">Score range</td> <td class=\"subtitle1\">Usual cutpoint<sup>&#9674;</sup></td> <td class=\"subtitle1\">Literacy level<sup>&#167;</sup></td> <td class=\"subtitle1\">Time to administer (minutes)</td> <td class=\"subtitle1\">Monitor severity or response</td> </tr> <tr> <td>BDI</td> <td class=\"centered\">90</td> <td class=\"centered\">79</td> <td class=\"centered\">21, 13, 7</td> <td class=\"centered\">Four&nbsp;statements of symptom severity per item</td> <td class=\"centered\">0 to 63</td> <td class=\"centered\"> <p>10 to 19 mild</p> <p>20 to 29 moderate</p> &#8805;30 severe</td> <td class=\"centered\">Easy</td> <td class=\"centered\">2 to 5</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>EPDS</td> <td class=\"centered\">82</td> <td class=\"centered\">86</td> <td class=\"centered\">10</td> <td class=\"centered\">Four&nbsp;frequency ratings</td> <td class=\"centered\">0 to 30</td> <td class=\"centered\">&#8805;10</td> <td class=\"centered\">Easy</td> <td class=\"centered\">&#60;2</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>GDS</td> <td class=\"centered\">81</td> <td class=\"centered\">78</td> <td class=\"centered\">15</td> <td class=\"centered\">Yes or no</td> <td class=\"centered\">0 to 15</td> <td class=\"centered\">&#8805;6</td> <td class=\"centered\">Easy</td> <td class=\"centered\">2 to 5</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>PHQ-2</td> <td class=\"centered\">83</td> <td class=\"centered\">90</td> <td class=\"centered\">2</td> <td class=\"centered\">Four&nbsp;frequency ratings</td> <td class=\"centered\">0 to 6</td> <td class=\"centered\">&#8805;3</td> <td class=\"centered\">Average</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">Limited</td> </tr> <tr> <td>PHQ-9</td> <td class=\"centered\">88</td> <td class=\"centered\">88</td> <td class=\"centered\">9</td> <td class=\"centered\">Four frequency ratings</td> <td class=\"centered\"> <p>0 to 9 for diagnosis</p> 0 to 27 for response</td> <td class=\"centered\"> <p>For diagnosis:<br /> 5 symptoms</p> For severity:<br /> 0 to 4 none<br /> 5 to 9 mild<br /> 10 to 14 moderate<br /> 15 to 19 major<br /> 20 to 27 severe</td> <td class=\"centered\">Average</td> <td class=\"centered\">&#60;2</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>WHO-5</td> <td class=\"centered\">93</td> <td class=\"centered\">64</td> <td class=\"centered\">5</td> <td class=\"centered\">Five&nbsp;frequency ratings</td> <td class=\"centered\">0 to 25</td> <td class=\"centered\">&#8804;12</td> <td class=\"centered\">Easy</td> <td class=\"centered\">&#60;2</td> <td class=\"centered\">Unknown</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BDI: Beck Depression Inventory; EPDS: Edinburgh Postnatal Depression Scale; GDS: Geriatric Depression Scale; PHQ: Patient Health Questionnaire; WHO-5: World Health Organization Well-being Index.<br />* Sensitivity describes the proportion of patients with major depressive disorder who score below the cutpoint.<br />¶ Specificity describes the proportion of patients without major depressive disorder who score below the cutpoint.<br />Δ Numbers refer to different versions of the same instrument and are listed from most to least number of items.<br /><FONT class=lozenge>◊</FONT> Cutpoint is given for the instrument version with the most number of items.<br />§ Easy: Third- to fifth-grade reading level; Average: sixth- to ninth-grade reading level.</div><div class=\"graphic_reference\">Adapted from: Williams JW, Jr. Update: Depression. In: The Rational Clinical Examination: Evidence-based Clinical Diagnosis, Simel DL, Rennie D (Eds), McGraw-Hill, New York 2009.</div><div id=\"graphicVersion\">Graphic 89929 Version 3.0</div></div></div>"},"89930":{"type":"graphic_table","displayName":"Comparison TKI for CML","title":"Comparison of tyrosine kinase inhibitors used for chronic myeloid leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of tyrosine kinase inhibitors used for chronic myeloid leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Dosing frequency and timing in relation to food</td> <td class=\"subtitle1\">Dose adjustments for baseline kidney/liver dysfunction</td> <td class=\"subtitle1\">Major toxicities</td> <td class=\"subtitle1\">Other</td> </tr> <tr class=\"divider_bottom\"> <td>Imatinib</td> <td>Daily (or twice daily) with food</td> <td>Yes (kidney, liver)</td> <td>Bone marrow suppression; fluid retention/edema; gastrointestinal effects; heart failure; hepatotoxicity</td> <td>Most long-term safety data</td> </tr> <tr class=\"divider_bottom\"> <td>Nilotinib</td> <td>Twice daily without food</td> <td>Yes (liver)</td> <td> <p>Bone marrow suppression; atherosclerosis-related events; electrolyte imbalance; hepatotoxicity</p> Black box: QT prolongation (screening required)</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Dasatinib</td> <td>Daily with or without food</td> <td>No</td> <td>Bone marrow suppression; pleural/pericardial effusions; pulmonary arterial hypertension; QT prolongation; aspirin like effect</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Bosutinib</td> <td>Daily with food</td> <td>Yes (kidney, liver)</td> <td>Bone marrow suppression; fluid retention/edema; gastrointestinal effects</td> <td>&nbsp;</td> </tr> <tr> <td>Ponatinib</td> <td>Daily with or without food</td> <td>Yes (liver)</td> <td> <p>Bone marrow suppression; fluid retention/edema; gastrointestinal effects; heart failure; hypertension; pancreatitis; aspirin-like effect</p> Black box: arterial thrombosis; hepatic toxicity</td> <td>Least long-term safety data; active in patients with BCR-ABL1 T315I mutation</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table provides general guidance regarding the administration and toxicities of these tyrosine kinase inhibitors. Further details are available within the package inserts and UpToDate topics.</div><div id=\"graphicVersion\">Graphic 89930 Version 2.0</div></div></div>"},"89932":{"type":"graphic_figure","displayName":"Reduction in creatinine clearance after NSAIDs","title":"Graph showing reduction in creatinine clearance after NSAIDs in patients with hepatic cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Graph showing reduction in creatinine clearance after NSAIDs in patients with hepatic cirrhosis</div><div class=\"cntnt\"><img style=\"width:536px; height:356px;\" src=\"images/NEPH/89932_Reduct_creatin_after_NSAIDs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reduction in glomerular filtration rate, as estimated from the creatinine clearance, from a mean of 73 mL/min down to 32 mL/min, after the administration of a nonsteroidal antiinflammatory drug (indomethacin or ibuprofen) to 12 patients with stable hepatic cirrhosis and ascites. Urinary prostaglandin E<sub>2</sub> excretion was initially elevated and then fell markedly following therapy.</div><div class=\"graphic_reference\">Reproduced with permission from: Zipser RD, Hoefs JC, Speckhart PF, et al. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979; 48:895-900. <a href=\"http://press.endocrine.org/journal/jcem\" target=\"_blank\">http://press.endocrine.org/journal/jcem</a>. Copyright &copy; 1979 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 89932 Version 2.0</div></div></div>"},"89933":{"type":"graphic_figure","displayName":"NSAIDs block the vasodilatory effect of prostaglandins","title":"NSAIDs block the vasodilatory effect of prostaglandins on the afferent arteriole and reduce glomerular filtration rate","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">NSAIDs block the vasodilatory effect of prostaglandins on the afferent arteriole and reduce glomerular filtration rate</div><div class=\"cntnt\"><img style=\"width:531px; height:336px;\" src=\"images/NEPH/89933_NSAIDs_block_eff_prostag.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Certain conditions that promote renal vasoconstriction and renal hypoperfusion require prostaglandins to vasodilate the afferent arteriole and blunt vasoconstriction to maintain a normal GFR (left). However in the presence of NSAIDs, which reduced prostaglandin production, afferent arteriole vasoconstriction dominates and reduces GFR (right).</div><div class=\"graphic_footnotes\">GFR: glomerular filtration rate; PGs: prostaglandins; Ang II: angiotensin II; NSAIDs: nonsteroidal anti-inflammatory drugs; COX: cyclooxygenase.</div><div class=\"graphic_reference\">Courtesy of Randy Luciano, MD, PhD, and Mark A Perazella, MD, FACP.</div><div id=\"graphicVersion\">Graphic 89933 Version 1.0</div></div></div>"},"89935":{"type":"graphic_picture","displayName":"Aplasia cutis congenita scalp","title":"Aplasia cutis congenita of the scalp","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Aplasia cutis congenita of the scalp</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/DERM/89935_Aplasia_cutis_congen_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosive lesion covered by a tense membrane on the scalp of an infant with aplasia cutis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89935 Version 2.0</div></div></div>"},"89936":{"type":"graphic_picture","displayName":"Syringocystadenoma papilliferum","title":"Syringocystadenoma papilliferum","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Syringocystadenoma papilliferum</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/DERM/89936_Syringocystade_papilliferum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A firm, pink, papillomatous plaque on the scalp of a child with syringocystadenoma papilliferum.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89936 Version 2.0</div></div></div>"},"89937":{"type":"graphic_picture","displayName":"Syringocystadenoma papilliferum histopathology","title":"Histologic features of syringocystadenoma papilliferum","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Histologic features of syringocystadenoma papilliferum</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89937_Syringocysta_papillif_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papillomatous epidermal invaginations lined with a double layer of columnar epithelium composed of basilar cuboid cells and an inner layer of apocrine secretory cells.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89937 Version 2.0</div></div></div>"},"89954":{"type":"graphic_picture","displayName":"Black piedra","title":"Black piedra","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Black piedra</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/89954_Black_piedra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small, dark brown concretions on hair shafts.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 89954 Version 2.0</div></div></div>"},"89955":{"type":"graphic_table","displayName":"Drugs associated with orthostatic hypotension","title":"Examples of drugs that can cause or exacerbate orthostatic hypotension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of drugs that can cause or exacerbate orthostatic hypotension</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Alcohol</td> </tr> <tr> <td>Alpha blockers: Terazosin (eg)</td> </tr> <tr> <td>Antidepressant drugs: Selective serotonin receptor reuptake inhibitors, trazodone, monoamine oxidase inhibitors, tricyclic antidepressants</td> </tr> <tr> <td>Antihypertensive drugs: Sympathetic blockers (eg)</td> </tr> <tr> <td>Antiparkinsonism drugs: Levodopa, pramipexole, ropinirole (egs)</td> </tr> <tr> <td>Antipsychotic drugs: Olanzapine, risperidone (egs)</td> </tr> <tr> <td>Beta-blocker drugs: Propranolol (eg)</td> </tr> <tr> <td>Diuretic drugs: Hydrochlorothiazide, furosemide (egs)</td> </tr> <tr> <td>Muscle relaxant drugs: Tizanidine (eg)</td> </tr> <tr> <td>Narcotic analgesic drugs: Morphine (eg)</td> </tr> <tr> <td>Phosphodiesterase inhibitors: Sildenafil, tadalafil (egs)</td> </tr> <tr> <td>Sedatives/hypnotic drugs: Temazepam (eg)</td> </tr> <tr> <td>Vasodilator drugs: Hydralazine, nitroglycerin, calcium channel blockers (egs)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Perlmuter LC, Sarda G, Casavant V, Mosnaim AD. A review of the etiology, associated comorbidities, and treatment of orthostatic hypotension. Am J Ther 2013; 20:279. DOI: <a href=\"http://journals.lww.com/americantherapeutics/Abstract/2013/05000/A_Review_of_the_Etiology,_Asssociated.10.aspx\" target=\"_blank\">10.1097/MJT.0b013e31828bfb7f</a>. Copyright &copy; 2013 Wolters Kluwer Health, Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 89955 Version 7.0</div></div></div>"},"89956":{"type":"graphic_picture","displayName":"Black piedra microscopy","title":"Black piedra","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Black piedra</div><div class=\"cntnt\"><img style=\"width:576px; height:379px;\" src=\"images/DERM/89956_Black piedra microscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic view of a concretion on the hair shaft in black piedra.</div><div class=\"graphic_reference\">Reproduced from: US Centers for Disease Control and Prevention Public Health Image Library. Photo courtesy of Dr. Lucille K Georg. Available from:&nbsp;<A href=\"http://phil.cdc.gov/phil/home.asp\">http://phil.cdc.gov/phil/home.asp</A> (Accessed on February 13th, 2014).</div><div id=\"graphicVersion\">Graphic 89956 Version 3.0</div></div></div>"},"89957":{"type":"graphic_table","displayName":"Blood glucose response to different types of exercise","title":"Blood glucose response to different types of exercise","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Blood glucose response to different types of exercise</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Activity</td> <td class=\"subtitle1\">Type of exercise</td> <td class=\"subtitle1\">Effect on blood glucose</td> </tr> <tr class=\"divider_bottom\"> <td>Walking, jogging, running, rollerblading, bicycling, cross-country skiing</td> <td>Mostly aerobic</td> <td>Usually &#8595;</td> </tr> <tr class=\"divider_bottom\"> <td>Basketball, soccer, tennis, lacrosse, field hockey, rowing/canoeing, downhill skiing, middle distance running, playground activities, speed skating, golf, skateboarding, hula hooping, hopscotch, dancing, yoga, tag, rope jumping, swimming, capture the flag, dodge ball</td> <td>Both aerobic and anaerobic</td> <td>May &#8595; or &#8593;</td> </tr> <tr class=\"divider_bottom\"> <td>Weightlifting, track (sprinting and field events), football, baseball, gymnastics, fencing, wrestling, volleyball, ice hockey, diving, swimming (sprints), climbing trees, tug of war</td> <td>Mostly anaerobic</td> <td>Usually &#8593;</td> </tr> <tr> <td>Competitions, try-outs or performances</td> <td>Either aerobic or anaerobic</td> <td>Usually &#8593; because of the \"stress\" of competition</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Michael Riddell, PhD.</div><div id=\"graphicVersion\">Graphic 89957 Version 1.0</div></div></div>"},"89958":{"type":"graphic_figure","displayName":"Patterns of substrate utilization during exercise","title":"Patterns of substrate utilization during exercise, based on exercise duration and intensity","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Patterns of substrate utilization during exercise, based on exercise duration and intensity</div><div class=\"cntnt\"><img style=\"width:603px; height:268px;\" src=\"images/PEDS/89958_Patt_sub_util_exer_dur_int.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Michael C Riddell, PhD.</div><div id=\"graphicVersion\">Graphic 89958 Version 1.0</div></div></div>"},"89959":{"type":"graphic_table","displayName":"Difficult airway equipment in the operating room","title":"Suggested contents of difficult airway cart in the operating room","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested contents of difficult airway cart in the operating room</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Rigid laryngoscope blades of alternate design and size from those routinely used; this may include a rigid fiberoptic laryngoscope.</td> </tr> <tr> <td>Videolaryngoscope.</td> </tr> <tr> <td>Tracheal tubes of assorted sizes.</td> </tr> <tr> <td>Tracheal tube guides. Examples include (but are not limited to) semirigid stylets, ventilating tube-changer, light wands, and forceps designed to manipulate the distal portion of the tracheal tube.</td> </tr> <tr> <td>Supraglottic airways (eg, LMAs or ILMAs of assorted sizes for noninvasive airway ventilation/intubation).</td> </tr> <tr> <td>Flexible fiberoptic intubation equipment.</td> </tr> <tr> <td>Equipment suitable for emergency invasive airway access.</td> </tr> <tr> <td>An exhaled carbon dioxide detector.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The items listed in this table represent suggestions. The contents of the portable storage unit should be customized to meet the specific needs, preferences, and skills of the practitioner and healthcare facility.</div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway; ILMA: intubating LMA.</div><div class=\"graphic_reference\">From: Apfelbaum JL, Hagberg CA, Caplan RA, et al. Practice guidelines for management of the difficult airway: an updated report by the American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Anesthesiology. 2013; 118:251. DOI: <A spellcheck=true href=\"http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1918684\" target=_blank>10.1097/ALN.0b013e31827773b2</A>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright © 2013 American Society of Anesthesiologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 89959 Version 5.0</div></div></div>"},"89960":{"type":"graphic_table","displayName":"Carbohydrate intake during exercise","title":"Recommended carbohydrate intake during exercise, according to body weight and activity performed","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended carbohydrate intake during exercise, according to body weight and activity performed</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Activity</td> <td class=\"subtitle1\" colspan=\"3\">Body weight</td> </tr> <tr> <td class=\"subtitle2\">20 kg (44 lbs)</td> <td class=\"subtitle2\">40 kg (88 lbs)</td> <td class=\"subtitle2\">60 kg (132 lbs)</td> </tr> <tr> <td>Basketball</td> <td class=\"centered\"> <p>47 grams CHO</p> </td> <td class=\"centered\">93&nbsp;grams CHO</td> <td class=\"centered\">140&nbsp;grams CHO</td> </tr> <tr> <td>Cross-country skiing</td> <td class=\"centered\">21</td> <td class=\"centered\">44</td> <td class=\"centered\">65</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Cycling</td> </tr> <tr> <td class=\"indent1\">10 km/h (6 mi/h)</td> <td class=\"centered\">14</td> <td class=\"centered\">23</td> <td class=\"centered\">37</td> </tr> <tr> <td class=\"indent1\">15 km/h (9 mi/h)</td> <td class=\"centered\">20</td> <td class=\"centered\">37</td> <td class=\"centered\">56</td> </tr> <tr> <td>Figure skating</td> <td class=\"centered\">37</td> <td class=\"centered\">74</td> <td class=\"centered\">112</td> </tr> <tr> <td>Ice hockey</td> <td class=\"centered\">47</td> <td class=\"centered\">93</td> <td class=\"centered\">140</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Running</td> </tr> <tr> <td class=\"indent1\">8 km/h (4 mi/h)</td> <td class=\"centered\">34</td> <td class=\"centered\">62</td> <td class=\"centered\">84</td> </tr> <tr> <td class=\"indent1\">12 km/h (7 mi/h)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">84</td> <td class=\"centered\">114</td> </tr> <tr> <td>Snow shoeing</td> <td class=\"centered\">31</td> <td class=\"centered\">62</td> <td class=\"centered\">93</td> </tr> <tr> <td>Soccer</td> <td class=\"centered\">34</td> <td class=\"centered\">67</td> <td class=\"centered\">100</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Swimming</td> </tr> <tr> <td class=\"indent1\">30 meters/min breast stroke</td> <td class=\"centered\">28</td> <td class=\"centered\">56</td> <td class=\"centered\">107</td> </tr> <tr> <td>Tennis</td> <td class=\"centered\">23</td> <td class=\"centered\">40</td> <td class=\"centered\">59</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Walking</td> </tr> <tr> <td class=\"indent1\">4 km/h (2 mi/h)</td> <td class=\"centered\">18</td> <td class=\"centered\">24</td> <td class=\"centered\">32</td> </tr> <tr> <td class=\"indent1\">6 km/h (3 mi/h)</td> <td class=\"centered\">24</td> <td class=\"centered\">32</td> <td class=\"centered\">40</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Values are the estimated number of grams of carbohydrate to consume for<STRONG>&nbsp;60 minutes</STRONG> of exercise, if the activity is performed during times of peak insulin action and no adjustments in insulin are made.</div><div class=\"graphic_footnotes\">CHO: carbohydrate.</div><div class=\"graphic_reference\">Modified based on data from:&nbsp;Robertson K, Riddell MC, Guinhouya BC, Adolfsson P, Hanas R; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Exercise in children and adolescents with diabetes. Pediatr Diabetes 2014; 15 Suppl 20:203.</div><div id=\"graphicVersion\">Graphic 89960 Version 1.0</div></div></div>"},"89962":{"type":"graphic_table","displayName":"Classification congenital thrombocytopenia by platelet size","title":"Classification of congenital thrombocytopenias by platelet size","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of congenital thrombocytopenias by platelet size</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Small platelets (MPV &#60;7 fL)</td> <td class=\"subtitle1\">Normal-sized platelets (MPV 7 to 11 fL)</td> <td class=\"subtitle1\">Large platelets (MPV &#62;11 fL)</td> </tr> <tr> <td>Wiskott-Aldrich syndrome</td> <td> <p>Inherited bone marrow failure syndromes:</p> <ul> <li>Fanconi anemia </li> <li>Dyskeratosis congenita </li> <li>Shwachman-Diamond syndrome </li> <li>Congenital amegakaryocytic thrombocytopenia </li> </ul> </td> <td>Bernard-Soulier syndrome </td> </tr> <tr> <td rowspan=\"8\">X-linked thrombocytopenia</td> <td>Thrombocytopenia-absent radius (TAR) syndrome</td> <td>DiGeorge syndrome</td> </tr> <tr> <td>Amegakaryocytic thrombocytopenia with radioulnar synostosis</td> <td> <p>MYH9-related disorders</p> </td> </tr> <tr> <td rowspan=\"6\"> <p>Familial platelet disorders with predisposition to myeloid malignancy:</p> <ul id=\"_telerik_insertedList_id\"> <li>Thrombocytopenia 2 (<em>ANKRD26 </em>mutation) </li> <li>Thrombocytopenia 5 (<em>ETV6 </em>mutation) </li> </ul> </td> <td> <p>Paris-Trousseau syndrome</p> </td> </tr> <tr> <td>Gray platelet syndrome</td> </tr> <tr> <td>X-linked thrombocytopenia with dyserythropoiesis/thalassemia</td> </tr> <tr> <td>Autosomal dominant deafness with thrombocytopenia (<em>DIAPH1 mutation)</em></td> </tr> <tr> <td>Sitosterolemia</td> </tr> <tr> <td><em>ACTN1</em>-related macrothrombocytopenia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MPV: mean platelet volume; MYH9: non-muscle myosin heavy chain.</div><div class=\"graphic_reference\">Original figure modified for this publication. Kumar R, Kahr W. Congenital thrombocytopenia: Clinical manifestations, laboratory abnormalities, and molecular defects of a heterogeneous group of conditions. Hematol Oncol Clin North Am 2013; 27:465. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 89962 Version 3.0</div></div></div>"},"89966":{"type":"graphic_picture","displayName":"Endometriosis diaphragm lesion","title":"Endometriotic lesion of the diaphragm","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Endometriotic lesion of the diaphragm</div><div class=\"cntnt\"><img style=\"width:574px; height:436px;\" src=\"images/OBGYN/89966_Endometrios_diaphrgm_lesion.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 89966 Version 1.0</div></div></div>"},"89967":{"type":"graphic_diagnosticimage","displayName":"CT epiploic appendagitis","title":"Epiploic appendagitis on CT scan","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Epiploic appendagitis on CT scan</div><div class=\"cntnt\"><img style=\"width:566px; height:434px;\" src=\"images/RADIOL/89967_CT_epiploic_appendag.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the upper pelvis shows an oval shaped fatty nodule abutting the descending colon (arrow) with surrounding induration (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 89967 Version 1.0</div></div></div>"},"89968":{"type":"graphic_figure","displayName":"Molecular correlates patient survival metabolic pathways A","title":"Molecular correlates of patient survival involve metabolic pathways: Part A","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Molecular correlates of patient survival involve metabolic pathways: Part A</div><div class=\"cntnt\"><img style=\"width:640px; height:808px;\" src=\"images/ONC/89968_Mole_corr_pat_surv_path_B.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When viewed in the context of metabolism, the molecular survival correlates highlight a widespread metabolic shift, with tumors altering their usage of key pathways and metabolites (red and blue shading representing the correlation of increased gene expression with worse or better survival respectively, univariate Cox based on extended cohort). Worse survival correlates with upregulation of pentose phosphate pathway genes (G6PH, PGLS, TALDO and TKT), fatty acid synthesis genes (ACC and FASN), and PI(3)K pathway enhancing genes (miR-21). Better survival correlates with upregulation of AMPK complex genes, multiple Krebs cycle genes and PI(3)K pathway inhibitors (PTEN, TSC2). Additionally, specific promoter methylation events, including hypermethylation of PI(3)K pathway repressor GRB10, associate with outcome.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Nature. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 49:47. Copyright © 2013. <A href=\"http://www.nature.com/nature/\" target=_blank>www.nature.com/nature/</A>.</div><div id=\"graphicVersion\">Graphic 89968 Version 1.0</div></div></div>"},"89969":{"type":"graphic_figure","displayName":"Molecular correlates patient survival metabolic pathways C","title":"Molecular correlates of patient survival involve metabolic pathways: Part C","html":"<div class=\"graphic\"><div style=\"width: 688px\" class=\"figure\"><div class=\"ttl\">Molecular correlates of patient survival involve metabolic pathways: Part C</div><div class=\"cntnt\"><img style=\"width:668px; height:184px;\" src=\"images/ONC/89969_Mole_corr_pat_surv_path_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Heat map of selected key features from the metabolic shift schematic (Part A) demonstrating coordinate expression by stage at DNA methylation, RNA, and protein levels (data from validation subset).</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Nature. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 49:47. Copyright © 2013. <A href=\"http://www.nature.com/nature/\" target=_blank>www.nature.com/nature/</A>.</div><div id=\"graphicVersion\">Graphic 89969 Version 1.0</div></div></div>"},"89970":{"type":"graphic_table","displayName":"Imaging comparison for thoracic aortic aneurysm and dissection","title":"Imaging comparison for thoracic aortic aneurysm and dissection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Imaging comparison for thoracic aortic aneurysm and dissection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">&nbsp;&nbsp; Multidetector CT angiography</td> </tr> <tr> <td class=\"indent1\">Rapid image acquisition, 3D reconstruction, near-universal availability, rapid interpretation</td> <td> <p>Need for iodinated contrast, radiation exposure, overestimation of aortic diameter if slices are not perpendicular to flow, image artifact at aortic root</p> </td> </tr> <tr> <td class=\"indent1\"><strong><span class=\"sublist1_start\"></span>MR angiography<span class=\"subtitle2_left\"></span></strong></td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">No radiation, 3D reconstruction, serial imaging</td> <td>Limited availability, need to hold breath, time consuming, contraindicated in hemodynamically unstable patients, caution in patients with renal failure</td> </tr> <tr> <td class=\"indent1\"><strong>TEE</strong></td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">No radiation, no iodinated contrast, can be performed at the bedside </td> <td>Does not image the&nbsp;entire aorta, semi-invasive, requires sedation and airway management</td> </tr> <tr> <td class=\"indent1\"><strong>TTE</strong></td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">No sedation needed, no radiation, no iodinated contrast, can be performed at the bedside</td> <td>Does not image the entire aorta, artifact from overlying ribs</td> </tr> <tr> <td class=\"indent1\"><strong></strong></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">CT: computed tomography; 3D: three-dimensional; MR: magnetic resonance; TEE: transesophageal echocardiography; TTE: transthoracic echocardiography.</div><div id=\"graphicVersion\">Graphic 89970 Version 2.0</div></div></div>"},"89974":{"type":"graphic_diagnosticimage","displayName":"Distal femoral physeal fracture","title":"Distal femoral physeal fracture with genu valgum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal femoral physeal fracture with genu valgum</div><div class=\"cntnt\"><img style=\"width:299px; height:745px;\" src=\"images/PEDS/89974_Distl_femorl_physel_fractur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Teleogram of a patient who sustained a right distal femoral physeal fracture treated with open reduction and internal fixation. Subsequent lateral physeal growth arrest resulted in genu valgum.</div><div id=\"graphicVersion\">Graphic 89974 Version 1.0</div></div></div>"},"89978":{"type":"graphic_table","displayName":"Causes of hyperphosphatemia","title":"Causes of hyperphosphatemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hyperphosphatemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Acute phosphate load</td> </tr> <tr> <td class=\"subtitle2_single\">Endogenous</td> </tr> <tr> <td class=\"indent1\">Cell lysis (tumor lysis syndrome, rhabdomyolysis)</td> </tr> <tr> <td class=\"subtitle2_single\">Exogenous</td> </tr> <tr> <td class=\"indent1\">Phosphate-containing medications (laxatives, fosphenytoin)</td> </tr> <tr> <td class=\"indent1\">Intestinal uptake (vitamin D toxicity)</td> </tr> <tr> <td class=\"subtitle1_single\">Cellular shift</td> </tr> <tr> <td class=\"subtitle2_single\">Lactic or ketoacidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Decreased renal clearance</td> </tr> <tr> <td class=\"subtitle2_single\">Reduced glomerular filtration rate</td> </tr> <tr> <td class=\"indent1\">Acute kidney injury</td> </tr> <tr> <td class=\"indent1\">Chronic kidney disease</td> </tr> <tr> <td class=\"subtitle2_single\">Increased tubular reabsorption</td> </tr> <tr> <td class=\"indent1\">Hypoparathyroidism or pseudohypoparathyroidism</td> </tr> <tr> <td class=\"indent1\">Acromegaly</td> </tr> <tr> <td class=\"indent1\">Bisphosphonates</td> </tr> <tr> <td class=\"indent1\">Cinacalcet</td> </tr> <tr> <td class=\"indent1\">Vitamin D toxicity (also increases intestinal absorption)</td> </tr> <tr> <td class=\"indent1\">Familial tumoral calcinosis</td> </tr> <tr> <td class=\"subtitle1_single\">Pseudohyperphosphatemia</td> </tr> <tr> <td class=\"subtitle2_single\">Endogenous</td> </tr> <tr> <td class=\"indent1\">Hyperglobulinemia (multiple myeloma, Waldenstr&#246;m macroglobulinemia)</td> </tr> <tr> <td class=\"indent1\">Hyperlipidemia</td> </tr> <tr> <td class=\"indent1\">Hemolysis</td> </tr> <tr> <td class=\"indent1\">Hyperbilirubinemia</td> </tr> <tr> <td class=\"subtitle2_single\">Exogenous</td> </tr> <tr> <td class=\"indent1\">Medications (amphotericin B, heparin, tissue plasminogen activator)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 89978 Version 2.0</div></div></div>"},"89983":{"type":"graphic_picture","displayName":"Primary microcephaly","title":"Primary microcephaly","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Primary microcephaly</div><div class=\"cntnt\"><img style=\"width:584px; height:361px;\" src=\"images/PEDS/89983_Primary_microcephaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Siblings with autosomal recessive primary microphaly, MCPH5, due to <em>ASPM</em> mutations.</div><div id=\"graphicVersion\">Graphic 89983 Version 1.0</div></div></div>"},"89985":{"type":"graphic_table","displayName":"Gemcitabine plus PLD for HCC","title":"Gemcitabine and pegylated liposomal doxorubicin for advanced hepatocellular carcinoma<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gemcitabine and pegylated liposomal doxorubicin for advanced hepatocellular carcinoma<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 4 weeks.<br /> <strong>Duration of therapy:</strong> Maximum of 8 cycles.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Gemcitabine</td> <td>1000 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline and administer over 30 minutes.</td> <td>Days 1 and 8</td> </tr> <tr class=\"divider_bottom\"> <td>Pegylated liposomal doxorubicin (PLD)*</td> <td>30 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 or 500 mL of 5% dextrose in water (D5W) and infuse initially at a rate of 1 mg/min to minimize risk of infusion reactions. If none are observed, increase rate of infusion to complete administration over one hour.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE on day 1 and<br /> LOW on day 8.</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>PLD is an irritant but it can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>The original protocol administered premedication with an H1 and an H2 receptor antagonist plus hydrocortisone 125 mg on day 1.</li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors is not warranted. Although the exact incidence of febrile neutropenia was not reported with this regimen, the incidence of grade 3 or 4 neutropenia was only 17%.<sup>[1]</sup></li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Although the original protocol permitted standard doses for patients with a total bilirubin up to 3 mg/dL, and for transaminase levels up to seven times the institutional limit of normal<sup>[1]</sup>, lower starting doses for gemcitabine and PLD may be needed for patients with liver impairment.</li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>PLD is associated with cardiomyopathy, the incidence of which is related to total dose. Assess baseline LVEF* prior to administration. PLD is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or other anthracycline-type drug.<sup>[2]</sup></li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel (including serum creatinine) and liver function prior to each cycle or when otherwise clinically indicated during treatment.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for infusion reactions.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for palmar-plantar erythrodysesthesia and stomatitis.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor the cumulative dose of PLD. Reassess LVEF periodically during treatment with PLD as clinically indicated. In clinical practice, PLD appears to have significantly less cardiotoxicity than unencapsulated anthracyclines, but this does not preclude the need to monitor cardiac function.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>A new cycle should not be initiated unless the ANC is &#8805;1500 cells/microL and platelets are &#8805;100,000/microL.<sup>[1]</sup> The original protocol recommended a decrease in the day 8 gemcitabine by 50% for grade 1 thrombocytopenia or grade 2 neutropenia; withhold for higher grades of thrombocytopenia or neutropenia on the day of treatment.<sup>[1]</sup> The original protocol provided no dose reduction guidelines for PLD in response to myelotoxicity. However, the United States Prescribing Information recommends a 25% dose reduction in PLD dose for nadir ANC &#60;500 cells/microL or platelet count &#60;25,000/microL.<sup>[2]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cardiotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>For deterioration in cardiac function associated with use of PLD, the benefit of continued therapy should be carefully evaluated against the risk of producing irreversible cardiac damage.<sup>[2]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cutaneous and mucosal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For &#8805;grade 2 palmar-plantar erythrodysesthesia the original protocol recommended 25% reduction in PLD dose.<sup>[1]</sup> The United States Prescribing Information recommends delay in therapy for to up to two weeks or until resolved to grade 0 or 1 for &#8805;grade 2 palmar-plantar erythrodysesthesia or stomatitis, and reduce dose by 25% for grade 3 or 4 toxicity; discontinue if toxicity persists.<sup>[2]</sup></li> <li>Refer to UpToDate topics on \"Oral toxicity associated with chemotherapy\" and \"Cutaneous complications of conventional chemotherapy agents\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.<sup>[3]</sup> Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>For flank pain, flushing, shortness of breath, and/or chest tightness during PLD, stop the infusion immediately; after resolution, restart treatment at reduced rate.<sup>[2]</sup> For recurrent infusion reactions, discontinue PLD and consider desensitization if severe (signs/symptoms of anaphylaxis). However, most reactions are mild, and many patients are able to tolerate a rechallenge using additional premedication and limiting the initial infusion rate to &#8804;1 mg/min.</li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>A variety of manifestations of pulmonary toxicity have been reported with gemcitabine.<sup>[3]</sup> Discontinue gemcitabine immediately and permanently.</li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">CBC: complete blood count; LVEF: left ventricular ejection fraction; IV: intravenous; ANC: absolute neutrophil count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies). Do not use with any diluent other than 5% dextrose injection. Do not use with in-line filters. Do not mix with other drugs. Do not use any bacteriostatic agent, such as benzyl alcohol.<SUP>[2]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lombardi G, et al. Cancer 2011; 117:125.</LI>&#xD;&#xA;<LI>Doxorubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed April 15, 2013).</LI>&#xD;&#xA;<LI>Gemcitabine hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed April 15, 2013).</LI></OL></div><div id=\"graphicVersion\">Graphic 89985 Version 8.0</div></div></div>"},"89986":{"type":"graphic_figure","displayName":"MRI and neuropathology of AHL","title":"Acute hemorrhagic leukoencephalitis: MRI and neuropathology findings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute hemorrhagic leukoencephalitis: MRI and neuropathology findings</div><div class=\"cntnt\"><img style=\"width:422px; height:514px;\" src=\"images/NEURO/89986_MRIneuropathologAHL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative axial T2-weighted (A), noncontrast T1-weighted (B), postcontrast T1-weighted (C), and fast fluid-attenuated inversion recovery (FLAIR) (D-F) 1.5-T MRI scans three days after neurologic symptom onset. Images show bilateral confluent asymmetric lesions in the posterior frontal, posterior temporal, parietal, and occipital lobes, and splenium of the corpus callosum. Lesions extend from the periventricular region to the subcortical white matter and gray-white junction. Lesions are seen with comparable sensitivity on T2-weighted vs FLAIR images and are mildly hypointense on T1-weighted images without contrast enhancement. There was no evidence of brain herniation or infratentorial lesions (not shown). (G) This slide of deep white matter exhibits fine vacuolation (arrowheads) due to edema, neutrophilic infiltrate (arrows), and a cluster of extravasation of erythrocytes (upper left-middle of image, thick arrows), all typical of acute hemorrhagic leukoencephalitis. Myelin stains showed loss of myelin staining in the edematous areas (not shown). There was no evidence of active infection. Hematoxylin and eosin; original magnification ×400.</div><div class=\"graphic_reference\">Reproduced with permission from: Kuperan S, Ostrow P, Landi MK, Bakshi R. Acute hemorrhagic leukoencephalitis vs ADEM: FLAIR MRI and neuropathology findings. Neurology 2003; 60:721. Copyright © 2003 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 89986 Version 6.0</div></div></div>"},"89988":{"type":"graphic_diagnosticimage","displayName":"Brain MRI of ADEM","title":"Brain MRI of acute disseminated encephalomyelitis (ADEM)","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Brain MRI of acute disseminated encephalomyelitis (ADEM)</div><div class=\"cntnt\"><img style=\"width:463px; height:276px;\" src=\"images/NEURO/89988_Brain_MRI_ADEM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial T2-weighted magnetic resonance imaging (MRI) showing multiple, bilateral, hyperintense lesions in the periventricular white matter.<br />(B) Axial T2-weighted MRI with extensive bihemispheric demyelinating lesions involving the white matter and basal ganglia, extending into the mesencephalon.</div><div class=\"graphic_reference\">Reproduced with permission from: Menkes JH, Sarnat HB, Maria BL, Child Neurology, 7th Edition, Philadelphia, Lippincott Williams &amp; Wilkins, 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 89988 Version 1.0</div></div></div>"},"89991":{"type":"graphic_picture","displayName":"Pinta hypopigmentation","title":"Pinta","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Pinta</div><div class=\"cntnt\"><img style=\"width:574px; height:533px;\" src=\"images/ID/89991_Pinta_hypopigmentation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous dyschromia in late pinta.</div><div class=\"graphic_reference\">Courtesy of Dr. Ted Rosen</div><div id=\"graphicVersion\">Graphic 89991 Version 1.0</div></div></div>"},"89994":{"type":"graphic_table","displayName":"DSM-5 criteria for a major depressive episode","title":"DSM-5 diagnostic criteria for a major depressive episode","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-5 diagnostic criteria for a major depressive episode</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>A.</strong> Five (or more) of the following symptoms have been present during the same two-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>NOTE:</strong> Do not include symptoms that are clearly attributable to another medical condition.</td> </tr> <tr> <td class=\"indent1\">1) Depressed mood most of the day, nearly every day, as indicated by either subjective report (eg, feels sad, empty, hopeless) or observations made by others (eg, appears tearful). (NOTE: In children and adolescents, can be irritable mood.)</td> </tr> <tr> <td class=\"indent1\">2) Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated by either subjective account or observation)</td> </tr> <tr> <td class=\"indent1\">3) Significant weight loss when not dieting or weight gain (eg, a change of more than 5% of body weight in a month), or decrease or increase in appetite nearly every day. (NOTE: In children, consider failure to make expected weight gain.)</td> </tr> <tr> <td class=\"indent1\">4) Insomnia or hypersomnia nearly every day</td> </tr> <tr> <td class=\"indent1\">5) Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down)</td> </tr> <tr> <td class=\"indent1\">6) Fatigue or loss of energy nearly every day</td> </tr> <tr> <td class=\"indent1\">7) Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick)</td> </tr> <tr> <td class=\"indent1\">8) Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by their subjective account or as observed by others)</td> </tr> <tr> <td class=\"indent1\">9) Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide</td> </tr> <tr> <td><strong>B.</strong> The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.</td> </tr> <tr> <td><strong>C.</strong> The episode is not attributable to the direct physiological effects of a substance or to another medical condition.</td> </tr> <tr> <td><strong>NOTE:</strong> Criteria A through C represent a major depressive episode.</td> </tr> <tr> <td><strong>NOTE:</strong> Responses to a significant loss (eg, bereavement, financial ruin, losses from a natural disaster, a serious medical illness or disability) may include the feelings of intense sadness, rumination about the loss, insomnia, poor appetite, and weight loss noted in Criterion A, which may resemble a depressive episode. Although such symptoms may be understandable or considered appropriate to the loss, the presence of a major depressive episode in addition to the normal response to a significant loss should also be carefully considered. This decision inevitably requires the exercise of clinical judgement based on the individual's history and the cultural norms for the expression of distress in the context of loss.</td> </tr> <tr> <td><strong>D.</strong> The occurence of the major depressive episode is not better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified and unspecified schizophrenia spectrum and other psychotic disorders.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>E.</strong> There has never been a manic or hypomanic episode.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>NOTE:</strong> This exclusion does not apply if all of the manic-like or hypomanic-like epsidoes are substance-induced or are attributable to the physiological effects of another medical condition.</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em>:</td> </tr> <tr> <td class=\"indent1\">With anxious distress</td> </tr> <tr> <td class=\"indent1\">With mixed features</td> </tr> <tr> <td class=\"indent1\">With melancholic features</td> </tr> <tr> <td class=\"indent1\">With atypical features</td> </tr> <tr> <td class=\"indent1\">With psychotic features</td> </tr> <tr> <td class=\"indent1\">With catatonia</td> </tr> <tr> <td class=\"indent1\">With peripartum onset</td> </tr> <tr> <td class=\"indent1\">With seasonal pattern</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright © 2013). American Psychiatric Association. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 89994 Version 12.0</div></div></div>"},"89995":{"type":"graphic_figure","displayName":"IgA monomer and dimer","title":"Structures of monomeric serum IgA and dimeric secretory IgA","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Structures of monomeric serum IgA and dimeric secretory IgA</div><div class=\"cntnt\"><img style=\"width:508px; height:322px;\" src=\"images/ALLRG/89995_IgA_monomer_dimer.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IgA: immunoglobulin A.</div><div id=\"graphicVersion\">Graphic 89995 Version 3.0</div></div></div>"},"89996":{"type":"graphic_picture","displayName":"Frozen shoulder PI","title":"Frozen shoulder: Limitations in movement","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Frozen shoulder: Limitations in movement</div><div class=\"cntnt\"><img style=\"width:620px; height:555px;\" src=\"images/PI/89996_Frozen_shoulder_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photographs in&nbsp;the top row show common movement restrictions that are found with frozen shoulder. Note how the affected left shoulder is limited in external rotation (A), abduction (movement away from the body) (B), and internal rotation (C), compared to the unaffected shoulder (photographs D, E, and F). Photographs A, B, D, and E show passive motion (controlled by the doctor, not the patient).</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 89996 Version 1.0</div></div></div>"},"89999":{"type":"graphic_picture","displayName":"Frozen shoulder early exercises PI","title":"Exercises to do for frozen shoulder early in healing process","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Exercises to do for frozen shoulder early in healing process</div><div class=\"cntnt\"><img style=\"width:603px; height:779px;\" src=\"images/PI/89999_Frozen_shoulder_early_ex_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 89999 Version 1.0</div></div></div>"}};